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ABSTRACT 
 
Natural Killer (NK) cells are an essential part of the immune system capable of controlling 
several viral infections, including HIV-1. Moreover, several studies have linked specific NK 
cell receptors, termed killer immunoglobulin-like receptors (KIR), and their human leukocyte 
antigen (HLA) ligands to favourable clinical outcomes in HIV-1 infected individuals. Recent 
studies have also highlighted the role of KIR and HLA in modulating the risk of adult HIV-1 
transmission and disease progression; however, little is known about the role of KIR and 
HLA in mother-to-child transmission (MTCT) of HIV-1. Therefore, this thesis specifically 
explores KIR/HLA-ligand combinations in HIV-1 infected mothers and their infants, as well 
as the KIR/HLA-ligand relationship between mother and infant, in the context of MTCT of 
HIV-1. The study of HIV-1 exposed uninfected (EU) infants in comparison with HIV-1 
in utero (IU) or intrapartum (IP) infected infants provides important information regarding 
the correlates of protection and/or susceptibility to HIV-1 acquisition. Moreover, having data 
on HIV-1 transmitting (TR) and non-transmitting (NT) mothers may also highlight maternal 
factors that increase or decrease HIV-1 transmission. 
 
Using samples from two distinct previously recruited Black South African mother-infant 
cohorts (MTCT1, N=217 and MTCT2, N=79) which differed in terms of antiretroviral 
therapy (ART) regimens (monotherapy and dual therapy, respectively) and overall rate of 
HIV-1 transmission (9.8% and 5.2%, respectively), KIRs and HLA-ligands (HLA-A, -B, -C 
and -G) were genotyped. Given the costly and laborious nature of both KIR genotyping by gel 
electrophoresis and HLA genotyping using a sequence based typing method, we developed, 
validated and published a real-time PCR detection assay that allowed for the quick, easy and 
cost effective detection of all 16 KIRs and their respective HLA-ligands (HLA-A, -B, -C). 
Thus, these real-time KIR and HLA-ligand PCR assays were used to genotype the second 
cohort, MTCT2, while MTCT1 samples were previously genotyped using the commercial 
Olerup KIR genotyping kit and published HLA-B and -C genotyping methods (Paximadis et 
al., 2011). Therefore, using these methods, the following were investigated (1) the effect of 
paired KIR/HLA gene combinations amongst mother and infant, (2) the role of KIR2DS4 
allelic variance, and (3) the role of the HLA-G (the HLA-ligand for KIR2DL4) in vertical 
transmission of HIV-1. 
 
We identified that certain KIR/HLA-ligand combinations between mother and infant are able 
to influence the risk of vertical transmission of HIV-1. In MTCT1, concordance amongst 
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mother and infant for KIR2DL3/KIR2DL3 in combination with C2/C2 significantly increased 
the risk for IP transmission (P=0.043, OR=4.48), while “matched” allorecognition between 
infant KIR2DL2/KIR2DL3 genotype with cognate HLA-C1/C1 ligands from the mother 
significantly associated with increased risk for IU acquisition of HIV-1 (P=0.047, OR=4.02). 
Moreover, both these associations maintained significance post adjustment for maternal viral 
load (VL) and ART administration. In MTCT2, where NT and TR mothers were matched 
according to VL, CD4+ T cell count and ART regimen, only one KIR genotype showed a 
significant association with risk of MTCT. Both IU-TR and IP-TR mothers had significantly 
higher representation of the Bx32 genotype compared to NT mothers (P=0.005 and P=0.038, 
respectively). Interestingly, although the AA1 haplotype was significantly under-represented 
in the maternal group compared to the infant group (13.9% vs. 33.7%, P=0.005), and the 
AA1 haplotype frequency was significantly lower in MTCT2 mothers compared to MTCT1 
mothers (13.9% vs. 27.2%, P=0.029), the AA1 haplotype did not significantly associate with 
risk of vertical transmission.  
 
Regarding HLA-ligand (HLA-A, -B and –C) comparisons, in MTCT2 both maternal and 
infant possession of HLA-A Bw4:80I significantly increased the risk for IU transmission and 
IU acquisition of HIV-1 (P=0.005, OR=3.67 and P=0.001, OR=7.99, respectively). 
Moreover, the risk of maternal IU transmission remained significant when KIR3DL1 was 
present (i.e. KIR3DL1+Bw4:80I, P=0.039, OR=6.25). Thus, these findings highlighted that 
the presence or absence of particular KIR genes and their HLA-ligands in mother and infant, 
and the KIR/HLA-ligand pairings between mother and infant could influence the risk of 
HIV-1 transmission.  
 
The influence of KIR allelic variance in transmission of HIV-1 is largely unknown, and no 
studies have addressed this in the context of MTCT of HIV-1. Thus, we evaluated the 
singular activating KIR gene that is present in the group A haplotype, KIR2DS4, as allelic 
variants of KIR2DS4 can encode either functional membrane bound (KIR2DS4-f) or non-
functional truncated (KIR2DS4-v) receptors. In MTCT1, we identified that maternal 
possession of KIR2DS4-f but absent in their infants (i.e. M+I- discordance) increased the risk 
for IP transmission (P=0.005, OR=3.84). While infant possession of KIR2DS4-v significantly 
increased the risk for IU acquisition of HIV-1 (P=0.022, OR=2.88) and this was enhanced 
when infants were homozygous for the group A haplotype (P=0.004, OR=18.40). In MTCT2, 
although the frequencies of KIR2DS4 variants did not significantly differ in the maternal, 
infant and paired mother-infant TR and NT groups, in infants there was a weak trend towards 
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higher representation of KIR2DS4-f in IU infected infants compared to EU infants (P=0.080, 
OR=2.61). Scatter plot comparisons of maternal KIR2DS4-v and the AA1 haplotype showed 
that the two MTCT cohorts differed considerably and this difference was largely due to the 
maternal AA1 haplotype. It could be postulated that the lack of a significant KIR2DS4 
association in MTCT2 was because other activating KIR genes or Bx haplotypes may be 
negating the effects of KIR2DS4 variants evident in MTCT1. Overall, these data highlighted 
the importance of evaluating KIR alleles in HIV-1 transmission.  
 
In addition, given that HLA-G is an immunotolerogenic molecule primarily expressed at the 
maternal-foetal interface and it is the cognate ligand for the framework KIR gene, KIR2DL4 
(virtually present in all individuals), we questioned whether HLA-G alleles and/or 
polymorphisms with the 3‟ untranslated region (UTR) of HLA-G might influence vertical 
transmission of HIV-1 in our two mother-infant cohorts. In MTCT1, we identified two 
independent HLA-G factors that associated with increased risk for maternal IU transmission: 
G*01:01:02 allele (P=0.036, OR=2.26) and the 3‟ UTR1 haplotype (P=0.011, OR=2.96). 
Linkage disequilibrium (LD) analysis identified that G*01:01:02 was in strong LD with a 
14-bp insertion (Ins) within the 3‟UTR, and G*01:01:01 was in strong LD with the UTR1 
haplotype that included several polymorphisms that have been associated with higher 
expression of HLA-G, including a 14-bp deletion (Del). While maternal HLA-G associated 
with risk of HIV-1 transmission, infant HLA-G alleles and 3‟UTR haplotypes were not found 
to associate with risk of HIV-1 acquisition. Therefore, for the MTCT2 cohort we selected to 
focus exclusively on maternal HLA-G polymorphisms. Interestingly, maternal possession of 
HLA-G genotype G*01:01:01/G*01:04:04 (in strong LD with the UTR1 and UTR3 
haplotypes) associated with increased risk for IP transmission (P=0.001 OR=29.2). In 
addition, the frequency of the UTR1 haplotype was significantly higher in IP-TR mothers 
compared to NT mothers (P=0.024, OR=3.27). These findings suggest that maternal HLA-G 
alleles and/or polymorphisms within the 3‟UTR that might alter expression of HLA-G 
potentially influence risk of mother-to-child transmission of HIV-1.  
 
To conclude, these immunogenetic findings add further to our understanding of factors that 
contribute to the vertical transmission of HIV-1 and highlight the importance of genetic 
studies in future attempts to unravel the influence of host genes in an ever-changing 
environment of antiviral drug usage for HIV-1 prevention.  
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CHAPTER 1 
Literature Review 
 
1.1 Introduction 
It has been more than three decades since the discovery of the human immunodeficiency 
virus (HIV) as the causative agent of acquired immunodeficiency syndrome (AIDS); however 
HIV/AIDS continues to be a global health concern. It is estimated that more than 25 million 
people have died of AIDS and more than 33 million are currently living with HIV/AIDS 
(Dieffenbach and Fauci, 2011). Sub-Saharan Africa remains the region most heavily affected 
by HIV and accounts for more than two thirds of all people living with HIV (UNAIDS, 
2011). 
 
South Africa was ranked as the country having the most people living with HIV/AIDS in 
2011, with an estimated figure of 5.6 million (UNAIDS, 2012). In the same year, over 
2 million deaths were attributed to AIDS related causes, and, while this number reflects many 
lives lost, this was still less than the figure reported in 2001, demonstrating the vast 
improvement in HIV-attributed mortality through the provision of antiretroviral therapy 
(ART). Nevertheless, HIV prevalence remains high at 17.3% with greatest burden amongst 
young adults, particularly, women. Approximately one in three women aged 25-29 are living 
with HIV, more than four times greater than that of men in the same age group. In addition, 
HIV in women is the leading cause of HIV infection in children, primarily acquired through 
vertical transmission of the virus from mother to child (Newell, 1998). 
 
Prior to preventative mother-to-child transmission (PMTCT) intervention, such as ART and 
selective caesarean section before labour and/or membrane rupture, MTCT rates ranged from 
12-45% (Bryson, 1996). This is surprisingly low in comparison to other congenital viral 
infections, such as rubella (Louvain de Souza et al., 2012). These HIV-1 seronegative and 
polymerase chain reaction (PCR) negative infants born to HIV-infected mothers represent a 
unique cohort of exposed but uninfected (EU) infants. Mechanisms that provide EU infants 
with “natural” protection/resistance to HIV-1 infection might provide relevant clues towards 
better vaccine and drug design. Recent evidence suggests that both virus and host factors play 
a role in MTCT. This study focuses on select host (both mother and infant) factors affecting 
the risk of MTCT, in particular the role of killer immunoglobulin like receptors (KIR) and 
their human leukocyte antigens (HLA) ligands. 
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1.2 The Biology of HIV Infection 
1.2.1 HIV Origin 
Based on genomic sequence similarity to simian immunodeficiency virus (SIV), two distinct 
types of HIV can be identified: HIV-1 and HIV-2. HIV-1 is the designation given to forms 
linked to SIV originating from the common chimpanzee, Pan troglodytes (SIVcpz,) and the 
gorilla, Gorrilla gorilla (SIVgor); and HIV-2 denotes human viruses related to virus from the 
sooty mangabey, Cercocebus atys (SIVsmm) (Sharp and Hahn, 2011, Hemelaar, 2012). 
Cross-species transmission likely occurred as result of hunting and butchering of these 
primates for bushmeat and/or their capture and trade as pets. While both types of HIV share 
many similarities including their basic gene arrangement, the modes of transmission, 
intracellular replication pathways and the same opportunistic infections, HIV-2 is less easily 
transmitted and appears to progress more slowly than HIV-1 (Nyamweya et al., 2013). 
Globally, HIV-1 is the predominant virus, while HIV-2 is mainly found in West African 
nations, such as Guinea Bissau, The Gambia, Senegal, Cape Verde, Cote d‟Ivoire, Mali, 
Sierra Leone, and Nigeria (Campbell-Yesufu and Gandhi, 2011). 
 
HIV-1 can be classified into four viral groups: M (main), N (non-M/non-O), O (outlier) and 
the newly discovered, P (Figure 1.1). These groups represent four separate introductions of 
SIV into humans. Group M accounts for the majority of HIV/AIDS cases, and can be divided 
into nine distinct subtypes (or clades) designated A, B, C, D, F, G, H, J and K. The clades E 
and I are no longer in use, as they likely resulted from the recombination of two viral 
subtypes, known as circulating recombinant forms (CRFs) (Robertson et al., 1995). Clade C 
is the most prevalent transmitted virus and its wide transmissibility is likely the result of a 
higher viral set point and higher viral load (VL) in the genital fluids compared to other clades 
(John-Stewart et al., 2005, Levy, 2009). Furthermore, clade C has been reported to be more 
frequently transmitted from mother-to-child compared to clade D, which in turn is more 
frequently transmitted than clade A in the absence of ART (Renjifo et al., 2004). 
 
Molecular epidemiological studies show that there is a specific geographic distribution 
pattern for HIV-1 subtypes (Figure 1.1); and this distribution pattern seems to be the 
consequence of either accidental trafficking (viral migration), with a resulting 
“founder effect,” or a prevalent route of transmission, which results in a strong advantage for 
and local predominance of the prevalent subtype transmitted in that population (Buonaguro et 
al., 2007). 
Chapter 1: Literature review  3 
Phylogenetic tree of HIV & SIV HIV-1 Geographic distribution 
 
A Central Africa, sub-Saharan Africa 
B 
South America, Brazil, United States, 
Thailand, Europe, Caribbean, India, 
Japan 
C Brazil, India, South Africa 
D Central Africa, sub-Saharan Africa 
F 
Brazil, Romania, Democratic Republic of 
Congo (Zaire) 
G 
Democratic Republic of Congo (Zaire), 
Gabon, Thailand, Russia, Central Africa 
H 
Democratic Republic of Congo (Zaire), 
Gabon, Russia, Central Africa 
J 
North, Central and West Africa, 
Caribbean 
K 
Democratic Republic of Congo (Zaire), 
Cameroon 
Figure 1.1 Phylogenetic tree of the SIV and HIV viruses as well as the geographic 
distribution of HIV-1 group M subtypes A D, F–H, J and K. Reproduced and modified from 
(Hemelaar, 2012). 
 
1.2.2 HIV-1 Life Cycle 
HIV-1 is an enveloped retrovirus from the Lentivirus genus. Characteristic of HIV-1 and 
other retroviruses are their ability use reverse transcriptase (RT), a DNA polymerase enzyme, 
to transcribe single-stranded RNA into single stranded DNA. Typical lentivirus infections 
show a chronic course of disease, with a long period of clinical latency, persistent viral 
replication and involvement of the central nervous system (Fanales-Belasio et al., 2010). The 
HIV-1 virion is about 110 nm in diameter and has a cone-shaped viral core that contains two 
single stranded RNAs of approximately 9.2 kb in length as well as the enzymes reverse 
transcriptase, protease, ribonuclease and integrase, all encased in an outer lipid envelope. The 
genome consists of nine genes, including two regulatory (rev, tat), four accessory (vif, vpu, 
nef and vpr) and three structural (env, gag and pol) genes.  
 
HIV-1 infection is usually initiated with a single virion infecting a target cell upon entry 
across the mucosal lining of either genital, rectal or oral tract (Coffin and Swanstrom, 2013). 
In Figure 1.2, HIV-1 uses its envelope glycoproteins, gp120 and gp41 to bind to target cells, 
CD4+ T cells and/or monocytes, macrophages, and dendritic cells. Both proteins undergo a 
conformational change allowing gp120 to interact with either an α- or CXC-chemokine or 
β- or CC-chemokine coreceptor, CXCR4 or CCR5, respectively, depending on viral tropism. 
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Macrophage-tropic isolates tend to use CCR5 for cellular entry, while T cell tropic isolates 
tend to use CXCR4 (Gorry and Ancuta, 2011). Following chemokine coreceptor engagement, 
other conformational changes are then initiated to expose the binding domain of the 
transmembrane protein, gp41. This change forms a stable structure that allows fusion of HIV 
and host cell membrane, with a fusion pore through which the viral core can enters the host 
cell cytoplasm (Simon et al., 2006).  
 
Once in the host cell cytoplasm, the viral core disassembles and the viral RNA is reverse 
transcribed into single-stranded DNA by RT. The single-stranded DNA is again reverse 
transcribed and synthesized as double-stranded DNA (Moss, 2013). Of note, in comparison to 
other viral and host DNA polymerases, HIV-1 RT lacks “proof-reading” ability and is 
extremely error prone (Preston et al., 1988, Roberts et al., 1988) and is thus responsible for 
the high mutation and recombination rates of HIV-1. This ability allows HIV-1 to evolve 
rapidly in response to selection pressures either within individual hosts or within populations 
(Zhang et al., 2010b).  
 
At the midpoint of infection, double-stranded viral DNA enters the nucleus and integrates 
with the host‟s chromosomal DNA by means of the viral enzyme, integrase. The integrated 
viral genome, or proviral DNA, is then transcribed by the cellular RNA polymerase II into 
messenger RNA (mRNA) when NF-kβ binds to proviral long terminal repeats (LTRs) that 
flank the viral genome. Transcribed mRNA is then spliced and results in the translation of 
viral proteins (Tat, Rev, and Nef). The Rev protein assists in transporting singly spliced or 
unspliced RNA transcripts into the cytoplasm, where mRNA is translated into structural 
HIV-1 proteins (i.e. the nucleocapsid). The nucleocapsid then associates with genomic viral 
RNA, which is followed by processing of several Gag polyproteins that assemble at the 
plasma membrane to initiate budding.  
 
The released virion undergoes subsequent processing of viral proteins by viral protease to 
transform the immature virion into a mature infectious virion, ready to infect other cells. 
However, in some cases viral budding from monocytes and macrophages results in 
intracellular vacuoles which remain in the host cell resulting in latent reservoirs of HIV-1 
(Fanales-Belasio et al., 2010). This creates one of the greatest challenges in the combat 
against HIV-1 infection, as ART is ineffective at targeting these reservoirs. 
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Figure 1.2 The main steps in the HIV-1 replication cycle: (1) binding to the CD4 receptor and 
co-receptors; (2) fusion with the host cell membrane; (3) uncoating of the viral capsid with 
release of the HIV RNA and proteins into the cytoplasm; (4) reverse transcription of HIV RNA to 
DNA; (5) formation of the pre-integration complex (PIC) and translocation into the nucleus; 
(6) provirus integration and protein synthesis; (7) viral proteins that translocate to the cell surface 
to assemble into new immature virus forms; (8) budding and (9) maturation. Also shown are the 
major families of antiretroviral drugs (green) and the step of the life cycle that they block; host 
HIV restriction factors (pink); and their corresponding viral antagonists (blue). CCR5, CC-
chemokine receptor 5; LTR, long terminal repeat; NRTIs, nucleoside reverse transcriptase 
inhibitors; NNRTIs, non-nucleoside reverse transcriptase inhibitors. Reproduced and modified 
from (Barre-Sinoussi et al., 2013). 
 
1.2.3 HIV-1 Pathogenesis 
Transmission of HIV-1 is a function of both where the virus appears in the body and how it is 
shed (Klatt, 2013). HIV-1 can be present in a variety of body fluids and secretions, such as 
blood, semen, vaginal fluid, pre-seminal fluid or breast milk and as such transmission can 
occur through sexual intercourse (anal, vaginal or oral), blood transfusion, intravenous drug 
use as well as mother-to-child transmission (MTCT, further discussed in section 1.3). 
Worldwide, sexual transmission across the genital mucosa accounts for the majority of cases 
of HIV-1 infection. Moreover, risk of HIV-1 sexual transmission as well as acquisition is 
increased when a person has a sexually transmitted disease (STD), as large amounts of HIV 
can be found in ulcers and the genital fluid of those infected with genital herpes, syphilis, and 
gonorrhoea (Moss, 2013). In addition, other factors include high viral load (VL) of the index 
partner, anal vs. vaginal intercourse and lack of male circumcision. Nevertheless, in each of 
the transmission routes exchange of fluids with either cell-free or cell-associated virus is 
1
2
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necessary for transmission. It has been suggested that cell-associated viruses may be the more 
efficient mediators of transmission because they can continue releasing virus while 
penetrating deeply into the recipient's tissues, whilst cell-free virus would need to cross the 
mucosal barriers of the genital tract as well as gain access to a suitable target cell (Jennes and 
Kestens, 2014). 
 
Clinically, there are three major phases of adult HIV-1 infection: acute, chronic, and AIDS 
(Figure 1.3). The eclipse phase is the initial stage of the acute infection before systemic viral 
dissemination. Within the first week, HIV is freely replicating and spreading from the initial 
site of infection, and viraemia is not yet detectable (Coffin and Swanstrom, 2013). This phase 
is followed by the acute phase (also known as primary infection) which is characterized by 
flu-like symptoms with fever, fatigue, muscle aches, nausea and/or diarrhoea (which may 
persist for 1 to 2 weeks). Acute infection is marked by high viraemia of up to 10
6
 copies of 
viral RNA per millilitre of blood, peaking one to two weeks after infection and severe 
CD4+ T cell loss. At this time point, the immune response starts to appear in the form of 
HIV-1 antibodies (known as seroconversion) and cytotoxic T-lymphocytes (CTLs, in the 
form of CD8+ T cells) that target HIV-1 antigens expressed on infected cells (Coffin and 
Swanstrom, 2013). During this acute phase of peak viraemia, the high titres of HIV-1 can be 
detectable in the blood using a p24 antigen test; however, HIV antibody tests (such as 
enzyme immunoassay) are often negative in the first three weeks (Klatt, 2013). Individuals in 
this stage of infection are the most infectious because of the high VL in blood and genital 
secretions, correspondingly, over half of all HIV infections may be transmitted during this 
period (Shaw and Hunter, 2012).  
 
At the end of the acute phase there is a marked drop in VL with the establishment of a viral 
set point, likely as the result of partial immune control as well as exhaustion of activated 
CD4+ T cells. Viral set point has been inversely associated with the rate of disease 
progression (Mellors et al., 1995). The asymptomatic chronic phase, or the latency period, 
ranges from 1-10 years and is distinguished by a constant, slow level of viraemia with a 
gradual decrease in CD4+ T cells (Bashirova et al., 2011). The final stage, AIDS, is 
characterised by progressive loss of the CD4+ T cells below 200 cells/l of blood, severe 
impairment of immune function and high levels of viraemia; consequently, allowing 
opportunistic infections (such as Candidiasis, cytomegalovirus and herpes simplex virus), 
neurological complications (AIDS dementia complex), and neoplasms (Kaposi‟s sarcoma) 
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that would seldom occur in persons with intact immune function (Hutchinson, 2001). On 
average, there is a period of 8 to 10 years from initial infection to clinical AIDS in adults, 
although about 10% of persons will rapidly progress to AIDS in 2 to 3 years following HIV 
infection (Klatt, 2013). Typically, the survival time of an untreated individual diagnosed with 
AIDS is approximately 1 year but can vary according to the AIDS defining condition. 
 
 
Figure 1.3 The clinical course of adult HIV-1 infection showing the dynamics of peripheral 
blood CD4+ T cell counts and plasma viral load during a typical course of HIV-1 infection. The 
three major phases of infection are shown: acute, chronic, and AIDS. Reproduced and modified 
from (Bashirova et al., 2011). 
 
1.3 Mother-to-child transmission (MTCT) of HIV-1 
MTCT of HIV-1, also termed vertical or perinatal transmission, is the spread of HIV-1 from 
an HIV-1-infected woman to her child during pregnancy (in utero), labour and/or delivery 
(intrapartum), or breastfeeding (post partum) (Ahmad, 1996, Newell, 1998, UNAIDS, 1998). 
In the absence of intervention, the overall risk of HIV-1 MTCT is approximately 15-30% 
during pregnancy and/or labour, with an additional risk of 10-20% with prolonged 
breastfeeding (Teasdale et al., 2011), making MTCT of HIV-1 the major contributor of 
HIV/AIDS in children. It is estimated that of the 35 million people living with HIV-1, 
3.3 million are children (UNAIDS, 2013). Moreover, in 2012, the overall HIV-1 prevalence 
estimate among antenatal women in South Africa was 29.5% (one of the highest in the world) 
with 260,280 pregnant women requiring treatment for prevention of mother-to-child 
transmission (PMTCT) of HIV-1 (National Department of Health, 2012). Without effective 
Onset of
symptoms
Opportunistic
infections
Appearance of
antibodies and CTLs
Death
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treatment, morbidity and mortality among infants born to HIV-1-positive women is high 
(Kuhn et al., 2005), and more than half of all infants born with HIV-1 will die before their 
second birthday (WHO, 2010). 
 
Clinically paediatric HIV-1 infection differs markedly from adult HIV-1 infection. In the 
weeks following acute infection in adults, plasma viraemia decreases by 100 to 1000-fold and 
is relatively stable at this „viral load set-point‟ for many years; however, during the first few 
months post-infection, infant plasma viraemia generally increases 10-fold to levels that are 
much higher than those in adults (Tobin and Aldrovandi, 2013). Disease progression is 
generally faster with rapid decline of CD4+ T cells and onset of recurrent infections, failure 
to thrive and delayed neurodevelopment (Muenchhoff et al., 2014). Moreover, the timing and 
route of infant infection also influences the disease progression; IU infants were reported to 
have a median survival time of 208 days compared to 380 days for infants infected at birth or 
> 500 days for infants with postnatal infection (Marinda et al., 2007). Similarly, premature 
infants delivered prior to 34 weeks gestation were twice as likely to become infected IP or PP 
through breast milk than full term infants born after 37 weeks of gestation (Fawzi et al., 
2001). While the exact reasons for these differences remain unknown it has been suggested 
that infant immunologic immaturity, high viraemia and/or the rapid expansion of CD4+ T 
cells that accompany somatic growth drive increased disease progression (Tobin and 
Aldrovandi, 2013). In agreement with this, peak viraemia was found to be lower in 
postnatally infected children compared to IP-infected children, suggesting that improved viral 
control may be due to the more mature immune system (Obimbo et al., 2009, Muenchhoff et 
al., 2014). 
 
Nevertheless, effective PMTCT and ART have transformed paediatric HIV-1 into a chronic 
disease. In South Africa, PMTCT guidelines were amended to the World Health 
Organization (WHO) 2010 guidelines and since then MTCT rates have dropped dramatically 
to 2.7% in 2011 (Goga et al., 2012). Early virologic suppression due to ART has been 
associated with normalization of B and T-cell numbers and function as well as enhanced 
immunologic recovery. Moreover, early ART may also influence the size and half-life of 
latent-viral reservoirs established early in infection, as is evident in the case of the 
„Mississippi Child‟ who was IU-infected and appeared to have been “functionally cured” 
after the early initiation of ART (Persaud et al., 2013). In this scenario, the infant initiated 
ART within 30 h of life and stayed on ART until 18 months of age when ART was 
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discontinued by the mother. However, in subsequent visits to the clinic half a year later and in 
the successive follow-up period, VL remained undetectable in the absence of ART and 
showed no signs of ongoing viral replication or HIV-1 specific T-cell or antibody responses 
were detected, thus presenting as “functionally cured.” Unfortunately though, after > 2 years 
follow up with undetectable HIV-1 RNA levels in the absence of ART, there was a rebound 
viraemia in this child. Nevertheless, this case still represents hope that one day novel 
therapeutic strategies can be developed to target the viral reservoir to potentially achieve 
drug-free remission. It should be noted that despite the current PMTCT strategies and ART 
for HIV-1-infected women and their children, in the absence of ART large proportions of 
infants remained HIV-1-uninfected and appeared to have “natural protection”. These exposed 
uninfected (EU) infants seem to evade infection despite an immature immune system and, in 
the case of breastfeeding prolonged repetitive, exposure (Tobin and Aldrovandi, 2013). Thus, 
the study of the mechanisms of natural resistance to HIV-1 in these EU infants might aid in 
the development of an effective HIV-1 vaccine.  
 
1.3.1 Modes of MTCT 
While the exact mechanisms and timing of MTCT remains poorly understood, three stages of 
MTCT have been defined based on the detection of viral DNA in the infant‟s blood, namely: 
in utero (IU), intrapartum (IP) and post-partum (PP). HIV-1 detection by DNA PCR in 
infant's blood collected at birth suggests that transmission occurred prior to delivery and 
indicates IU transmission, while IP transmission is considered if DNA PCR is negative at 
birth but positive 6 or more days later in the absence of breastfeeding. However, in breastfed 
infants the timing of IP or PP transmission can be difficult, although it is generally assumed 
that PP infected infants are DNA PCR negative at birth but positive approximately 3 to 5 
months later within the breastfeeding period (Toth et al., 2001). Knowledge about the timing 
of transmission and factors involved is crucial to planning of intervention strategies to 
decrease vertical transmission (John and Kreiss, 1996). 
 
1.3.1.1 In utero (IU) transmission 
Despite 9 months of exposure at the maternal-foetal interface and evidence of bi-directional 
cellular trafficking between mother and foetus, only 5–10% of children become IU-infected, 
demonstrating that IU or transplacental HIV-1 transmission is the least efficient form of 
MTCT (Tobin and Aldrovandi, 2013). Nevertheless, a number of maternal, infant and viral 
factors have been found to increase the risk of IU transmission, of which the strongest 
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evidence for an association includes high maternal VL and the presence of ascending 
infections with chorioamnionitis (inflammation of the foetal membranes) (Lehman and 
Farquhar, 2007, Ellington et al., 2011, Tobin and Aldrovandi, 2013). High maternal VL 
during primary HIV-1 infection has been consistently associated with increased risk of 
MTCT, especially in the absence of ART (Magder et al., 2005, Taha et al., 2011). In a South 
African study, women who seroconverted during pregnancy were shown to be 2.3 times more 
likely to transmit HIV-1 to their infants as opposed to women with established HIV-1 
infection (Moodley et al., 2011). Similarly, women acquiring HIV-1 post partum were 
reported to have a two-fold increased risk of transmitting HIV-1 via breast milk (Dunn and 
Newell, 1992), suggesting that primary infection increases the risk of transmission. 
Additionally, co-infections with sexually transmitted infections (STIs), such as syphilis and 
gonorrhoea, have also been associated with increased risk for IU transmission. These 
ascending bacterial infections cause inflammation of the placenta, chorion and amnion and 
possibly allow the migration of HIV-1-infected maternal cells into the amniotic cavity, 
predisposing infants to HIV-1 acquisition (Chi et al., 2006, Lehman and Farquhar, 2007).  
 
Similarly Kumar et al. (2012) found an association between elevated levels of 
interleukin (IL)-4, IL-5, IL-6, IL-7, IL-9, eotaxin, IL-1Ra and interferon gamma-induced 
protein 10 (IP-10) in placental plasma and IU transmission, but not IP transmission. 
Moreover, IP-10 levels were independently associated with IU MTCT, and this association 
remained after controlling for maternal CD4+ T cell count and other confounding variables 
such as maternal age and gestational age (Kumar et al., 2012). Despite these two important 
factors that contribute to the risk IU transmission, interestingly, infant gender has also been 
implicated. Several reports found female infants to have a twofold increased risk of HIV-1 
infection at birth when compared to male infants (Galli et al., 2005, Taha et al., 2005, Biggar 
et al., 2006b). It was suggested that Y chromosome-derived antigens, present in male and 
absent in female foetuses, activate maternal lymphocytes and either cause release of 
cytokines that have direct antiviral effects or limit maternal HIV-1-infected lymphocyte 
survival in male infants (Biggar et al., 2006b). Other evidence of IU transmission comes from 
(1) the early detection (as early as 8 weeks gestation) of HIV-1 in foetal specimens, placental 
tissue and amniotic fluid, (2) viral isolation from 20-60% of infected infants at the time of 
birth, (3) the presence of p24 antigen in foetal serum and (4) IU onset of symptomatic HIV-1 
disease (Sprecher et al., 1986, Mundy et al., 1987, Rudin et al., 1993, Newell, 1998, 
UNAIDS, 1998). However, others have suggested that a high proportion of IU infections 
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occur over the last 1 to 2 months of pregnancy (Chouquet et al., 1999) or in the days just 
before delivery (Rouzioux et al., 1995, Kourtis et al., 2001, Lehman and Farquhar, 2007). In 
both cases, infants have detectable virus within the first 48 hours of birth (Bryson et al., 
1992).  
 
1.3.1.2 Intrapartum (IP) transmission 
In the absence ART, the majority of MTCT occurs at the time of delivery (Tobin and 
Aldrovandi, 2013). The primary factors that influence IU transmission, such as high maternal 
VL and chorioamnionitis, have also been associated in IP transmission; however, other 
factors that have been found to increase IP transmission. These include viral subtype and 
level of viral shedding in genital tract, the presence of genital ulcers, maternal-foetal 
microtransfusions (i.e. placental tears) as well as complications during delivery, such as 
prolonged membrane rupture and cervicovaginal lacerations (Lehman and Farquhar, 2007). 
IP transmission risk was higher in pregnant women infected with HIV-1 subtype C than were 
those infected with subtype A or D, because of increased shedding of HIV-1-infected vaginal 
cells (John-Stewart et al., 2005) as well as  mothers having high cervicovaginal VL and the 
presence of genital ulcers (John et al., 2001). In addition, when there was damage to the 
placental barrier, maternal–foetal microtransfusions increased the risk for IP MTCT (Kwiek 
et al., 2006). In each of these, IP transmission likely occurs when there is (1) direct contact of 
the foetus/infant with infectious maternal blood and genital secretions during passage through 
the birth canal, (2) through ascending infection from the vagina or cervix to the foetal 
membranes and amniotic fluid, and/or (3) through absorption in the foetal–neonatal digestive 
tract (Nielsen et al., 1996).  
 
Early evidence of IP transmission came from the study of twins born to HIV-1 infected 
mothers which reported that the first born twin had a two-fold higher risk of contracting 
HIV-1 than the second born twin (Goedert et al., 1991). The authors suggested that the 
increased risk of HIV-1 transmission in the first born twin was likely due to increased 
exposure to infected blood and/or mucus in the birth channel, or if surgical delivery followed 
rupture of the mother's membranes, the first born twin (who would be closer to the uterine 
opening) would also have greater exposure to material fluids entering the uterus.  Therefore, 
Goedert et al. (1991) proposed that risk of MTCT may be reduced by performing surgical 
deliveries before membranes rupture. Since then elective caesarean section before the onset 
of labour and/or membrane rupture has reduced the incidence of IP transmission (The 
European Collaborative Study, 1994, Kourtis et al., 2001, Teasdale et al., 2011). 
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1.3.1.3 Post-partum (PP) transmission 
While the mechanism of PP transmission is still not completely understood, breast milk 
HIV-1 transmission, like sexual transmission, depends on (1) breaching an epithelial barrier 
that limits the amount of HIV-1 in the transmitting fluid, (2) remaining in an infectious form 
within the secretion, and (3) traversing another mucosal surface to infect a new host (Tobin 
and Aldrovandi, 2013). More importantly, these are dependent on HIV-1 viral levels in breast 
milk and the duration of breastfeeding. HIV-1 in breast milk can originate either from blood 
cell–free virus released into breast milk or can be produced by local replication in 
macrophages and in ductal and alveolar mammary epithelial cells, as such HIV-1 can be 
detected both in the cellular compartment of breast milk and in cell-free milk, and is at its 
highest concentration in the colostrums (Bulterys et al., 2010). In general, breast milk HIV-1 
RNA concentrations are 2–3 log10 lower than levels in plasma, ranging from undetectable to 
greater than 10
5
 log10 copies/ml, and are highly correlated with plasma HIV-1 VL (Rousseau 
et al., 2003a). Additionally, the presence of mastitis (clinical or subclinical) or breast abscess 
can also increase breast milk virus levels and PP MTCT risk (John et al., 2001).  
 
Without ART, PP transmission accounts for 5-20% of MTCT (WHO et al., 2013), but with 
extended breastfeeding the risk of PP MTCT increased due to its cumulative nature (Fowler 
et al., 2012). In high-income countries where clean water is available WHO 2013 guidelines 
recommend that breastfeeding be avoided completely and infants be given commercial infant 
formula; in addition, these infants are also treated with once daily nevirapine (NVP) or twice 
daily azidothymidine (AZT) for 4 to 6 weeks (WHO et al., 2013). However, in low- and 
middle-income countries (where there is little access to clean water, sanitation and health 
services), early weaning prior to 6 months was associated with increased infant morbidity and 
mortality due to diarrheal disease, pneumonia, and other infectious diseases (Kafulafula et al., 
2010). Furthermore, abrupt weaning was associated with increased risk of PP transmission if 
infants resumed breastfeeding after a period of cessation due to elevated levels breast milk 
VL (Thea et al., 2006). Thus, the WHO in 2013 revised the PMTCT guidelines and 
encouraged mothers who chose to breastfeed to do so exclusively for 6 months and if they 
could then safely use breast milk substitutes, wean over several weeks and then stop 
breastfeeding if suitable breast milk substitutes can be safely used and sustained. Mothers 
who cannot provide safe breast milk substitutes at 6 months should continue breastfeeding for 
12 months or longer, along with providing nutritious locally available complementary foods. 
During this period, infants are also given once daily NVP for 6 weeks or the duration of 
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breastfeeding (WHO et al., 2013). In these resource limited settings breast milk provides 
nutrients and antibodies that protect the infant from childhood diseases; where replacement 
feeding with unsafe water puts the infant at greater risk for gastrointestinal diseases. 
Moreover, mixed feeding with the early introduction of non–breast milk foods was associated 
with a increased risk of transmission, likely due to the delayed closure of the enterocyte 
junctions in the intestinal mucosal barrier, or, alternatively, from intestinal immune activation 
resulting from early introduction of foreign antigens or pathogens (Bulterys et al., 2010). 
Current WHO guidelines now recommended that ART be provided for all pregnant and 
breastfeeding mothers; thus, breastfeeding is highly recommended in low- and middle-
income countries. However, a caveat to this is that there must be 100% adherence to taking 
the drugs correctly, otherwise there is a risk that the baby can become infected with HIV-1 or 
become infected with drug-resistant virus (Fogel et al., 2011). 
 
1.3.1.4 The exposed uninfected (EU) infant 
Through successful implementation of PMTCT policies, children born to HIV-1 infected 
mothers are now much less likely to acquire HIV-1 infection and MTCT rates have been 
reduced from 30% to 2.7% (Afran et al., 2014). However, even in the absence of ART large 
proportions of infants escape infection and are called exposed-uninfected (EU) infants. These 
EU infants seem to have “natural protection” and have raised many questions: Why does 
HIV-1 transmission not occur effectively in every mother-infant pair? What is different in 
transmitting versus non-transmitting mothers? What is different in highly exposed HIV-1 
uninfected children versus those who get infected? (Louvain de Souza et al., 2012). 
 
EU infants are not the only ones who “escape” HIV-1 infection;  a number of individuals 
with vastly different exposure profiles have also been reported, including health care workers 
with occupational exposure (Pinto et al., 1995), seronegative heterosexual or homosexual 
partners of subjects with HIV-1 infection (Clerici et al., 1992, Goh et al., 1999), commercial 
sex workers (CSW) (Fowke et al., 1996, Rowland-Jones et al., 1998, Songok et al., 2012), 
and intravenous drug users (Scott-Algara et al., 2003). Other terms that have been used to 
describe these individuals that resist infection despite multiple high risk exposure include: 
exposed seronegative persons (ESP), highly exposed persistently seronegative (HEPS) or 
highly exposed seronegative (HESN). Thus, studies of persons who remain uninfected 
despite extensive exposure to HIV-1 continue to provide valuable information on 
mechanisms of natural protection, which can then be applied to both novel drug and vaccine 
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design (Kulkarni et al., 2003). However, despite their escape from HIV-1 infection, there is 
an increasing body of evidence that EU infants/children suffer immunologic harm both with 
and without exposure to ART (Tobin and Aldrovandi, 2013). In resource-poor countries, EU 
children have higher mortality rates than do infants born to HIV-1 uninfected mothers, even 
when feeding patterns are similar (Newell et al., 2004). Nevertheless, these risks outweigh 
the mortality risk that is associated with being HIV-1 infected. 
 
1.3.2 Factors involved in MTCT 
Many factors have been identified to influence the risk of MTCT of HIV-1 (Table 1.1). 
Chief amongst these is high maternal VL and advanced disease (Kourtis and Bulterys, 2010). 
 
Viral factors 
High maternal VL (mVL), measured at delivery, has been described as the strongest risk 
factor for both IU and IP transmission (Mock et al., 1999). Similarly, in a multivariate 
Tanzanian study, mVL, CD4+ T cell count and clinical stage of infection were the most 
significant predictors of transmission, of which a mVL of 50 000 HIV-1 RNA copies/mL or 
more at delivery was associated with a four-fold increase in the risk MTCT (Fawzi et al., 
2001). Correspondingly, higher mVL in the genital tract VL has also been independently 
associated with a higher risk of MTCT of HIV-1 (Tuomala et al., 2003). Likewise, adult 
transmission is also dependent on the biologic properties of the virus, its concentration in the 
exposed body fluid, and the nature of the host susceptibility both at the cellular and 
immunological levels (Levy, 2009). Furthermore, it has been reported that a strong genetic 
bottleneck occurs during MTCT of HIV-1. This is evident through population diversity and 
phylogenetic pattern analysis of the HIV-1 subtype C envelope glycoprotein, where a single 
viral variant appeared to be responsible for infection in the infants, and as a result the newly 
transmitted viruses were less diverse and harboured significantly less glycosylated envelope 
(Zhang et al., 2010a). This suggested that viruses with the restricted glycosylation in 
envelope glycoprotein appeared to be preferentially transmitted during HIV-1 subtype C 
perinatal transmission. Nevertheless, transmission of multiple variants have been described. 
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Table 1.1 Factors associated with risk of MTCT of HIV-1 
Factors  Description  
Viral 
Viral load in plasma, cervicovaginal tract and breast milk 
Viral genotype and phenotype 
Viral resistance to antiretroviral therapy 
HIV-1 co-receptor (tropism) 
Maternal 
Clinical stage of mothers infection (AIDS) 
Maternal CD4+ T cell count 
Nutritional status (vitamin A deficiency)  
Antiviral treatment 
Maternal immune factors (the level of neutralizing antibodies and cytokines) 
Sexually transmitted diseases (Herpes simplex virus type 2 and syphilis) 
Co-infections (malaria, TB) 
Behavioural factors (cigarette smoking, drug use) 
Cracked or bleeding nipples 
Clinical or subclinical mastitis 
The type of breast milk (colostrums vs. later milk) 
Duration of breast-feeding 
Obstetric 
Chorioamnionitis and placental pathology 
Prolonged membrane rupture 
Timing of delivery 
Mode of delivery 
Invasive monitoring (amniocentesis) and other obstetric procedures (forceps) 
Duration of labour 
Foetal/infant  
Genetic factors (mother-infant HLA concordance) 
Background infections 
Birth order 
Birth weight 
Breastfeeding  
Infant gastrointestinal maturity 
Foetal immune response 
Reproduced and modified from references (Bryson et al., 1992, The European Collaborative 
Study, 1994, Ahmad, 1996, Bryson, 1996, Nielsen et al., 1996, Newell, 1998, Garcia et al., 1999, 
Kuhn et al., 1999, Semba et al., 1999, The European Collaborative Study, 1999, International 
Perinatal HIV Group, 2001, Rousseau et al., 2003a, John-Stewart et al., 2004, Newell et al., 2004, 
Chen et al., 2005, John-Stewart et al., 2005, Chi et al., 2006, Kourtis and Bulterys, 2010, Ahmad, 
2011, Louvain de Souza et al., 2012). 
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IU transmitters were more likely to transmit single or multiple major maternal viral variants; 
whereas, IP transmitters were more likely to transmit minor HIV-1 variants, indicating that 
different selective pressures may be involved in determining the pattern of maternal HIV-1 
variant transmission (Dickover et al., 2001). Similarly in another study, viral sequences from 
the blood and cervicovaginal fluid from HIV-1 transmitting mothers were compared to those 
in their infants and showed the presence of more than one HIV-1 variant in the neonate‟s 
plasma that derived from the maternal blood and vaginal compartment (Kourtis et al., 2011). 
This suggested that more than one episode of transmission with more than one viral strain 
from different maternal compartments occurred, which included both cell-free and cell-
associated maternal virus. Other reports have also suggested that the HIV-1 subtype 
influences MTCT. In a Tanzanian study, subtype C was found to be preferentially transmitted 
IU when compared to subtypes A and D (Renjifo et al., 2004); while in Kenyan women, 
MTCT was more common among mothers infected with subtype D compared with subtype A 
(Yang et al., 2003). However, these findings have not been observed in other population 
groups (Martinez et al., 2006). 
 
Host/genetic factors 
Host factors can be broadly divided into innate and adaptive immune parameters and several 
components have been identified (Table 1.2). Innate factors include the chemokines and 
chemokine receptors. The -chemokines CCL3 (macrophage inflammatory protein 1α, 
MIP-1α), CCL4 (MIP-1β), and CCL5 (RANTES, regulated on activation, normal T cell 
expressed and secreted) are natural ligands for CCR5 and therefore chemokine receptor-
ligand interactions represent a barrier to HIV-1 binding to its coreceptor. Both qualitative and 
quantitative traits in either chemokine receptors or ligands have been described to influence 
susceptibility to HIV-1 MTCT (Louvain de Souza et al., 2012). 
 
A well-known genetic factor that has received considerable attention over the last decade is 
the CCR5 locus and its CCR532 (rs333) allele. The 32-bp deletion within the coding region 
of the CCR5 gene generates a premature stop codon that forms a truncated protein that is not 
expressed on the cell surface. In this manner CCR532 homozygosity has been found to 
confer near complete resistance to sexual transmission of HIV-1 infection by R5-type HIV-1 
isolates (Liu et al., 1996, Samson et al., 1996), as well as protection against MTCT (Philpott 
et al., 1999). In addition, individuals with at least one copy of CCR532 exhibit improved 
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resistance relative to wild-type individuals, and if heterozygotes do become infected, they 
have reduced HIV-1 VL with slowed progression to AIDS by an additional 2–3 years 
(Zimmerman et al., 1997). However CCR532 is rare and has an average allele frequency of 
10%, translating into a homozygote frequency of about 1% in Europeans of Caucasian 
descent, while being virtually absent in African and Asian populations (Martinson et al., 
1997).  
 
Additionally, other CCR5 single nucleotide polymorphisms (SNPs) have also been associated 
with protection against HIV-1 transmission in adults and with delayed progression to AIDS. 
In a Malawian MTCT study, two CCR5 SNPs, -2459G and -2135T, were found to be 
protective among infants of mothers with low mVL (Pedersen et al., 2007). The authors 
proposed that protection might be due to reduced expression of the CCR5 receptor but was 
dependent on a delicate ratio of virus to receptor, above which changes in the receptor 
concentration would have no effect on viral infectivity. Conversely, high expression of 
CC chemokines (the natural ligands for CCR5) in EU infants has suggested that chemokines 
may possibly have a role in mediating inhibition of MTCT. In fact, copy number variation 
(CNV) in CCL3L1 and CCL4L2 chemokine genes has been linked to HIV-1 susceptibility 
and  possessing a lower copy number of CCL3L1 (relative to population mean) is associated 
with increased risk of HIV-1 infection and with HIV-1 disease progression in adults 
(Gonzalez et al., 2005). CCL3L1 gene copy number also associated with CCL3 production 
and with vertical transmission (Meddows-Taylor et al., 2006). Moreover, high CCL3L1 gene 
copies in the infant, but not maternal, were associated with reduced HIV transmission (Kuhn 
et al., 2007), and conversely MTCT was greatest if mother and infant both had low CCL3L or 
CCL4L copy numbers (Shostakovich-Koretskaya et al., 2009). More recently, two CCL3 
haplotypes (Hap-A1 and Hap-A3) were found to influence MTCT (Paximadis et al., 2013). 
The authors reported that Hap-A1 in infants (which also associated with higher CCL3L copy 
number) associated with protection from IU HIV-1 infection, whereas, Hap-A3 in mothers 
was associated with increased risk of IP transmission. These studies highlight the importance 
of understanding the gene content and gene copy number in disease susceptibility and/or 
resistance. 
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Table 1.2 Genetic variations associated with risk of MTCT of HIV-1 
Gene Polymorphism  Carrier MTCT risk 
CCR5 
CCR532/CCR532 Infant Decreased 
CCR5/CCR532 Mother Decreased 
59029A or 59353T in promoter region  Infant Increased  
CCR2 CCR2- 64I Mother Decreased  
CXCL12 (SDF-1)  3‟ UTR 801A Mother Contradictory 
CCL3 Seven-SNP haplotype (Hap-A1) Infant Increased 
CCL3L1 Reduced gene copy number Infant Increased 
CCL4L2 Reduced gene copy number M-I Increased 
HLA-A 
HLA-A*23:01 Mother Increased 
HLA-A*2 (6802) Infant Decreased 
HLA-A*29 Infant Increased  
HLA-B 
HLA-B*18 Infant Decreased 
HLA-B*13:02 Mother Increased 
HLA-B*35 Infant No effect 
HLA-B*35:01 Mother Increased 
HLA-B*35:03 Mother Increased  
HLA-B*44:02 Mother Increased  
HLA-B*49:01 Mother Decreased 
HLA-B*50:01 Mother Increased  
HLA-B*53:01 Mother Decreased 
HLA-C 
HLA-Cw07 Infant Increased  
HLA-Cw08 Infant Increased  
TLR9 
Haplotype AA and GG of the c.4- 44G/A and 
c.1635A/G alleles 
Infant  Increased 
APOBEC3G  
rs8177832 A/G Infant No effect 
rs17496018 C/T Infant No effect 
FCGR2A  rs1801274 A/A Infant Increased  
Reproduced and modified from (Rowland-Jones et al., 1993, Rowland-Jones et al., 1995, Liu et 
al., 1996, Martinson et al., 1997, MacDonald et al., 1998, Philpott et al., 1999, Kulkarni et al., 
2003, Kuhn et al., 2004, Gonzalez et al., 2005, Paximadis et al., 2009, Shostakovich-Koretskaya 
et al., 2009, Kourtis and Bulterys, 2010, Ahmad, 2011, Ellington et al., 2011, Louvain de Souza 
et al., 2012).  
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Immune factors 
With regard to adaptive immune factors both humoral and cellular immune responses have 
been found to play an important part in influencing MTCT. Several studies have correlated 
the presence of neutralizing antibodies (nAbs) in maternal serum with protection from MTCT 
of HIV-1 (Scarlatti et al., 1993, Tranchat et al., 1999). Maternal anti-p24 and anti-gp120 
antibodies were inversely associated with vertical transmission rates (Pitt et al., 2000). Whilst 
in another study, IU-transmitting mothers were significantly less likely to have autologous 
NABS to their own HIV-1 strains at delivery compared to non-transmitting mothers 
(Dickover et al., 2006). Furthermore, both heteroduplex and phylogenetic analyses showed 
that there was selective MTCT and/or outgrowth of maternal autologous neutralization 
escape HIV-1 variants, which indicated that maternal autologous NABS could exert powerful 
protective and selective effects in perinatal HIV-1 transmission.  
 
With regards to cellular immune responses, a number of studies have identified HIV-1 
specific CD4+ and CD8+ T cell responses in HIV-1 exposed but uninfected individuals, with 
the suggestion that these specific responses are a correlate of immune protection from HIV-1 
infection. These HIV-1 specific responses have been observed and characterized in the 
Pumwani Kenyan cohort of sex workers both at systemic (Rowland-Jones et al., 1998, 
Alimonti et al., 2006) and mucosal levels (Kaul et al., 2000), in injecting drug users 
(Makedonas et al., 2002), in men who have sex with men (MSM) (Erickson et al., 2008) as 
well as EU infants (Rowland-Jones et al., 1993, McFarland et al., 1994, Kuhn et al., 2002). 
The detection of HIV-1 specific CTLs in ESN individuals thus seems to indicate that HIV-1 
has managed to initially infect the host, but that its further propagation has been contained by 
immune mechanisms and completely eliminated.  
 
In addition, specific HLA genes have also been implicated in risk of MTCT. One study found 
that mothers with HLA-B variants (B*13:02, B*35:01, B*35:03, B*44:02, B*50:01) 
transmitted HIV-1 to their infant even in the context of low VL, whereas mothers with other 
variants (B*49:01, B*53:01) did not transmit the virus despite high VL (Winchester et al., 
2004). Furthermore, since the infant shares at least half of his or her HLA genes with the 
mother, both cell-free and cell-associated HIV-1 virions of maternal origin display maternal 
HLA, then foetal/newborn anti-HLA antibodies or alloreactive T cell responses could 
potentially protect against infection from the mother, if there is some degree of HLA 
discordance between mother and child. Indeed, mother-infant HLA concordance has been 
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associated with increased risk of MTCT (MacDonald et al., 1998, Polycarpou et al., 2002, 
Mackelprang et al., 2008). These studies suggested that infants whose HLA matched their 
mothers may be less able to recognize HIV-1 that has evolved to evade maternal immune 
responses via HLA-mediated selection, or that matched HLA might decrease the likelihood 
of infant alloimmune responses against maternally derived lymphocytes in that HLA 
molecules on the surface of HIV-1 infected or uninfected maternal cells will be recognized as 
“self” by infant cytotoxic T lymphocytes or NK cells, and will thus be less likely to be 
destroyed (Mackelprang et al., 2008). In addition, children who were homozygous or who 
shared both alleles with their mothers at more than one HLA class I locus were more likely to 
progress to AIDS or death than other children (Kuhn et al., 2004), which suggested the level 
of mother-infant concordance may compromise the child's capacity to control HIV-1 
replication when the virus is acquired from the mother. 
 
Our laboratory has described NK cell responses to HIV-1 Envelope and Regulatory peptides, 
in a whole blood assay, that were associated with reduced maternal-to-infant HIV-1 
transmission (Tiemessen et al., 2009). These responses were significantly more highly 
represented in non-transmitting mothers and in exposed uninfected infants, and were not 
detected in uninfected control mothers or their infants. The detection of these HIV-1 specific 
NK cell responses in EU infants adds to the intriguing possibility that NK cells may possess 
memory of prior exposure to maternal HIV-1, or mediate these responses through interaction 
with maternal HIV-1 specific antibodies, a process termed antibody dependent cellular 
cytotoxicity (ADCC), either or both of which may have an important role in infant resistance 
to HIV-1 acquisition. 
 
Obstetric factors 
Several obstetric factors such as preterm delivery, prolonged membrane rupture and the use 
of invasive procedures (amniocentesis) have been associated with MTCT. However, elective 
caesarean section prior to onset of labour and rupture of the amniotic sac has dramatically 
reduced the risk of MTCT (The European Collaborative Study, 1994, The European 
Collaborative Study, 1999). This is likely due to the avoidance of microtransfusions of 
maternal blood to the foetus during labour contractions and of direct contact of the foetus‟s 
skin and mucosal membranes with infected secretions or blood in the maternal genital canal. 
Furthermore, in addition to elective caesarean section, if ART was provided antepartum, 
intrapartum, and post-partum, risk of MTCT was reduced even further (Kind et al., 1998). 
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1.3.3 Prevention of MTCT 
With increasing knowledge about the underlying mechanisms of MTCT has come an 
increased emphasis on the search for interventions to prevent or reduce the risk of 
transmission (UNAIDS, 1998). Consequently, the WHO has promoted a comprehensive 
approach that includes four PMTCT components: (1) primary prevention of HIV-1 infection, 
(2) prevention of unintended pregnancies among HIV-1 infected women, (3) prevention of 
HIV-1 transmission from HIV-1 infected mothers to their infants and (4) care, treatment and 
support for HIV-1 infected mothers, their children and families (WHO, 2010). Most 
important has been administration of ART to mothers and their infants. It is estimated that in 
the absence of ART, 25% of infants infected with HIV-1 progress rapidly to AIDS or death 
within the first year of life (Teasdale et al., 2011). However, effective ART has reduced the 
rate MTCT to 2.7%, and where infants are infected, ART has transformed paediatric HIV-1 
into a chronic disease (Tobin and Aldrovandi, 2013). ART can reduce MTCT in one or more 
of the following ways: (1) by reducing viral replication and thus lowering plasma VL in 
pregnant women, (2) through pre-exposure prophylaxis (PrEP) of babies by crossing the 
placenta, (3) through post-exposure prophylaxis (PEP) of babies after delivery and 
(4) through reducing transmission via breast-feeding (Siegfried et al., 2011). 
 
1.3.3.1 Antiretroviral drugs  
In the early 1990s, few ART options for HIV-1 infection existed (Figure 1.4), and ART 
largely consisted of monotherapy with zidovudine (ZDV), a nucleoside analog initially called 
azidothymidine (3'-azido-3'-deoxythymidine) or AZT. Initial HIV-1 treatment with AZT led 
to a sense of excitement in the medical field arising from the possibility that perhaps HIV-1 
could be controlled, but it soon became clear that monotherapy was inadequate for long term 
viral suppression as HIV-1 with its high rate of replication, the low fidelity of reverse 
transcription and capacity for recombination lead to an elevated genetic diversity and the 
development of drug resistant strains (Boulet, 2009). As such treatment evolved over the 
years to dual therapy and combination therapy, also known as highly active antiretroviral 
therapy (HAART). To date, six distinct classes have been classified according to their effect 
on HIV-1 replication: (1) nucleoside reverse transcriptase inhibitors (NRTIs), (2) nucleotide 
reverse transcriptase inhibitors (NtRTIs), (3) non-nucleoside reverse transcriptase inhibitors 
(NNRTIs), (4) protease inhibitors (PIs), (5) entry inhibitors (EIs) and (6) integrase inhibitors 
(INIs), of which the INIs represent the most recent antiviral drug class (De Clercq, 2010). 
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Figure 1.4 A timeline of FDA approved antiretroviral drugs used in the treatment of HIV-1 
infection and the impact of these drugs on HIV-related deaths in the UK from 1894-2005. 
EI, entry inhibitors; HAART, highly active antiretroviral therapy; NNRTI, non-nucleoside 
reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease 
inhibitor. Reproduced and modified from  (Oversteegen et al., 2007) and 
(http://depts.washington.edu/hivaids/index.html).  
 
Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs) 
At present, there are seven NRTIs licensed for clinical use in the treatment of HIV-1 
infections: zidovudine (ZDV or AZT), didanosine (ddI), zalcitabine (ddC), stavudine (d4T), 
lamivudine (3TC), abacavir (ABC), and emtricitabine (FTC), as well as one NtRTI (tenofovir 
disoproxil fumarate, TDF) (De Clercq, 2013). Briefly, both NRTIs and NtRTIs (structural 
analogs of endogenous 2‟-deoxy-nucleosides and –nucleotides but lack the 3‟-hydroxyl group 
required for DNA elongation) act in a similar fashion. In their parent forms they are inactive 
and require successive phosphorylation steps by host cell kinases and phosphotransferases to 
form deoxynucleoside triphosphate (dNTP) analogs capable of viral inhibition (Cihlar and 
Ray, 2010). Following intracellular phosphorylation, NRTIs and NtRTIs compete with the 
endogenous substrates (dNTPs) for incorporation in the RT reaction where they serve as 
chain-terminators to prevent further chain linkages and inhibiting proviral synthesis. Thus, 
N(t)RTIs can be considered as pro-drugs that are active against HIV-1 RT as well as other 
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retroviral RTs, e.g. HIV-2 and SIV (de Bethune, 2010). The success of NRTIs in antiviral 
therapy is due, in part, to their intracellular persistence in their active triphosphoraleted form 
which allows for more constant viral inhibition. Some NRTI metabolites, for example ddI, 
despite having only a 1.5 h plasma half-life, is administered once a day because its active 
metabolite, 2‟,3‟-dideoxyadenosine triphosphate (ddATP), has an intracellular half-life of 
24 h (Cihlar and Ray, 2010). 
 
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
In contrast to NRTI and NtRTI, NNRTIs are active and do not require intracellular 
phosphorylation. NNRTIs prevent viral synthesis by directly binding to the RT enzyme in a 
hydrophobic pocket which prevents the normal dynamic movement of the enzyme complex 
(De Clercq, 2013). To date there are four NNRTIs: NVP, delavirdine (DLV), efavirenz 
(EFV) and etravirine (ETR). Of these four, NVP remains one of the most widely used 
PMTCT interventions as it is rapidly absorbed when given orally and readily crosses the 
placenta, it has a long half-life in pregnant women (61–66 h) and infants (45–54 h), its potent 
antiretroviral activity and because of its low cost (Siegfried et al., 2011). However, use of 
NVP as monotherapy leads to rapid development of resistant virus, which limits its 
usefulness when treating HIV-1 infection in the long term. Nevertheless, NNRTIs are highly 
specific inhibitors of HIV-1. 
 
Protease inhibitors (PIs) 
PIs selectively bind to and inhibit HIV-1 protease, the enzyme that cleaves viral Gag and 
GagPol precursor proteins, consequently inhibiting the viral maturation process (De Clercq, 
2013). Currently there are ten PIs approved for the treatment of HIV-1 infections: saquinavir, 
ritonavir, indinavir, nelfinavir, amprenavir, lopinavir, atazanavir, fosamprenavir, tipranavir, 
and darunavir, all of which, with the exception of tipranavir, are competitive inhibitors that 
mimic the natural substrate of the viral protease (Wensing et al., 2010). 
 
Entry inhibitors (EIs) 
Blocking HIV-1 entry into host cells is another pharmacologic strategy and drugs that block 
HIV-1 entry are collectively known as entry inhibitors. These include a complex group of 
drugs with multiple mechanisms of action depending on the stage of the entry process at 
which they act (Tilton and Doms, 2010). In general, EIs can target the different stages of viral 
entry: attachment and CD4 binding, coreceptor binding, and fusion. To date only two 
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antagonists have been approved: Maraviroc (a CCR5 antagonist) binds to the CCR5 
coreceptor causing a conformational change in the coreceptor that prevents the HIV-1 gp120 
from binding, and Enfuvirtide (a fusion inhibitor) which mimics the HIV-1 gp41 peptide, 
thereby preventing the conformational change needed to form a stable complex required for 
viral membrane fusion to target cells.  
 
Integrase inhibitors 
Lastly, HIV-1 integrase was the most recent HIV-1 enzyme to be successfully targeted for 
drug development. Raltegravir was the first approved integrase strand transfer inhibitor 
(InSTI) and specifically targets the final step of the three steps by which viral DNA is 
inserted in to the cellular genome, thus preventing the insertion of the viral genome into the 
DNA of the host cell (Hicks and Gulick, 2009). Raltegravir is currently administered in 
combination with other antiretrovirals for the treatment of HIV-1 infection in treatment-
experienced adult patients with multi-drug-resistant HIV-1 strains.  
 
Highly active antiviral therapy (HAART) 
In general HAART consists of three or more HIV-1 drugs of which the two NRTIs form the 
backbone of current combinations in addition to a NNRTI, protease inhibitor or, more 
recently, integrase inhibitor (Cihlar and Ray, 2010). The first fixed-dose drug combinations 
used for the treatment of HIV-1 infections were Combivir (AZT+3TC) in 1997; Trizivir 
(AZT+3TC+ABC) in 2000; Epzicom (3TC+ABC) and Truvada (FTC+TDF) in 2004; Atripla 
(FTC+TDF+EFV) in 2006; and Complera/Eviplera (FTC+TDF and rilpivirine) in 2011 (De 
Clercq, 2013). To date, HAART has dramatically suppressed viral replication and the plasma 
HIV-1 VL to below the limits of detection of the most sensitive clinical assays 
(< 50 RNA copies/mL) resulting in a significant reconstitution of the immune system as 
measured by an increase in circulating CD4+ T cells (Arts and Hazuda, 2012). 
 
As with ART therapy, the criteria for the initiation of ART have changed over the years. 
These criteria include plasma viraemia concentration, absolute or relative CD4+ T cell counts 
and clinical manifestations of HIV/AIDS (Simon et al., 2006). Historically, ART was 
initiated when patients presented with clinical signs of AIDS-defining illness or had 
CD4+ T cell count of ≤ 200 cells/μL (normal values being 500-1200 cells/μL). These 
individuals were already in advanced HIV-1 disease, and ART at this stage failed to improve 
CD4+ T cell counts to > 500 cells/μL. It was later reported that the magnitude of CD4+ T cell 
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recovery directly correlated with CD4+ T cell count at ART initiation (Moore and Keruly, 
2007). Consequently, in 2010 the WHO guidelines changed ART initiation from 200 cells/μL 
to 350 cells/μL, and more recently recommended that HIV therapy start at CD4+ T cell 
counts less than 500 cells/μL. 
 
Prior to 2010, the early South African PMTCT program included the administration of 
single-dose (sd) NVP to a mother during labour as well as sdNVP administration to the infant 
within 48 to 72 hours (National Department of Health, 2008). This was then updated to dual 
therapy, with a short-course of AZT added to the sdNVP protocol: mothers received daily 
AZT from 28 weeks gestation as well as sdNVP during labour/delivery, and infants received 
sdNVP at birth and either 7 or 28 days of AZT depending on whether the mother had 
received prophylaxis for ≤ 4 weeks (National Department of Health, 2008). In addition, 
lifelong ART was limited to mothers with CD4+ T cell counts ≤ 200 cells/μL. Subsequently 
in 2010, South African PMTCT guidelines were updated and aligned with WHO 
recommendations (WHO, 2009). Pregnant women were offered a single rapid HIV-1 
antibody assay at their first antenatal care (ANC) visit. If negative, a second test was offered 
after 32 weeks gestation. Positive results were confirmed with a second rapid test and 
CD4+ T cell count dictated further management. Women with CD4+ T cell 
counts ≤ 350 cells/μL were initiated on lifelong ART and women with CD4+ T cell 
counts > 350 cells/μL received twice-daily AZT from 14 weeks gestation, with sdNVP, 
3-hourly AZT and sd-FTC/TDF during labour. HIV-1 exposed infants received 
daily-dose (dd) NVP for 6 weeks or throughout the duration breastfeeding if mothers were 
not on ART (Technau et al., 2014). In addition, HIV-1 exposed infants had an HIV-1 DNA 
PCR test at their 6-week immunization visit. These guidelines were then further amended in 
March 2013 and combination ART was offered to all HIV-1 positive pregnant women 
irrespective of the CD4+ T cell count. 
 
Although several studies reported that monotherapy with short-course AZT or sdNVP 
reduced the incidence of MTCT by 40% or more (Guay et al., 1999, Wiktor et al., 1999, 
Stringer et al., 2003), with dual therapy the reduction was more successful (Lallemant et al., 
2004). Short-course AZT was found to reduce maternal VL in plasma and genital secretions 
(Chuachoowong et al., 2000, Mbori-Ngacha et al., 2003), and was also able to cross the 
placenta as determined by detection of therapeutic levels of AZT in cord blood (Bhadrakom 
et al., 2000). AZT likely reduced MTCT as a result of reduced maternal VL at delivery, as 
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well as acting as an infant prophylaxis against viral exposure during birth. However, maternal 
AZT would not likely reduce PP transmission due to its short half-life of 1–2 hours (Lehman 
and Farquhar, 2007). In contrast, sdNVP has a long half-life (60 hours in adults and 45 hours 
in neonates) and sdNVP given to the mother at the onset of labour is rapidly absorbed and 
crosses the placenta within 1 hour of oral ingestion resulting in levels well above the 100 
ng/ml therapeutic target in both maternal breast milk and infant blood during the first few 
days of life (Musoke et al., 1999). Therefore, it is hypothesised that similar to short-course 
AZT, sdNVP may act as pre and/or post-exposure prophylaxis to the neonate (Figure 1.5).  
 
 
Figure 1.5 Short course antiretrovirals (ARVs) in PMTCT. Left panel: without maternal ARVs, 
virus ingested by the infant can result in infection. Right panel: ARVs given to the mother 
substantially reduce maternal viral load thereby reducing viral exposure to the infant. Reproduced 
from (Lehman and Farquhar, 2007). 
 
In neonates whose mothers did not receive ART during pregnancy, prophylaxis with a two-
drug ART regimen (AZT/NVP) or three-drug ART regimen (AZT/3TC/nelfinavir) was found 
to be far better than AZT alone for the prevention of IP transmission; moreover, the rates of 
IU transmission were lower with the two-drug (2.2%) and three-drug (2.4%) groups as 
compared to AZT (4.8%) alone (Nielsen-Saines et al., 2012). Additionally, a 1 week “tail” of 
3TC or AZT following the sdNVP would prevent most NVP resistance (Van Dyke et al., 
2012).  
Cell-associated virus Cell-free virus
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1.3.3.2 Drug resistance 
Drug resistance evolution is a primary phenomenon that helps a pathogen survive and 
replicate even under harsh drug pressure (Das and Arnold, 2013). In the case of HIV-1, the 
high mutation rate that occurs during reverse transcription of HIV-1 to proviral DNA 
enhances the development of antiretroviral drug resistance. Clinical use of AZT or sdNVP 
revealed that treatment of HIV-1 infection with a single drug was not effective in keeping the 
VL down for a prolonged period; furthermore, drug resistance increased with the duration of 
therapy, as multiple amino acid changes accumulate over time to yield resistant viruses 
(Klatt, 2013). Resistance to NRTIs is mediated by two mechanisms: (1) ATP-dependent 
pyrophosphorolysis, which is the removal of NRTIs from the 3‟ end of the nascent chain and 
reversal of chain termination, and (2) increased discrimination between the native 
deoxyribonucleotide substrate and the inhibitor (Arts and Hazuda, 2012). Single dose NVP 
prophylaxis selects for NVP-resistant (NVP-R) variants in a high proportion of women 
(19-75%) and their infected infants (33–87%) and these variants remain detectable for a year 
or more (Palmer et al., 2006, Arrive et al., 2007, Martinson et al., 2007, Permar et al., 2013). 
Moreover, NVP-R variants emerge more frequently and persist longer after exposure to 
extended NVP prophylaxis; while sdNVP administration increases the risk of virologic 
failure to subsequent ARV treatment (Permar et al., 2013). Such transmitted drug resistance 
(TDR) has the potential to limit the response to subsequent treatment and can be transmitted 
to newly infected individuals. Factors contributing to acquired drug resistance in Africa 
include the lack of plasma VL monitoring, treatment interruptions due to drug shortages, drug 
interactions and the use of substandard antiretroviral regimens (Hamers et al., 2013). 
 
Meta-analysis revealed the high prevalence of NVP resistant mutants in mothers and infants 
who had received sdNVP as compared to mothers and infants who had received sdNVP as 
well as additional ART, such as AZT+3TC (Arrive et al., 2007). Similarly, in the Kesho Bora 
randomized study, HIV-1 drug resistance was present in 17.1% of mothers who received 
sdNVP along with AZT versus 1.4% who received triple ART (Kesho Bora Study and de 
Vincenzi, 2011). Thus, PMTCT interventions were updated and advocated the use of 
combined ART to reduce NVP resistance. The WHO proposed a new strategy (Option B+) to 
treat all HIV-1 infected pregnant women with triple ART for life (WHO, 2012), but no 
studies have yet investigated the effects on resistance development. Furthermore the 
feasibility of this plan in low- to middle-income (resource poor) countries is questionable.  
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Overall, there is a great need to monitor drug resistance. However, very few molecular 
diagnostic laboratories in the region have the capacity to conduct HIV-1 genotypic resistance 
testing (Parkin et al., 2012). Nevertheless, other ways to address TDR is to improve national 
HIV-1 treatment programmes by optimizing their functioning and sustainability, including 
robust supply chains, access to routine VL monitoring and alternative regimens, strategies to 
maximize patient retention and enhanced surveillance of drug resistance (Hamers et al., 
2013). Importantly, it must be stressed that failure to prevent and/or manage ART resistance 
can lead to greater evolution of viral resistance that can include cross-resistance that requires 
more complex antiretroviral regimens that may be less tolerable, making patient adherence 
more difficult, with a downward spiral to shorter duration of HIV-1 suppression and 
re-emergence of virologic failure (Klatt, 2013). 
 
1.4 The Immune System 
The human immune system has evolved a number of mechanisms to protect the host from a 
selection of pathogens and/or toxins. A key feature of the immune system is the recognition 
of “self” from “non-self”, and as such host-pathogen or host-toxin discrimination is essential 
to permit the host to eliminate the threat without damaging its own tissues (Chaplin, 2010). 
However in the case of HIV-1 infection, the virus is able to overcome the immune system 
and in the absence of ART, infection is marked by the steady decline of CD4+ T cells and 
constant immune activation leading to an immunodeficient state. Therefore, by understanding 
how/why the immune system fails to remove this threat may help to develop more effective 
treatments. How does the immune system differentiate self from non-self? Overall, the 
immune system can be divided into two functional categories, namely innate and adaptive 
immunity. 
 
1.4.1 Innate immunity 
Innate immunity, also known as the first line of defence, is hardwired with germline-encoded 
receptors, such as toll like receptors (TLRs), that recognize either highly conserved structures 
expressed by large groups of microbes, or common biologic consequences of infection 
(Turvey and Broide, 2010). It can be further divided into two parts, namely physical and 
bloodborne barriers. Physical barriers prevent infection from establishing and includes intact 
skin, vigorous mucociliary clearance mechanisms of the respiratory, gastrointestinal and 
genitourinary tracts, as well as bacteriolytic lysozyme in tears, saliva, and other secretions 
(Turvey and Broide, 2010). Bloodborne barriers include haematopoietic cells such as 
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macrophages, dendritic cells, mast cells, neutrophils, eosinophils, and natural killer (NK) 
cells (NK cells are further discussed in section 1.4.3). These cells can be simplistically 
grouped according to their functional characteristics, i.e. neutrophils, monocytes, and 
macrophages are phagocytic cells that are able to engulf foreign particles; basophils, mast 
cells, and eosinophils release inflammatory mediators such as chemokines and cytokines that 
recruit other immune cells to the site of infection; and NK cells are able to mediate direct 
lysis of target cells with the release granzymes and perforin which induce apoptosis. To 
augment these cellular defences, innate immunity also has a humoral component that 
facilitates in the clearance of the infection, which includes complement proteins, 
lipopolysaccharide (LPS) binding protein, C-reactive protein and other antimicrobial peptides 
(Turvey and Broide, 2010). Furthermore, the innate immunity plays a central role in 
activating the adaptive immune response. 
 
1.4.2 Adaptive immunity 
Since the adaptive response is encoded by gene elements that somatically rearrange to 
assemble antigen-binding molecules with unique specificity for foreign structures, there is lag 
time between antigen exposure and maximal response ranging from hours to days (Chaplin, 
2010). A key feature of the adaptive response is its capacity to produce long-lived memory 
cells that enables the host to mount a more rapid and efficient immune response upon 
subsequent exposure to the antigen (Warrington et al., 2011). Adaptive immunity can be 
divided into humoral and cell-mediated responses.  
 
The humoral response involves antibody-producing cells, the B lymphocytes, which arise in 
the bone marrow (Bonilla and Oettgen, 2010). B cells constitute approximately 15% of 
peripheral blood lymphocytes and once mature, plasma cells express antigen specific 
membrane associated B cell antigen-binding receptors (BCR) that are secreted upon antigen 
binding and activation of the B cell. BCR are dimers of immunoglobulin heavy and light 
chains and upon secretion, BCR are referred to as antibodies/immunoglobulins (Ig). Based on 
structure and function, five classes of immunoglobulins exist, namely: IgG1-4, IgA1-2, IgM, 
IgE, and IgD. IgG is the most abundant class of immunoglobulins, constituting 80% to 85% 
of the immunoglobulins in the blood and accounting for most of the protective activity 
against infections. IgM is the largest immunoglobulin and usually exists as a pentamer that is 
stabilized by a J chain. It is also the first antibody produced during the initial response to 
antigens and is synthesized early in neonatal life. IgD is found in low concentrations in the 
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blood, and primarily acts as an antigen receptor on the surface of early B cells. IgE is 
typically seen in individuals who are having an allergic reaction or in parasitic infections. 
Antibodies can either act directly or indirectly to protect the host from infection. Directly, 
antibodies can affect infectious agents or their toxic products by neutralization, agglutination, 
or precipitation, and indirectly, antibodies activate components of innate resistance, such as 
complement cascade and phagocytes (Bonilla and Oettgen, 2010). 
 
The cell-mediated immune response is regulated by the major histocompatibility complex 
(MHC), so named because it is responsible for graft rejection or tissue compatibility. The 
MHC genes encode the human leukocyte antigens (HLAs) on the cell surface. There are two 
major classes of MHC molecules that differ not only structure but also function within the 
immune system, namely: (1) MHC class I molecules (MHC I) expressed on all nucleated 
cells consisting of one membrane-spanning α chain (heavy chain) produced by MHC genes, 
and one β chain (light chain or β2-microglobulin) produced by the β2-microglobulin gene, 
and (2) MHC class II molecules (MHC II) which consist of two membrane-spanning 
chains, α and β, of similar size and both produced by MHC genes. MHC class II are only 
expressed on B lymphocytes, activated T lymphocytes, and antigen-presenting cells (APC) 
such as monocytes, macrophages, Langerhans cells, dendritic cells, endothelium, and 
epithelial cells. 
 
Naive T lymphocytes (thymocytes) develop in the thymus and undergo positive and negative 
selection. Cells bearing a T cell receptor (TCR) that recognises self MHC are positively 
selected in the cortex and pass into the corticomedullary junction. T cells that react with self-
antigens are deleted by apoptosis in a process known as negative selection (Chaplin, 2010). 
The cells that exit are self-tolerant but able to recognise foreign antigen when presented with 
self MHC. T lymphocytes can be broadly divided into cytotoxic CD8+ T lymphocytes (CTL) 
cells and CD4+ T helper (Th) cells that control both cell-mediated and humoral immune 
responses. Naive CD4+ and CD8+ T cells then traffic to lymph nodes where they encounter 
multiple APCs in the process of education. Mature T cells are activated on interaction of their 
TCRs with antigenic peptides complexed with MHC molecules (Bonilla and Oettgen, 2010).  
 
TCRs on CD8+ T cells can interact with peptides on all nucleated cells expressing the 
classical MHC class I (HLA-A, HLA-B, and HLA-C). These MHC class I restricted peptides 
are generally produced from proteins translated within the cell (endogenous antigens) 
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encoded either in the host genome, by infecting viruses or other pathogens replicating 
intracellularly (Parkin and Cohen, 2001). In contrast, the TCRs of CD4+ T cells engage 
extracellular proteins (exogenous antigens) bearing MHC class II (HLA-DR, HLA-DQ, and 
HLA-DP). MHC class II molecules are present on APCs and are inducible by innate immune 
stimuli, including ligands for TLRs. APCs are present in large numbers in the skin and 
mucosal sites, where they actively sample exogenous proteins by means of phagocytosis or 
endocytosis. Endogenous antigens complexed with MHC class I molecules activate CD8+ 
cytotoxic T cells inducing targeted cell death. While these CD8+ T cell responses are highly 
specific to the cell that they recognise, CD4+ T cell activation leads to production of 
cytokines which in turn activates a wide range of cells around them. 
 
The CD4+ Th cells can be subdivided functionally by the pattern of cytokines they produce. 
On stimulation, precursor Th0 lymphocytes become either Th1 or Th2 cells. The difference 
between these cells is only in the cytokines secreted; they are morphologically 
indistinguishable (Parkin and Cohen, 2001). However, the response they generate is very 
different. Th1 cells mainly produce interleukin (IL)-2 and interferon (IFN)-. IL-2 induces 
T cell proliferation (of both CD4+ and CD8+ T cells) and stimulates CD8+ T cell 
cytotoxicity, while IFN- activates macrophages to phagocytise pathogens such as 
mycobacteria, fungi, and protozoa and induces NK cell cytotoxicity. Th1 cytokines therefore 
induce mainly a cell-mediated inflammatory response. Conversely, Th2 cells produce IL-4, 
IL-5, IL-6 and IL-10 which favour antibody production. 
 
Mounting evidence suggests that the early events following HIV-1 infection determine the 
course of disease progression in such a way that more robust control of viral replication in 
acute HIV-1 infection results in lower viral set-points and is associated with slower HIV-1 
disease progression (Pantaleo et al., 1997, Carrington and Alter, 2012). Furthermore, it has 
been reported that during acute HIV-1 infection the innate response plays an important part in 
reducing viral replication even before the induction of adaptive immune responses (Alter et 
al., 2007b). In particular, the role of NK cells in the control and clearance of HIV-1 infection 
and other viral infections has become an important area of research. 
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1.4.3 Natural killer (NK) cells 
NK cells are large bone marrow derived lymphocytes that constitute about 10-15% of the 
peripheral blood lymphocyte population (Farag and Caligiuri, 2006). NK cells are distinct 
from T and B cells in that they do not express receptors that require somatic gene 
rearrangements to generate receptor diversity and specificity. Instead, NK cell functions are 
controlled by a wide array of germline-encoded inhibitory and activating receptors that are 
expressed in a stochastic, variegated pattern, resulting in many subsets of functionally distinct 
NK cells (Orr and Lanier, 2010), several of which are specific for HLA class I ligands. 
Consequently, NK cells represent the major effector cell population of the innate immune 
system. 
 
Upon recognition of target cells, either viral-infected or tumour cells, NK cells have the 
ability to respond rapidly in one of three ways: (1) by directed release of the contents of 
cytolytic granules (perforin and granzymes) onto target cells, (2) by expressing apoptotic 
ligands (i.e. Fas ligand and TNF-related apoptosis-inducing ligand, TRAIL) that engage death 
receptors on infected cells, and (3) by secreting cytokines, such as IFN-, that impede or 
prevent virus replication (Sowrirajan and Barker, 2011). In addition, NK cells, through their 
CD16 receptor (FcγRIIIa, a low-affinity receptor for the Fc portion of Ig-G), also engage with 
antibody-coated cells to induce the antibody-dependent cellular cytotoxicity (ADCC) 
response. NK cells also express TLRs, including TLR2, TLR3, TLR7/8 and TLR9, which can 
sense pathogen-associated molecular patterns (Sivori et al., 2004). 
 
The importance of NK cells in controlling viral infection has been shown in individuals who 
lack or have dysfunctional NK cells that develop fatal viral infections, such as herpes or 
varicella infections (Biron et al., 1989, Etzioni et al., 2005). More importantly, NK cells have 
been shown to play an important role in the control and prevention of HIV-1 infection (Fauci 
et al., 2005, Carrington et al., 2008, Tiemessen et al., 2009, Biron, 2010, Berger and Alter, 
2011, Tiemessen et al., 2011, Jost and Altfeld, 2013). Moreover, recent studies have 
described strategies evolved by HIV-1 to specifically evade NK cell-mediated immune 
responses, demonstrating that NK cells significantly impact HIV-1 evolution (Alter et al., 
2011, Jost and Altfeld, 2012). Added to this, other studies have identified the expansion of 
pathogen specific NK cells and the generation of long-lasting “memory” cells that persist 
after cognate antigen encounter (Sun et al., 2009). Other groups have also shown that NK 
cells contain intrinsic adaptive immune features when primed using inflammatory cytokines 
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(Cooper et al., 2009). Thus, NK cells are no longer just confined to bridging the gap between 
the innate and the adaptive immune system, but actively play a crucial part in the adaptive 
immune response with their ability to mount an enhanced secondary recall response. 
 
Using flow cytometry (Figure 1.6), peripheral NK cells have been classically defined as 
being CD3
- 
CD56
+
, which can be further subdivided into three subsets with distinct 
functional properties, namely: CD56
bright
, CD56
dim
 and CD56
-
 NK cells. In healthy 
individuals, over 90% of the peripheral blood NK cells consist of the CD56
dim
 NK cells, 
which express CD16 and KIRs (Cooper et al., 2001, Caligiuri, 2008). These NK cells have 
strong cytotoxic activity with a modest ability to secrete cytokines. While in the lymph nodes, 
the dominant NK cell subset consists of CD56
bright
 cells that lack the expression of CD16 and 
KIRs; these NK cells have high proliferation potential and are able to secrete large amounts 
of pro-inflammatory cytokines and thus might have important immunoregulatory functions 
(Jost and Altfeld, 2013). Additionally, an expanded subset of NK cells that are CD56
-
 CD16
+
 
has been reported in HIV-1 infection and other chronic viral infections (Mavilio et al., 2003, 
Mavilio et al., 2005). These NK cells do not respond to stimulation with HLA class I-devoid 
target cells or mitogens, despite the expression of KIRs, suggesting that these NK cells 
represent an exhausted/anergic subset of NK cells (Jost and Altfeld, 2013). 
 
Of note, there also exists a unique set of NK cells found in the uterus, called uterine NK 
(uNK) cells, which represents up to 70% of the leukocyte population in first trimester 
deciduas (Moffett-King, 2002). Importantly, unlike their CD56
bright
 peripheral counterparts, 
uNK cells have been phenotypically defined as being CD56
super bright
 CD16
−
 cells that also 
express KIRs, NKG2C and NKG2E, as well as CD69 and CD94 (Moffett-King, 2002). 
Although the exact function of uNK cells remains largely unknown, available evidence points 
to a role in regulating the complex process of placentation. In particular, they are thought to 
be involved in co-ordinating access of the placental trophoblast cells to the uterine arteries 
resulting in high conductance vessels, ensuring an adequate supply of oxygen and nutrients to 
the foetal-placental unit (Colucci et al., 2011). In addition, since the uNK cells can express 
activating and inhibitory KIRs and are in close proximity to interact with the invading foetal 
placental cells (or trophoblast cells) that express both maternal and paternal HLA-C allotypes 
(Chazara et al., 2011), they are likely candidates for fine-tuning the maternal immune 
responses that might regulate placentation as well as infectious disease. 
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Figure 1.6 Natural killer (NK) cell subsets in human peripheral blood based on the relative 
expression of CD16 and CD56. Normal peripheral blood mononuclear cells (PBMC) were stained 
with anti-CD3, anti-CD14, anti-CD16, anti-CD19 and anti-CD56 antibodies conjugated to five 
different fluorochromes, a gate was set on CD3− CD19− cells (NK cells) and CD16 expression vs. 
CD56 expression is shown: (1) CD56bright CD16−; (2) CD56bright CD16dim; (3) CD56dim CD16−; 
(4) CD56dim CD16+; and (5) CD56− CD16+. Reproduced from (Poli et al., 2009). 
 
NK cells are regulated by a set of inhibitory and activating cell surface receptors that finely 
tune their potent effector functions. The NK cell receptors include: (1) killer 
immunoglobulin-like receptors (KIR), (2) killer cell lectin-like receptors (KLR) such as 
CD94/NKG2, (3) leukocyte immunoglobulin-like receptors (LILR), and (4) natural 
cytotoxicity receptors (NCR), such as NKp46, NKp44, and NKp30, and 2B4 (Rajalingam, 
2012). These receptors have been shown to recognize both cellular and viral ligands, 
including major histocompatibility complex (MHC), MHC-like and non-MHC molecules. 
It is the dynamic interplay between these signals that ultimately determines the outcome of 
NK cell–target cell encounters (Li and Mariuzza, 2014). Simplistically, NK cell activity is 
controlled as a consequence of binding to their cognate ligands, NK cell cytolysis is induced 
when the dominant signal received is activating or NK cell cytolysis is inhibited when the 
dominant signal received is inhibitory.  
 
Under normal physiologic circumstances, healthy cells express an abundance of inhibitory 
ligands (HLA-A, -B, -C and –G) and are resistant to NK cell attack (Lanier, 2008, 
Rajalingam, 2012). However, if HLA class I expression is downregulated by certain viral 
infections, tumour transformation processes or other forms of stress, the inhibitory signal on 
NK cell is attenuated and the NK cell undergoes activation with targeted elimination of the 
Chapter 1: Literature review  35 
viral-infected or tumour cell (Figure 1.7). This process by which NK cell receptors direct the 
cytolytic activity of NK cells against those cells that have lost HLA expression was originally 
described as the “missing-self” hypothesis (Ljunggren and Karre, 1990). In addition, 
NK cell attack may also be induced when there is up-regulation of stress–induced proteins, 
such as MHC class I chain-related molecules (MICA and MICB) due to viral infection or 
tumour transformation, termed “induced-self”, or when HLA class I molecules present 
foreign peptide, termed “altered-self”, or when pathogen encoded molecules trigger 
“non-self” recognition (Rajalingam, 2012) . 
 
 
Figure 1.7 NK cell responses against healthy and abnormal cells. (A) By expressing normal 
levels of multiple HLA class I molecules, the healthy cells are resistant to NK cell attack and 
(B) down-regulation of HLA class I expression due to viral-infection or tumour transformation 
relieves the inhibitory influence on NK cells, permitting NK cells to lyse the unhealthy target cell, 
a process termed “the missing-self” hypothesis. Reproduced and modified from 
(www.immunopaedia.org). 
 
However, the “missing-self” hypothesis did not fully explain the absence of NK cell 
autoreactivity in MHC class I deficient cells. Several studies reported that NK cells were 
self-tolerant and failed to kill MHC-I-deficient cells (Fernandez et al., 2005, Kim et al., 
2005). Thus, the “licensing” hypothesis was introduced and proposed, in which NK cells 
require a process of education to obtain their full effector function (Kim et al., 2005, Raulet 
A) Healthy cell B) Abnormal cell
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and Vance, 2006). In this model, NK cells had to engage with self-MHC in order to be 
responsive to subsequent signals received through activating receptors, thus setting or tuning 
their optimal NK cell reactivity threshold. However, in the absence of self-MHC, NK cells 
would remain unlicensed and hyporesponsive. This mechanism was then further adapted to 
the “arming/disarming” model which proposed that the main factor in the adaptation of 
NK cell reactivity resided in the duration of stimulation. According to this model, an acute 
downregulation of MHC-I expression would lead to NK cell activation, whereas a chronic 
downregulation of MHC-I would lead to the chronic activation of NK cells and induce their 
hyporeactivity (Jaeger and Vivier, 2012). Nevertheless, while these models are suggestive of 
mechanisms controlling NK cell function, further studies are required to decipher the 
diversity of the mechanisms regulating NK cell reactivity and to fully understand how 
NK cell education and/or tolerance is achieved in physiological conditions. 
 
It is also important to note that while every individual will inherit a full complement of 
NK receptors, not all are expressed on every NK cell in that individual, but every NK cell 
will have an inhibitory receptor for a self HLA-A, B or C molecule, which can either be a 
KIR or CD94/NKG2A receptor (Middleton et al., 2002). Moreover, because NK cells vary in 
the affinity and number of self-MHC-I inhibitory receptors they express, the strength of the 
educating signal varies from cell to cell (Brodin and Hoglund, 2008). In addition, compared 
to other NK cell receptors, the KIRs are the most polymorphic and are considered to be the 
key receptors that control the development and function of human NK cells (Rajalingam, 
2012). KIRs recognize an array of polymorphic HLA class I molecules that evolved rapidly 
to mount effective adaptive immune response against rapidly evolving viruses. Furthermore, 
the genes encoding KIR and HLA class I ligands are located on different chromosomes 
(chromosome 19 and 6, respectively) and this independent segregation results in variable 
KIR-HLA combinations in individuals, which may to some extent explain the differential 
responses to viral infections across different individuals and/or population groups (Carrington 
et al., 2008). This thesis will focus on the role of KIR/HLA-ligands in MTCT of HIV-1. 
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1.4.3.1 Killer immunoglobulin-like receptors (KIR) 
The KIRs are found on NK cells, but also on subgroups of CD4+ and CD8+ T lymphocytes 
(van Bergen and Koning, 2010). The KIR genes are arranged in a “head-to-tail” cluster 
encoded in a 100-200 kb region within the Leukocyte Receptor Complex (LRC) on 
chromosome 19 (19q13.4) (Trowsdale, 2001). Thus far, 14 functional KIR genes and 
2 pseudogenes have been identified; these encode eight inhibitory receptors (KIR2DL1, 
KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5A and B, KIR3DL1 and KIR3DL2), six 
activating molecules (KIR2DS2, KIR2DS3, KIR2DS5, KIR3DS1, KIR2DS1 and KIR2DS4) 
and the two pseudogenes KIR2DP1and KIR3DP1. As of 15 July 2014, 678 KIR alleles and 
493 KIR genotypes were recorded on the IPD-KIR Database (release 2.5.0, 
http://www.ebi.ac.uk/ipd/kir/stats.html) and the Allele Frequencies KIR database 
(http://www.allelefrequencies.net), respectively. Together KIR gene content and allelic 
polymorphism add to the genetic diversity of the KIR locus. 
 
The KIR genes can have between four to nine exons (Figure 1.8A) and based on their 
structure can be divided into three groups, namely: (1) Type I KIR2D genes, which encode 
two extra-cellular domain proteins with a D1 and D2 conformation, (2) Type II KIR2D genes 
which encode two extra-cellular domain proteins with a D0 and D2 conformation, 
and (3) KIR3D genes encoding proteins with three extra-cellular Ig-like domains (D0, D1 
and D2) (Vilches and Parham, 2002). Type I KIR2D genes (KIR2DL1-3, KIR2DS1-5 and 
KIR2DP1) have eight exons as well as a pseudoexon 3. Type II KIR2D genes (KIR2DL4 and 
KIR2DL5), have a translated exon 3 but have a deleted exon 4. KIR2DL4 is further 
differentiated from KIR2DL5, in that exon 1 of KIR2DL4 is six nucleotides longer and 
possesses an initiation codon different from those present in the other KIR genes. 
KIR3D genes (such as KIR3DL1, KIR3DL2 and KIR3DS1) possess nine exons but differ in 
the length of exon 9. KIR3DL3 and KIR3DP1 are unique in that KIR3DL3 completely lacks 
exon 6, and KIR3DP1 completely lacks exons 6 through 9, and occasionally also exon 2. 
Furthermore, KIRs can either have a long cytoplasmic tail (2DL or 3DL) or a short 
cytoplasmic tail (2DS or 3DS) (Figure 1.8B). Long cytoplasmic tails contain 
immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and confer an inhibitory signal 
when the receptors are engaged with their ligands, while short tailed receptors have a 
transmembrane lysine residue which allows binding to the immunoreceptor tyrosine-based 
activating motif (ITAM) containing adaptor molecule DAP12 allowing activation of the NK 
cell, leading to IFN-γ production, cytotoxicity and proliferation (Rajalingam, 2012). 
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Figure 1.8 Structure of the KIR gene groups. (A) KIR gene organisation showing coding regions 
of the exons, represented as blue and the pseudoexon 3 and the deleted exon 2 of KIR3DP1 are 
shown in pink. (B) KIR protein structures, which have either two or three Ig-like domains that 
associate with activating (shown in green) or inhibitory (shown in red) signals. Reproduced 
modified from (http://www.ebi.ac.uk/ipd/kir). (C) Organization of KIR genes in the KIR locus, 
showing the centromeric and telomeric regions which are separated by a unique recombination 
site (RS). The conserved framework genes are shaded grey, B haplotype genes are blue and A 
haplotype genes are red. Reproduced from (Cooley et al., 2010). 
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Based on KIR gene content two broad haplotypes, termed A and B, have been defined 
(Uhrberg et al., 1997). Haplotype A has a uniform set of nine KIR genes that are mostly 
inhibitory receptors (KIR2DL1, KIR2DL3, KIR2DL4, KIR2DS4, KIR3DL1, KIR3DL2, 
KIR3DL3, KIR2DP1 and KIR3DP1), whereas the haplotype B contains several activating 
KIR genes in addition to inhibitory ones. Therefore, individuals can be assigned to the A/A 
genotype (homozygous for A haplotypes) or the B/x genotype (having 1 or 2 B haplotypes). In 
addition, the whole KIR region can be divided into centromeric (A or B) and telomeric (A or 
B) halves, based on the framework KIR genes KIR2DL4, KIR3DL2, KIR3DL3 and KIR3DP1 
present in all haplotypes (Cooley et al., 2010). KIR3DL3 and KIR3DP1 mark the centromeric 
region and KIR2DL4 and KIR3DL2 mark the telomeric region (Figure 1.8C). 
 
Within the centromeric half, KIR2DL2 and KIR2DL3 segregate as alleles of a single locus 
and can be designated as KIR2DL2/3, while KIR3DL1 and KIR3DS1 (or KIR3DL1/S1) 
behave as alleles of the same locus within the telomeric half. Virtually all haplotypes will 
contain either KIR2DL2 or KIR2DL3, and KIR3DL1 or KIR3DS1 within their KIR genome 
(Rajalingam, 2012). The KIR genes KIR2DL1, KIR2DL2, KIR2DL3, and KIR2DS2 are 
specific to the centromeric half, while KIR3DL1, KIR3DS1, KIR2DS1, and KIR2DS4 are 
specific to the telomeric half, and KIR2DL5, KIR2DS3 and KIR2DS5 are found in both 
centromeric and telomeric locations. The KIR genes show significant linkage disequilibrium 
within each half, but much less for genes in the two different halves (Middleton et al., 
2007b). Group A haplotype diversity is primarily associated with allelic polymorphism, while 
the group B haplotypes have greater diversity in gene content exhibiting only moderate allelic 
polymorphism (Biassoni et al., 2012).  
 
For example, KIR2DS4, the only activating gene within the A haplotype, can encode 
functional (KIR2DS4-f) or non-functional (KIR2DS4-v) variants, with only KIR2DS4-f 
serving as membrane-bound receptors to activate NK cells. To date, 13 KIR2DS4 alleles have 
been described (IPD-KIR: Release 2.5.0, 2013-10-11), of which only four KIR2DS4 alleles 
(KIR2DS4*001, *011, *014 and *015) encode cell surface KIR2DS4-f and the remaining 
nine alleles (KIR2DS4*003, *004, *006, *007, *008, *009, *010, *012, *013) encode the 
truncated KIR2DS4-v. KIR2DS4-v alleles carry a 22-bp deletion in exon 5, which causes a 
frame shift mutation yielding a truncated KIR2DS4 protein that lacks the transmembrane and 
cytoplasmic domains of the full length KIR2DS4 protein (Hsu et al., 2002, Maxwell et al., 
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2002, Maxwell et al., 2004). Therefore, individuals who are homozygous for the Group-A 
haplotype and that harbour KIR2DS4-v alleles will not have a membrane-bound KIR2DS4 
protein and thus lack an activating KIR. Instead KIR2DS4-v alleles encode a soluble form of 
the protein that is potentially secreted (Middleton et al., 2007a). Genetic studies have shown 
that frequencies of individuals with zero activating KIR genotypes vary between ethnic 
populations, of which populations of Caucasian decent have been reported to have higher 
KIR2DS4-v frequencies than Africans and Asians. Interestingly, populations with the highest 
frequency of AA haplotypes show a trend to have lower prevalence of the KIR2DS4-v 
(Maxwell et al., 2004, Whang et al., 2005, Middleton et al., 2007a, Middleton et al., 2007b).  
 
However, amongst the framework gene-encoding KIRs, KIR2DL4 is an unusual KIR because 
of its structure, expression, and function. Firstly, KIR2DL4 contains one N-terminus ITIM as 
well as a charged residue (arginine) in its transmembrane domain, allowing KIR2DL4 to have 
both inhibitory and activating potential (Rajagopalan and Long, 1999, Faure and Long, 
2002). Secondly, KIR2DL4 is constitutively expressed by all NK cells whereas other KIRs 
are rather distributed clonally on some NK cells. Furthermore, in contrast to other KIRs 
which function as cell surface receptors, KIR2DL4 is localized in endosomes of resting NK 
cells (Rajagopalan and Long, 2012). Thirdly, intracellular engagement with stored soluble 
HLA-G ligand has been reported to result in the production of chemokines and cytokines 
such as IFN-, IL-1β, TNF-α, IL-6 and IL-8 that can either directly or indirectly act on other 
cell types in the local environment (Rajagopalan and Long, 1999, Rajagopalan et al., 2001, 
Rajagopalan et al., 2006). This intracellular feature may prove advantageous as it may escape 
regulation by other inhibitory receptors at the NK cell surface. Nevertheless, the exact 
function of KIR2DL4 remains uncertain.  
 
In addition to allelic and haplotypic diversity, individuals may also carry more than two 
copies of a KIR gene. The copy number variation (CNV) is likely to influence mRNA 
transcript level and the proportion of an individual‟s NK cells that expresses the KIR 
(McErlean et al., 2010). Indeed, CNV in KIR3DL1 and KIR3DS1 has been shown to have 
immunological relevance. For example in HIV-1 infection, individuals with high KIR3DS1 
copy numbers were found to have higher KIR3DS1 expression on NK cells that correlated 
with more robust inhibition of HIV-1 replication (Pelak et al., 2011), and in the case of 
hepatitis C virus (HCV), individuals with two copies of KIR2DL3 had increased HCV 
clearance compared to those with one or no copies (Khakoo et al., 2004). 
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1.4.3.2 Human leukocyte antigen (HLA) ligands 
Thus far, only HLA class I molecules (HLA-A, B, C and G) have been identified as the 
ligands for some KIR (Table 1.3). Both the KIR and its cognate HLA ligand must be 
expressed in order to regulate NK cell activity (Biassoni et al., 2012). Since 
KIR and HLA genes are located on different chromosomes (number 19 and 6, respectively) 
and are inherited independently, it is possible that an individual may have KIRs with no HLA 
ligands and vice versa; consequently, this interaction or lack thereof can affect NK cell 
function and the susceptibility of an individual to disease (Gaudieri et al., 2005, Farag and 
Caligiuri, 2006, Kulkarni et al., 2008). The KIRs recognize specific motifs of HLA class I 
molecules and they bind in a nearly orthogonal orientation across the α1 and α2 helices of 
HLA class I molecules, which overlaps with, but is distinct from that of the TCR binding site 
(Boyington et al., 2000). Since the KIR binds to the polymorphic peptide binding groove of 
HLA class I molecules, it is constantly subjected to changes driven by rapidly evolving 
viruses and therefore, the KIR binding motifs are often variable between individuals and their 
distribution differs substantially between populations (Rajalingam, 2012). 
 
Table 1.3 Known KIR molecules and their HLA ligands  
KIR HLA-ligand Function 
2DL1 HLA-C2 (Lys 80) allotypes  Inhibitory 
2DL2 and 2DL3 
HLA-C1 (Asn 80) allotypes 
Select HLA-C2 alleles (C*05:01, C*02:02 and C*04:01) 
Select HLA-B alleles (B*46:01 and B*73:01) 
Inhibitory 
3DL1 
HLA-A and HLA-B allotypes expressing Bw4 epitope 
Select HLA-B alleles (B*08, B*27, B*57 and B*58) 
Select HLA-A alleles (A*24, A*23 and A*32) 
Inhibitory 
3DL2 Select HLA-A alleles (A*03 and A*11) Inhibitory 
2DL4 HLA-G Activating? 
2DS1 Putatively HLA-C2 (Lys 80) allotypes Activating 
2DS2 Putatively HLA-C1 (Asn 80) allotypes Activating 
2DS4 
Select HLA-C1 alleles (C*01:02, C*14:02 and C*16:01) 
Select HLA-C2 alleles (C*02:02, C*04:01 and C*05:01) 
Select HLA-A alleles (A*11:01 and A*11:02) 
Activating 
3DS1 Putatively HLA-Bw4? Activating 
Ligands for KIR2DL5, KIR2DS3, KIR2DS5, and KIR3DL3 remain undefined. Reproduced and 
modified from (Jamil and Khakoo, 2011, Biassoni et al., 2012, Jost and Altfeld, 2013) 
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HLA-C molecules constitute the dominant ligands for many KIR receptors, and HLA-C 
alleles can be grouped as: C1 or C2, depending on a dimorphism present in the α1 domain at 
position 80 (Wagtmann et al., 1995, Mandelboim et al., 1996, Mandelboim et al., 1997). 
Of the HLA-C allotypes currently defined on the IMGT/HLA Database (Robinson et al., 
2013b), nearly half of the HLA-C allotypes (C*02, C*04, C*05, C*06 and C*15) carry a 
lysine (K) at position 80 (80K) and are termed C2, these bind to inhibitory receptor 
KIR2DL1; the remaining HLA-C allotypes (C*01, C*03, C*07 and C*08) carry an 
asparagine (N) at position 80 (80N) and are termed C1, these bind inhibitory receptors 
KIR2DL2 and KIR2DL3 (Rajalingam, 2012). Additionally, two diverse HLA-B allotypes, 
B*46:01 and B*73:01 (that have the N80 motifs) as well as several C2 allotypes (notably 
C*05:01 and C*02:02) can serve as ligands for KIR2DL2/3 (Moesta et al., 2008). 
Furthermore, from functional analysis and binding assays, Moesta et al. (2008) reported that 
KIR2DL2 bound with greater affinity to HLA-C1 than KIR2DL3, and thus mediated stronger 
inhibition of NK cells than KIR2DL3. However, the inhibitory signals triggered by the 
2DL2/3-C1 interaction were relatively weaker compared to those triggered by the 2DL1-C2 
interaction (Winter et al., 1998). The same group identified that a dimorphism at position 44 
in the D1 domain of the KIR determined their ability to discriminate between the two groups 
of HLA-C allotypes (Winter and Long, 1997). 
 
The activating KIR ligands have not been as thoroughly defined, but KIR2DS1 has similar 
Ig-like domains to inhibitory KIR2DL1 and also binds HLA-C2, but with reduced avidity 
(Stewart et al., 2005). The same cannot be said for KIR2DS2, although KIR2DS2 and 
KIR2DL2 have high homology, KIR2DS2 shows no detectable avidity for HLA-C1 (Winter 
et al., 1998). The only other activating KIR with defined binding specificity is KIR2DS4, 
wherein KIR2DS4-f variants have been reported to interact with a select group of HLA-C 
allotypes carrying the C1 (C*01:02, C*14:02 or C*16:01) or C2 (C*02:02, C*04:01 or 
C*05:01) epitope (Mandelboim et al., 1996), as well as two HLA-A allotypes, A*11:01 and 
A*11:02 (Graef et al., 2009).  
 
While the binding of KIR2D receptors to HLA-C molecules has been shown to display 
preferences for certain peptides (Zappacosta et al., 1997), is not clear whether peptide 
selectivity has a role in NK receptor function. In chronically HIV-1 infected individuals, 
KIR-associated HIV-1 sequence polymorphisms were found to increase the binding of 
inhibitory KIRs to CD4+ T cells infected with HIV-1, decreasing the anti-viral activity of 
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KIR-positive NK cells (Alter et al., 2011). Since the peptide positions recognized by KIRs 
(i.e. the C-terminal residues P7 and P8 of the HLA-bound peptide) are not usually directly 
involved in TCR binding site (the central P5 position of the peptide), HLA molecules may be 
able to evolve their polymorphic regions to present diverse peptides for T cell-mediated 
immunity, while at the same time maintaining non-variant regions to bind self-peptides for 
KIR recognition and NK-cell-mediated immune defence (Li and Mariuzza, 2014). 
 
With regards to HLA-B alleles, these can be classified as either Bw4 or Bw6 as designated by 
five variable amino acids spanning positions 77-83 on the HLA class I α1 helix (Cella et al., 
1994, Gumperz et al., 1997). Bw4 epitopes have either isoleucine (80I) or threonine (80T) at 
position 80, and these include the HLA-B alleles: B*13, B*17, B*27, B*37, B*38, B*44, 
B*47, B*49, B*51, B*52, B*53, B*57, B*58, B*59, B*63 and B*77, as well as several 
HLA-A alleles: A*09, A*23, A*24, A*25 and A*32. In addition, Bw4:80T variants can vary 
with an alanine (81A) or leucine (81L) at position 81 (Muller et al., 1989, Cella et al., 1994). 
All other HLA-B alleles that lack the Bw4 motif are termed Bw6 (80N) and are not known to 
bind to any KIRs. KIR3DL1 recognize HLA allotypes that contain the Bw4, and have been 
reported to bind more strongly those with Bw4:80I than to Bw4:80T (Cella et al., 1994, 
Gumperz et al., 1997), furthermore, affinity seemed to be peptide dependent (Carr et al., 
2007). However, certain Bw4:80T allotypes, such as B*27:05, have been reported to be better 
ligands for certain KIR3DL1 subtypes (Luque et al., 1996). As with KIR2DL2 and 
KIR2DS2, KIR3DL1 and KIR3DS1 share >95% similarity in their extracellular domain, but 
there is no direct evidence of interactions between KIR3DS1 and Bw4 allotypes; 
nevertheless, genetic epidemiological, functional and population genetic data strongly 
support such an interaction (Kulkarni et al., 2008). KIR3DL2 was reported to be specific for 
HLA-A*03 and A*11 allotypes but with a limited ability to inhibit NK-mediated lysis 
(Dohring et al., 1996).  
 
Another unique KIR/HLA interaction includes KIR2DL4 with the non-classical class I 
HLA-G (Munz et al., 1997, Rajagopalan and Long, 1999). As mentioned previously, 
KIR2DL4 has both activating and inhibitory potential and it is one of the framework genes 
virtually present in all haplotypes and hence this receptor is constitutively expressed by all 
NK cells (Ivarsson et al., 2014). In addition, unlike all other KIRs, which are expressed on 
the surface of NK cells, KIR2DL4 as well as soluble forms of HLA-G (sHLA-G) can reside 
in endosomes and can signal from this intracellular site for a pro-inflammatory and 
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pro-angiogenic response, using a novel endosomal signalling pathway that involves the 
serine/threonine kinase cascade involving DNA-dependent protein kinases (DNA-PKcs), 
Protein kinase B (PKB) and nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κβ) (Rajagopalan et al., 2001, Rajagopalan et al., 2006, Rajagopalan and Long, 2012). 
HLA-G differs from the classical class I molecules (HLA-A, -B and –C) in that it has limited 
allelic variability, several membrane-bound and soluble isoforms, restricted tissue 
distribution and immune modulatory properties (Donadi et al., 2011, Alegre et al., 2014). 
HLA-G has been found to be highly expressed on foetal trophoblasts at the maternal-foetal 
interface and interaction with uNK cells promotes vascularisation of the maternal decidua, 
implying a role for KIR2DL4 and HLA-G during implantation and placentation (Kikuchi-
Maki et al., 2003, Dahl et al., 2014a). Several studies have shown that higher cell surface 
expression of KIR2DL4 is associated with successful pregnancy (Yan et al., 2007). However, 
ectopic expression of HLA-G molecules has been observed during conditions, such as viral 
infection, cancer, transplantation and in inflammatory diseases (Alegre et al., 2014). 
 
Thus, if a specific KIR/HLA combination is important for recognizing a host cell infected by 
a specific virus, then individuals who have a repertoire with more NK cells expressing that 
specific receptor may have a better immune response to that specific infection; conversely, 
NK cells that do not express a receptor for self-MHC class I may be less responsive to 
pathogen (Jamil and Khakoo, 2011). Therefore, diversity within the KIR system at the level 
of the locus, allele, expression pattern and HLA-ligand may influence the host immune 
response to infection. We will now focus on the role of KIR/HLA in HIV-1. 
 
1.5 KIR/HLA in HIV-1 infection 
By virtue of their expression on NK cells (central components of the innate immune system), 
the KIR with their HLA ligand interactions are important in the surveillance of viral-infected 
and tumour transformed cells. In general, some KIR haplotypes display a tendency toward 
more activation and this tendency in combination with the appropriate ligands have been 
associated with increased risk for inflammatory diseases, but also stronger anti-viral 
responses (Figure 1.9), whilst strong inhibitory haplotypes, such as the AA1 haplotype, have 
been associated with disorders in pregnancy (Khakoo and Carrington, 2006). Thus, the role of 
KIR/HLA in disease is dependent on a fine balance between NK cell activation and 
inhibition. 
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Figure 1.9 A model of KIR disease associations. In this model, KIR/HLA genotypes that provide 
either an „activating‟ or „inhibitory‟ potential on NK or T cells are associated with differing 
susceptibility to and protection against a range of diseases. Reproduced and modified from 
(Khakoo and Carrington, 2006). 
 
During acute HIV-1 infection, NK cells rapidly expand in response to a variety of cytokines 
prior to the CD8+ T cell response (Alter et al., 2007a, Alter et al., 2009). However, in an 
effort to escape CD8+ T cell lysis, as well as NK cell lysis, Nef selectively down-regulates 
HLA-A and HLA-B by triggering their retention in the golgi apparatus, while sparing HLA-C 
and HLA-E, the ligands for inhibitory receptors, KIR2D and CD94/NKG2A, respectively 
(Martin and Carrington, 2013). Nef also down-regulates stress-induced molecules, such as 
MICA which serve as ligand for the activating C-type lectin NK cell receptor, NKG2D 
(Cerboni et al., 2007). Additionally, during the course of infection the phenotype of 
peripheral NK cells change, wherein the predominant CD56
dim
 CD16
+
 NK cell population 
with strong cytolytic potential starts to diminish with appearance of functionally anergic 
CD56
-
 CD16
+
 NK cells, that express significantly higher levels of inhibitory receptors and 
lower levels of NCR compared with that of CD56+ NK cells (Jost and Altfeld, 2013, Martin 
and Carrington, 2013). Similarly other cross-sectional studies of NK cells in chronically 
HIV-1-infected patients have shown NK cell hypofunctionality (Mavilio et al., 2003, Fauci et 
al., 2005), which would suggest that the NK cells are unable to lyse autologous targets. 
 
The early events following HIV-1 infection have been reported to determine the course of 
disease progression in such a way that more robust control of viral replication during acute 
HIV-1 infection results in lower viral set-point and slower disease progression. Therefore, the 
early expansion of cytolytic NK cells prior to the adaptive response would suggest that 
NK cells play an important part in the establishing the viral set-point. In keeping with this, 
HIV-1 peptide-specific NK cell responses were associated with markers of less severe disease 
progression among chronically HIV-1-infected women (lower VL and higher CD4+ T cell 
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counts) as well as stronger HIV-1-specific T cell responses (Tiemessen et al., 2010). In 
addition, other studies have shown that early expansion of cytolytic CD56
dim
 CD16
+
 NK cells 
appears to be regulated to some extent by the individual‟s KIR/HLA genotype.  
 
Initial reports documented that there was significant suppression of HIV-1 viraemia and 
slower HIV-1 disease progression associated with homozygosity for HLA-Bw4 alleles 
(Flores-Villanueva et al., 2001). It was later discovered that the HLA-Bw4 effect on viraemia 
was associated with NK cells expressing the KIR3DL1/S1. HIV-1-infected individuals 
expressing KIR3DS1 as well as HLA-Bw4 alleles with an isoleucine in position 80 (HLA 
Bw4-80I) experienced significantly slower progression to AIDS and lower VL (Figure 1.10) 
as well as protection against opportunistic infections compared to individuals without 
HLA-Bw4-80I (Martin et al., 2002, Qi et al., 2006, Martin et al., 2007). These findings 
suggested that KIR3DS1 may bind HLA-B Bw4-80I ligands on HIV-1-infected target cells 
and delay AIDS progression; thus demonstrating an epistatic interaction between KIR and 
HLA in disease association (Bashirova et al., 2011). In vitro studies demonstrated that 
KIR3DS1+ NK cells were able to degranulate more potently in response to HIV-1-infected 
CD4+ T cells bearing HLA-Bw4:80I (Alter et al., 2007a), and KIR3DS1+ NK cells were 
highly enriched in the peripheral blood of individuals with acute infection, but only in 
individuals that had HLA-Bw4 alleles (Alter et al., 2009). 
 
Moreover, in the context of HIV-1 acquisition, NK cell activity was found to be significantly 
greater in a group of EU intravenous drug users compared to HIV-1-infected patients and 
unexposed individuals, and this was associated with significantly higher KIR3DS1 
expression in the EU individuals (Scott-Algara et al., 2003, Ravet et al., 2007). Other studies 
reported that KIR3DS1 homozygosity is enriched in EU individuals (Boulet et al., 2008b, 
Guerini et al., 2011), suggesting that KIR3DS1 may also be involved in protection from 
infection. Guerini et al. (2011) reported that the frequency of the KIR3DL1 allele and the 
KIR3DL1+/Bw4+ inhibitory complex was significantly lower, whereas the 
Bw4+/3DL1-/3DS1+ complex was significantly higher in EU individuals when compared to 
HIV-1-infected patients, suggesting that the reduced quantity of the KIR3DL1 in conjunction 
with Bw4 would reduce KIR3DL1-mediated inhibition of NK cells, thereby allowing NK 
cells to control acute HIV-1 infection in EU individuals. However, the KIR3DS1 protective 
association is not always evident: one study reported that individuals with KIR3DS1 and 
Bw4-80I actually exhibited an accelerated progression to AIDS, as did individuals carrying 
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the B haplotype, of which KIR3DS1 is associated with (Gaudieri et al., 2005). Furthermore, 
in a cohort of elite controllers (HIV-1 infected individuals who maintain a clinically 
undetectable VL without ART) HIV-1 control was not found to be associated with 
KIR3DS1/HLA genotype (O'Connell et al., 2009). Similarly, in another study, lower 
CD4+ T cell counts were associated with possession of group B haplotypes that lacked 
specific inhibitory ligands (Jennes et al., 2011).  
 
 
Figure 1.10 The effect of KIR3DS1 and HLA-B Bw4-80I on HIV-1 infection. (A) Kaplan-Meier 
survival analysis comparing individuals homozygous for HLA-B Bw6 and individuals with the 
KIR3DS1/Bw4-80I compound genotype in HIV-1 seroconverters. Modified from (Martin et al., 
2002). (B) Inhibition of viral replication by NK cells derived from subjects expressing both 
KIR3DS1 and Bw4-80I, HLA-B Bw4 and no KIR3DS1, KIR3DS1 and no HLA-B Bw4, and 
neither KIR3DS1 nor HLA-B Bw4. Reproduced and modified from (Alter et al., 2007a, 
Bashirova et al., 2011). 
 
In contrast, other studies identified that the inhibitory counterpart of KIR3DS1, KIR3DL1, 
was associated with HIV-1 disease progression. Martin et al. (2007) showed that various 
distinct allelic combinations of the KIR3DL1 and HLA-B loci significantly and strongly 
influenced both AIDS progression and plasma HIV-1 RNA abundance. Individuals encoding 
for HLA-Bw4 and highly expressed KIR3DL1 allotypes had significantly lower levels of 
HIV-1 replication as compared to individuals encoding for the same HLA-Bw4 alleles but 
KIR3DL1 allotypes associated with low expression (Martin et al., 2007). The authors 
suggested that during NK cell development, the higher expressing KIR3DL1 alleles that 
exhibited stronger inhibitory capacity would have greater potential for NK cell activation 
upon interaction with aberrant target cells in the event of viral infection, given that HIV-1 
infected cells downregulate cell surface expression of HLA-B. Likewise, when comparing the 
functional profile of NK cells from individuals carrying different KIR3DL1 and HLA-B allele 
A B
(P<0.001)
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combinations, NK cells from individuals with high KIR3DL1 expression and B*57 
(a Bw4:80I allele) exhibited an increased representation of polyfunctional NK cells as 
compared to other individuals carrying other Bw4 or Bw6 alleles (Boulet et al., 2010, Kamya 
et al., 2011). 
 
Other KIR/HLA interactions have also been found to influence HIV-1 transmission. In a 
cohort of commercial sex workers (CSW), Jennes et al. (2006b) showed that the EU CSW 
were characterised by KIR2DL2/KIR2DL3 heterozygosity in the absence of HLA-C1, and 
KIR3DL1 homozygosity in the absence of HLA-Bw4, while HIV-1 infected CSW were 
characterized by KIR2DL3 homozygosity together with HLA-C1 and a trend toward 
KIR3DL1/HLA-Bw4 homozygosity (Jennes et al., 2006b). This group further reported that 
KIR/HLA incompatibility between sexual partners conferred protection against HIV-1 
transmission and was possibly due to recipient NK cell-mediated killing of the HIV-1 
infected partner‟s cells, i.e. allorecognition (Jennes et al., 2013). HIV-1 discordant couples 
were characterized by recipient partners with homozygous KIR2DL2, and by a mismatched 
recipient partner KIR2DL1/HLA-C2 index partner HLA-C1/C1 combination expected to allow 
licensed „missing self‟ NK cell killing of index partners‟ cells. HIV-1 concordant couples on 
the other hand were characterized by KIR2DL3 homozygous recipient partners with 
HLA-C1/C2 bearing index partners, resulting in a matched KIR/HLA combination expected 
to inhibit NK cell killing.  
 
Other evidence from Zambian serodiscordant couples showed that carriage of KIR2DS4-f was 
associated with relatively higher HIV-1 VL in index (HIV-1 seroprevalent) partners 
compared with index partners without the allele (Merino et al., 2011). In addition, carriage of 
KIR2DS4-f was associated with accelerated transmission of HIV-1 to cohabiting seronegative 
partners. This suggested that KIR2DS4-f might increase the likelihood of HIV-1 transmission. 
Furthermore, the same group observed that in chronically infected HIV-1 positive individuals 
with NK cells that did or did not express KIR2DS4 often differed in their functional 
properties, especially in terms of degranulation (production of CD107a) and/or induction of 
IFN- and MIP-1β (Merino et al., 2014). They observed that after stimulation with 
HLA-deficient K562 cells, NK cells that were positive for the 
KIR2DS4-f genotype (designated g+) but negative for the membrane-bound KIR2DS4 
staining (designated p−) universally behaved like those that were negative for both (g−/p−), 
while polyfunctional NK cells co-expressing CD107a, IFN-γ and MIP-1β were highly 
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enriched in the g+/p+ NK cells when compared with the g+p− and g−p− NK cells. The 
authors postulated that prolonged or excessive NK cell activation (as seen in chronic HIV-1 
infection) may fuel inflammation and promote HIV-1 pathogenesis in two possible ways: 
firstly, over-activation of NK cells created a pro-inflammatory environment promoting HIV-1 
replication, or secondly NK cell activation promoted early senescence of NK cells with 
subsequent loss of viral control (Merino et al., 2014). 
 
Regarding the ligand for KIR2DL4, several studies have shown specific HLA-G 
polymorphisms to be associated with altered risk of HIV-1 infection (Matte et al., 2004, 
Lajoie et al., 2010, Segat et al., 2010). In Zimbabwean women, Matte et al (2004), reported 
that null allele, G*01:05N, significantly associated with protection from HIV-1 infection, 
whereas, G*01:01:08 was associated with a 2.5 fold increased risk of HIV-1 infection. 
Conversely, in HIV-1 infected Caucasians from North Eastern Italy, Segat et al (2010) 
reported that G*01:05N correlated with increased risk for HIV-1 infection. Other work done 
by Lajoie et al (2010) on HIV-1 infected and uninfected female commercial sex workers 
(CSW) from Benin demonstrated that HIV-1 infected CSW had significantly lower levels of 
plasma sHLA-G compared with those in both the HIV-1-uninfected CSW and the non-CSW 
groups. In addition, they also found that the presence of G*01:01:01, and G*01:04:04 alleles 
were significantly associated with lower plasma sHLA-G levels in the HIV-1-infected CSWs. 
Nevertheless, while these studies seem to disagree, they do provide evidence that modulation 
of HLA-G expression may contribute to the risk of HIV-1 infection. 
 
1.5 KIR/HLA genotypes in MTCT of HIV-1 
With regards to the role of KIR and HLA ligands in MTCT of HIV-1, very little is known 
and to our knowledge we are the only group to have assessed KIR/HLA gene combinations in 
MTCT of HIV-1. Initial findings showed that mothers and infants who were less likely to 
transmit and/or acquire HIV-1 infection, respectively, had CD3-negative cells that were able 
to responded to HIV-1 peptides (Tiemessen et al., 2009). Using a whole blood intracellular 
cytokine staining (ICS) assay measuring both IFN- and IL-2 production, CD3-negative cells 
from HIV-1 non-transmitting (NT) mothers were found to respond with remarkable 
specificity to HIV-1 peptides from Env and Reg protein regions when compared to NK cells 
from the HIV-1 transmitting (TR) mothers; moreover, these cells from EU infants of NT 
„responder‟ mothers were also able to respond to HIV-1 peptides (Figure 1.11).  
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Figure 1.11 Representative flow cytometric plots showing unstimulated (US) and Env or Reg 
peptide-stimulated, CD3-negative response in a non-transmitting (NT) mother (top row) as well 
as her exposed uninfected (EU) infant‟s response (bottom row). The x-axis shows anti-CD3-
allophycocyanin and the y-axis shows anti-IL-2-PE plus anti-IFN--PE (anti-IL-2 was included 
for the detection of T cell responses, however, IL-2 is not produced by NK cells). Percentages in 
red indicate positive CD3-negative responses in the relevant quadrant. Reproduced from 
(Tiemessen et al., 2009). 
 
Through further flow cytometric analyses and review of the above results, the authors 
inferred that these HIV-1-specific CD3-negative cells were NK cells based on the following 
criteria: (1) the responding CD3-negative subsets did not contain B cell (CD19) or monocyte 
markers (CD14) and gated monocytes did not produce IFN- in the ICS assay, 
(2) CD3-negative cell subset responses all correlate positively and significantly when 
comparing the same protein region responses across the CD8+ and CD8- subsets, with or 
without the NK cell marker (CD56), suggesting that it was highly likely these CD8+ and 
CD8- subsets were from the same cell type that respond similarly to specific peptides, 
(3) early activation marker (CD69) which correlates with cytotoxic activity was expressed on 
all HIV-1-specific IFN- expressing CD3-negative cells, (4) where anti-CD56 was included 
in the staining panel, CD56+ cells were CD56
dim
, suggesting that they are cytotoxic NK cells 
and capable of perforin and granzymes production, and lastly (5) IFN--producing CD3-
negative cells also expressed NKp46, an NK cell receptor present on all NK cells (Tiemessen 
et al., 2009). Thus, the data suggested that HIV-1 exposure took place in the infants of HIV-
1-infected mothers and that the immune responses mounted by NK cells in the EU infant 
potentially contributed to protection from infection. These specific NK cell responses to 
HIV-1 peptides lead the authors to further postulate that these “responders” would possess a 
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more activating KIR gene profile and/or particular KIR/HLA combinations that would 
explain the ability of their NK cells to overcome inhibitory signals and so be able to mount 
NK cell responses in the presence of HIV-1 peptides (Tiemessen et al., 2009). Therefore, 
Tiemessen et al. (2011) undertook to evaluate the relationship of NK cell responsiveness of 
the particular KIR gene repertoires and HLA-ligands in HIV-1 infected mothers and their 
infants who did/did not respond to HIV-1 peptides. It was shown that maternal NK cell 
responses to HIV-1 Env peptides were more likely to occur amongst individuals with at least 
one C1 allele together with a KIR genotype supporting a more activated NK cell phenotype 
(Tiemessen et al., 2011). Evidence of the C1 association with HIV-1 peptide-specific NK cell 
responses highlighted the importance of its KIR partners KIR2DL2, KIR2DL3, and 
KIR2DS2. Thus, correspondingly, it was the combination of KIR2DL3 plus HLA-C1 (the 
presence of its ligand) that showed a trend towards increased representation in the responders, 
and homozygous KIR2DL3+C2/C2 (the absence of its ligand) that showed a trend towards 
increased representation in the non-responders. 
 
More in-depth analysis of mother and infant KIR/HLA genotypes revealed that KIR2DL2 and 
KIR2DL3 as well as their HLA-C ligands emerged as important factors in both maternal 
transmission and infant acquisition of HIV-1 (Paximadis et al., 2011). By comparing TR 
mothers to NT mothers, it was also shown that KIR haplotypes, Bx32 and Bx20, had 
opposing effects on maternal transmission of HIV-1, wherein Bx32 was associated with 
increased risk for transmission (particularly IP transmission) and Bx20 was associated with 
decreased risk for transmission. Examination of these two KIR genotypes showed that the 
only difference between them was the presence of KIR2DL2 in Bx20. In addition, 
representation of KIR2DL2 as well as KIR2DL2/KIR2DL3 was higher in NT mothers 
compared to IP-TR mothers (P=0.053, OR=0.43 and P=0.008, OR=0.29, respectively), whilst 
KIR2DL2 homozygosity in combination with C1/C1 was significantly higher in TR mothers 
compared to NT mothers (P=0.041, OR=5.36). Therefore, suggesting both KIR2DL2 and 
KIR2DL3 where important factors in vertical transmission of HIV-1. 
 
Furthermore, it was found that maternal possession of KIR2DL3 homozygosity alone and in 
combination with C1/C2 allotypes was associated with increased risk for IP transmission 
(P=0.034, OR=2.42 and P=0.010, OR=3.63, respectively). However in infants, KIR2DL2 
homozygosity was higher in EU infants compared to IP infected (P=0.052, OR=0.16) and 
representation of KIR2DL3 homozygosity in combination with C1/C2 ligand was 
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significantly higher in EU infants compared to HIV-1 infected infants (P=0.038, OR=0.40). 
The possession of KIR2DL3/KIR2DL3+C1/C2 in mothers and infants was only shown to 
associate with protection in infants when the genotype was absent in the mother. Comparison 
of concordance and discordance for KIR2DL3/KIR2DL3+C1/C2 between mother and infant 
was noticeably different in EU infants compared to the total HIV-1-infected (INF) and IP 
infected infants (Figure 1.12). In IP infants the frequency of KIR2DL3/KIR2DL3+C1/C2 
genotype concordance between mother and infant was greater than that of the EU infants 
(Paximadis et al., 2011). These findings suggested that the risk of vertical transmission, 
particularly IP-transmission, is in part dependent of the KIR/HLA gene combination across 
mothers and infants. Moreover, the data also suggested that EU protection was associated 
with the presence of the weaker inhibitory KIR2DL3 (Moesta et al., 2008) in combination 
with at least one C1 ligand which would have a lower threshold for NK cell activation than 
the KIR2DL2/KIR2DL2 with C1/C1 combination, and thus homozygous KIR2DL3 NK cells 
may be more competent in targeting HIV-1-infected maternal cells. 
 
 
Figure 1.12 Maternal-infant concordance (M+I+) and discordance (M+I- or M-I+) with respect 
to KIR2DL3/KIR2DL3+C1C2. (A) The percentage of maternal subgroups all harbouring 
KIR2DL3/KIR2DL3+C1C2 that are concordant (M+I+) and discordant (M+I-) with their 
respective infants for the KIR2DL3/KIR2DL3+C1C2 genotype. (B) The percentage of infant 
subgroups all harbouring KIR2DL3/KIR2DL3+C1C2 that are concordant (I+M+) and discordant 
(I+M-) with their respective mothers for the KIR2DL3/KIR2DL3+C1C2 genotype. M: Mother; 
I: Infant; +: positive; -: negative; NT: non-transmitting mothers; T: total transmitting mothers; IP: 
intrapartum-transmitting mothers. EU: exposed-uninfected infants; INF: total infected infants; IP: 
infants infected through the intrapartum route. Reproduced from (Paximadis et al., 2011). 
 
Overall, the findings by Tiemessen et al. (2009, 2010, and 2011) and Paximadis et al. (2011) 
highlighted that both variation at the KIR locus, KIR genotype and ligand dosage impact on 
the ability of NK cells to respond to HIV-1 peptides and thus could influence both maternal 
transmission as well as infant acquisition of HIV-1. Moreover, KIR/HLA gene combinations 
A) B)
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favouring NK cell activation over inhibition may be beneficial in the prevention of MTCT of 
HIV-1. However, it was emphasized by Paximadis et al. (2011) that a number areas within 
KIR/HLA analysis required further investigation to elucidate the exact role of KIR/HLA on 
MTCT of HIV-1. These included: (1) mother-infant KIR/HLA genotype concordance, (2) 
infant NK cell allorecognition of infected maternal cells, (3) KIR allelic variation, and (4) the 
role of HLA-G, the ligand for KIR2DL4, given that HLA-G is localized at the maternal–
foetal interface and has an important role in regulating maternal–foetal immunity. For this 
reason, this thesis aimed to further explore these areas in two mother-infant cohorts that had 
different PMTCT therapies.  
 
1.6 Study Rationale 
It has been more than 30 years since the discovery of HIV-1 and to date there is still no 
preventative vaccine for HIV-1. This highlights the need to more thoroughly understand what 
constitutes an effective immune response against the virus. In particular, studying the 
immune response in those individuals who have been exposed to HIV-1 but remain 
uninfected (EU) may offer key insights into what might qualify as protective responses. 
Using the mother-to-child transmission model provides us the unique opportunity to study 
correlates of protection in EU infants. Importantly, having both mother (transmitter and non-
transmitter) and infant (infected and uninfected) provides insight into which immunological 
factors contribute to HIV-1 transmission and acquisition. Evidence indicates that NK cells 
through their KIR and HLA-ligand interactions have a role to play in the control of adult 
HIV-1 infection; however, little is known about the role of KIR/HLA genes in vertical 
transmission. Using the mother-infant transmission model, Paximadis et al. (2011) suggested 
that certain inhibitory KIR/HLA-ligand gene combinations alter the risk of maternal HIV-1 
transmission as well as infant susceptibility to HIV-1 acquisition. The authors emphasized the 
need to further explore the relationship of KIR and HLA-ligands amongst mother-infant pairs, 
the effect of specific KIR alleles and other HLA-ligands in MTCT of HIV-1. Thus, we set out 
to evaluate whether specific KIR/HLA gene combinations would equally associate with risk 
of transmission in two distinct mother-infant cohorts characterised by differing ART 
regimens and different rates of HIV-1 transmission. The overall purpose was therefore to gain 
better insight into the role of immunogenetic mechanisms of KIR and HLA in MTCT of 
HIV-1 in the context of changing PMTCT ART therapies. Knowledge of these mechanisms 
may ultimately assist in designing strategies for vaccination and therapy. 
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1.7 Study objectives  
The overall purpose of this study was to identify immunogenetic factors of KIR and HLA that 
associate with MTCT of HIV-1. To address this, two mother-infant cohorts (MTCT1 and 
MTCT2) distinguished by differing ART regimens and transmission rates were studied. In 
MTCT1 (N=217) the overall HIV-1 transmission rate was 9.8% and approximately half the 
mothers received sdNVP, whilst in MTCT2 (N=79) the overall HIV-1 transmission rate was 
5.2%, more than half the mothers received dual ART consisting of short course AZT as well 
as sdNVP at the onset of labour.  
 
The specific objectives were:  
1. To develop and validate in-house real-time PCR KIR and HLA-ligand genotyping 
methods and compare with conventional KIR and HLA Class 1 genotyping methods for 
the purpose of reducing cost, time and sample requirement, while maintaining 
specificity and sensitivity. 
2. To determine whether KIR/HLA-ligand combinations of mothers and infants associate 
with resistance and/or susceptibility to vertical transmission of HIV-1. 
3. To determine whether functional or non-functional allelic variants of KIR2DS4 
(KIR2DS4-f and KIR2DS4-v, respectively) associate with resistance or susceptibility to 
vertical transmission of HIV-1. 
4. To determine the association between HLA-G (alleles and 3‟UTR polymorphisms) and 
resistance or susceptibility to vertical transmission of HIV-1. 
5. To establish if immunogenetic relationships (KIR/HLA-ligands, KIR2DS4 and HLA-G 
genotypes) found in MTCT1 are maintained with increased ART exposure in MTCT2. 
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CHAPTER 2 
Materials and Methods 
 
2.1 Study Cohorts 
This thesis describes the findings from the study of multiple mother-child cohorts, recruited 
from 1996 onwards (Figure 2.1). Selections of samples from four earlier cohorts were 
combined into one large cohort for analyses, and for the purpose of this thesis are termed 
“MTCT1”. Numerous publications have resulted from studies of the individual cohorts, 
sub-cohorts within these as well as the greater cohort, MTCT1 (Kuhn et al., 2001, Kuhn et 
al., 2002, Petra_Study, 2002, Shalekoff et al., 2004, Gray et al., 2005, Meddows-Taylor et al., 
2006, Schramm et al., 2006, Kuhn et al., 2007, Schramm et al., 2007, Tiemessen and Kuhn, 
2007, Shalekoff et al., 2009a, Shalekoff et al., 2009b, Tiemessen et al., 2009, Schramm et al., 
2010, Paximadis et al., 2011). In addition, a fifth cohort, termed “MTCT2” was recruited 
several years later at a time when the primary ART consisted of dual therapy regimens; 
likewise several publications have resulted from the study of this cohort (Lilian et al., 2012, 
Lilian et al., 2013, Lilian et al., 2014). Data generated from these two cohorts (MTCT1 and 
MTCT2) are presented in Chapters 4, 5 and 6. 
 
 
Figure 2.1 A schematic representation of the mother-infant cohorts used in this thesis designated 
MTCT1 (Cohorts 1 – 4 combined) and MTCT2 (Cohort 5). Monotherapy largely consisted of 
sdNVP given to the mother at the onset of labour and the infant within 72 hours of birth; dual 
therapy for the mother consisted of daily dose AZT from 28 - 37 weeks gestation as well as 
sdNVP at the onset of labour, while their infants received sdNVP at birth and daily AZT for a 
minimum of 1 week; early HAART consisted of triple drug therapy using the South African 
regimen 1B (d4T/3TC/NVP). 
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2.1.1 MTCT1 
MTCT1 represents a retrospective, nested case–control study combining data from four 
cohorts of HIV-1 infected mothers and their infants that were enrolled between 1996 and 
2005 from two hospitals in Johannesburg, South Africa. The cohorts are described in detail 
below: 
 
I. Cohort 1: included a selection of mother-infant samples from an earlier trial that took 
place at Chris Hani Baragwanath Academic Hospital (CHBAH) from 1996 to 2000. The 
greater trial aimed to assess the efficacy of three short-course regimens of AZT and 3TC 
in preventing early and late transmission of HIV-1 from mother to child in Tanzania, 
South Africa, and Uganda (Kuhn et al., 2001, Petra_Study, 2002). Within this study, 
HIV-1 positive women who had not accessed antenatal HIV-1 testing were identified 
through a post-partum voluntary counselling and testing (PP-VCT) service that had been 
set up for the trial. These women had received no antiretroviral drugs before delivery; 
however their infants received either AZT or sdNVP as a post-exposure prophylaxis 
(PEP). Small aliquots (3-5 ml) of cord blood were collected from all deliveries, and if the 
woman enrolled, the cord blood was retained for research, otherwise it was discarded. 
Blood was drawn from mothers and infants at enrolment. Infants were scheduled for 
follow-up at 6 weeks and, if still breast-feeding, for continued follow-up for a minimum of 
4 weeks after cessation of breast-feeding. Infant samples were tested for HIV-1 DNA by 
PCR to determine their infection status. From this cohort, 20 mother-infant pairs were 
selected for MTCT1, wherein all of the mothers were ART naive (Table 2.1). 
 
II. Cohort 2: included mother-infant samples that were part of a PEP trial conducted at 
CHBAH from 2000 to 2002 (Gray et al., 2005). Women were eligible for the trial if they 
tested HIV-1-positive for the first time after delivery and were drug naive, usually because 
they received no prenatal care or had attended prenatal clinics where HIV-1 testing was 
not available at the time. However, as in cohort 1, their infants were randomized to receive 
either AZT or sdNVP to reduce the risk of vertical transmission. Additionally, drug-
exposed, HIV-1-positive mothers (as well as their infants) were recruited amongst mothers 
delivering at the hospital around the same time. To qualify, these mothers needed to have 
attended the prenatal clinic at CHBAH, received HIV-1 counselling and testing there, and 
had accepted sdNVP as part of a demonstration of antiretroviral therapy (DART) 
initiative. NVP was given as a single maternal 200 mg oral dose at the onset of labour and 
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a single 0.6 mL infant dose within 72 hours of birth. Infants were followed up 
prospectively after birth to determine their HIV-1 status until 3 months or for a minimum 
of 4 weeks after cessation of breast-feeding. HIV-1 DNA PCR was performed on infant 
peripheral blood samples collected at birth and at 6 weeks of age. From this cohort, 
61 mother-infant pairs were selected for MTCT1, wherein 14 (23%) mothers received 
sdNVP at the onset of labour (Table 2.1). 
 
III. Cohort 3: mother-infant samples were collected at CHBAH but from 2003 to 2005, as 
part of a study to investigate immunogenetic factors involved in MTCT under 
antiretroviral treatment (Kuhn et al., 2001, Kuhn et al., 2002, Shalekoff et al., 2004, 
Meddows-Taylor et al., 2006, Schramm et al., 2006, Schramm et al., 2007, Shalekoff et 
al., 2009a, Shalekoff et al., 2009b, Schramm et al., 2010). Women in the maternity ward 
who were identified as being HIV-1 positive as part of the PP-VCT program were enrolled 
and maternal and infant blood was collected soon after delivery. Infants were given 
sdNVP as PEP and mothers were counselled about infant feeding options. In addition, 
women who were identified as being HIV-1 positive during pregnancy and who 
participated in routine PMTCT services were also enrolled. These women received sdNVP 
at the onset of labour and their infants received sdNVP within 72 hours of birth. As above, 
maternal and cord blood was collected soon after delivery. In addition, where possible a 
venous blood sample was collected from infants at 4 and 9 months to determine their 
HIV-1 status. From this cohort 75 mother-infant pairs were selected for MTCT1, 
wherein 52 (69%) mothers received sdNVP at the onset of labour (Table 2.1). 
 
IV. Cohort 4: included mother-infant samples collected from mothers who were currently 
enrolled in PMTCT services at the former Coronation Hospital, now known as the Rahima 
Moosa Mother and Child Hospital (RMMCH) from 2004 to 2005. Mothers were identified 
at 6 weeks post-partum when they returned for postnatal follow-up services, at which time 
blood was drawn from mothers and infants. These mothers received either sdNVP or 
combination ART (lopinavir/ritonavir, stavudine (d4T), lamivudine (3TC) or efavirenz) if 
identified with low CD4+ T cell counts early enough during pregnancy (combination 
therapy would have been initiated at any stage of pregnancy but adherence in these women 
may not have been complete however, NVP or other ART intervention would have been 
taken prior to delivery). From this cohort 61 mother-infant pairs were selected for 
MTCT1, wherein 55 (90%) mothers received sdNVP at the onset of labour (Table 2.1). 
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Table 2.1 Distribution of the mothers across the four cohorts represented within MTCT1 with 
their respective PMTCT ART 
MTCT1 Mothers 
Cohort 1 
N=20 
Cohort 2 
N=61 
Cohort 3 
N=75 
Cohort 4 
N=61 
Total 
N=217 
TR mothers 6 22 24 20 72 
NT mothers 14 39 51 41 145 
PMTCT ART (maternal)      
None 20 (100%) 47 (77%) 23 (31%) 0 (0%) 90 (41%) 
sdNVP 0 (0%) 14 (23%) 52 (69%) 55 (90%) 121 (56%) 
Other ART 0 (0%) 0 (0%) 0 (0%) 6 (10%) 6 (3%) 
PMTCT, prevention of mother-to-child transmission; ART, antiretroviral therapy; NT, HIV-1 
non-transmitting mother; TR: HIV-1 transmitting mother; sdNVP, single-dose nevirapine. 
 
In each of these cohorts, mothers who met the eligibility criteria for these studies were 
counselled about the objectives and methods of the study. Eligibility criteria were: older than 
18 years of age, or legal age of consent, evidence of HIV-1 infection, ability to give informed 
consent, estimated gestational period of less than 36 weeks at enrolment, absence of severe 
foetal anomalies within the limits of local diagnostic possibilities, absence of life-threatening 
disease, haemoglobin above 8 g/dL at enrolment and an 18 months' follow-up. Mothers 
interested in participating in the study were given a patients' information sheet describing the 
study. Women who met all eligibility criteria and signed informed consent were enrolled. In 
total, out of 849 HIV-1 infected mothers enrolled in the four cohorts, 83 mothers transmitted 
HIV-1 to their infants, thus the MTCT rate was calculated at 9.77%.  
 
All blood specimens were collected in ethylenediaminetetraacetic acid (EDTA) tubes and 
samples were processed by standard procedures within 24 hours of collection. Plasma and 
buffy coats were stored at −70°C. Maternal plasma samples were sent for HIV-1 RNA 
quantitative testing using the Roche Amplicor HIV-1 RNA Monitor assay version 1.5 (Roche 
Diagnostic Systems, Inc., Branchburg, NJ) and CD4+ T cell counts were quantified using the 
commercially available FACSCount System from Becton Dickinson (San Jose, CA). Infant 
HIV-1 status was determined by HIV-1 DNA PCR tests (Roche Amplicor version 1.5) at 
birth, 6 weeks and 3 months of age. In utero (IU) infected infants were defined as PCR 
positive at birth and at 6 weeks and intrapartum (IP) infected infants were defined as PCR 
negative at birth but positive at 6 weeks. Infants with positive PCR results were recalled for 
confirmatory tests. A summary of the maternal clinical characteristics and ART regimen for 
the collective MTCT1 cohort (N=217) are presented in Table 2.2. 
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For MTCT1, all available HIV-1 transmitting mother-infant samples (TR, N=72) from the 
four transmission studies were selected as “cases” for the nested analysis. As controls, two 
HIV-1 non-transmitting mother-infant samples (NT, n=144) for each case were randomly 
selected from each of the four transmission studies giving rise to the cases (Table 2.1). 
HIV-1 infected infants were further characterized according to timing of transmission as 
determined by an HIV-1 DNA PCR test (Roche Amplicor version 1.5) at birth and at 6 weeks 
of age. In total 19 (26.4%) were IU infected, 29 (40.3%) were IP infected and the remaining 
24 infants were found to be positive at 6 weeks but had no birth sample available (unknown 
whether IU or IP).  
 
For analyses confined to mother-infant pairs who received maternal sdNVP (Table 2.2), 
within the total group of TR mothers (n=72), 29 mothers IP transmitted, wherein the majority 
of these mothers were ART naive (19/24, 65.5%) as compared to mothers that received 
sdNVP (10/19, 34.5%), P=0.035. Conversely, in IU-transmitting mothers (n=19), the 
majority of these mothers received sdNVP (12/19, 63.2%) as compared to mothers that were 
ART naive (7/19, 36.8%), P=0.194. We also analysed associations for an IU-enriched group 
called IU2. In IU2 we combined the 19 known IU-infected infants with the 24 infected 
infants of unknown transmission on the basis that 79% (19/24) of these mothers received 
sdNVP as compared to mothers that were ART naive (3/24, 12.5%), P<0.001 (Table 2.2). 
The rationale for this is that maternal sdNVP administration given only at the onset of labour 
is known to have little to no effect on reducing IU infection. Thus, we can infer that when 
infection does occur in an sdNVP-exposed infant, there is a greater likelihood that it is due to 
IU infection than due to IP infection.  
 
Table 2.2 Clinical characteristics of MTCT1 mothers and their antiretroviral therapy (ART) 
HIV+ mothers 
Median (IQR) 
NT 
(N=144) 
TR 
(N=72) 
IP-TR 
(N=29) 
IU-TR 
(N=19) 
Unknown-TR 
(N=24) 
Age (years) 27 (22-30) 29 (24-31) 29 (22-31) 29 (22-31) 28 (25-30) 
log10 VL (copies/ml) 4.0 (3.2-4.6) 4.8 (3.7-5.4) 4.8 (3.9-5.3) 4.9 (4.2-5.5) 4.6 (2.6-5.4) 
CD4 (cells/l) 449 (319-681) 375 (253-575) 378 (262-508) 350 (182-647) 437 (301-590) 
ART Naive 60 (41.7%) 29 (40.3%) 19 (65.5%) 7 (36.8%) 3 (12.5%) 
sdNVP at labour 80 (55.5%) 41 (56.9%) 10 (34.5%) 12 (63.2%) 19 (79.2%) 
Other ART 4 (2.8%) 2 (2.8%) 0 (0%) 0 (0%) 2 (0%) 
IQR: interquartile range (25th and 75th percentile); VL: viral load; NT: HIV-1 non-transmitting 
mothers; TR: total group of HIV-1 transmitting mothers; IP-TR: intrapartum HIV-1 transmitting 
mothers; IU-TR: in utero HIV-1 transmitting mothers; Unknown-TR: HIV-1 transmitting 
mothers unknown whether IU or IP 
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2.1.2 MTCT2 
The study involving this cohort was also a nested case–control design and utilized samples 
collected from a prospective, observational study that was conducted at RMMCH in 
Johannesburg, South Africa, from August 2008 to December 2010. HIV-1 infected women 
over 18 years of age, who were identified during antenatal testing and who planned to attend 
RMMCH for follow-up PMTCT care were eligible to participate in the study (Lilian et al., 
2012). According to national PMTCT guidelines at the time, routine PMTCT care was 
offered to all mother-infant pairs enrolled in the study, which primarily consisted of maternal 
sdNVP at the onset of labour together with daily AZT from 28 weeks gestation (full term 
gestation considered to be 39 weeks). In addition, infants received sdNVP at birth and daily 
AZT for a minimum of 1 week. If maternal PMTCT care was suboptimal, defined as less than 
4 weeks of AZT, the infant received 4 weeks of AZT (National Department of Health, 2008). 
All women with CD4+ T cell counts of ≤ 200 were eligible for HAART. Furthermore at the 
time of this study, most women at RMMCH elected to exclusively formula feed. Thereafter, 
national PMTCT guidelines were updated again in 2010, wherein maternal AZT commenced 
from 14 weeks gestation and all HIV-1-exposed infants provided with a daily dose of NVP 
for 6 weeks or for the duration of breast-feeding. Furthermore, all women with CD4+ T cell 
counts of ≤ 350 were eligible for HAART.  
 
Infants underwent HIV-1 DNA PCR testing (Amplicor HIV-1 DNA PCR, version 1.5; Roche 
Molecular Systems Inc., Branchburg, NJ) on peripheral blood at 6 weeks, and test results 
were provided to the infants‟ caregivers at the 10 week visit. Where the PCR result was 
negative, the mother was counselled regarding the risk of postnatal transmission of HIV-1 
and the infant discharged. Where the PCR result was positive, a confirmatory baseline VL 
test and a CD4+ T cell count were performed and the infant was referred for HAART 
initiation. 
 
Dried blood spots (DBS) samples were obtained from the infants at each visit. At birth and 
2 weeks, blood was collected by heel prick onto Schleicher & Schuell 903 (S&S 903 W-041) 
filter paper cards, and at the 4- and 6-week visits, blood was collected by venesection and 
spotted onto filter paper cards. Each DBS card was stored at RMMCH at ambient room 
temperature in a zip-lock plastic bag with a dessicant sachet. 
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Overall, the study enrolled 848 mother-infant pairs, of which 10 (1.2%) mothers withdrew 
during the course of the study and 128 (15.3%) HIV-1-exposed infants were excluded from 
all analyses because they were lost to follow-up or died before an HIV-1 status could be 
established. Of the remaining 710 mother-infant pairs, 557 (78.5%) received optimal 
maternal PMTCT care, defined as 4 or more weeks of AZT or HAART. sdNVP in 
combination with variable durations of AZT was administered to 653 (92.0%) infants, 
56 (7.9%) infants received daily-dose NVP, and a single infant did not receive any PMTCT 
prophylaxis. Antenatal CD4+ T cell counts were available for 638 women, of which a 
CD4+ T cell count of ≤ 350 cells/µL was recorded for 316 (49.5%) women, accounting for 
60.6% of vertical transmissions. Of the 710 infants, 691 (97.3%) had their HIV-1 status 
determined by the 6-week PCR and the remaining 19 (3%) infants had their HIV-1 status 
established from stored DBS samples. Out of 710 infants, 37 infants were HIV-1 infected, 
thus the MTCT rate was 5.21%. HIV-1 infected infants where further classified as 
IU-infected (N=25, 67.6%) or IP-infected (N=12, 32.4%). 
 
For MTCT2, all available TR mother-infant samples were matched 1:1.2 with a NT mother-
infant sample of similar maternal VL, maternal CD4+ T cell count, as well as mother and 
infant PMTCT regimen. In total, 79 mother-infant pairs were selected (Figure 2.2), which 
consisted of 36 TR mothers and their IP- or IU- infected infants as well as 43 NT mothers and 
their EU infants (n=44, one NT mother had twins). Clinical characteristics and ART for 
MTCT2 mothers is shown in Table 2.3.  
 
 
Figure 2.2 A Schematic representations of the two mother-infant cohorts used in this thesis, 
termed MTCT1 and MTCT2. TR, transmitting mother; NT, non-transmitting mother; IP, 
intrapartum infected infant; IU, in utero infected infant; IU2, IU-enriched group of infants; and 
EU, exposed uninfected infants. 
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Table 2.3 Clinical characteristics of MTCT2 mothers and their antiretroviral therapy (ART) 
HIV+ mothers (Median, IQR) NT (N=43) IP-TR (N=11) IU-TR (N=25) 
Age (years) 27 (26-30) 25 (24-29) 26 (21-30) 
log10 VL (copies/ml) 4.7 (3.9-5.1) 4.8 (4.5-5.2) 4.5 (3.2-4.9) 
CD4 (cells/l) 342 (244-447) 245 (171-406) 286 (234-424) 
Maternal ART (n, %)    
ART naive 4 (9.1%) 2 (18.2%) 0 (0%) 
sdNVP+AZT (< 2weeks) 14 (31.8%) 3 (27.3%) 11 (44.0%) 
sdNVP+AZT (> 2weeks) 25 (56.8%) 6 (54.6%) 13 (52.0%) 
HAART 1 (2.3%) 0 (0%) 1 (4.0%) 
Infant ART (n, %) EU (N=44) IP (N=11) IU (N=25) 
sdNVP+1week AZT 17 (38.6%) 5 (45.4%) 13 (52.0%) 
sdNVP+4week AZT 20 (45.4% 6 (54.6%) 10 (40.0%) 
NVP for 6weeks or duration of BF 7 (15.9%) 0 (0%) 2 (8.0%) 
IQR: interquartile range (25th and 75th percentile); VL: viral load; NT: HIV-1 non-transmitting 
mothers; IP-TR: intrapartum HIV-1 transmitting mothers; IU-TR: in utero HIV-1 transmitting 
mothers. 
 
2.1.3 Comparison of clinical characteristics between MTCT1 and MTCT2 
Given that the two MTCT cohorts were recruited over different years and differed with 
respect to overall HIV-1 transmission rate and ART regimens we compared the clinical 
characteristics amongst mothers from MTCT1 and MTCT2. As expected with dual therapy, 
the rate of HIV-1 transmission was significantly lower in MTCT2 compared to MTCT1 
(Figure 2.3A, P<0.001). Moreover, since NT and TR mothers from MTCT2 were matched 
according to VL, CD4+ T cell count and ART regimen, it is not surprising that NT mothers 
from MTCT2 had significantly higher VLs and lower CD4+ T cell counts compared to NT 
mothers from MTCT1 (Figure 2.3B, P<0.001 and P=0.003, respectively). For TR mothers, 
while the median VL between MTCT1 and MTCT2 did not significantly differ, TR mothers 
from MTCT2 had significantly lower CD4+ T cell counts compared to TR mothers from 
MTCT1 (P=0.015). In MTCT1, median VL significantly differed between NT mothers and 
TR mothers (IP-TR, IU-TR and IU2-TR) (Figure 2.4A). Comparisons of median VL and 
CD4+ T cell counts with respect to varying ART regimens across MTCT1 and MTCT2 
mothers (NT and total TR mothers) are shown (Figure 2.4B). 
 
2.2 Ethical Clearance 
For each of the above cohorts, written informed consent was obtained from women at the 
time of enrolment and ethical approval was provided by each of the principle investigators‟ 
institutional review boards. Studies specifically described in this thesis were approved by the 
Human Research Ethics Committee of the University of Witwatersrand, ethical clearance 
certificate: M130874 (Appendix A, page 193). 
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Figure 2.3 Comparison of the clinical characteristics amongst the total group of HIV-1 infected 
mothers from MTCT1 and MTCT2. (A) Comparison of overall rate HIV-1 transmission in 
MTCT1 (Green) and MTCT2 (Red), (B) Comparison of median viral load (VL, Log10 copies/ml) 
and CD4+ T cell counts (cells/L) amongst HIV-1 non-transmitting mothers (NT, Blue) and 
HIV-1 transmitting mothers (TR, Pink). VL and CD4+ T cell counts were performed on maternal 
samples taken at the onset of birth.  
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Figure 2.4 Comparison of clinical characteristics amongst HIV-1 transmitting (TR) and non-
transmitting (NT) in MTCT1 and MTCT2. (A) Maternal viral load (VL, Log10 copies/ml) and 
CD4+T cell counts (cells/L), (B) Median VL and CD4+ T cell counts in MTCT1 and MTCT2 
stratified according to maternal antiretroviral therapy (ART) regimens. SdNVP (single dose 
Nevirapine), AZT (Azidothymidine) and HAART (a combination therapy of three or more 
drugs). 
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2.3 Genomic DNA extraction 
Genomic DNA (gDNA) from 217 mother-infant samples from the MTCT1 cohort was 
previously extracted as described in Kuhn et al. (2007) and Paximadis et al. (2011) using the 
QIAamp DNA Blood Mini Kit (Qiagen, Dusseldorf, Germany) according to the 
manufacturer‟s instructions. For the 79 mother-infant samples from MTCT2, gDNA was 
extracted from stored maternal and infant buffy coat samples using the QIAamp DNA Blood 
Mini Kit. In some cases where infants did not have buffy coat stored, gDNA was extracted 
from infant dried blood spots (DBS) as per the QIAamp DNA Blood Mini kit instructions. 
DNA concentration and quality were determined using a Nanodrop spectrophotometer 
(Thermo Scientific, Wilmington, MA). Typical DNA yield from 200 µl of buffy coat was 
approximately 50 µg of DNA; while three punched-out circles (each 3 mm in diameter) from 
the infant DBS generally yielded approximately 75 ng of DNA.  
 
2.4 Conventional KIR and HLA-ligand genotyping 
2.4.1 Olerup sequence-specific KIR genotyping for MTCT1 
KIR genotyping on the MTCT1 samples was performed by Paximadis et al. (2011) using the 
commercial Olerup sequence-specific primers (SSP) KIR genotyping kit (Olerup SSP AB, 
Stockholm, Sweden) as per the manufacturer‟s instructions. The KIR SSP genotyping kit 
contained pre-optimized SSP for PCR amplification for 14 KIR genes (KIR2DL1, KIR2DL2, 
KIR2DL3, KIR2DL4, KIR2DL5, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, 
KIR3DL1, KIR3DL2, KIR3DL3 and KIR3DS1) and 2 pseudogenes (KIR2DP1 and KIR3DP1). 
In addition, the kit also allowed for the allelic discrimination of full-length (KIR2DS4-f: 
2DS4*001:01:01-001:04, *011:01-011:02, *014 and *015) from truncated (KIR2DS4-v: 
2DS4*003, 004, *006, *007-010, *012 and *013) KIR2DS4 alleles. PCR amplicons were 
visualised on a 2% agarose gel stained with ethidium bromide on a UV transilluminator and 
the presence/absence of specific KIR products, as well as the internal positive control bands 
was recorded for interpretation. 
 
2.4.2 HLA-B and HLA-C genotyping for MTCT1 
For MTCT1, 217 mother-infant samples were HLA-B and HLA-C genotyped using a 
previously described high resolution sequence-based typing (SBT) strategy (Cereb et al., 
1995). Briefly, the method for both HLA-B and HLA-C typing involved a single PCR 
amplification of exon 2, intron 2 and exon 3 using gDNA as the template, followed by 
bi-directional sequencing of exon 2, intron 3 and exon 3 (regions that contain the defining 
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polymorphisms for most alleles). The PCR reaction contained 5 l gDNA (20-100 ng/l), 
dNTPs (0.2 mM), two HLA primers (0.2 mM each), and Taq DNA polymerase (2.5 units) in a 
total volume of 100 l; thermocycling conditions: 96°C for 5 minutes, followed by 30 cycles 
of 94°C for 22 seconds, 65°C for 50 seconds, 72°C for 30 seconds, and 72°C for 7 minutes. 
Nucleotide sequencing was performed on an ABI 3730 Genetic Analyzer using Big Dye 
Terminator v1.1 chemistry (Applied Biosystems, Foster City, CA). Allele assignment was 
performed using SeqScape v2.5 software (Applied Biosystems) and a library compiled from 
the 2.17.0 release of the IMGT/HLA Database. 
 
2.5 Real-time PCR assays for MTCT2 
2.5.1 Validation samples used to develop real-time PCR assays 
Stored gDNA was available for 270 samples that were previously genotyped using well-
known assays for KIR and HLA class I. The real-time PCR KIR genotyping assay was 
validated against 50 samples that were KIR genotyped using the Olerup SSP KIR genotyping 
kit, wherein the samples consisted of 24 Black individuals and 26 Caucasian individuals from 
South Africa. The real-time PCR HLA-ligand assay was validated against 190 samples, made 
up of 107 Black individuals and 83 Caucasians from South Africa, that had previously been 
HLA Class I (A, B and C) genotyped using the Applied Biosystems SBT kits (Applied 
Biosystems, Foster City, CA) (Paximadis et al., 2012). In addition, in order to accommodate 
HLA class I allelic variation and avoid population bias, 30 reference samples obtained from 
the International Histocompatibility Working Group (www.ihwg.org) were also tested with 
the real-time HLA-ligand assay. Importantly, these validation samples represented all sixteen 
KIR and HLA-ligand variants at position 80. In addition, the KIR and HLA-ligand real-time 
PCR assays were used to genotype 81 Black women in the Carletonville mining area, South 
Africa. 
 
2.5.2 Real-time PCR KIR assay for MTCT2 
To date, few real-time PCR-based KIR genotyping and HLA-ligand identification assays have 
been described (Alves et al., 2009, Koehler et al., 2009). In our system, we wished to avoid 
the use of fluorescent probe chemistry and nested PCR methods used by Koehler et al. (2009) 
in favour of SYBR® green chemistry. We selected previously published KIR primer 
sequences (Vilches et al., 2007, Martin and Carrington, 2008, Alves et al., 2009) which we 
mapped to updated KIR gene alignments in the IPD database (Robinson et al., 2013a). 
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A combination of primers was used to improve detection of KIR allelic variants, with the 
exception of KIR2DL3 and KIR3DP1, where a single primer set was used (Table 2.4). The 
KIR2DL3 primer set detects all known alleles, however, the pseudogene KIR3DP1 primer set 
does not detect KIR3DP1*004 and KIR3DP1*0090 alleles. Furthermore, an internal control 
gene galactosylceramidase (GALC) was included (Alves et al., 2009).  
 
For real-time PCR, each 5 μL reaction contained 2X SYBR® Green master mix (Roche, 
Mannheim, Germany), 0.2 μM KIR primers, 0.2 μM GALC primers and 5 ng of gDNA. PCR 
cycling was performed in 96-well format on an ABI PRISM® 7500 real-time instrument 
(Applied Biosystems, Foster City, CA) as follows: 10 min at 95°C, 30 cycles of 15 s at 95°C 
and 1 min at 60°C. Melt curve analysis was performed after cycling to distinguish GALC 
(Tm = 74.89°C) from KIR amplicons (Tm = 78.5.5°C-85.9°C) (Figure 2.5A), thereby 
making it simple to identify the presence/absence of specific KIR genes. The presence of an 
internal control amplicon ensured that the absence of a KIR amplicon was a true result and 
not as a result of failed amplification. 
 
2.5.3 Real-time PCR HLA-ligand assay for MTCT2 
We designed our HLA-ligand primers from HLA class I alignments available at the 
IMGT/HLA database (Robinson et al., 2013a). Briefly, HLA-ligand primers were designed to 
detect HLA-C group 1 (C1) allotypes, which have an asparagine at position 80, designated as 
C1:80N, HLA-C group 2 (C2) allotypes, which have a lysine at position 80, designated as 
C2:80K, HLA-B allotypes with the Bw4 motif as designated by five variable amino acids 
spanning positions 77–83, were classified as either Bw4:80I (with an isoleucine at 
position 80) or Bw4:80T (with a threonine at position 80) (Cella et al., 1994, Gumperz et al., 
1995). In addition, Bw4:80T variants can vary with alanine (Bw4:80T81A) or leucine 
(Bw4:80T81L) at position 81 (Muller et al., 1989, Cella et al., 1994, Gumperz et al., 1995). 
Some HLA-A allotypes also have the Bw4 motif (Bw4:80I) and bind KIR3DL1 and 
putatively KIR3DS1, whereas HLA-A allotypes lacking the Bw4 motif (non-Bw4:80T) and 
HLA-B Bw6 allotypes (Bw6:80N) are not known to bind any KIRs. All primers were 
synthesised with 3‟ locked nucleic acid (LNA) bases (Exiqon, Vedbaek, Denmark) in order to 
increase template specificity (Table 2.5). Each PCR reaction included an internal positive 
control amplification of the albumin (ALB) gene (Douek et al., 2002).  
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For real-time PCR, each 5 μL reaction contained 2X SYBR® Green master mix (Roche, 
Mannheim, Germany), 0.2 μM HLA-ligand primers, 0.2 μM ALB primers and 5 ng of gDNA. 
PCR cycling was performed in 96-well format on an ABI PRISM® 7500 real-time 
instrument (Applied Biosystems, Foster City, USA) as follows: 10 min at 95°C, 30 cycles of 
15 s at 95°C, 5s at 60°C and 1 min at 72°C. Melt curve analysis was performed after cycling, 
and as with the KIR assay, differences in melting temperature could differentiate ALB 
(Tm=75.62°C) from HLA-ligand amplicons (Tm=87.3°C-88.3°C) (Figure 2.5B).  
 
Table 2.4 PCR primer sets used for real-time KIR genotyping assay 
KIR Primers Sequences (5’ – 3’) 
Binding 
site 
Product 
Tm, C 
Alleles not detected 
2DL1 
F1
a
 GTTGGTCAGATGTCATGTTTGAA Exon 4 
80.36  
R1
a
 GGTCCCTGCCAGGTCTTGCG Exon 4 
F1
a
 TGGACCAAGAGTCTGCAGGA Exon 8 
82.12 KIR2DL1*005 
R1
a
 TGTTGTCTCCCTAGAAGACG 3‟UTR 
2DL2 
F1
a
 CTGGCCCACCCAGGTCG Exon 4 
80.68 
KIR2DL2*004, *00601, 
*00602, *00303, *004 R1
a
 GGACCGATGGAGAAGTTGGCT Exon 4 
F1
b
 AAACCTTCTCTCTCAGCCCA Exon 5 
83.30 KIR2DL2*009 
R1
b
 GCCCTGCAGAGAACCTACA Exon 5 
2DL3 
F
b
 AGACCCTCAGGAGGTGA Exon 9 
79.47  
R
b
 CAGGAGACAACTTTGGATCA Exon 9 
2DL4 
F1
a
 CAGGACAAGCCCTTCTGC Exon 3 
78.08  
R1
a
 CTGGGTGCCGACCACT Exon 3 
F1
a
 ACCTTCGCTTACAGCCCG Exon 5 
84.21  
R1
a
 CCTCACCTGTGACAGAAACAG Exon 5 
2DL5 
F1
a
 GCGCTGTGGTGCCTCG Exon 3 
82.19  
R1
a
 GACCACTCAATGGGGGAGC Exon 3 
F1
a
 TGCAGCTCCAGGAGCTCA Exon 5 
83.09  
R1
a
 GGGTCTGACCACTCATAGGGT Exon 5 
2DS1 
F1
b
 TCTCCATCAGTCGCATGAG Exon 4 
79.34  F2
b
 TCTCCATCAGTCGCATGAA Exon 4 
R
b
 GGTCACTGGGAGCTGAC Exon 4 
2DS2 
F1
a
 TTCTGCACAGAGAGGGGAAGTA Exon 4 
80.55  
R1
a
 GGGTCACTGGGAGCTGACAA Exon 4 
F1
a
 CGGGCCCCACGGTTT Exon 5 
83.47 KIR2DS2*00104 
R1
a
 GGTCACTCGAGTTTGACCACTCA Exon 5 
2DS3 
F1
c
 AAACCTTCTCTCTCAGCCCA Exon 5 
84.07  
R1
b
 GCATCTGTAGGTTCCTCCT Exon 5 
F1
a
 CTATGACATGTACCATCTATCCAC Exon 5 
83.07  
R1
a
 AAGCAGTGGGTCACTTGAC Exon 5 
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Table 2.4 Continued    
KIR Primers Sequences (5’ – 3’) 
Binding 
site 
Product 
Tm, C 
Alleles not detected 
2DS4 
F1
a
 CTGGCCCTCCCAGGTCA Exon 4 
80.83  
R1
a
 TCTGTAGGTTCCTGCAAGGACAG Exon 4 
F1
a
 GTTCAGGCAGGAGAGAAT Exon 5 
84.35  
R1
a
 GTTTGACCACTCGTAGGGAGC Exon 5 
2DS5 
F1
a
 TGATGGGGTCTCCAAGGG Exon 4 
81.54 KIR2DS5*003 
R1
a
 TCCAGAGGGTCACTGGGC Exon 4 
F1
a
 ACAGAGAGGGGACGTTTAACC Exon 4 
82.18  
R1
a
 ATGTCCAGAGGGTCACTGGG Exon 4 
2DP1 
F1
a
 GTCTGCCTGGCCCAGCT Exon 3 
80.67  
R1
a
 GTGTGAACCCCGACATCTGTAC Exon 3 
F1
a
 CCATCGGTCCCATGATGG Exon 4 
79.28  
R1
a
 CACTGGGAGCTGACAACTGATG Exon 4 
3DL1 
F1
a
 CGCTGTGGTGCCTCGA Exon 3 
79.62 
KIR3DL1*009, *042, 
*057 R1
a
 GGTGTGAACCCCGACATG Exon 3 
F1
b
 CCATCGGTCCCATGATGCT Exon 4 
79.13  
F2
b
 CCATT GGTCCCATGATGCT Exon 4 
F3
b
 TCCATCGGTCCCATGATGTT Exon 4 
R
b
 CCACGATGTCCAGGGGA Exon 4 
3DL2 
F1
a 
CAAACCCTTCCTGTCTGCCC Exon 3 
82.94 KIR3DL2*013, *014 
R1
a
 GTGCCGACCACCCAGTGA Exon 3 
F1
a
 CCCATGAACGTAGGCTCCG Exon 5 
83.70 KIR3DL2*018 
R1
a
 CACACGCAGGGCAGGG Exon 5 
3DL3 
F1
a
 GTCAGGACAAGCCCTTCCTC Exon 3 
82.32  
R1
a
 GAGTGTGGGTGTGAACTGCA Exon 3 
F1
a
 TTCTGCACAGAGAGGGGATCA Exon 4 
82.47  
R1
a
 GAGCCGACAACTCATAGGGTA Exon 4 
3DS1 
F1
a
 AGCCTGCAGGGAACAGAAG Exon 8 
81.41  
R1
a
 GCCTGACTGTGGTGCTCG 3‟UTR 
F1
b
 CATCGGTTCCATGATGCG Exon 4 
80.38  F2
b
 CATCAGTTCCATGATGCG Exon 4 
R
b
 CCACGATGTCCAGGGGA Exon 4 
3DP1 
F
b
 GTACGTCACCCTCCCATGATGTA 5‟UTR 
85.97 
KIR3DP1*004, 
*009002 R
b
 GAAAACGGTGTTTCGGAATAC Exon 3 
GALC 
F
c
 TTACCCAGAGCCCTATCGTTCT 
 74.89  
R
c
 GTCTGCCCATCACCACCTATT 
GALC, galactosylceramidase; KIR, killer immunoglobulin-like receptor; PCR, polymerase chain 
reaction; UTR, untranslated region. aprimers designed by (Martin and Carrington, 2008); bprimers 
designed by (Vilches et al., 2007); cprimers designed by (Alves et al., 2009). Melting temperature 
(Tm) for each PCR product was determined automatically following melt curve analysis. 
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Table 2.5 PCR primer sets used for real-time PCR HLA-ligand genotyping assay 
HLA-ligand Primers Sequences (5’ – 3’) 
a
 Product Tm, C 
HLA-A 
Bw4:80I
 F CCATTGGGTGTCGGGTTTC[C] 
87.39 
R 
b
 CTCTGGTTGTAGTAGCGGAGCGCG[A] 
Non-Bw4:80T 
F AATCAGTGTCGTCGCGGTC[G] 
87.65 
R TGTAGTAGCCGCGCAGG[G] 
HLA-B 
Bw6:80N 
F TCAGCGTCGCCGGGGTCCC[A] 
87.73 
R TGTAGTAGCCGCGCAGG[T] 
Bw4:80I 
F ACCCGGACTCAGAATCTCC[T] 
87.96 
R 
b
 CTCTGGTTGTAGTAGCGGAGCGCG[A] 
Bw4:80T81A 
F ACCCGGACTCAGAATCTCC[T] 
88.08 
R TGTAGTAGCGGAGCGCG[G] 
Bw4:80T81L 
F ACCCGGACTCAGAATCTCC[T] 
87.73 
R CTCTGGTTGTAGTAGCGGAGCAGG[G] 
HLA-C 
C1:80N 
F AGCCAATCAGCGTCTCCGC[A] 
88.34 
R GCTCTGGTTGTAGTAGCCGCGCAG[G] 
C2:80K 
F CCATTGGGTGTCGGGTTCT[A] 
88.06 
R GCTCTGGTTGTAGTAGCCGCGCAG[T] 
Albumin 
c
 
F TCGATGAGAAAACGCCAGTAA 
75.62 
R ATGGTCGCCTGTTCACCAA 
KIR (killer immunoglobulin–like receptor); HLA (human leukocyte antigen); PCR (polymerase 
chain reaction); a 3‟ Locked nucleic acid bases are indicated in square brackets. b The same 
reverse primer is used for detection of HLA-A and -B Bw4:80I alleles. c Albumin primer design 
was adapted from (Douek et al., 2002) 
 
Figure 2.5 Typical melt curve analysis of real-time PCR KIR and HLA-ligand products using 
SYBER green chemistry, (A) Melt curve analysis of real-time PCR KIR products melting to the 
right of the internal control galactosylceramidase (GALC) (74.89C), and (B) HLA-ligand PCR 
amplicons melting to the right of the internal control albumin (ALB) (75.62C). 
A B
GALC
KIR
ALB
HLA-LIGAND
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2.5.4 Real-time PCR KIR2DS4 variant assay for MTCT2 
Previously published primers and probes specific for KIR2DS4-f and KIR2DS4-v (Jiang et al., 
2012) were used in a real-time PCR assay to detect the presence or absence of allelic variants 
of KIR2DS4 (Table 2.6 and Figure 2.6). Control DNA for the KIR2DS4-f/v assay was 
derived from a haplotype AA1 donor with one copy each of KIR2DS4-f and KIR2DS4-v. 
Briefly, real-time PCR was performed in 96-well microtitre plates using an ABI 7500 real-
time PCR instrument (Life Technologies, Carlsbad, USA). Reaction volumes were 5 µl 
containing 5 ng of gDNA, 2X Lightcycler 480 probes Mastermix (Roche, Mannheim, 
Germany), 0.5 µM KIR2DS4-f/v forward and reverse primers, and 0.1 µM VIC-labelled, 
3‟-MGB KIR2DS4-f/v probe (Life Technologies, Carlsbad, USA). Cycling conditions were 
an initial incubation of 95
◦
C for 10 min followed by 40 cycles of 95
◦
C for 15 s, 60
◦
C for 60 s. 
All samples were run in duplicate and repeated if the values were discordant. 
 
Table 2.6 Real-time KIR2DS4 primers and probes 
Name Primer sequences (5’ – 3’) 
KIR2DS4-f f1 CCGGAGCTCCTATGACATG 
KIR2DS4-f/v r1 TGACGGAAACAAGCAGTGG[A] 
KIR2DS4-f/v probe VIC-AACATTCCAGGCCGACTTTCCTCTG-MGB 
KIR2DS4-v f1 CCTTGTCCTGCAGCTCCAT 
KIR2DS4-f/v r1 TGACGGAAACAAGCAGTGG[A] 
KIR2DS4-f/v probe VIC-AACATTCCAGGCCGACTTTCCTCTG-MGB 
VIC, probe reporter fluorescent dyes; MGB, minor groove binding protein (non-fluorescent 
quencher); 3‟ locked nucleic acid (LNA) base modifications are indicated in square brackets. 
 
 
Figure 2.6 An amplification plot of the real-time PCR KIR2DS4 assay 
KIR2DS4-f/v
positive
KIR2DS4-f/v
negative
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2.6 HLA-G genotyping for MTCT1 and MTCT2 
2.6.1 Sequence-based typing of HLA-G alleles 
Exons 2, 3 and 4 of HLA-G were amplified from gDNA and sequenced using previously 
published primers (Hviid et al., 1997, Turk et al., 2013) and are shown in Table 2.7. Briefly, 
a 994-bp fragment encompassing exons 2 and 3 was amplified using primers 
HLAG_2/3PCRF and HLAG_2/3PCRR. Primers HLAG_4PCRF and HLAG_4PCRR were 
used to amplify a 463-bp fragment spanning exon 4. Thermocycling conditions were: 94˚C 
for 2 min followed by 35 cycles of 94˚C for 30 sec, 61.5˚C/60˚C for 30 sec (for exons 2-3 
and exon 4, respectively) and 72˚C for 1 min followed by a final extension step of 72˚C for 
7 min. Purified PCR amplicons were sequenced in both directions by capillary 
electrophoresis using an ABI 3100 DNA analyzer (Applied Biosystems, Foster City, 
California, USA) using the sequencing primers listed in Table 2.7. HLAG_2SeqF was 
designed using HLA_G intron 1 alignments on Sequencher, version 4.10.1 (Gene Codes 
Corporation, Ann Arbor, Michigan, USA) and synthesised with a LNA modified 3‟ end 
(indicated in square brackets). Sequence analysis and allele assignment were performed using 
Assign™ SBT version 4.7 software (Conexio Genomics, Fremantle, Western Australia) with 
the IMGT/HLA-G 2013 reference library compiled and supplied by Conexio Genomics 
(personal request). 
 
2.6.2 HLA-G 3’UTR genotyping 
Nucleotide sequence variation of the HLA-G 3‟UTR region was evaluated by direct 
sequencing of a 343-bp fragment encompassing the genomic positions +2885 through to 
+3228 using published primers (Sizzano et al., 2012). Briefly, the 3‟UTR region was 
amplified using HLAG_3UTRF and HLAG_3UTRR primers (Table 2.7) with the following 
thermocycling conditions: 95˚C for 15 min followed by 30 cycles of 93˚C for 1 min, 58˚C for 
1 min, 72˚C for 1 min. A final extension step was carried out at 72˚C for 10 min. Purified 
amplicons were sequenced in both directions by capillary electrophoresis using an ABI 3100 
DNA analyzer (Applied Biosystems, Foster City, California, USA) using the same PCR 
primers. The chromatograms obtained were analysed using Sequencher version 4.10.1 (Gene 
Codes Corporation, Ann Arbor, Michigan, USA) and sequences were aligned with an 
available reference sequence (GenBank Accession number NG_029039.1) to identify known 
polymorphic positions (Castelli et al., 2010) and any other polymorphism that had not been 
previously described.  
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Table 2.7 HLA-G allele and 3‟UTR PCR and sequencing primers  
Name Primer sequences (5’ – 3’) 
HLAG_2/3PCRF CGGCCCCTGCGCGGAGGAGGGAGGGG 
HLAG_2/3PCRR TCAGGACCAGAGGGAGGGCGATATTC 
HLAG_4PCRF AGGTGCTGCTGGAGTGTC 
HLAG_4PCRR TCTGGGAAAGGAGGTGAAG 
HLAG_2SeqF CTCCATGAGGTATTTCAGC[G] 
HLAG_2SeqR TCGTGATCTGCGCCCTG 
HLAG_3SeqF TGGGCGGGGCTGACCGAGGGGGTGGG 
HLAG_3SeqR TCAGGACCAGAGGGAGGGCGATATTC 
HLAG_4SeqF GTGCTTGAATTTTCTGACTCTT 
HLAG_4SeqR TGCTTTCCCTAACAGACATGAT 
HLAG_3‟UTRF TCACCCCTCACTGTGACTGA 
HLAG_3‟UTRR CCCATCAAT CTCTCTTGGAAA 
3‟ locked nucleic acid (LNA) base modifications are indicated in square brackets 
 
2.6.3  HLA-G 3’UTR haplotypes 
Arrangement of variations in the HLA-G 3‟UTR into haplotypes was predicted both by visual 
examination of the genotypic data as well as using the Bayesian algorithm through the 
HAPLOTYPER software (Niu et al., 2002). Observed haplotypes were compared to 
published 3‟UTR haplotypes and assigned the published nomenclature when the haplotypes 
corresponded in sequence/structure (Sabbagh et al., 2014). The frequencies of haplotypes 
were calculated by counting the number of alleles harbouring the haplotypes and dividing by 
the total number of alleles. Counting of the haplotypes was irrespective of the presence of 
additional SNPs not forming part of the haplotypes in question. 
 
2.7 Data analysis 
2.7.1 KIR descriptions 
In this study, to explore any possible associations with MTCT of HIV-1 we first examined 
the presence or absence of all 16 KIR genes in mothers and their infants. Then, based on 
results of single KIR gene content, we assessed haplotypes A and B. Group A Haplotypes 
were defined by the presence of 9 KIR genes: KIR3DL3, KIR2DL3, KIR2DL1, KIR2DP1, 
KIR3DP1, KIR2DL4, KIR3DL1, KIR2DS4 and KIR3DL2 only, while Group B haplotypes 
were defined by the presence of one or more of the following genes: KIR2DL5, KIR2DS1, 
KIR2DS2, KIR2DS3, KIR2DS5, and KIR3DS1. The group B haplotypes were collectively 
termed Bx, since they represent a mixture of AB and BB haplotypes. Furthermore, KIR 
genotype profiles were assigned to the AA and Bx haplotype groups using the online 
Allele Frequency Net Database (Gonzalez-Galarza et al., 2011). 
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For KIR2DS4 variants, we grouped KIR2DS4 carriers into KIR2DS4-f (one or two copies of 
the functional alleles: KIR2DS4*0010101-00103), KIR2DS4-v (one or two copies of deleted 
alleles: KIR2DS4*003, *004, *006, *007, *009) or KIR2DS4-fv (one copy of each). This 
comparison allows one to look at the presence (but not dose) of one or the other, given one 
may expect opposing functional effects of full length and soluble protein versions. 
Consequently, AA genotypes carrying KIR2DS4-f, KIR2DS4-fv or KIR2DS4-v were classified 
as AA-f, AA-fv and AA-v, respectively.  
 
2.7.2 HLA-ligand allotypes 
HLA-B and HLA-C alleles genotyped through the SBT method (for MTCT1) were further 
grouped as HLA-Bw4 (Bw4) and Bw6 allotypes based on five variable amino acids spanning 
residues 77-83 at the carboxyl-terminal end of the α1 helix. The Bw4 allotype subset 
Bw4:80Ile contains an isoleucine at position 80 as opposed to the Bw4:80Thr subset that 
contains a threonine at the same position and serves as the better ligand for KIR3DL1, and is 
a putative ligand for KIR3DS1 based on epidemiologic data. HLA-C alleles were grouped as 
C1 allotypes (asparagine at residue 80 and are known ligands for KIR2DL2, KIR2DL3, and 
KIR2DS2) or C2 allotypes (lysine at residue 80, known ligands for KIR2DL1 and 
KIR2DS1). Data were analyzed between groups as presence of at least one allele of a 
particular allotype (C1 or C2, Bw4 or Bw6) and total allelic representation or allelic dose 
(C1/C1, C2/C2, C1/C2 and Bw4/Bw4, Bw6/Bw6, Bw4/Bw6).  
 
2.7.3 Classification of mother-infant gene concordance 
To assess the effect of specific gene/allele concordance on MTCT of HIV-1, we scored the 
number of matching mother-infant pairs following the previously reported method 
(MacDonald et al., 1998, Polycarpou et al., 2002, Biggar et al., 2006a, Mackelprang et al., 
2008). Since an infant will inherit one allele from the mother and one from the father, the 
infant will match at least 50% of the mother‟s alleles. Therefore, when the mother was 
homozygous for a given genotype which matched one of the child‟s alleles this was also 
considered as concordant, likewise, if the two alleles of the child matched two alleles of the 
mother, they were considered concordant and were classified as M+I+. Discordance was 
defined as either the presence (+) of the given genotype that was absent (−) in either the 
mother or the infant, i.e. M+I− or M−I+, respectively.  
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2.7.4 Computational and statistical analysis 
2.7.4.1 Power analysis 
Given that the MTCT cohorts were recruited prior to the initiation of this PhD thesis and the 
ratio of cases to controls were defined on the basis of sample availability, 1:2 for MTCT1 and 
1:1.2 for MTCT2, we performed a retrospective power analysis for each MTCT cohort. 
Power analysis is the probability of correctly rejecting the null hypothesis that the sample 
estimates (Suresh and Chandrashekara, 2012). Here, the actual sample size and alpha-level 
are known, and the variance observed in the sample provides an estimate of variance of 
population. Having a high power means that the study has a high chance of detecting a 
difference between groups if one exists. Consequently, if the study demonstrates no 
difference between groups, the study can confidently conclude that none exists. 
 
For MTCT1: using the example of the KIR AA1 haplotype (the most common KIR haplotype 
in the NT group) having a frequency of 26.9% and based on our 1:2 case-control design 
(cases=72), assuming an alpha of 5% and a minimum odds ratio of 2.5 to detect a difference, 
the overall power of the MTCT1 cohort was calculated at 86.4%, using the online statistical 
program (http://sampsize.sourceforge.net). However, within the IP- and IU- TR groups 
overall power decreased (IP-TR vs. NT: 60.6% and IU-TR vs. NT: 47.5%) and we 
acknowledge this as a limitation. Nevertheless, upon evaluation of the IU-enriched group 
(IU2-TR, n=43) power within this comparison increased to 73.1%. Thus, we feel that our data 
can be accurately interpreted. 
 
For MTCT2: since cases and controls were matched on mVL, CD4+ T cell count and ART, 
the power of MTCT2 was less stringent. Therefore, using the example of the Bx21 haplotype 
(the most common KIR haplotype in the NT group) having a having a frequency of 16.3% 
and based on our 1:1 matched case-control design (cases=36), assuming an alpha of 5% and a 
minimum odds ratio of 2.5 to detect a difference, the overall power of the MTCT1 cohort was 
calculated at 40.2%. Additionally for power across IP-TR and IU-TR was calculated at 25.8% 
and 35.4%, respectively. As in MTCT1, we acknowledge this is a limitation but given the 
MTCT transmission rates have fallen from ~32% in the early 1990s to <2.5% in 2012 with 
current ART regimens (Ramkisoon and Coovadia, 2014), the data obtained from MTCT2 has 
relevance to understanding the role of KIR/HLA gene combinations in HIV-1 transmission.  
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2.7.4.2 Hardy-Weinberg Equilibrium (HWE) 
HWE is the theorem that states that allele and genotype frequencies in a population will 
remain constant from generation to generation in the absence of other evolutionary 
influences, such as mate choice, mutation, selection, genetic drift, gene flow and meiotic 
drive (Ryckman and Williams, 2008). Because one or more of these influences are typically 
present in real populations, the HWE principle describes an ideal condition against which the 
effects of these influences can be analyzed. Thus, for this study, deviations from HWE were 
assessed using the conventional Monte Carlo exact test (Guo and Thompson, 1992) using the 
computer program TFPGA (Tools for Population Genetic Analyses version 1.3; 1997: author 
Mark. P. Miller).  
 
2.7.4.3 Linkage Disequilibrium (LD) 
LD, the non-random association of alleles at two loci, finds applications in diverse contexts, 
including the inference of demographic events in human evolutionary history, the fine-
mapping of disease genes after localization via linkage analysis, and the modelling, selection, 
and evaluation of sets of informative SNPs for use in detecting disease susceptibility alleles 
in genetic association studies (VanLiere and Rosenberg, 2008). In our MTCT cohorts, LD 
was estimated and visualised using the method described by Lewontin (1964) as well as 
Haploview bioinformatics software, version 4.2 (Barrett et al., 2005).   
 
For the Lewontin calculation, the LD coefficient D was calculated (Dij = HFij - pipj) and to 
account for differing allele frequencies at the loci, D was normalized (D‟) or standardized by 
the maximum value it can take (Dmax) using the formula D‟ij = Dij/Dmax, where HFij is the 
frequency of the haplotype carrying alleles i and j, pi and pj are the frequencies of alleles i 
and j, respectively. Dmax is either min[pipj, (1 - pi) (1 - pj)] if Dij < 0; or min[(1 - pi) pj, 
pi(1 - pj)] if Dij > 0 (Lewontin, 1964b, Lewontin, 1964a) The statistical significance of the 
LD between each of the allele pairs was evaluated by the approximate chi-square test 
(χ2, below) described by (Liau et al., 1984); where GF refers to the genotypic frequency of 
the particular allele, i.e., i or j (equivalent to pi or pj described above). 
 
χ2= 
 4n[HF(ij)-GF(i)GF(j)]
2
  
1+ 
 [HF(ij)-GF(i)GF(j)] 
2  
 GF(i)GF(j)[2-GF(i)][2-GF(j)]   2[1-GF(i)][1-GF(j)]  
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2.7.4.3 Statistical analysis 
Chapter 3: KIR and HLA-ligand identification by real-time PCR 
For both sets of data (SSP-PCR, SBT and real-time PCR), carrier frequencies for the 
observed KIR and HLA-ligands were determined by direct counting (individuals positive for 
the gene divided by the individuals tested per population ×100). Real-time PCR KIR and 
HLA-ligand assays were validated by direct comparison with SBT- and SSP-PCR based 
typing results of the same samples. 
 
Chapter 4, 5 and 6: KIR genes and HLA-ligands in MTCT  
Gene, genotype and haplotype frequencies of KIR and HLA-ligands were determined by 
direct counting. Their fit to Hardy–Weinberg equilibrium proportions was examined and 
established, using the Monte Carlo exact test. Differences in the frequency distributions 
between maternal, as well as infant groups were compared using 2x2 contingency tables and 
a Fisher‟s exact test at 95% confidence interval (CI) limit using the online statistical program 
VassarStats (http://www.vassarstats.net), which was also used to estimate the odds ratio 
(OR). Two-sided P values less than 0.05 were considered significant. Graphical 
representation and Mann-Whitney U tests were performed with GraphPad Prism Version 4.02 
software (GraphPad Software, San Diego CA).  
 
For all MTCT1 analyses Bonferroni correction was not applied, as adjustment for multiple 
comparisons correct for type 1 errors but increase the risk of type 2 errors. Thus, given the 
complexity and multifactorial nature of maternal-infant HIV-1 transmission, we considered it 
more important to identify potential factors that may play a role in this route of infection 
rather than simply dismissing these leads as due to chance variations brought about by 
multiple comparisons. Thus, to analyse maternal and infant KIR/HLA associations with HIV-
transmission, we used logistic regression with infant infection as the outcome. Unconditional 
logistic regression (Pezzullo, 2005) was used to adjust for the effects of the following 
variables: maternal viral load (mVL), maternal sdNVP, as well as infant possession of 
KIR2DS4-v which we recently reported to impact on IU MTCT in the same cohort (Hong et 
al., 2013). With regards to MTCT2, NT and TR mother-infant samples were matched 
according to maternal VL, CD4+ T cell count as well PMTCT regiments, which negated the 
need to adjust for these factors. 
  
Chapter 3: KIR and HLA-ligand identification by real-time PCR  78 
CHAPTER 3 
KIR and HLA-ligand Identification by Real-Time PCR 
The following section has been published: Hong et al. (2011) Tissue Antigens 78, 185 – 194. 
 
3.1 Introduction 
It is well recognised that NK cells are one of the critical components of the innate immune 
system and have great potential to mediate antiviral activity in the early stages of HIV-1 
infection (Chavan et al., 2014). To date, 14 functional KIR genes and two pseudogenes have 
been described on human chromosome 19q13.4, 10 of which encode receptors with two 
immunoglobulin domains (2D) and four encoding receptors with three domains (3D). The 
KIRs can be further classified as inhibitory (2DL1, 2DL2, 2DL3, 2DL5A and B, 3DL1, 
3DL2 and 3DL3) or activating (2DL4, 2DS1, 2DS2, 2DS3, 2DS4, 2DS5, 2DS5 and 3DS1) 
based on the length of their cytoplasmic tail. KIRs with long tails (L) have an 
immunoreceptor tyrosine-based inhibitory motif (ITIM) and are able to suppress NK cell 
activation, whereas short-tail (S) receptors are characterized by a charged residue in the 
transmembrane portion that allows their association with the adaptor molecule (DAP12) 
required to generate activating signals that induce the secretion of IFN-γ and the release of 
perforin and granzymes.  
 
Despite the framework KIR genes (KIR2DL3, KIR2DL4, KIR3DL2, and KIR3DP1) that are 
virtually present in all individuals, other KIR genes display a high degree of variability at the 
level of gene presence or absence. Moreover the frequency of these genes has been found to 
vary in different population groups with different ethnic-history, linguistic and geographic 
backgrounds. Therefore, based on KIR gene content, KIR haplotypes can be divided into two 
broad groups, namely group A and B. The group A haplotype contains one activating 
KIR gene, KIR2DS4, and six inhibitory KIR genes: KIR2DL1, KIR2DL3, KIR2DL4, 
KIR3DL1, KIR3DL2, and KIR3DL3. Group B haplotypes are more diverse as they have more 
activating receptors and are characterized by KIR2DL2, KIR2DS1, KIR2DS2, KIR2DS3, and 
KIR2DS5 genes (Rajalingam, 2012). Several KIRs bind to HLA class I molecules as their 
ligands. KIR2DL1/S1 recognise HLA-C group 2 (C2) allotypes which have a lysine at 
position 80 (80K), whereas KIR2DL2/L3 recognise HLA-C group 1 (C1) allotypes that have 
an asparagine at position 80 (80N) (Mandelboim et al., 1996). KIR2DS4 recognise a select 
group of C1 and C2 allotypes (C*01:02, C*14:02, C*16:01, C*02:02, C*04:01 and 
Chapter 3: KIR and HLA-ligand identification by real-time PCR  79 
C*05:01) as well as two HLA-A alleles (A*11:01 and A*11:02) (Graef et al., 2009). Whilst 
KIR3DL1, and putatively KIR3DS1, bind to HLA-B allotypes with the Bw4 motif which 
either have an isoleucine or a threonine at position 80 (Bw4:80I and Bw4:80T, respectively) 
(Gumperz et al., 1995). The HLA-B Bw4:80T variants further differentiate at position 81 
with an alanine or leucine (Bw4:81A and Bw4:81L, respectively). HLA-A and -B allotypes 
that lack the Bw4 motif are not known to bind any KIRs, which we have been termed 
non-Bw4:80T
 
and Bw6:80N, respectively. 
 
As NK cell receptors, the KIR and their HLA-ligand interactions have an important role in 
modulating outcomes of infectious diseases, transplantation as well as pregnancy, and have 
become subjects of intense research (Roberts et al., 2014). Furthermore, with regards to 
HIV-1 infection, NK cell function and KIR have not only been linked to HIV-1 disease 
progression, but also with resistance and susceptibility to HIV-1 infection (Ballan et al., 
2007, Carrington et al., 2008, Tiemessen et al., 2009, Tiemessen et al., 2010, Paximadis et al., 
2011, Jost and Altfeld, 2013). However, their genotyping and subsequent use in association 
studies and histocompatibility matching are made difficult by the underlying structural and 
sequence complexity in the KIR region. Conventionally both KIR and HLA genotyping is 
routinely performed using SSP-PCR and SBT assays, respectively. These methods are often 
cumbersome, expensive and have low throughput, but moreover require large quantities of 
high-quality genomic DNA. In addition, amplified products are visualized by agarose gel 
electrophoresis, which is time-consuming as well as hazardous if using ethidium bromide 
staining. Thus, we developed and validated two real-time PCR assays for KIR and HLA-
ligand genotyping using samples that have been previously characterized by SSP-PCR and 
SBT, respectively. The use of a real-time PCR assay allows for the quick, easy and cost 
effective detection of sixteen KIR genes and the presence/absence of HLA-ligands based on 
allelic discrimination at codon 80 in HLA-A, -B and -C genes.  
 
3.2 Results 
3.2.1 Validation of real-time PCR KIR assay 
Using samples that represented the full spectrum of the KIR genes, we tested 50 validation 
samples that were KIR genotyped with the conventional Olerup SSP KIR Genotyping kit 
(Chapter 2, section 2.4.1) and compared these results with our real-time PCR KIR assay 
(Chapter 2, section 2.5.2). We found the real-time PCR KIR assay was 100% concordant with 
conventional SSP-PCR methods (Table 3.1). 
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Table 3.1 Validation of real-time PCR KIR genotyping assay (n=50)  
KIR genes 
Carriers / Non-carriers 
Concordant (%) 
SSP KIR PCR Real-time PCR KIR assay 
2DL1 48 / 2 48 / 2 100 
2DL2 27 / 23 27 / 23 100 
2DL3 41 / 9 41 / 9 100 
2DL4 50 / 0 50 / 0 100 
2DL5 26 / 24 26 / 24 100 
2DS1 15 / 35 15 / 35 100 
2DS2 27 / 23 27 / 23 100 
2DS3 10 / 40 10 / 40 100 
2DS4 47 / 7 47 / 7 100 
2DS5 21 / 29 21 / 29 100 
2DP1 48 / 2 48 / 2 100 
3DL1 47 / 3 47 / 3 100 
3DL2 50 / 0 50 / 0 100 
3DL3 50 / 0 50 / 0 100 
3DS1 13 / 37 13 / 37 100 
3DP1 50 / 0 50 / 0 100 
SSP KIR PCR (Olerup SSP AB, Stockholm, Sweden) and real-time PCR KIR genotyping 
concordance was established by directly comparing the number of individuals who did/did not 
carry the KIR gene divided by the KIR genes present/absent ×100. 
 
3.2.2 Validation of real-time PCR HLA-ligand assay 
On comparison with the commercial high-resolution SBT method, the real-time HLA-ligand 
assay correctly genotyped 99.1 % (218/220) of individuals tested. All HLA-ligand primer 
sets, with the exception of HLA-B Bw4:80T 81A, were 100% concordant with SBT results 
(Table 3.2). In our real-time PCR HLA-ligand assay, the HLA-B Bw4:80T 81A primer failed 
to correctly assign HLA-B*38:02 to the Bw4:80T 81A allotype in two of the DNA samples 
obtained from the IHWG database. These two samples were re-typed using the SBT method 
and confirmed to be correctly assigned based on exon 2, 3 and 4 sequences. Additionally, the 
genomic sequences for HLA-B*38:02:01, B*38:02:02 and B*38:02:03 were available to 
confirm that the reverse primer binding site had no changes. SBT typing did not include the 
5‟UTR, however, genomic sequences were available for HLA-B*38:01:01, B*38:02:01 and 
B*38:14 and confirmed that the forward primer was conserved except for one mismatch 
seven bases from the 3‟ end. It is unlikely that this was the cause of a failed real-time PCR 
amplification since the forward primer was found to successfully amplify other HLA-B alleles 
with the same mismatch. It is therefore possible that these two samples are un-described 
Chapter 3: KIR and HLA-ligand identification by real-time PCR  81 
B*38:02 alleles with changes in the 5‟UTR. Nevertheless, the HLA-B*38:02 allele is 
prevalent at a low frequency in people of Taiwanese/Chinese descent (0.11% and 0.08%, 
respectively) and to our knowledge has not been reported within the African continent 
(Gonzalez-Galarza et al., 2011). 
 
Table 3.2 Validation of real-time PCR HLA-ligand genotyping assay (n=220)  
HLA-ligand 
Carriers / Non-carriers 
Concordant (%) 
Sequence based typing Real-Time PCR Assay 
HLA-A 
Bw4:80I 62 / 158 62 / 158 100 
Non-Bw4:80T 215 / 5 215 / 5 100 
HLA-B 
Bw6:80N 180 / 40 180 / 40 100 
Bw4:80I 93 / 127 93 / 127 100 
Bw4:80T81A 49 / 171 47 / 171 95.9 
Bw4:80T81L 11 / 209 11 / 209 100 
HLA-C 
C1:80N 173 / 47 173 / 47 100 
C2:80K 161 / 59 161 / 59 100 
Concordance between HLA sequence based typing (SBT) and real-time PCR assay for 
HLA-ligand genotyping was established by directly comparing the number of individuals who 
did/did not carry the KIR gene divided by the KIR genes present/absent ×100. 
 
3.2.3 Characterising KIR and HLA-ligand genes in a small South African population 
The real-time PCR KIR and HLA-ligand assays were used to genotype a small group of 
81 Black South African women from the Carletonville mining district in Johannesburg, 
South Africa. We identified twenty different KIR genotype profiles (Table 3.3), the three 
most common KIR genotypes were AA1 (24.7%), Bx21 (13.6%) and Bx5 (8.6%) which 
account for 47% of the total KIR genotypes. In addition, we found two KIR genotypes (Bx46 
and Bx70) that had not been previously reported in other South Africa studies (Wong et al., 
2010, Paximadis et al., 2011), as well as one unique KIR Bx* genotype with all KIR genes 
present with the exception of KIR2DL2, KIR2DL3, KIR2DS1, KIR2DS2 and KIR3DS1 which 
had not been described at the time of manuscript publication (Hong et al., 2011), but has 
since been classified as Bx555 and was reported in low frequency (<1%) in a Northeast 
Indian Adivasi population (Dutta et al., 2013). 
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Table 3.3 Real-time PCR KIR genotyping of a South African cohort (N=81) showing KIR gene and genotype frequencies 
KIR 
genotype 
KIR genes # KIR 
genes 
Genotype 
N (%) 2DL1 2DL2 2DL3 2DL4 2DL5 2DS1 2DS2 2DS3 2DS4 2DS5 2DP1 3DL1 3DL2 3DL3 3DS1 3DP1 
AA1                 9 20 (24.7) 
Bx21                 13 11 (13.6) 
Bx5                 13 7 (8.6) 
Bx10                 11 6 (7.4) 
Bx20                 12 6 (7.4) 
Bx112                 13 5 (6.2) 
Bx73                 15 5 (6.2) 
Bx92                 13 4 (4.9) 
Bx228                 12 3 (3.7) 
Bx6                 16 2 (2.5) 
Bx9                 14 2 (2.5) 
Bx91                 14 2 (2.5) 
Bx118                 14 1 (1.2) 
Bx27                 12 1 (1.2) 
Bx32                 11 1 (1.2) 
Bx35                 12 1 (1.2) 
Bx4                 11 1 (1.2) 
Bx46                 13 1 (1.2) 
Bx70                 14 1 (1.2) 
Bx*                 11 1 (1.2) 
Gene 
N (%) 
81 
(100) 
56 
(69) 
60 
(74) 
81 
(100) 
54 
(67) 
19 
(23) 
50 
(62) 
24 
(30) 
80 
(99) 
46 
(57) 
81 
(100) 
80 
(99) 
81 
(100) 
81 
(100) 
10 
(12) 
81 
(100) 
 
The purple boxes indicate the presence of the gene; white boxes indicate the absence of the gene. #, Number of KIR genes present in the KIR genotype. 
Frequency of each KIR gene is defined as the number of individuals having the gene divided by the number of individuals in the cohort expressed as a 
percentage. KIR genotype frequency is defined by the number of individuals having a particular genotype divided by the number of individuals within 
the cohort expressed as a percentage. Based on KIR gene content, genotypes (AA and Bx) were grouped according to (Gonzalez-Galarza et al., 2011). 
Bx* is a new KIR genotype that has not been previously identified. KIR (killer immunoglobulin–like receptor).  
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With regards to HLA-ligand typing, we found 2 (2.5%) women were homozygous for 
Bw4:80I (the ligand for KIR3DL1/S1), 56 (69.1%) were homozygous for non-Bw4:80T and 
the remaining 23 (28.4%) were heterozygotes at the HLA-A locus (Figure 3.1). At the HLA-B 
locus, more than half (48/81) the women carried a Bw4 allele, the ligand for KIR3DL1/S1; of 
which, 39 (48.1%) were heterozygous for Bw6:80N/Bw4:80I, 3 (3.7%) were heterozygous 
for Bw4:80I/80T and 6 (7.4%) were Bw4:80I homozygous. Bw4:80I/80T allotypes were 
further divided into Bw4:80I/80T81A and Bw4:80I/80T81L which were present in 2.5% and 
1.2% of the women, respectively. Bw4:80T81L homozygotes or Bw4:80T81L/Bw6:80N 
heterozygotes were not detected in this population. At the HLA-C locus, 13 (16.0%) women 
were homozygous for C1:80N, 30 (37.1%) were homozygous for C2:80K and the remaining 
38 (46.9%) were C1/C2 heterozygous. 
 
 
Figure 3.1 Frequencies of various allotype combinations of the HLA-ligands in a South African 
Cohort (n=81). On the basis of allelic discrimination at codon 80 the HLA-ligand assay can 
identify the presence/absence of the HLA-ligands, HLA-A (Bw4:80I and non-Bw4:80T) and 
HLA-B (Bw4:80I, Bw4:80T81A, Bw4:80T81L and Bw6:80N) and HLA-C (C1:80N and 
C2:80K). 
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Furthermore when analysing KIR and HLA-ligand data together (Table 3.4), the frequency of 
activating KIR/HLA-ligand pairs was lower than that of the inhibitory KIR/HLA-ligand pairs. 
Activating KIR2DS1 paired with HLA-C C2 ligand was found at a frequency of 16% and 
KIR3DS1 paired with the putative HLA-B Bw4 ligand was present in 6.2% of individuals. 
Inhibitory KIR genes and their ligands: KIR2DL1+HLA-C C2, KIR2DL2/3+HLA-C C1 and 
KIR3DL1+HLA-A/B Bw4 had frequencies of 84%, 44%, 44% and 58%, respectively. 
 
Table 3.4 KIR/HLA-ligand frequencies in a South African cohort (N=81) 
KIR Gene 
KIR Gene 
N (%) 
HLA-ligand 
HLA-ligand 
N (%) 
KIR+HLA-ligand 
N (%) 
Inhibitory 
KIR 
2DL1 81 (100) C2 68 (84) 68 (84) 
2DL2 56 (69) C1 51 (63) 36 (44) 
2DL3 6 (74) C1 51 (63) 36 (44) 
3DL1 80 (99) Bw4 58 (72) 47 (58) 
Activating 
KIR 
2DS1 19 (23) C2 68 (84) 13 (16) 
3DS1 10 (12) Bw4* 58 (72) 5 (6) 
Frequency of each KIR+HLA-ligand combination is defined as the number of individuals having 
the paired KIR/HLA-ligand (N) divided by the number of individuals within the cohort (N=81) 
expressed as a percentage. *Putative HLA-ligand for KIR3DS1 based on homology to KIR3DL1. 
 
3.3 Discussion 
Conventional KIR and HLA genotyping methodologies involve gel-based SSP-PCR and SBT 
methods, respectively. These methods can be expensive, labour-intensive and time-
consuming. We developed a fast and effective tool to determine KIR and HLA-ligand profiles 
using real-time PCR and SYBR® Green chemistry. Our KIR and HLA-ligand assays were 
validated against commercial and published methods and were found to be 100% and 99.1% 
concordant, respectively.  
 
The advantage of our real-time PCR assays (Chapter 2, section 2.5.2) compared to 
commercial gel-based KIR SSP-PCR and HLA SBT methods as well as other published 
KIR/HLA-ligand typing methods included low DNA input, simple technique and ease of 
result interpretation. Melt curve analysis offers straightforward determination of the presence 
or absence of KIRs or known HLA-ligands for KIRs, thus generating results much faster than 
conventional methods. Furthermore, to enhance the detection of KIR genes that may contain 
sequence variations in the primer binding sites, multiple primers were used for all except 
three KIR genes (Chapter 2, Table 2.1). In addition, each of the real-time PCR assays 
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utilised a single internal positive control gene with a melting peak significantly lower than the 
KIR and HLA-ligand amplicon melting peak (Chapter 2, Figure 2.3). This enabled accurate 
discrimination between the absence of a target gene and a failed PCR reaction. Most 
importantly, provided that the users have access to a real-time PCR instrument, the KIR and 
HLA-ligand assays proved to be very cost effective; costing as little as 15 – 20% of the price 
of commercial KIR and SBT HLA typing kits, and even in comparison to other real-time PCR 
methods that made use of fluorescent probes (Koehler et al., 2009). Nevertheless, with 
respect to the HLA SBT genotyping one must keep in mind the level of allele-specific detail 
that sequencing provides as opposed to the real-time HLA-ligand allotype designations 
(HLA-A/B Bw4 and HLA-C C1/C2).  
 
A limitation of the KIR and HLA-ligand assay design was that due to the large number of 
KIR and HLA genes described and allelic variation within these, certain alleles can be either 
undetected or misclassified. The KIR primers used in our KIR assay were able to detect all 
known allelic variants, with the exception of two KIR3DP1 alleles (KIR3DP1*004 and 
KIR3DP1*009:02). With regards to the HLA-ligand assay, the HLA-ligand primers were 
designed to discriminate Bw4 from Bw6 at codon 80, of which amino-acid residues at 
position 77 and 80-83 are important in defining the Bw4 (NXXIALR, NXXTALR, 
SXXIALR, DXXTLLR and SXXTLLR) and Bw6 (SXXNLRG and GXXNLRG) amino-acid 
motifs (Gumperz et al., 1995, Gumperz et al., 1997). Therefore, the limitation of our 
approach is that unclassified HLA-B alleles such as HLA-B*44:11, B*51:50, B*57:08 and 
HLA-A*24:61 that contain amino-acid changes within the Bw4 motif will be classified as 
Bw4. Likewise, unclassified HLA-B alleles such as B*07:11, B*07:57, B*08:17, B*35:56, 
B*39:20, B*40:37, B*55:12, B*78:06, B*95:35, B*08:29, B*27:42, B*37:05, B*25:52, 
B*37:14, B*47:03, B*40:76 and B*41:05 that have amino-acid changes that are divergent 
from the Bw6 motifs will be classified as Bw6. Moreover a number of HLA-B alleles that 
encode the C1 amino-acid motif (B*07:13, B*07:15, B*08:15, B*15:57, B*18:06, B*35:74, 
B*39:27, B*40:73, B*46:01-18, B*55:03, B*67:02 and B*73:01) and will be misclassified as 
Bw6 allotypes by our assay. Therefore, complementary HLA-A SBT genotyping would be 
necessary in the geographic regions where these genes have high frequencies, for example 
HLA-B46*01 in Asian populations (Gonzalez-Galarza et al., 2011). 
 
Thus following validation of the real-time PCR KIR and HLA-ligand assays, these assays 
were applied to a small South African sample set of 81 Black individuals. We found similar 
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KIR gene frequencies as compared to other published South African cohorts (Wong et al., 
2010, Paximadis et al., 2011), wherein the AA1 and Bx21 genotype (25% and 14%, 
respectively) were the most frequent KIR genotypes. In addition, we also identified one 
unique Bx genotype (Bx*, that had all KIR genes present with the exception of KIR2DL2, 
KIR2DL3, KIR2DS1, KIR2DS2 and KIR3DS1) that at the time of publication had not been 
reported (Hong et al., 2011). This genotype has since been classified as Bx555 and was also 
reported in low frequency (<1%) in a Northeast Indian Adivasi population (Dutta et al., 
2013).  
 
To conclude, several interactions between KIRs and their HLA-ligands have been found to be 
associated with a variety of outcomes in autoimmune and infectious diseases (Qi et al., 2006, 
Kulkarni et al., 2008, Martin and Carrington, 2008, Rajalingam, 2012), highlighting the 
importance of their systematic characterization in disease association studies. We describe 
two easy and inexpensive real-time PCR assays for the detection of KIR and HLA-ligands 
that were optimised and validated against commercial and published methods. These two 
assays allow for high throughput data generation with straightforward determination of the 
presence/absence of KIRs and their known HLA-ligands. Furthermore, using real-time PCR 
input DNA is less stringent requiring as little as 5ng of genomic DNA and allowing typing of 
samples with limited genomic DNA. Therefore, given the availability of small volumes of 
buffy coat samples and/or blood spots for some infants on MTCT2, these methods were 
therefore used to obtain KIR and HLA-ligand genotype data for this particular cohort. 
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CHAPTER 4 
KIR and their HLA-ligands in risk of vertical transmission of HIV-1 
 
4.1 Introduction 
There are many factors contributing to MTCT of HIV-1 and a better understanding of these 
mechanisms is crucial for the design of interventions other than ART for prevention of HIV-1 
transmission. Current evidence strongly suggests that NK cells and their KIR/HLA-ligand 
interactions have an important role in modulating HIV-1 disease susceptibility as well as 
disease progression (Khakoo and Carrington, 2006, Qi et al., 2006, Carrington et al., 2008, 
Jamil and Khakoo, 2011, Carrington and Alter, 2012, Jost and Altfeld, 2013, Martin and 
Carrington, 2013).  
 
In the context of HIV-1 disease progression, Martin et al. (2002) showed that HIV-1 infected 
individuals who possessed the activating KIR3DS1 gene in combination with HLA-Bw4 with 
an isoleucine at position 80 (HLA-Bw4:80I) progressed significantly more slowly to AIDS. 
However, in the absence of HLA-Bw4:80I alleles, KIR3DS1 significantly associated with 
more rapid progression to AIDS (Martin et al., 2002). This protective effective effect of 
KIR3DS1+HLA-Bw4 was further strengthened by evidence that individuals carrying both 
KIR3DS1 and HLA-Bw4:80I suppress HIV-1 replication in vitro to a greater extent than NK 
cells from individuals carrying KIR3DS1 in the absence of HLA-Bw4:80I, or vice versa, i.e. 
carrying HLA-Bw4:80I in the absence of KIR3DS1 (Alter et al., 2007a). In addition, an 
increased KIR3DS1 count generated by copy number variants of KIR3DL1/S1 associated with 
a lower viral set point in the presence of HLA-Bw4:80I alleles (Pelak et al., 2011). Taken 
together, these data support a role for KIR3DS1+ve NK cells in conjunction with their 
putative ligand Bw4:80I in restricting HIV-1 infection (Carrington and Alter, 2012, Korner 
and Altfeld, 2012). Likewise, the inhibitory counterpart, KIR3DL1, also associated with 
delayed HIV-disease progression. Co-carriage of high expression KIR3DL1 genotypes with 
HLA-B*57 (a Bw4:80I allele) were found to associate with both slow HIV disease 
progression and protection from infection (Martin et al., 2007, Boulet et al., 2008a).  
 
Other data supporting the fact that KIR/HLA combinations have a major role in HIV-1 
infection are that HIV-1 has devised strategies to evade recognition by NK cells (Carrington 
and Alter, 2012). Although the HIV-1 Nef protein has been shown to be able to downregulate 
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HLA-A and HLA-B expression on the surface of infected cells in order to escape 
CD8+ T cell recognition and lysis, HLA-C and HLA-E expression were not significantly 
affected (Cohen et al., 1999). It was proposed that the selective downregulation allows 
HIV-1-infected cells to avoid NK cell-mediated lysis and may represent, for HIV-1, a balance 
between escape from CTL and maintenance of protection from NK cells since HLA-C 
molecules represent the ligands for the inhibitory KIRs and HLA-E is the ligand for the other 
inhibitory NK cell receptor CD94/NKG2A (Martin and Carrington, 2013). In addition, it was 
also reported that KIR-associated HIV-1 sequence polymorphisms can enhance the binding 
of inhibitory KIRs to HIV-1-infected CD4+ T cells, leading to reduced antiviral activity of 
KIR+ve NK cells (Alter et al., 2011). It was shown that KIR+ve NK cells can place 
immunological pressure on HIV-1, and that the virus can evade such NK cell mediated 
immune pressure by selecting for such sequence polymorphisms.  
 
With regards to resistance to HIV-1 transmission, Jennes et al. (2006) reported that certain 
inhibitory KIR genes in the absence of their matching ligand were associated with the HIV-1 
negative status of female sex workers (FSW) from Abidjan, Côte d‟Ivoire. HIV-1-exposed 
seronegative FSW had increased frequencies of KIR2DL2/KIR2DL3 heterozygosity in the 
absence of the HLA-C1 ligand (i.e., C2/C2 homozygous), KIR3DL1 homozygosity in the 
absence of HLA-Bw4 (i.e., Bw6 homozygous) and also possessed a greater proportion of 
Bx genotypes (which meant a higher number of activating KIR); whilst HIV-1-seropositive 
FSW were characterized by KIR2DL3 homozygosity together with HLA-C1 and a trend 
toward KIR3DL1/HLA-Bw4 homozygosity (Jennes et al., 2006b). The authors postulated that 
the absence of HLA ligands for inhibitory KIR may lower the threshold for NK cell 
activation via activating KIR, resulting in NK cytotoxic activity and early elimination of 
HIV-1-infected cells. 
 
Moreover, KIR/HLA gene combinations between index and recipient partners have also been 
found to influence HIV-1 transmission. In Senegalese HIV-1 discordant and concordant 
couples, HIV-1 acquisition was associated with the KIR/HLA genotype of the recipient 
partners and transmission correlated with recipient/index allogeneic KIR/HLA combinations 
predictive of recipient NK cell alloreactivity towards index target cells (Jennes et al., 2013). 
In particular, it was noted that HIV-1-discordant couples were characterized by recipient 
partners with homozygous KIR2DL2, and by a mismatched recipient partner 
KIR2DL1/HLA-C2 with index partner HLA-C1/C1 combination, expected to allow licensed 
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„missing self‟ NK cell killing of index partners' cells. However, HIV-1-concordant couples 
were characterized by KIR2DL3 homozygous recipient partners with HLA-C1/C2 bearing 
index partners, resulting in a matched KIR/HLA combination expected to inhibit NK cell 
killing. Jennes et al. (2013) concluded that HIV-1 transmission and/or the lack thereof in the 
HIV-1 concordant and discordant couples was associated with mismatched KIR/HLA ligand 
combinations predictive of alloreactive NK cells targeting incoming HIV-1 infected index 
cells. Similarly, along these lines, NK cell alloreactivity has been used in the treatment of 
leukaemia (Ruggeri et al., 2005). In this setting, donor-versus-recipient NK cell alloreactivity 
was induced when there was a mismatch between donor NK clones, carrying specific 
inhibitory receptors for self MHC class I molecules, and MHC class I ligands on recipient 
cells, which resulted in donor NK clones recognizing „missing self HLA‟ on recipient cells 
and inducing alloreactivity towards residual leukaemic cells. In this manner haematopoietic 
transplantation from NK alloreactive donors cells were associated with clearance of 
leukaemia, reduction in rate of relapse as well as improved engraftment without causing 
graft-versus-host disease (Ruggeri et al., 2002, Ruggeri et al., 2005). 
 
Overall a number of studies have associated KIR/HLA with the outcome of HIV-1 infection 
(mainly concerning heterosexual transmission), however only one study thus far has 
associated KIR/HLA genotypes with mother-to-child transmission (MTCT) of HIV-1 
(Paximadis et al., 2011), wherein KIR2DL2 and KIR2DL3 (and their HLA-C ligands) 
emerged as important factors in both maternal transmission and infant acquisition of HIV-1. 
Representation of KIR2DL3 homozygosity alone and in combination with C1/C2 allotypes 
was significantly higher in intrapartum transmitting (IP-TR) mothers compared to 
non-transmitting (NT) mothers (P=0.034, OR=2.42 and P=0.01, OR=3.63 respectively) and 
after adjustment for maternal VL (P=0.033, OR=2.70 and P=0.027, OR=3.26, respectively), 
suggesting that maternal possession of KIR2DL3 homozygosity increased the risk of 
IP transmission of HIV-1 (Paximadis et al., 2011). Yet conversely in infants, possession of 
KIR2DL3 in combination with its C1 ligand as well as homozygosity for KIR2DL3 with 
C1C2, were both found to be significantly higher in exposed uninfected (EU) infants 
compared to HIV-1-infected infants (P=0.06, OR=0.41 and P=0.038, OR=0.40 respectively) 
and these associations were stronger after correction for maternal VL (P=0.02, OR=0.47 and 
P=0.009, OR=0.25, respectively), suggesting that in infants KIR2DL3 homozygosity in 
combination with at least one copy of the C1 ligand was protective against HIV-1 acquisition 
(Paximadis et al., 2011).  
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Although this study thoroughly assessed the role of KIR genes, KIR genotypes, KIR/HLA 
ligand associations, and the effect of KIR2DL3/KIR2DL3+C1/C2 concordance/discordance 
amongst mother-infant pairs in MTCT of HIV-1, the authors stated that there were a number 
of areas that required further investigation to elucidate the exact role of KIR/HLA on MTCT 
of HIV-1 (Paximadis et al., 2011). Firstly, since concordance for KIR3DL3/KIR2DL3+C1/C2 
genotype amongst mother and infant showed an association with increased risk for 
IP transmission, there was a need to further explore the influence of other KIR/HLA gene 
combinations amongst mother-infant pairs. Moreover, this association also suggests that 
infant allorecognition of maternal cells might play a role in HIV-1 acquisition, similar to the 
associations reported by Jennes et al. (2011) regarding KIR and HLA discordance amongst 
HIV-1 serodiscordant adults. Secondly, Paximadis et al. (2011) also emphasized the need to 
explore the role of KIR allelic variation, as the detection of a particular KIR gene does not 
equate with expression of that gene nor the presence of that gene on the NK cell surface, and 
thirdly to determine the role of the non-classical HLA-G molecule, the putative ligand for 
KIR2DL4, a framework KIR gene that has both activating and inhibitory potential.  
 
Thus in this chapter, analyses build on the KIR/HLA associations with mother-to-child HIV-1 
transmission first reported by Paximadis et al. (2011) in the MTCT1 cohort, and establish if 
the same and/or other KIR/HLA gene combinations are associated with vertical transmission 
in mother-infant pairs from another MTCT cohort (MTCT2). The roles of mother-infant 
KIR/HLA concordance, as well as mother-infant KIR/HLA gene combinations that may 
indicate the potential for infant allorecognition of infected maternal cells were evaluated. 
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4.2 Results 
4.2.1 Mother-infant concordance for KIR/HLA in MTCT1 
A total of 217 mother-infant pairs from MTCT1 were KIR and HLA-B and -C genotyped 
using the conventional methods described in Chapter 2, section 2.4 and the findings have 
been published (Paximadis et al., 2011). However with regards to mother-infant KIR/HLA 
concordance, only one KIR/HLA genotype (KIR2DL3/KIR3DL3+C1/C2) was evaluated with 
respect to HIV-1 transmission. Paximadis et al. (2011) reported that two thirds of the 
mothers, irrespective of transmissibility (i.e. TR or NT), harbouring the KIR2DL3/KIR3DL3 
in combination with C1/C2 ligand genotype were discordant with their infants (i.e. mother 
positive for genotype and corresponding infant negative for genotype) compared to a third 
that were concordant (i.e. the genotype was present in both mother and infant). Here we 
evaluated if mother-infant concordance for other known inhibitory and activating KIR/HLA 
ligand combinations are associated with MTCT.  
 
We found that mother-infant concordance for the inhibitory KIR combination, 
KIR2DL1+C1/C2 was significantly over-represented in NT/EU mother-infant pairs compared 
to IU2-TR/IU mother-infant pairs (Table 4.1, P=0.041, OR=0.34), which maintained 
significance post adjustment for mVL (P=0.011, OR=0.23) but not after adjustments for 
sdNVP or CD4+ T cell count (Table 4.3). In addition, concordant representation of 2DL3 
homozygosity in the absence of C1 ligand (i.e. C2/C2) was significantly higher in IP-TR/IP 
mother-infant pairs compared to NT/EU mother-infant pairs (P=0.043, OR=4.48) and this 
association remained significant after adjusting for mVL as well as maternal sdNVP 
administration (Table 4.3). Of note, concordance for the KIR2DL3/KIR3DL3+C1/C2 
genotype reported by Paximadis et al. (2011) showed a trend towards increased 
representation in IP-TR/IP mother-infant pairs compared to NT/EU mother-infant pairs 
(P=0.064, OR=3.71), which gained significance post adjustment for maternal CD4+ T cell 
count (P=0.021, OR=5.62, Table 4.3). With regards to the activating KIR (KIR2DS1 and 
KIR2DS2) and their putative HLA ligands (C2 and C1, respectively), we found no significant 
associations (Table 4.1). 
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4.2.2 Allogeneic KIR/HLA combinations in MTCT1 
It has been hypothesized that HIV-1 transmission in heterosexual couples is in part dependant 
on the KIR/HLA genotype of the recipient partner, in such a way that resistance to HIV-1 
acquisition may be characterized by a mismatched allogeneic KIR/HLA combination and 
HIV-1 infected cells present in genital secretions of the index partner could be efficiently 
targeted by the recipients allogeneic NK cell responses (Jennes et al., 2013). Here we 
evaluated whether the level of allogeneic KIR/HLA incompatibility between mothers and 
infants could determine HIV-1 transmission. Thus we compared frequencies of „matched‟ 
and „missing self‟ KIR/HLA combinations between NT and TR mother-infant pairs. We 
found that IU2 infants had significantly greater representation of homozygous 
iKIR2DL2+C1/C2 with mothers bearing the mC2/C2 combination (Table 4.2, P=0.011, 
OR=ND), which would theoretically allow licensed „missing self‟ NK cell killing of maternal 
cells through KIR2DL2. However, this association was not maintained post adjustment for 
mVL, maternal sdNVP or CD4+ T cell count (Table 4.3). Nevertheless, when infants were 
iKIR2DL2/KIR2DL3 heterozygous (irrespective of their HLA-C ligands) and mothers 
possessed the mC1/C1 combination, resulting in a matched KIR/HLA combination, there was 
increased risk for IU acquisition of HIV-1 (IU: P=0.047, OR=4.02 and IU2: P=0.019, 
OR=3.45). Furthermore, these two IU associations maintained significance after adjusting for 
mVL as well as sdNVP (Table 4.3). With regards to allogeneic combinations of KIR3DL1 
and KIR3DS1 with HLA-Bw4 between TR (IP, IU and IU2) and NT mother-infant pairs, no 
significant differences were seen. 
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Table 4.1 Representation of mother-infant concordance with known KIR/HLA ligand combinations in MTCT1, N (%) 
KIR/HLA ligand 
NT/EU 
(N=145) 
IP-TR/IP 
(N=29) 
IU-TR/IU 
(N=19) 
IU2-TR/IU2 
(N=43) 
IP-TR/IP vs. NT IU-TR/IU vs. NT IU2-TR/IU2 vs. NT 
OR (95% CI) P OR (95% CI) P OR (95% CI) P 
2DL1+C1/C1 10 (6.90) 1 (3.45) 3 (15.79) 5 (11.63) 0.48 (0.06-3.92) 0.694 2.53 (0.63-10.2) 0.367 1.78 (0.57-5.51) 0.340 
2DL1+C1/C2 40 (27.59) 7 (24.14) 3 (15.79) 5 (11.63) 0.83 (0.33-2.11) 0.821 0.49 (0.14-1.78) 0.406 0.34 (0.12-0.93) 0.041 
2DL1+C2/C2 24 (16.55) 6 (20.69) 2 (10.53) 7 (16.28) 1.31 (0.48-3.57) 0.789 0.59 (0.13-2.73) 0.547 0.98 (0.39-2.46) 1.000 
2DL2/2DL2+C1/C1 1 (0.69) 0 (0.00) 0 (0.00) 1 (2.33) - 1.000 - 1.000 3.42 (0.21-55.9) 0.406 
2DL2/2DL2+C1/C2 7 (4.83) 0 (0.00) 1 (5.26) 1 (2.33) - 0.364 1.09 (0.13-9.42) 1.000 0.47 (0.06-3.93) 0.685 
2DL2/2DL2+C2/C2 2 (1.38) 0 (0.00) 0 (0.00) 1 (2.33) - 1.000 - 1.000 1.70 (0.15-19.2) 1.000 
2DL2/2DL3+C1/C1 5 (3.45) 1 (3.45) 1 (5.26) 1 (2.33) 1.00 (0.11-8.89) 1.000 1.56 (0.17-14.1) 1.000 0.67 (0.07-5.86) 1.000 
2DL2/2DL3+C1/C2 13 (8.97) 2 (6.90) 0 (0.00) 0 (0.00) 0.75 (0.16-3.53) 1.000 - 0.236 - 0.078 
2DL2/2DL3+C2/C2 6 (4.14) 1 (3.45) 0 (0.00) 0 (0.00) 0.83 (0.09-7.14) 1.000 - 0.616 - 0.339 
2DL3/2DL3+C1/C1 3 (2.07) 0 (0.00) 1 (5.26) 1 (2.33) - 1.000 2.62 (0.26-26.6) 0.392 1.13 (0.11-11.1) 1.000 
2DL3/2DL3+C1/C2 6 (4.14) 4 (13.79) 0 (0.00) 0 (0.00) 3.71 (0.97-14.1) 0.064 - 0.616  0.339 
2DL3/2DL3+C2/C2 5 (3.45) 4 (13.79) 1 (5.26) 3 (6.98) 4.48 (1.12-17.8) 0.043 1.56 (0.17-14.1) 1.000 2.10 (0.48-9.17) 0.386 
3DL1/3DL1+Bw4/Bw4 8 (5.52) 2 (6.90) 2 (10.53) 4 (9.30) 1.26 (0.25-6.30) 1.000 2.01 (0.39-10.3) 0.607 1.75 (0.50-6.14) 0.475 
3DL1/3DL1+Bw4/Bw6 25 (17.24) 6 (20.69) 4 (21.05) 7 (16.28) 1.25 (0.46-3.39) 0.790 1.28 (0.39-4.18) 0.749 0.93 (0.37-2.33) 1.000 
3DL1/3DL1+Bw6/Bw6 27 (18.62) 8 (27.59) 2 (10.53) 8 (18.60) 1.60 (0.66-4.15) 0.311 0.51 (0.11-2.35) 0.531 0.99 (0.42-2.39) 1.000 
3DL1/3DS1+Bw4/Bw4 1 (0.69) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
3DL1/3DS1+Bw4/Bw6 1 (0.69) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
3DL1/3DS1+Bw6/Bw6 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
2SD1+C1/C1 1 (0.69) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
2SD1+C1/C2 1 (0.69) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
2SD1+C2/C2 1 (0.69) 1 (3.45) 0 (0.00) 0 (0.00) 5.14 (0.31-84.7) 0.306 - 1.000 - 1.000 
2SD2+C1/C1 6 (4.14) 1 (3.45) 1 (5.26) 3 (6.98) 0.82 (0.09-7.14) 1.000 1.29 (0.15-11.3) 1.000 1.73 (0.41-7.26) 0.687 
2SD2+C1/C2 21 (14.48) 2 (6.90) 2 (10.53) 3 (6.98) 0.44 (0.09-1.98) 0.375 0.69 (0.15-3.23) 0.746 0.44 (0.12-1.56) 0.297 
2SD2+C2/C2 12 (8.28) 3 (10.34) 0 (0.00) 1 (2.33) 1.27 (0.34-4.85) 1.000 - 0.363 0.26 (0.03-2.09) 0.304 
NT/EU, non-transmitting mother and her exposed uninfected infant; IP-TR/IP, intrapartum transmitting mother and her infant; IU-TR/IU, in utero transmitting 
mother and her infant; IU2-TR/IU2, in utero enriched transmitting mother and her infant. Bold and highlighted P values indicate significant differences (P<0.05).  
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Table 4.2 Frequencies of allogeneic combinations of KIR2DL1, KIR2DL2, KIR2DL3, KIR3DL1 and KIR3DS1 in recipient infants with 
HLA-ligands (C1/C2 or Bw4/Bw6, respectively) in index mothers in MTCT1, N (%) 
Type* 
Recipient (Infant) Index (Mother) EU 
(N=145) 
IP 
(N=29) 
IU 
(N=19) 
IU2 
(N=43) 
IP vs. EU IU vs. EU IU2 vs. EU 
KIR HLA HLA OR (95% CI) P OR (95% CI) P OR (95% CI) P 
Matched 2DL1 Any C1/C2 71 (48.97) 18 (62.07) 7 (36.84) 15 (34.88) 1.71 (0.75-3.86) 0.226 0.61 (0.23-1.63) 0.342 0.56 (0.28-1.13) 0.119 
Matched 2DL1 Any C2/C2 53 (36.55) 10 (34.48) 6 (31.58) 16 (37.21) 0.91 (0.39-2.11) 1.000 0.80 (0.29-2.23) 0.802 1.03 (0.51-2.08) 1.000 
Missing self 2DL1 C1/C2 C1/C1 10 (6.90) 0 (0.00) 2 (10.53) 6 (13.95) - 0.217 1.58 (0.32-7.86) 0.633 2.19 (0.75-6.42) 0.208 
Missing self 2DL1 C2/C2 C1/C1 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
Matched 2DL2/2DL2 Any C1/C1 3 (2.07) 0 (0.00) 0 (0.00) 2 (4.65) - 1.000 - 1.000 2.30 (0.37-14.2) 0.590 
Matched 2DL2/2DL2 Any C1/C2 19 (13.10) 1 (3.45) 5 (26.32) 7 (16.28) 0.24 (0.03-1.84) 0.204 2.36 (0.76-7.32) 0.161 1.28 (0.50-3.31) 0.618 
Missing self 2DL2/2DL2 C1/C1 C2/C2 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
Missing self 2DL2/2DL2 C1/C2 C2/C2 0 (0.00) 0 (0.00) 1 (5.26) 3 (6.98) - 1.000 - 0.116 - 0.011 
Matched 2DL2/2DL3 Any C1/C1 9 (6.21) 1 (3.45) 4 (21.05) 8 (18.60) 0.54 (0.06-4.43) 0.700 4.02 (1.11-14.7) 0.047 3.45 (1.24-9.60) 0.019 
Matched 2DL2/2DL3 Any C1/C2 33 (22.76) 8 (27.59) 2 (10.53) 6 (13.95) 1.29 (0.52-3.19) 0.633 0.40 (0.09-1.81) 0.257 0.55 (0.21-1.42) 0.285 
Missing self 2DL2/2DL3 C1/C1 C2/C2 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
Missing self 2DL2/2DL3 C1/C2 C2/C2 12 (8.28) 3 (10.34) 0 (0.00) 3 (6.98) 1.28 (0.34-4.85) 1.000  0.363 0.83 (0.22-3.09) 1.000 
Matched 2DL3/2DL3 Any C1/C1 8 (5.52) 0 (0.00) 1 (5.26) 1 (2.33) - 0.355 0.95 (0.11-8.05) 1.000 0.41 (0.05-3.35) 0.471 
Matched 2DL3/2DL3 Any C1/C2 20 (13.79) 8 (27.59) 0 (0.00) 2 (4.65) 2.38 (0.92-6.10) 0.093 - 0.133 0.30 (0.07-1.36) 0.114 
Missing self 2DL3/2DL3 C1/C1 C2/C2 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
Missing self 2DL3/2DL3 C1/C2 C2/C2 17 (11.72) 0 (0.00) 3 (15.79) 3 (6.98) - 0.080 1.41 (0.37-5.35) 0.707 0.56 (0.16-2.02) 0.422 
Matched 3DL1/3DL1 Any Bw4/Bw4 21 (14.48) 4 (13.79) 4 (21.05) 7 (16.28) 0.94 (0.29-2.99) 1.000 1.57 (0.47-5.21) 0.496 1.14 (0.45-2.92) 0.808 
Matched 3DL1/3DL1 Any Bw4/Bw6 60 (41.38) 12 (41.38) 6 (31.58) 14 (32.56) 1.00 (0.44-2.24) 1.000 0.65 (0.23-1.82) 0.466 0.68 (0.33-1.40) 0.375 
Missing self 3DL1/3DL1 Bw4/Bw4 Bw6/Bw6 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
Missing self 3DL1/3DL1 Bw4/Bw6 Bw6/Bw6 25 (17.24) 4 (13.79) 4 (21.05) 7 (16.28) 0.77 (0.24-2.40) 0.789 1.28 (0.39-4.18) 0.749 0.93 (0.37-2.33) 1.000 
Matched 3DL1/3DS1 Any Bw4/Bw4 2 (1.38) 0 (0.00) 0 (0.00) 2 (4.65) - 1.000 - 1.000 3.48 (0.47-25.5) 0.225 
Matched 3DL1/3DS1 Any Bw4/Bw6 6 (4.14) 0 (0.00) 1 (5.26) 2 (4.65) - 0.591 1.28 (0.15-11.3) 1.000 1.13 (0.22-5.81) 1.000 
Missing self 3DL1/3DS1 Bw4/Bw4 Bw6/Bw6 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
Missing self 3DL1/3DS1 Bw4/Bw6 Bw6/Bw6 2 (1.38) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
EU, exposed uninfected infants; IP, intrapartum infected infants; IU, in utero infected infants; IU2, IU-enriched group of infants. 
*
According to models described by 
Moretta et al. (2011) and Jennes et al. (2013): „Matched‟ occurs when the specified inhibitory KIR of the recipient recognizes an HLA allele present in the index 
(regardless of recipient HLA) and „Missing self‟ occurs when the specified inhibitory KIR of the recipient recognizes an HLA allele present in the recipient that is 
lacking in the index. Bold and highlighted P values indicate significant differences (P<0.05). 
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Table 4.3 Logistic regression analysis, adjustments made for maternal viral load (mVL), single dose nevirapine (sdNVP) and CD4+ T cell count 
Mother-infant KIR/HLA combination Association 
Adjusted mVL Adjusted sdNVP Adjusted CD4+ T cell count 
OR (95% CI) P OR (95% CI) P OR (95%CI) P 
Concordance 
2DL3/2DL3+C2/C2 IP-TR/IP vs. NT/EU 8.81 (1.56-49.5) 0.014 5.74 (1.29-25.5) 0.022 3.30 (0.71-15.2) 0.125 
2DL1+C1/C2 IU2-TR/IU2 vs. NT/EU 0.23 (0.07-0.71) 0.011 0.41 (0.15-1.14) 0.088 0.39 (0.14-1.11) 0.077 
2DL3/2DL3+C1/C2 IP-TR/IP vs. NT/EU 2.25 (0.46-11.1) 0.316 3.05 (0.78-11.9) 0.108 5.62 (1.29-24.5) 0.021 
Allorecognition 
i2DL2/2DL2(C1/C2)+mC2/C2 IU2 vs. EU - 1.000 - 1.000 - 1.000 
i2DL2/2DL3(Any)+mC1/C1 IU vs. EU 4.64 (1.10-19.5) 0.036 4.30 (1.14-16.2) 0.031 4.40 (0.99-19.5) 0.051 
i2DL2/2DL3(Any)+mC1/C1 IU2 vs. EU 3.26 (1.02-10.3) 0.045 3.86 (1.26-11.8) 0.018 3.46 (1.16-10.3) 0.026 
NT/EU, HIV-1 non-transmitting mothers and exposed uninfected infants; IP-TR/IP, intrapartum HIV-1 transmitting mothers and their infants, IU-TR/IU, in utero 
HIV-1 transmitting mothers and their infants; IU2-TR/IU2, in utero enriched HIV-1 transmitting mothers and their infants. Bold and highlighted P values indicate 
significant differences (P<0.05). 
 
  
Chapter 4: KIR/HLA ligands in MTCT  96 
4.2.3 Diversity of KIR genes in MTCT2 
To determine if KIR genes were associated with MTCT of HIV-1 in mother and infants from 
MTCT2 we used the real-time PCR method described in Chapter 2, section 2.5. All 16 KIR 
genes were detected in the MTCT2 cohort and their observed frequencies are shown in 
Table 4.4. The framework genes were found in all individuals whereas all other KIR genes 
were present in varying percentages. Overall, inhibitory KIR genes had higher frequencies 
than activating KIR genes, however, comparison of individual KIR gene frequencies between 
TR (IP-TR and IU-TR) and NT mothers, as well as their infants, showed no significant 
differences (Table 4.4). With regards to KIR gene numbers, comparison of the total KIR, 
inhibitory KIR and activating KIR genes between TR and NT mothers as well as their infants 
showed no significant differences (Table 4.5).  
 
Based on KIR gene presence or absence, and using the KIR allele frequencies database 
(http://www.allelefrequencies.net), we identified 29 distinct KIR genotypes in MTCT2 
mothers, of which the three most common KIR genotypes were Bx21 (16.3%), AA1 (13.9%) 
and Bx32 (8.9%) which accounted for 40.5% of the total KIR genotypes (Figure 4.1). In 
addition, we found one unique Bx genotype (Bx?) that had not been described in the KIR 
allele frequencies database. This „Bx?‟ genotype had a total of 12 KIR genes (2DL1, 2DL2, 
2DL4, 2DL5, 2DS1, 2DS2, 2DS5, 2DP1, 3DL1, 3DL2, 3DL3 and 3DP1) and was identified in 
one NT mother. While in the infant group, out of 23 distinct KIR genotypes, AA1 was the 
most common KIR genotype with 33.7% representation followed by Bx21 and Bx5 
(Figure 4.1). Comparison of the total AA1 haplotype frequency between mothers and infants 
showed that the AA1 haplotype was significantly under-represented in mothers (13.9% vs. 
33.7%, P=0.005), while the other common KIR haplotypes were similar amongst mothers and 
infants (Figure 4.1A). Moreover, within the maternal group, both IP-TR and IU-TR mothers 
were found to have significantly higher representation of Bx32 genotype compared to NT 
mothers (Figure 4.1B, P=0.038 and P=0.005, respectively). This finding was similar to the 
findings reported by Paximadis et al. (2011) where TR mothers had significantly higher 
representation of Bx32 compared to NT mothers (5.4% vs. 0.7%; P=0.04; OR=8.5). 
Comparison of the Bx32 genotype in relation to Bx21, the other most common Bx genotype 
in MTCT2 mothers, showed that two genotypes were similar except for the absence of 
KIR2DL2 and KIR2DS2 in Bx32. 
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Table 4.4 KIR gene frequencies in mothers and their infants in MTCT2, N (%) 
Maternal KIR 
NT 
(N=43) 
IP-TR 
(N=11) 
IU-TR 
(N=25) 
IP-TR vs. NT IU-TR vs. NT 
OR (95% CI) P OR (95% CI) P 
2DL1 43 (100.00) 11 (100.00) 25 (100.00) - 1.000 - 1.000 
2DL2 31 (72.09) 7 (63.64) 13 (52.00) 0.68 (0.17-2.74) 0.714 0.42 (0.15-1.17) 0.118 
2DL3 34 (79.07) 9 (81.82) 21 (84.00) 1.19 (0.22-6.51) 1.000 1.38 (0.37-5.09) 0.754 
2DL4 43 (100.00) 11 (100.00) 25 (100.00) - 1.000 - 1.000 
2DL5 28 (65.12) 8 (72.73) 18 (72.00) 1.42 (0.33-6.19) 0.733 1.38 (0.47-4.04) 0.602 
2DP1 42 (97.67) 10 (90.91) 25 (100.00) 0.24 (0.01-4.14) 0.369 - 1.000 
2DS1 8 (18.60) 2 (18.18) 4 (16.00) 0.97 (0.17-5.39) 1.000 0.83 (0.22-3.11) 1.000 
2DS2 25 (58.14) 6 (54.55) 12 (48.00) 0.86 (0.23-3.27) 1.000 0.66 (0.24-1.79) 0.458 
2DS3 8 (18.60) 3 (27.27) 5 (20.00) 1.64 (0.35-7.60) 0.676 1.09 (0.31-3.80) 1.000 
2DS4 40 (93.02) 11 (100.00) 24 (96.00) - 0.600 1.80 (0.18-18.2) 1.000 
2DS5 34 (79.07) 7 (63.64) 15(60.00) 0.46 (0.11-1.93) 0.429 0.39 (0.13-1.17) 0.103 
3DL1 43 (100.00) 11 (100.00) 25 (100.00) - 1.000 - 1.000 
3DL2 43 (100.00) 11 (100.00) 25 (100.00) - 1.000 - 1.000 
3DL3 43 (100.00) 11 (100.00) 25 (100.00) - 1.000 - 1.000 
3DP1 43 (100.00) 11 (100.00) 25 (100.00) - 1.000 - 1.000 
3DS1 4 (9.30) 1 (9.09) 1 (4.00) 0.97 (0.09-9.71) 1.000 0.41 (0.04-3.85) 0.645 
Infant KIR 
EU 
(N=44) 
IP 
(N=11) 
IU 
(N=25) 
IP vs. EU  IU vs. EU  
OR (95% CI) P OR (95% CI) P 
2DL1 44 (100.00) 11 (100.00) 25 (100.00) - 1.000 - 1.000 
2DL2 25 (56.82) 8 (72.73) 12 (48.00) 2.03 (0.47-8.68) 0.495 0.70 (0.26-1.87) 0.616 
2DL3 40 (90.91) 8 (72.73) 19 (76.00) 0.27 (0.05-1.42) 0.134 0.32 (0.08-1.25) 0.152 
2DL4 44 (100.00) 11 (100.00) 25 (100.00) - 1.000 - 1.000 
2DL5 26 (59.09) 8 (72.73) 15 (60.00) 1.80 (0.43-7.92) 0.502 1.04 (0.38-2.82) 1.000 
2DP1 43 (97.73) 11 (100.00) 25 (100.00) - 1.000 - 1.000 
2DS1 6 (13.64) 3 (27.27) 3 (12.00) 2.37 (0.49-11.6) 0.362 0.86 (0.19-3.80) 1.000 
2DS2 23 (52.27) 8 (72.73) 2 (48.00) 2.43 (0.57-10.4) 0.314 0.84 (0.31-2.25) 0.805 
2DS3 6 (13.64) 3 (27.27) 7 (28.00) 2.37 (0.49-11.6) 0.362 2.46 (0.72-8.39) 0.201 
2DS4 43 (97.73) 11 (100.00) 25 (100.00) - 1.000 - 1.000 
2DS5 22 (50.00) 7 (63.64) 12 (48.00) 1.75 (0.45-6.84) 0.510 0.92 (0.34-2.46) 1.000 
3DL1 44 (100.00) 11 (100.00) 24 (96.00) - 1.000 - 0.362 
3DL2 44 (100.00) 11 (100.00) 25 (100.00) - 1.000 - 1.000 
3DL3 44 (100.00) 11 (100.00) 25 (100.00) - 1.000 - 1.000 
3DP1 44 (100.00) 11 (100.00) 25 (100.00) - 1.000 - 1.000 
3DS1 5 (11.36) 3 (27.27) 2 (8.00) 2.92 (0.58-14.7) 0.335 0.67 (0.12-3.78) 1.000 
NT, non-transmitting mother; IP-TR, intrapartum transmitting mother; IU, in utero transmitting 
mother; EU, exposed uninfected infants; IP, intrapartum infected infants; IU, in utero infected 
infants. 
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Table 4.5 Mann-Whitney U tests of KIR gene numbers in mothers and infants from MTCT2 
KIR gene number Median (range) Mann-Whitney U test, P value 
Mothers NT IP-TR IU-TR IP-TR vs. NT IU-TR vs. NT 
Total 12 (9-15) 12 (9-16) 12 (8-16) 0.855 0.314 
Inhibitory 7 (6-8) 7 (6-8) 7 (6-8) 0.923 0.673 
Activating 3 (1-5) 2 (1-6) 2 (0-6) 0.554 0.213 
Infants EU IP IU IP vs. EU IU vs. EU 
Total 12 (9-16) 13 (9-16) 11 (9-15) 0.230 0.793 
Inhibitory 7 (6-8) 7 (6-8) 7 (6-8) 0.728 0.243 
Activating 2 (1-6) 3 (1-6) 2 (1-6) 0.155 0.920 
NT, HIV-1 non-transmitting mother; IP-TR, intrapartum transmitting mother; IU, in utero transmitting 
mother; EU, exposed uninfected infants; IP, intrapartum infected infants; IU, in utero infected infants. 
 
 
Figure 4.1 KIR genotypes in MTCT2. (A) Representation of the most common KIR genotypes in 
mothers and infants from MTCT2, (B) individual KIR genotypes in MTCT2 mothers, and 
(C) individual KIR genotypes in MTCT2 infants.  
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4.2.4 Characterization of HLA-ligands in MTCT2 
Given that the majority of KIR function is reliant on their interaction with HLA-ligands, we 
evaluated the frequency HLA-ligands in MTCT2 using the real-time PCR method described 
in Chapter 2, section 2.5. The observed allele and genotype frequencies for MTCT2 mothers 
are shown in Figure 4.2 and Table 4.6, respectively. With regards to the major inhibitory 
HLA ligand, HLA-C, mothers were predominantly C1/C2 heterozygous (43.0%) while the 
remaining were C1/C1 homozygous (25.3%) or C2/C2 homozygous (31.6%). Similarly for 
HLA-A and -B, representation of Bw4/Bw6 heterozygosity was higher compared to Bw4 and 
Bw6 homozygosity (54.4%, 13.9% and 31.6%, respectively). Comparison of HLA-ligand 
frequencies amongst TR and NT mothers showed that maternal possession of HLA-A 
Bw4:80I was associated with increased risk for IU HIV-1 transmission (Figure 4.2). IU-TR 
mothers had significantly higher representation of HLA-A Bw4:80I than NT mothers 
(P=0.005, OR=3.67) and conversely, possession of non-Bw4 HLA-A alleles was found to be 
protective in NT mothers (P=0.005, OR=0.27). Furthermore, analysis of HLA-A ligand 
genotypes showed representation of Bw4:80I/Non-Bw4 heterozygosity was significantly 
higher in IP-TR and IU-TR mothers compared to NT mothers (P=0.025, OR=7.61 and 
P=0.031, OR=5.18, respectively), whilst non-Bw4 homozygosity was elevated in NT mothers 
(P=0.009, OR=0.21). Comparison of HLA-B ligand alleles showed an association with 
reduced risk for HIV-1 transmission; HLA-B Bw4:80T allele frequency was significantly 
higher in NT mothers compared to IU-TR mothers (P=0.030, OR=0.20), but HLA-B 
genotypes did not significantly differ amongst NT and TR mothers. In contrast, HLA-C 
genotype frequencies showed no differences amongst MTCT2 mothers (Figure 4.2).  
 
Similarly within the infant group (Figure 4.3), representation of HLA-A Bw4:80I allele was 
significantly higher in IU infants compared to EU infants (P=0.001, OR=7.99) of which the 
heterozygous HLA-A Bw4:80I/Non-Bw4 genotype was also significantly higher in IU infants 
compared to EU infants (Table 4.6: P=0.003, OR=7.69), whereas the absence of HLA-A 
Bw4 ligand (Non-Bw4/Non-Bw4) was associated with protection from IU acquisition of 
HIV-1 (P=0.001, OR=0.11). However, no other significant differences were detected when 
comparing infant HLA-B and HLA-C alleles‟ and/or genotypes in those infants that did or did 
not acquire HIV-1. 
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Figure 4.2 Maternal allele frequencies for HLA-A, -B and –C ligands in non-transmitting (NT), 
intrapartum transmitting (IP-TR) and in utero transmitting (IU-TR) mothers from MTCT2. *The 
frequency of HLA-A Bw4:80I was significantly higher in IU-TR mothers compared to NT 
mothers (P=0.005, OR=3.67, CI: 1.46-9.18); whereas the frequency of HLA-B Bw4:80T was 
significantly lower in IU-TR mothers compared to NT mothers (P=0.030, OR=0.20, 
CI: 0.04-0.90).  
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Figure 4.3 Infant allele frequencies for HLA-A, -B and -C ligands in exposed uninfected (EU), 
intrapartum (IP) and in utero (IU) infected infants from MTCT2. *The frequency of HLA-A 
Bw4:80I was significantly higher in IU infants compared to EU infants (P=0.001, OR=7.99, 
CI: 2.11-30.3) 
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Table 4.6 Representation of mother and infant genotype frequencies for HLA-A, -B and –C 
ligands in MTCT2 
Mothers 
NT 
(N=43) 
IP-TR 
(N=11) 
IU-TR 
(N=25) 
IP-TR vs. NT IU-TR vs. NT 
OR (95% CI) P OR (95% CI) P 
HLA-A 
Bw4/Bw4 3 (6.98) 0 (0.00) 4 (16.00) - 0.600 2.53 (0.52-12.4) 0.409 
Bw4/Non 3 (6.98) 4 (36.36) 7 (28.00) 7.61 (1.39-41.7) 0.025 5.18 (1.20-22.3) 0.031 
Non/Non 37 (86.05) 7 (63.64) 14 (56.00) 0.28 (0.06-1.27) 0.185 0.21 (0.06-0.66) 0.009 
HLA-B 
Bw4/Bw4 6 (13.95) 3 (27.27) 2 (8.00) 2.31 (0.47-11.2) 0.367 0.54 (0.10-2.88) 0.700 
Bw4/Bw6 19 (44.19) 4 (36.36) 11 (44.00) 0.72 (0.18-2.83) 0.741 0.99 (0.36-2.67) 1.000 
Bw6/Bw6 18 (41.86) 4 (36.36) 12 (48.00) 0.79 (0.20-3.12) 1.000 1.28 (0.47-3.45) 0.800 
HLA-A/B 
Bw4/Bw4 8 (18.60) 3 (27.27) 5 (20.00) 1.64 (0.35-7.60) 0.676 1.09 (0.31-3.80) 1.000 
Bw4/Non 20 (46.51) 6 (54.55) 15 (60.00) 1.38 (0.36-5.21) 0.741 1.72 (0.63-4.68) 0.323 
HLA-C 
C1/C1 11 (25.58) 2 (18.18) 7 (28.00) 0.65 (0.12-3.46) 0.715 1.13 (0.37-3.43) 1.000 
C1/C2 17 (39.53) 4 (36.36) 13 (52.00) 0.87 (0.22-3.44) 1.000 1.65 (0.61-4.47) 0.448 
C2/C2 15 (34.88) 5 (45.45) 5 (20.00) 1.56 (0.41-5.95) 0.728 0.47 (0.15-1.49) 0.272 
Infants 
EU 
(N=44) 
IP 
(N=11) 
IU 
(N=25) 
IP vs. EU IU vs. EU 
OR (95% CI) P OR (95% CI) P 
HLA-A 
Bw4/Bw4 0 (0.00) 0 (0.00) 1 (4.00) - 1.000 - 0.362 
Bw4/Non 3 (6.82) 0 (0.00) 9 (36.00) - 1.000 7.69 (1.84-32.1) 0.003 
Non/Non 41 (93.18) 11 (100.00) 15 (60.00) - 1.000 0.11 (0.03-0.45) 0.001 
HLA-B 
Bw4/Bw4 7 (15.91) 1 (9.09) 4 (16.00) 0.53 (0.06-4.81) 0.681 1.01 (0.26-3.84) 1.000 
Bw4/Bw6 21 (47.73) 7 (63.64) 12 (48.00) 1.91 (0.49-7.49) 0.503 1.01 (0.37-2.70) 1.000 
Bw6/Bw6 16 (36.36) 3 (27.27) 9 (36.00) 0.65 (0.15-2.83) 0.730 0.98 (0.35-2.73) 1.000 
HLA-A/B 
Bw4/Bw4 7 (15.91) 1 (9.09) 5 (20.00) 0.52 (0.06-4.81) 0.681 1.32 (0.37-4.71) 0.746 
Bw4/Non 22 (50.00) 7 (63.64) 16 (64.00) 1.75 (0.45-6.84) 0.510 1.78 (0.65-4.87) 0.319 
HLA-C 
C1/C1 5 (11.36) 1 (9.09) 4 (16.00) 0.78 (0.08-7.45) 1.000 1.48 (0.36-6.13) 0.714 
C1/C2 21 (47.73) 5 (45.45) 15 (60.00) 0.91 (0.24-3.43) 1.000 1.64 (0.61-4.44) 0.453 
C2/C2 18 (40.91) 5 (45.45) 16 (64.00) 1.20 (0.32-4.560 1.000 0.46 (0.15-1.37) 0.194 
NT, non-transmitting mother; IP-TR, intrapartum transmitting mother; IU, in utero transmitting mother; 
EU, exposed uninfected infants; IP, intrapartum infected infants; IU, in utero infected infants 
 
4.2.4 Characterization of KIR/HLA genotypes in MTCT2 
Analysis of the interactions between inhibitory KIR and their known HLA-ligands (KIR2DL1 
with C2, KIR2DL2 and KIR2DL3 with C1 and KIR3DL1 with Bw4) as well as the putative 
activating KIR/HLA combinations (2DS1, 2DS2 and 3DS1) are shown in Table 4.7. Unlike 
the NT mothers from MTCT1 that had significantly higher representation of 
KIR2DL2/KIR2DL3 compared to TR mothers (P=0.044; OR=0.53) and IP-TR mothers 
(P=0.008; OR=0.29), in MTCT2, neither KIR2DL2/KIR2DL3 heterozygosity nor 
homozygosity for KIR2DL2 or KIR3DL3 showed any significant differences amongst the TR 
and NT mothers. In addition, when paired with HLA-C ligands (C1/C1, C1/C2 and C2/C2), 
KIR/HLA frequencies did not significantly differ amongst TR and NT mothers from MTCT2. 
Next, we analyzed frequencies of inhibitory KIR3DL1 and activating KIR3DS1 (also alleles 
of the same gene locus) together with the HLA-Bw4 ligand. Whilst the KIR3DL1+Bw4 
representation was similar across TR and NT mothers, stratification of Bw4 alleles into those 
Chapter 4: KIR/HLA ligands in MTCT  103 
with an isoleucine or threonine at position 80 showed an association with risk of HIV-1 
transmission. KIR3DL1 in combination with Bw4:80I was significantly higher in IP-TR and 
IU-TR mothers compared to NT mothers (P=0.039, OR=6.25 and P=0.047, OR=2.95, 
respectively), whilst KIR3DL1+Bw4:80T was over-represented in NT mothers compared to 
IU-TR mothers (P=0.038, OR=0.20). This finding was not evident when comparing 
KIR3DL1/S1 genotypes, or KIR3DL1 homozygosity in combination with Bw4/Bw4 or 
Bw4/Bw6 (Table 4.6), suggesting that these findings were dependant on the HLA alone. In 
MTCT2 infants, no significant differences were detected in KIR alleles (KIR2DL2/L3 and 
KIR3DL1/S1), HLA ligands (C1/C2 and Bw4/Bw6) and KIR/HLA combinations amongst 
HIV-1-infected and EU infants (data not shown).  
 
Table 4.7 Representation of maternal KIR/HLA combinations in MTCT2, N (%) 
Maternal KIR/HLA 
NT 
(N=43) 
IP-TR 
(N=11) 
IU-TR 
(N=25) 
IP-TR vs. NT IU-TR vs. NT 
OR (95% CI) P OR (95% CI) P 
2DL1+C2 32 (74.42) 9 (81.82) 18 (72.00) 1.54 (0.29-8.29) 0.715 0.88 (0.29-2.68) 1.000 
2DL1+C2/C2 15 (34.88) 5 (45.45) 5 (20.00) 1.56 (0.41-5.95) 0.728 0.47 (0.15-1.49) 0.272 
2DL2+C1 20 (46.51) 4 (36.36) 11 (44.00) 0.66 (0.17-2.57) 0.736 0.90 (0.33-2.43) 1.000 
2DL2+C1/C1 7 (16.28) 1 (9.09) 4 (16.00) 0.51 (0.06-4.68) 0.678 0.97 (0.26-3.75) 1.000 
2DL3+C1 24 (55.81) 5 (45.45) 17 (68.00) 0.65 (0.17-2.49) 0.736 1.68 (0.59-4.73) 0.442 
2DL3+C1/C1 10 (23.26) 2 (18.18) 6 (24.00) 0.73 (0.13-3.96) 1.000 1.04 (0.32-3.32) 1.000 
2DS1+C2 7 (16.28) 2 (18.18) 1 (4.00) 1.14 (0.20-6.45) 1.000 0.21 (0.02-1.85) 0.242 
2DS1+C2/C2 7 (16.28) 2 (18.18) 1 (4.00) 1.14 (0.20-6.46) 1.000 0.21 (0.02-1.85) 0.242 
2DS2+C1 17 (39.53) 3 (27.27) 10 (40.00) 0.57 (0.13-2.47) 0.510 1.02 (0.37-2.79) 1.000 
2DS2+C1/C1 6 (13.95) 1 (9.09) 4 (16.00) 0.62 (0.07-5.73) 1.000 1.17 (0.29-4.64) 1.000 
2DL2/2DL2+C1C1 1 (2.33) 0 (0.00) 1 (4.00) - 1.000 1.75 (0.10-29.3) 1.000 
2DL2/2DL2+C1C2 3 (6.98) 1 (9.09) 2 (8.00) 1.33 (0.12-14.2) 1.000 1.15 (0.18-7.45) 1.000 
2DL2/2DL2+C2C2 5 (11.63) 1 (9.09) 1 (4.00) 0.76 (0.08-7.26) 1.000 0.32 (0.03-2.87) 0.402 
2DL2/2DL3+C1C1 6 (13.95) 1 (9.09) 3 (12.00) 0.62 (0.07-5.73) 1.000 0.84 (0.19-3.71) 1.000 
2DL2/2DL3+C1C2 10 (23.26) 2 (18.18) 5 (20.00) 0.73 (0.13-3.96) 1.000 1.28 (0.42-3.95) 0.773 
2DL2/2DL3+C2C2 6 (13.95) 2 (18.18) 1 (4.00) 1.37 (0.24-7.95) 1.000 0.26 (0.03-2.69) 0.248 
2DL3/2DL3+C1C1 4 (9.30) 1 (9.09) 3 (12.00) 0.97 (0.10-9.71) 1.000 1.32 (0.27-6.49) 1.000 
2DL3/2DL3+C1C2 4 (9.30) 1 (9.09) 6 (24.00) 0.97 (0.10-9.71) 1.000 3.07 (0.77-12.2) 0.154 
2DL3/2DL3+C2C2 4 (9.30) 2 (18.18) 3 (12.00) 2.17 (0.34-13.7) 0.590 1.32 (0.27-6.49) 1.000 
3DL1+A/B Bw4 28 (65.12) 9 (81.82) 17 (68.00) 2.41 (0.46-12.6) 0.470 1.14 (0.39-3.24) 1.000 
3DL1+A/B Bw4:80I 18 (41.86) 9 (81.82) 17 (68.00) 6.25 (1.20-32.5) 0.039 2.95 (1.05-8.32) 0.047 
3DL1+B Bw4:80T 13 (30.23) 2 (18.18) 2 (8.00) 0.51 (0.10-2.71) 0.488 0.20 (0.04-0.97) 0.038 
3DS1+A/B Bw4 3 (6.98) 1 (9.09) 0 (0.00) 1.33 (0.12-14.2) 1.000 - 0.292 
3DS1+A/B Bw4:80I 1 (2.33) 1 (9.09) 0 (0.00) 4.20 (0.24-73.1) 0.369 - 1.000 
3DS1+B Bw4:80T 2 (4.65) 1 (9.09) 0 (0.00) 2.05 (0.17-24.9) 1.000 - 0.528 
3DL1/3DL1+A/B Bw4/Bw4 7 (16.28) 2 (18.18) 2 (20.00) 1.14 (0.20-6.46) 1.000 1.28 (0.36-4.58) 0.748 
3DL1/3DL1+A/B Bw4/Bw6 18 (41.86) 6 (54.55) 15 (60.00) 1.67 (0.44-6.31) 0.510 2.08 (0.76-5.68) 0.209 
3DL1/3DS1+A/B Bw4/Bw4 1 (2.33) 1 (9.09) 0 (0.00) 4.20 (0.24-73.1) 0.369 - 1.000 
3DL1/3DS1+A/B Bw4/Bw6 2 (4.65) 0 (0.00) 0 (0.00) - 1.000 - 0.528 
NT, non-transmitting mothers; IP-TR, intrapartum transmitting mothers; IU, in utero transmitting 
mothers. 
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4.2.5 Mother-infant concordance for KIR/HLA in MTCT2 
Given that mother-infant concordance for KIR/HLA in MTCT1 showed two significant 
associations with risk of transmission, we analysed KIR/HLA concordance in MTCT2. 
Concordant comparisons for both inhibitory and activating KIR/HLA genotypes are shown in 
Table 4.8. We found that concordant KIR/HLA frequencies were similar across TR and NT 
mother-infant pairs and did not show an association with MTCT of HIV-1.  
 
Table 4.8 Representation of mother-infant KIR/HLA concordance in MTCT2, N (%) 
KIR/HLA 
NT/EU 
(N=43) 
IP-TR/IP 
(N=11) 
IU-TR/IU 
(N=25) 
IP-TR/IP vs. NT/EU IU-TR/IU vs. NT/EU 
OR (95% CI) P OR (95% CI) P 
2DL1+C1/C1 2 (4.55) 0 (0.00) 3 (12.00) - 1.000 2.86 (0.44-18.4) 0.344 
2DL1+C1/C2 9 (20.45) 3 (27.27) 10 (40.00) 1.45 (0.32-6.63) 0.689 2.59 (0.87-7.67) 0.098 
2DL1+C2/C2 13 (29.55) 3 (27.27) 4 (16.00) 0.89 (0.20-3.91) 1.000 - 1.000 
2DL2/2DL2+C1C1 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 
2DL2/2DL2+C1C2 1 (2.27) 1 (9.09) 1 (4.00) 4.30 (0.24-74.8) 0.363 1.79 (0.11-29.9) 1.000 
2DL2/2DL2+C2C2 0 (0.00) 1 (9.09) 1 (4.00) - 0.200 - 0.362 
2DL2/2DL3+C1C1 1 (2.27) 0 (0.00) 1 (4.00) - 1.000 1.79 (0.11-29.9) 1.000 
2DL2/2DL3+C1C2 3 (6.82) 0 (0.00) 2 (8.00) - 1.000 1.19 (0.18-7.64) 1.000 
2DL2/2DL3+C2C2 2 (4.55) 0 (0.00) 1 (4.00) - 1.000 0.87 (0.08-10.2) 1.000 
2DL3/2DL3+C1C1 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 
2DL3/2DL3+C1C2 1 (2.27) 0 (0.00) 3 (12.00) - 1.000 5.86 (0.57-59.7) 0.132 
2DL3/2DL3+C2C2 3 (6.82) 1 (9.09) 2 (8.00) 1.37 (0.13-14.6) 1.000 1.19 (0.18-7.64) 1.000 
3DL1/3DL1+Bw4Bw4 4 (9.09) 1 (9.09) 2 (8.00) 1.00 (0.10-9.95) 1.000 0.87 (0.15-5.12) 1.000 
3DL1/3DL1+Bw4Bw6 10 (22.73) 3 (27.27) 11 (44.00) 1.27 (0.28-5.72) 1.000 2.67 (0.92-7.70) 0.101 
3DL1/3DL1+Bw6Bw6 7 (15.91) 1 (9.09) 1 (4.00) 0.53 (0.06-4.81) 0.681 0.22 (0.02-1.90) 0.243 
3DL1/3DS1+Bw4Bw4 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 
3DL1/3DS1+Bw4Bw6 1 (2.27) 0 (0.00) 0 (0.00) - 1.000 - 1.000 
3DL1/3DS1+Bw6Bw6 0 (0.00) 0 (0.00) 1 (4.00) - 1.000 - 0.362 
2SD1+C1/C1 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 
2SD1+C1/C2 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 
2SD1+C2/C2 1 (2.27) 0 (0.00) 0 (0.00) - 1.000 - 1.000 
2SD2+C1/C1 0 (0.00) 0 (0.00) 2 (8.00) - 1.000 - 0.128 
2SD2+C1/C2 5 (11.36) 1 (9.09) 5 (20.00) 0.78 (0.08-7.45) 1.000 1.95 (0.50-7.53) 0.478 
2SD2+C2/C2 5 (11.36) 1 (9.09) 2 (8.00) 0.78 (0.08-7.45) 1.000 0.67 (0.12-3.78) 1.000 
NT, non-transmitting mothers; IP-TR, intrapartum transmitting mothers; IU, in utero 
transmitting mothers. 
 
4.2.6 Allogeneic KIR/HLA ligand combinations in MTCT2 
As in MTCT1, allogeneic KIR/HLA gene combinations between mother and infant may 
influence susceptibility to HIV-1 acquisition, thus we compared frequencies of „matched‟ and 
„missing self‟ KIR/HLA combinations between TR and NT and mother-infant pairs from 
MTCT2 (Table 4.9). However, in MTCT2 we found no significant differences in allogeneic 
combinations of KIR2DL1, KIR2DL2/L3 or KIR3DL1/S1 with HLA-C or HLA-B ligands 
between TR and NT mother-infant pairs.  
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Table 4.9 Frequencies of allogeneic combinations of KIR2DL1, KIR2DL2, KIR2DL3, KIR3DL1 and KIR3DS1 in recipient infants with HLA-ligands (C1/C2 
or Bw4/Bw6, respectively) in index mothers in MTCT2, N (%) 
Type* 
Recipient (Infant) Index (Mother) EU 
(N=44) 
IP 
(N=11) 
IU 
(N=25) 
IP vs. EU IU vs. EU 
KIR HLA HLA OR (95% CI) P OR (95% CI) P 
Matched 2DL1 any C1/C2 17 (38.64) 4 (36.36) 13 (52.00) 0.91 (0.23-3.57) 1.000 1.72 (0.64-4.64) 0.320 
Matched 2DL1 any C2/C2 16 (36.36) 5 (45.45) 5 (20.00) 1.45 (0.38-5.54) 0.731 0.44 (0.14-1.39) 0.184 
Missing self 2DL1 C1/C2 C1/C1 9 (20.45) 1 (9.09) 4 (16.00) 0.38 (0.04-3.45) 0.667 0.74 (0.20-2.71) 0.756 
Missing self 2DL1 C2/C2 C1/C1 0 (0.00) 1 (9.09) 0 (0.00) - 0.200 - 1.000 
Matched 2DL2/2DL2 any C1/C1 1 (2.27) 1 (9.09) 2 (8.00) 4.30 (0.25-74.8) 0.363 3.73 (0.32-43.5) 0.549 
Matched 2DL2/2DL2 any C1/C2 2 (4.55) 1 (9.09) 2 (8.00) 2.10 (0.17-25.5) 1.000 1.82 (0.24-13.8) 0.617 
Missing self 2DL2/2DL2 C1/C1 C2/C2 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 
Missing self 2DL2/2DL2 C1/C2 C2/C2 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 
Matched 2DL2/2DL3 any C1/C1 6 (13.64) 1 (9.09) 2 (8.00) 0.63 (0.07-5.88) 1.000 0.55 (0.10-2.96) 0.701 
Matched 2DL2/2DL3 any C1/C2 8 (18.18) 1 (9.09) 4 (16.00) 0.45 (0.05-4.03) 0.669 0.85 (0.23-3.19) 1.000 
Missing self 2DL2/2DL3 C1/C1 C2/C2 0 (0.00) 1 (9.09) 0 (0.00) - 0.200 - 1.000 
Missing self 2DL2/2DL3 C1/C2 C2/C2 3 (6.82) 1 (9.09) 0 (0.00) 1.37 (0.13-14.6) 1.000 - 0.297 
Matched 2DL3/2DL3 any C1/C1 4 (9.09) 0 (0.00) 2 (8.00) - 0.573 0.86 (0.15-5.12) 1.000 
Matched 2DL3/2DL3 any C1/C2 7 (15.91) 2 (18.18) 7 (28.00) 1.17 (0.21-6.63) 1.000 2.06 (0.62-6.75) 0.350 
Missing self 2DL3/2DL3 C1/C1 C2/C2 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 
Missing self 2DL3/2DL3 C1/C2 C2/C2 0 (0.00) 0 (0.00) 1 (4.00) - 1.000 - 0.362 
Matched 3DL1/3DL1 any Bw4/Bw4 5 (11.36) 2 (18.18) 2 (8.00) 1.73 (0.29-10.4) 0.617 0.68 (0.12-3.78) 1.000 
Matched 3DL1/3DL1 any Bw4/Bw6 19 (43.18) 5 (45.45) 14 (56.00) 1.09 (0.29-4.13) 1.000 1.67 (0.62-4.50) 0.328 
Missing self 3DL1/3DL1 Bw4/Bw4 Bw6/Bw6 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 
Missing self 3DL1/3DL1 Bw4/Bw6 Bw6/Bw6 7 (15.91) 0 (0.00) 5 (20.00) - 0.323 1.32 (0.37-4.71) 0.746 
Matched 3DL1/3DS1 any Bw4/Bw4 1 (2.27) 1 (9.09) 0 (0.00) 4.30 (0.25-74.7) 0.363 - 1.000 
Matched 3DL1/3DS1 any Bw4/Bw6 3 (6.82) 1 (9.09) 0 (0.00) 1.37 (0.13-14.6) 1.000 - 0.297 
Missing self 3DL1/3DS1 Bw4/Bw4 Bw6/Bw6 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 
Missing self 3DL1/3DS1 Bw4/Bw6 Bw6/Bw6 0 (0.00) 1 (9.09) 0 (0.00) - 0.200 - 1.000 
EU, exposed uninfected infants; IP, intrapartum infected infants; IU, in utero infected infants; IU2. 
*
According to models described by Moretta et al. (2011) and Jennes et al. 
(2013): „Matched‟ occurs when the specified inhibitory KIR of the recipient recognizes an HLA allele present in the index (regardless of recipient HLA) and „missing self‟ 
occurs when the specified inhibitory KIR of the recipient recognizes an HLA allele present in the recipient that is lacking in the index. Bold and highlighted P values indicate 
significant differences (P<0.05). 
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4.3 Discussion 
In this chapter, we evaluated two mother-infant cohorts (MTCT1 and MTCT2, discussed in 
Chapter 2, Section 2.1.1, that were recruited from 1996 to 2010, and as such mothers and 
infants from MTCT1 and MTCT2 differed in their PMTCT therapy as well as their overall 
HIV-1 transmission rates (9.8% and 5.2%, P<0.001). In MTCT1 approximately half (56%) 
the mothers received sdNVP at the onset of labour, whereas the majority (89.9%) of mothers 
from MTCT2 received daily AZT ranging from 28 – 37 weeks gestation as well as sdNVP at 
the onset of labour. While all infants from MTCT1 received sdNVP within 72 hours of birth 
and all infants from MTCT2 received sdNVP within 72 hours of birth and a minimum 1 week 
course of daily AZT. 
 
In the initial findings reported on the MTCT1 cohort Paximadis et al. (2011) identified the 
KIR genes, KIR2DL2 and KIR2DL3, strongly associated with risk of vertical transmission.  
Importantly, (1) maternal KIR2DL2/KIR2DL3 heterozygosity associated with decreased risk 
for IP transmission (P=0.008, OR=0.29), (2) maternal KIR2DL3 homozygosity (alone and in 
combination with C1/C2) associated with increased risk for IP transmission (P=0.034, 
OR=2.42 and P=0.010, OR=3.63, respectively), and (3) infant KIR2DL3 homozygosity in 
combination with C1/C2 associated with protection from HIV-1 acquisition (P=0.038, 
OR=0.40). Moreover, because the KIR/HLA gene combination, KIR2DL3/KIR2DL3+C1/C2, 
appeared to have conflicting associations in mothers and infants, the influence of gene 
concordance between mother and infant was only determined with respect to 
KIR2DL3/KIR2DL3+C1/C2 and not the other KIR/HLA gene combinations. Expanding on 
these analyses we found two additional KIR/HLA gene combinations that influenced the risk 
of HIV-1 transmission when mother and infant were KIR/HLA gene concordant, namely 
(1) KIR2DL3/KIR2DL3+C2/C2 (i.e. lacking a C1 ligand) associated with increased risk for 
IP transmission, and (2) KIR2DL1+C1/C2 associated with decreased risk for IU transmission. 
Moreover both these associations were maintained post adjustment for mVL (Table 4.3) and, 
strikingly, when adjusting for mVL, there was almost a nine-fold increased risk of 
IP transmission when mother-infant were concordant for KIR2DL3/KIR2DL3+C2/C2 
(OR=8.81). We postulated that mother-infant KIR/HLA concordance influenced the risk of 
transmission in a similar fashion to that of the „arming‟ and „disarming‟ model of NK cell 
self-tolerance first proposed by Roulet and Vance (2006).  
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In this model (Figure 4.4), immature NK cells become functionally mature and „armed‟ 
through the interactions with HLA-class-I-expressing target cells, whereas NK cells that fail 
to interact with HLA-class-I-expressing target cells remain unarmed and unresponsive, and 
therefore do not attack MHC-class-I-deficient target cells (Raulet and Vance, 2006). 
Therefore, in the case of KIR2DL3/KIR2DL3+C2/C2 concordance, when both mother and 
infant lack their cognate ligand (C1) for KIR2DL3, NK cells which expressed KIR2DL3 in 
the absence of C1 were not licensed and are unresponsive to HIV-1-infected target cells 
which may contribute to increased risk of IP-transmission. Furthermore given that, KIR2DL3 
is a fixed locus of the group A haplotype (Gendzekhadze et al., 2009) and 9 (75%) out of 12 
mother-infant pairs that were concordant for KIR2DL3/KIR2DL3+C2/C2 were homozygous 
for the A haplotype, this suggested that having this inhibitory genotype in both mother and 
infant may increase the risk of MTCT of HIV-1. Alternatively, the increased risk for 
IP transmission may also be due to NK cell anergy. NK cells that fail to express inhibitory 
receptor specific for self-MHC during their development receive continuously stimulating 
signals because of normal activating receptor expression leading to a status of 
hyporesponsiveness or anergy (Hasenkamp et al., 2008). It may be that each of these factors 
contribute towards increased the risk of HIV-1 transmission.  
 
 
Figure 4.4 Comparison of arming and disarming mechanisms of NK cell self-tolerance. NK cells 
detect the loss but not the absence of MHC-I. (A) In the absence of self MHC-I, inhibitory 
receptors on NK cells are not engaged and NK cells remain unresponsive. (B) In the presence of 
MHC-I, inhibitory KIR deliver an inhibitory signal that prevents disarming and/or a signal that 
renders NK cells responsive (i.e., arming signal). The two options are not mutually exclusive and 
have the same outcome: NK cells become licensed by either maintaining or acquiring 
responsiveness to kill target cells. (C) NK cells that lack inhibitory receptors for self MHC-I are 
not licensed. Reproduced from (Long et al., 2013). 
A) B) C)
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Conversely, using the „altered self” model, the protective association observed with 
KIR2DL1+C1/C2 concordance (i.e. decreasing the risk for IU-transmission) may be 
explained in that engagement of KIR2DL1 NK cells (a gene that had a 99% frequency in 
MTCT1 mothers) with C2 ligands would license NK cells, thus enabling them to recognize 
and kill HIV-1 infected target cells that have been altered.  
 
In addition, with regards to the role of infant NK cell alloreactivity in HIV-1 acquisition 
and/or the lack thereof, in MTCT1 we found that both „matched‟ and „missing self‟ KIR/HLA 
combinations were associated with IU acquisition of HIV-1. When infants were heterozygous 
for KIR2DL2/KIR2DL3 and mothers possessed the cognate ligands, C1/C1, there was 
increased risk for IU acquisition of HIV-1 (IU: P=0.047, OR=4.02 and IU2: P=0.019, 
OR=3.45) which was maintained post adjustments for mVL and sdNVP, thereby suggesting 
that when HIV-1 infected maternal cells possessed C1/C1 inhibitory ligands possible 
engagement with infant NK cells bearing KIR2DL2/KIR2DL3 would not result in activation 
and thus allow IU HIV-1 infection to occur. Similarly, this hypothesis is in accordance with 
the principles of „self-recognition‟ and NK cell education (Hoglund and Brodin, 2010), 
wherein recipient NK cells sensing self HLA on incoming index cells (matched) would result 
in NK cell inhibition and therefore fail to eliminate HIV-1 infected cells.  
 
Likewise, Jennes et al. (2013) investigated whether allogeneic KIR/HLA combinations 
between HIV-1 concordant (HIV-1 transmission from one partner to the other) and HIV-1 
discordant (one partner HIV-1 positive, the other HIV-1-negative) Senegalese couples would 
influence adult HIV-1 transmission and found that HIV-1 concordant couples showed an 
increased frequency of a specific "matched" KIR/HLA combination, while, HIV-1 discordant 
couples showed an increased frequency of a specific "missing self" KIR/HLA combinations. 
Thus, in agreement with the “self-recognition” model, NK cells sensing "missing self" as 
opposed to "matched" KIR/HLA combinations could potentially provoke alloreactive NK cell 
killing of HIV-1 infected partner cells preventing HIV-1 acquisition (Jennes et al., 2013). 
However, in MTCT1 “missing self‟ associated with increased risk for IU acquisition. 
IU infants had significantly greater representation of KIR2DL2/KIR2DL2+C1/C2 in the 
presence of mothers that possessed C2/C2 compared to EU infants (Table 4.2, 7% vs. 0%, 
P=0.011), but this association was not maintained post adjustments for mVL, maternal 
sdNVP or CD4+ T cell count. It is possible that this finding may be an artefact caused by the 
low representation of this KIR/HLA combination. Nonetheless, these allogeneic associations 
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found in MTCT1 suggest that alloreactive NK cells have an important role in MTCT 
transmission, particularly IU transmission of HIV-1, in a manner comparable to that of sexual 
transmission reported by Jennes et al. (2013). 
 
In MTCT2, where mothers primarily received dual ART and the overall rate of HIV-1 
transmission was significantly lower than that of MTCT1 (P<0.001, Chapter 2, Figure 2.3), 
maternal and infant KIR/HLA genotypes reported by Paximadis et al. (2011) that associated 
with decreased risk of transmission in MTCT1 were not evident in MTCT2. While NT 
mothers in MTCT1 had significantly higher total KIR gene number and greater number of 
inhibitory KIR genes than IU-TR mothers (Paximadis et al., 2011), no significant associations 
were seen in either mothers or infants when KIR gene numbers (total, inhibitory and 
activating) were compared in MTCT2. However, the total AA1 haplotype frequency was 
significantly lower in MTCT2 mothers compared to MTCT1 mothers (13.9% vs. 27.2%, 
P=0.029). This lower representation in MTCT2 was more evident in NT than IP-TR or IU-
TR mothers (9.3% vs. 18.2% or 20%, respectively) but was not associated with decreased 
risk for HIV-1 transmission. Furthermore, given the similarity in AA1 representation between 
IP-TR and IU-TR, we compared the AA1 haplotype in NT to the total group of TR mothers 
(IP- + IU- TR mothers), but found no association with vertical transmission (P=0.328). In 
addition, comparison of the AA1 haplotype frequency in MTCT2 mothers to their infants 
showed a significant difference (13.9% vs. 33.7%, P=0.005, Figure 4.1A), suggesting that 
the majority of infants inherited an A Haplotype from their father. Nevertheless, in infants the 
higher prevalence of AA1 haplotype did not associate with increased/decreased risk for 
HIV-1 acquisition (Figure 4.1C). 
 
Thus, given that the AA1 haplotype differed significantly across the two MTCT cohorts we 
compared our KIR data to another cohort of HIV-1 negative Black South Africans (Gentle 
et al, unpublished data). The KIR data represented a diverse cross-section of the Black ethnic 
groups of South Africa (n=167) sourced from the ESKOM (Electricity Supply Commission) 
cohort, termed as such because it involved collection of blood from individuals working at 
sites of this South African electricity public utility countywide. Overall, the total 
AA1 haplotype frequency in HIV-1-uninfected Black South Africans was 26.9% (45/167) 
which was most comparable to AA1 haplotype frequency in MTCT1. However, when 
stratifying these KIR data according to home language, namely: Xhosa (N=33), Northern 
Sotho (previously termed Pedi, N=24), Zulu (N=23), Venda (N=21), Tswana (N=20), South 
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Sotho (N=16), Swati (N=13), Ndebele (N=12) and Tsonga (N=5), we found the AA1 
haplotype frequency was the highest in individuals that spoke Tswana or Tsonga (45% and 
40%, respectively) and lowest in individuals who spoke Xhosa, South Sotho or Northern 
Sotho (12%, 13% and 17%, respectively), whereas the other dialects Zulu, Ndebele, Venda 
and Swati ranged from 30% to 38%. In agreement, the Xhosa AA1 haplotype frequency 
matched the Xhosa group reported by Middleton et al. (2007a). Thus, it is possible in our 
study that mothers from MTCT1 represented a more diverse ethnic group compared to 
mothers from MTCT2, which may have been skewed towards individuals having a Xhosa or 
Sotho background. Moreover, it could further be postulated that in MTCT2 paternal origins 
may have come from the South African dialects with the greater AA1 haplotype frequencies 
(Tswana or Tsonga), but since paternal data are not available this remains speculation. Thus, 
when comparisons are made between MTCT1 and MTCT2, this difference should be kept in 
mind. 
 
Nevertheless, in both MTCT cohorts the Bx32 genotype associated with increased risk of 
transmission. In MTCT1, Paximadis et al. (2011) reported that IP-TR mothers had 
significantly higher frequency of Bx32 than NT mothers (P=0.014, OR=17.2), and in 
MTCT2 (Figure 4.1), both IP-TR and IU-TR mothers had increased representation of Bx32 
compared to NT mothers (P=0.038 and P=0.005, respectively). Moreover, in MTCT1 Bx20 
also associated with decreased risk of transmission (P=0.02, OR=0.12). Examination of KIR 
gene components revealed that the only difference between Bx32 (consisting of KIRs 2DL1, 
2DL3, 2DL4, 2DL5, 2DS4, 2DS5, 2DP1, 3DL1, 3DL2, 3DL3 and 3DP1) and Bx20 was the 
presence of KIR2DL2 in Bx20. Likewise highlighting the fact that the Bx32 genotype is 
KIR2DL3 homozygous and is one of the few homozygous KIR3DL3 genotypes currently 
reported in South Africa; others in MTCT1 included AA1, Bx2, Bx10, Bx27, Bx35 and Bx48 
(Paximadis et al., 2011). 
 
While we observed no significant differences in distribution of KIR2DL2/L3 genotypes 
among MTCT2 groups, in MTCT1 maternal KIR2DL3 homozygosity significantly associated 
with increased risk for IP transmission (Paximadis et al., 2011). Similarly in another study, 
proportions of KIR2DL3 homozygosity alone and in the presence of C1/C2 heterozygosity 
were significantly higher in seropositive sex workers compared to exposed seronegative sex 
workers (Jennes et al., 2006b). Conversely, although not HIV related, KIR2DL3 and HLA-C1 
were also reported to play a role in the resolution of HCV in the context of low infectious 
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doses of HCV but not in individuals with high-dose exposure. (Khakoo et al., 2004). The 
authors suggest that distinct KIR/HLA genotypes are able to regulate NK cell activity 
sufficiently to alter the outcome when faced with low-dose HCV, but not in those with high-
dose exposure during which the innate immune response is likely overwhelmed. However, in 
each of these studies as well as our own, the actual mechanisms that may be at play remain 
elusive. 
 
We then evaluated the role of HLA-ligands in MTCT2, using the real-time PCR method 
described in Chapter 2 (Section 2.5). We found that both maternal and infant possession of 
the HLA-A Bw4:80I allele significantly increased the risk for IU transmission and/or 
acquisition of HIV-1 (Figure 4.2 and 4.3). Since our real-time PCR assay broadly grouped 
the HLA-A alleles into two main groups: those with an isoleucine at position 80 as Bw4:80I 
(A*23, A*24, A*25 and A*32) and those without as non-Bw4:80I, we were unable to identify 
which specific Bw4:80I allele was responsible for the increased risk of IU transmission in 
mothers and infants. However, using the HLA-A, -B and –C frequency data for the Black 
ESKOM cohort (Paximadis et al., 2012) as a reference, we could extrapolate that the most 
likely HLA-A Bw4:80I alleles contributing towards increased IU-transmission in MTCT2 
were A*23:01 (8.04%), A*24:02 (2.01%) or A*32:01 (1.26%). In agreement with our finding, 
in perinatal cohort from Nairobi, Kenya maternal possession of A*23:01 was found to 
associated with increased risk of HIV-1 transmission (Mackelprang et al., 2010). In addition, 
the same study reported that maternal A*23:01 associated with higher plasma HIV-1 RNA 
VL and the A*23:01/B*15:03/C*02:02 haplotype, but not the B*15:03/C*02:02 haplotype 
associated with increased transmission. Of note, since A*23:01 associated with increased risk 
for HIV-1 transmission both before and after adjusting for maternal VL the Mackelprang 
et al. (2010) suggested that A*23:01 may alter infectivity through mechanisms other than 
influencing HIV-1 VL. This further supports our findings, given our NT and TR mothers 
MTCT2 cohort were matched on the basis of maternal VL, CD4+ T cell count and ART 
regimens.  
 
Similarly other studies have also associated A*23:01 with HIV-1 transmission, in a group of 
Kenyan commercial sex workers, women carrying A*23:01 were found to have a 3.6-fold 
increased risk of HIV-1 seroconversion (MacDonald et al., 2000), and in Zambian HIV-1 
serodiscordant couples, possession of the A*23/B*07/Cw*07 haplotype was enriched in the 
transmitter group (Tang et al., 2008). Thus, these A*23:01 associations as well as our own 
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finding of HLA-A Bw4:80I increasing the risk of IU HIV-1 transmission, might suggest that 
HLA-A Bw4:80I alleles in MTCT2 might exert immune pressure that selects for viral isolates 
that are more infectious in infants. Alternatively, since KIR3DL1 is able to bind to HLA-A 
antigens with the Bw4 epitope, recognition of these inhibitory ligands would allow HIV-
1infected cells to escape lysis by KIR3DL1-expressing NK cells (Stern et al., 2008).  
 
With regards to the other HLA-ligands (HLA-B and HLA-C), in the HLA-B group, although 
IU-TR mothers had significantly lower representation of Bw4:80T compared to NT mothers 
(P=0.030, OR=0.20), frequencies of HLA-B ligand genotypes (Bw4/Bw4, Bw4/Bw6 and 
Bw6/Bw6) did not significantly differ amongst TR and NT mothers. Additionally, maternal 
HLA-C ligands showed no differences amongst MTCT2 mothers. Thus, we analysed paired 
KIR/HLA combinations in MTCT2 and found two KIR/HLA combinations that significantly 
associated with transmission of HIV-1 (Table 4.7). KIR3DL1 in combination with HLA-A/B 
Bw4:80I was significantly higher in both IP-TR and IU-TR mothers compared to NT 
mothers, whilst KIR3DL1+Bw4:80T was over-represented in NT mothers compared to 
IU-TR mothers, suggesting that the Bw4 allotype in combination with KIR3DL1 influenced 
the risk of HIV-1 transmission. This differs from the other reports that implicated the 
KIR3DL1 and Bw4 (HLA-B*57) with protection against HIV-1 infection as well as slower 
time to AIDS and viral control (Martin et al., 2007, Boulet et al., 2008a, Boulet et al., 2010).  
 
Given that KIR3DL1 alleles are highly polymorphic and differ in their cell surface expression 
levels ranging from high (*h), intermediate (*i), low (*l) and null (KIR3DL1*004), Boulet 
et al. (2008a, 2008b and 2010) sought to determine which KIR3DL1/S1 genotypes associated 
with decreased susceptibility to HIV-1 infection observed in EUs. They reported that co-
carriage of the KIR3DL1 genotypes that possess high expressing alleles in the absence of any 
low expressing alleles together with HLA-B*57 (a Bw4:80I) conferred elevated NK cell 
functional potential and reduced risk of HIV-1 infection (Boulet et al., 2008a, Boulet et al., 
2010). They proposed that the stronger inhibitory KIR3DL1 partnership with its Bw4:80I 
ligand enhanced „licensing‟ of KIR3DL1+ NK cells that when HIV-1-infected cells 
downregulate cell surface expression of HLA-B, NK cells „licensed‟ through KIR3DL1 
would be NK cells activated to eliminate target. Therefore, one could speculate that in our 
MTCT2 cohort, the KIR3DL1+Bw4:80I associations with increased risk for both IP and IU 
HIV-1 transmission may be due to KIR3DL1 alleles that represent the low to intermediate or 
null expressing alleles, which potentially may result in reduced NK cell functionality and thus 
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the inability to effectively target HIV-1-infected cells. However, this needs to be determined. 
Notably, NT mothers that possessed the weaker Bw4:80T ligand (Cella et al., 1994) in 
combination with KIR3DL1 associated with protection from IU transmission, but individually 
neither KIR3DL1 nor Bw4:80T showed a protective association, suggesting that the combined 
KIR/HLA-ligand interaction was necessary for a protective effect.  
 
Considering that mother-infant pairs in MTCT1 showed significant associations with respect 
to concordance for KIR/HLA combinations, as well as infant allorecognition of maternal 
HLA, we also evaluated whether KIR/HLA concordance and allorecognition altered risk of 
HIV-1 transmission in mother-infant pairs from MTCT2, but found no significant 
associations. Overall, the study of these MTCT cohorts revealed various KIR/HLA-ligand 
combinations that associated with vertical transmission, some shared (e.g. the maternal Bx32 
genotype associating with IP transmission in both MTCT1 and MTCT2), some different 
(e.g. both findings of mother-infant concordance for KIR2DL3/KIR2DL3+C2/C2 associating 
with IP transmission, and infant allorecognition iKIR2DL2/KIR2DL3+mC1/C1 associating 
with IU transmission in MTCT1 but neither not observed in MTCT2), and the presence of 
HLA-A Bw4 associated with IU transmission in MTCT2 but was not evaluated in MTCT1. 
It is possible that the ability to show common and/or different associations within these 
MTCT cohorts are limited by the small sample numbers in MTCT2 and/or the overall under-
representation of the maternal KIR AA1 haplotype. Moreover, these findings may also reflect 
the influence of different drug therapies, as the ever-changing drug environment may be 
selecting for infants with a higher susceptibility risk. Nevertheless, collectively, our results 
suggest that at the KIR gene-level as well as the KIR/HLA genotype level, irrespective of 
ART regimen, KIR and HLA-ligands play a significant role in MTCT of HIV-1. 
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CHAPTER 5 
Differential effects of KIR2DS4 on MTCT of HIV-1 
The findings from MTCT1 presented in this Chapter have been in published: Hong et al. 
(2013) Clinical Immunology 149, 498 - 508. 
 
5.1 Introduction 
As previously mentioned, the ability of NK cells to recognize and kill virus-infected or 
tumour-transformed cells is determined by the action of different surface receptors that either 
activate or inhibit NK cell cytolytic activity. Among the 14 functional KIR genes, KIR2DS4 is 
the only activating KIR gene in the Group A haplotype (Figure 5.1), and of the 13 KIR2DS4 
alleles described to date, only four (KIR2DS4*001, *011, *014 and *015) encode full-length 
(KIR2DS4-f) receptors while the remaining nine alleles (KIR2DS4*003, *004, *006, *007, 
*008, *009, *010, *012 and *013) encode truncated/deleted (KIR2DS4-v) protein products 
(Robinson et al., 2013a). Alleles encoding KIR2DS4-v have a 22-bp deletion in exon 5 which 
causes a frame shift mutation yielding a truncated KIR2DS4 protein with loss of the 
transmembrane and cytoplasmic domains, thus, these variants are not anchored to the cell 
membrane but are potentially secreted (Hsu et al., 2002, Maxwell et al., 2002, Middleton et 
al., 2007a). Therefore, only KIR2DS4-f variants can serve as activating receptors upon 
binding to their specific HLA ligands (HLA-A: A*11:01, A*11:02 and HLA-C: C*01:02, 
C*14:02, C*16:01, C*02:02, C*04:01 and C*05:01) (Mandelboim et al., 1997, Graef et al., 
2009).  
 
 
Figure 5.1 A schematic representation of the Group A haplotype and the allelic variants of 
KIR2DS4 (KIR2DS4-f and KIR2DS4-v). Within the Group A haplotype inhibitory KIR genes are 
indicated in blue, the singular activating KIR gene (KIR2DS4) is indicated in pink, and the 
pseudogenes KIR2DP1 and KIR3DP1 are indicated in grey.  
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Several studies have described the importance of NK cells in the control of HIV-1 infection 
through recognition of virally infected cells by both activating and inhibitory KIRs (Alter and 
Altfeld, 2009, Berger and Alter, 2011, Tiemessen et al., 2011, Carrington and Alter, 2012, 
Jost and Altfeld, 2013) and the strategies evolved by HIV-1 to specifically evade NK 
cell-mediated immune responses (Jonjic et al., 2008, Alter et al., 2011, Jost and Altfeld, 
2012). With regards to KIR2DS4, Merino et al. (2011) identified that KIR2DS4-f alleles in 
HIV-1-chronically infected Zambians independently associated with accelerated transmission 
of HIV-1 to cohabiting seronegative partners, as well as with higher VL (Merino et al., 2011). 
In addition, they also observed a positive association between KIR2DS4-f and the presence of 
genital ulcers in the seroprevalent index partners but not in the seroconverters. This suggested 
that in chronically HIV-1-infected individuals KIR2DS4-f might increase the likelihood of 
HIV-1 transmission through tissue inflammation and/or increased shedding of HIV-1. 
Furthermore, the KIR2DS4-f association with HIV-1 transmission was only weakly enhanced 
by the presence of its reported C2 ligand, HLA-C*04. More recently, the same group 
reported that KIR2DS4-f promoted HIV-1 pathogenesis during chronic infection. They 
observed that KIR2DS4
+
 and KIR2DS4
−
 NK cells (determined through flow cytometric 
staining) derived from subjects with chronic HIV-1 infection often differed in their functional 
properties after stimulation with HLA-deficient K562 cells, especially in terms of 
degranulation (production of CD107a) and/or induction of IFN-γ and MIP-1β. By all three 
measurements (individually or in various combinations), NK cells with the 
KIR2DS4-f genotype (g+) but negative for the membrane-bound KIR2DS4 staining (p−) 
universally behaved like those that were negative for both (g−/p−), while polyfunctional NK 
cells co-expressing CD107a, IFN-γ and MIP-1β were highly enriched in the g+/p+ NK cells 
when compared with the g+p− and g−p− NK cells. It was postulated that prolonged or 
excessive NK cell activities (as seen in chronic HIV-1 infection) may fuel inflammation and 
promote HIV-1 pathogenesis. Similarly, in line with this hypothesis elevated levels of pro-
inflammatory cytokines and activated NK cells were found to be predictive of HIV-1 
acquisition in African women (Naranbhai et al., 2012).  
 
These observations have raised the question of how allelic variants of KIR2DS4 might 
influence the likelihood of MTCT of HIV-1 in the context of single or dual ART. Thus, the 
aim of this chapter was to investigate the distribution of KIR2DS4-f and KIR2DS4-v in HIV-1 
TR and NT mothers and their HIV-1 infected and uninfected infants, using the two MTCT 
cohorts (MTCT1 and MTCT2) receiving different PMTCT regimens. 
Chapter 5: KIR2DS4 variants in MTCT  116 
5.2 Results 
5.2.1 Distribution of KIR2DS4 in mothers and infants from MTCT1 
Upon genomic KIR typing using the commercial Olerup kit (Chapter 2, section 2.4.1), we 
found KIR2DS4 was present in 98.6% (214/217) mothers from cohort 1 (MTCT1). In 
mothers the total allelic frequency for KIR2DS4-f was 87.8% (188/214) and 50.9% (109/214) 
for KIR2DS4-v (Figure 5.2A), of which 105 (49.1%) mothers were homozygous for 
KIR2DS4-f and 26 (12.1%) mothers were homozygous for KIR2DS4-v. Out of 59 (27.1%) 
mothers who were homozygous for Group-A haplotype (AA1), six were KIR2DS4-v carriers 
(10.2%), therefore in MTCT1, only 2.8% (6 of 214) of the mothers lacked a functional 
activating KIR gene. When comparing mVL and CD4+ T cell counts of mothers with 
KIR2DS4-f and those without (KIR2DS4-v), no significant associations were found 
(Figure 5.2B and 5.2C). We then compared the frequency of the AA1 genotype and the 
presence of KIR2DS4-v to other population groups (Figure 5.3) and found MTCT1 was 
clearly separate from the Caucasian and Asian cluster and most comparable to the Mexican 
population. 
 
5.2.2 Frequency of putative KIR2DS4 HLA-C ligands in MTCT1 
Putative HLA-C ligands for functional KIR2DS4 are reported in Table 5.1. The ratio of total 
maternal C1 to C2 alleles was 1:2 (7.4 % vs. 16.4%) with C*16:01 (6.5%) being the most 
common in the C1 group and C*04:01 (14.5%) in the C2 group. Frequencies of HLA–C 
ligands between the NT and TR (IP, IU and IU2) mothers did not significantly differ. Infants 
had comparable C1 and C2 frequencies to the maternal group, however comparison of 
HLA-C ligands in the infants, showed C*16:01 frequency was significantly higher in 
IP infants compared to EU infants (15.5% vs. 6.9%; P=0.038, OR=2.48) and in combination 
with KIR2DS4-v, showed a strong trend towards increased risk of IP HIV-1 acquisition 
(P=0.074, OR=10.52) but post adjustment for mVL, sdNVP, CD4+ T cell count and 
combined adjustments, both associations were not significant (data not shown). Since the 
majority of the KIR2DS4 HLA-C alleles had a frequency below 10%, the C1 and C2 alleles 
were grouped together (i.e. C1+C2) and were compared across the maternal and infant groups 
(Table 5.1). We found no evidence of combined C1+C2 ligands having an effect on maternal 
transmission of HIV-1 or infant acquisition of HIV-1. 
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Figure 5.2 (A) Total KIR2DS4-f and KIR2DS4-v frequencies in mothers from MTCT1 (n=214); 
(B) comparison of maternal VL and (C) maternal CD4+ T cell count amongst mothers with at 
least one copy of KIR2DS4-f and those without (KIR2DS4-v). 
 
 
 
Figure 5.3 A scatter plot comparison of AA1 haplotype frequencies and the prevalence of 
KIR2DS4-v within different population groups, including MTCT1 (Blue). Reproduced and 
modified from (Whang et al., 2005, Middleton et al., 2007a). 
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Table 5.1 Carrier frequencies for KIR2DS4 HLA-C ligands in mothers and infants from MTCT1, N (%) 
Maternal 
HLA-C ligands 
Total 
(2N=434) 
NT 
(2N=290) 
IP-TR 
(2N=58) 
IU-TR 
(2N=38) 
IU2-TR 
(2N=86) 
IP-TR vs. NT IU-TR vs. NT IU2-TR vs. NT 
OR (95% CI) P OR (95% CI) P OR (95% CI) P 
C1 32 (7.37) 20 (6.90) 6 (10.34) 3 (7.89) 6 (6.98) 1.56 (0.59-4.06) 0.409 1.16 (0.32-4.09) 1.000 1.01 (0.39-2.61) 1.000 
C*01:02 1 (0.23) 1 (0.34) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
C*14:01 3 (0.69) 3 (1.03) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 0.590 
C*16:01 28 (6.45) 16 (5.52) 6 (10.34) 3 (7.89) 6 (6.98) 1.66 (0.62-4.41) 0.397 1.47 (0.41-5.29) 0.709 1.28 (0.49-3.39) 0.795 
C2 71 (16.36) 45 (15.52) 8 (13.79) 8 (21.05) 18 (20.93) 0.87 (0.39-1.96) 0.843 1.45 (0.62-3.37) 0.481 1.44 (0.78-2.65) 0.251 
C*02:02 3 (0.69) 1 (0.34) 1 (1.72) 1 (2.63) 1 (1.16) 5.07 (0.31-82.3) 0.306 7.81 (0.47-127.5) 0.219 3.40 (0.21-54.9) 0.406 
C*04:01 63 (14.52) 41 (14.14) 7 (12.07) 6 (15.79) 15 (7.44) 0.83 (0.35-1.96) 0.835 1.14 (0.44-2.89) 0.806 1.28 (0.67-2.45) 0.491 
C*05:01 5 (1.15) 3 (1.03) 0 (0.00) 1 (2.63) 2 (2.33) - 1.000 2.59 (0.26-25.5) 0.390 2.28 (0.37-13.9) 0.593 
C1+C2 103 (23.73) 65 (22.41) 14 (24.14) 11 (28.95) 24 (27.91) 1.10 (0.56-2.13) 0.864 1.41 (0.66-2.99) 0.413 1.34 (0.77-2.31) 0.313 
Infant 
HLA-C ligands 
Total 
(2N=434) 
EU 
(2N=290) 
IP 
(2N=58) 
IU 
(2N=38) 
IU2 
(2N=86) 
IP vs. EU  IU vs. EU  IU2 vs. EU  
OR (95% CI) P OR (95% CI) P OR (95% CI) P 
C1 37 (8.53) 23 (7.93) 9 (15.52) 2 (5.26) 5 (5.81) 2.13 (0.93-4.88) 0.081 0.65 (0.14-2.85) 0.752 0.72 (0.26-1.94) 0.643 
C*01:02 1 (0.23) 1 (0.34) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
C*14:01 2 (0.46) 2 (0.69) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
C*16:01 34 (7.83) 20 (6.90) 9 (15.52) 2 (5.26) 5 (5.81) 2.48 (1.07-5.76) 0.038 0.75 (0.17-3.34) 1.000 0.83 (0.30-2.29) 0.811 
C2 69 (15.90) 48 (16.55) 7 (12.07) 7 (18.42) 14 (16.28) 0.69 (0.29-1.61) 0.439 1.34 (0.47-2.74) 0.817 0.98 (0.51-1.88) 1.000 
C*02:02 9 (2.07) 8 (2.76) 0 (0.00) 1 (2.63) 1 (1.16) - 0.361 0.95 (0.11-7.83) 1.000 0.41 (0.05-3.36) 0.477 
C*04:01 57 (13.13) 38 (13.10) 7 (12.07) 5 (13.16) 12 (13.95) 0.91 (0.38-2.15) 1.000 1.00 (0.37-2.73) 1.000 1.08 (0.53-2.16) 0.857 
C*05:01 3 (0.69) 2 (0.69) 0 (0.00) 1 (2.63) 1 (1.16) - 1.000 3.89 (0.34-43.97) 0.310 1.69 (0.15-18.9) 1.000 
C1+C2 106 (24.42) 71 (4.48) 16 (27.59) 9 (23.68) 19 (22.09) 1.17 (0.62-2.21) 0.740 0.96 (0.43-2.12) 1.000 0.87 (0.49-1.55) 0.670 
C1 constitutes one or more HLA-C alleles C*01:02, C*14:02 and C*16:01 and C2 constitutes one or more HLA-C alleles C*02:02, C*04:01 and 
C*05:01. C1+C2 represent the combination of C1 and C2 alleles. Bold P values indicate significant differences (P<0.05). 
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5.2.3 KIR2DS4 alleles in HIV-1 transmission in MTCT1 
KIR2DS4-f, KIR2DS4-fv and KIR2DS4-v representation alone and in combination with 
putative HLA-C ligands (C1+C2) did not significantly differ between NT and any of the TR 
(IP, IU and IU2) maternal groups in MTCT1 (Figure 5.4A and Table 5.2). IU2 infants had 
significantly higher representation of KIR2DS4-v alone (Figure 5.4B, P=0.022, OR=2.88) 
and in combination with C1+C2 ligands (P=0.006; OR=5.52, Table 5.2) compared to EU 
infants. However after adjusting for maternal VL, sdNVP, CD4+ T cell count and the 
combined group, only KIR2DS4-v in combination with C1+C2 maintained significance 
throughout the adjustments (Table 5.3). Since individuals homozygous for the A haplotype 
carry KIR2DS4 as the only activating KIR gene, we subdivided AA1 haplotypes into AA-f 
(KIR2DS4-f), AA-fv (KIR2DS4-f and KIR2DS4-v) and AA-v (KIR2DS4-v). We found no 
significant differences between the NT and TR mothers (Figure 5.4C). In the infant group 
comparisons however (Figure 5.4D), EU infants had a significantly lower representation of 
AA-v compared to both IU and IU2 infants (P=0.04; OR=15.33 and P=0.004; OR=18.40, 
respectively), however only the EU versus IU2 comparison remained significant post 
adjustments for mVL (P=0.013, OR=16.8), sdNVP (P=0.036, OR=8.70) and CD4+ T cell 
count (P=0.046, OR=14.47). 
 
5.2.4 Mother-infant concordance and discordance in MTCT1 
In order to distinguish how KIR2DS4 might impact on viral transmission from the mother 
versus HIV-1 acquisition by the infant, we analysed mother-infant pairs for concordant and 
discordant possession of KIR2DS4-f, KIR2DS4-fv and KIR2DS4-v. Possession of the select 
KIR allele in both mother and matched infant, i.e. mother-infant concordance (M+I+), 
showed no significant differences among any of the groups compared (Figure 5.5A). 
Similarly when determining if possession of putative KIR2DS4 ligands (C1+C2) altered 
HIV-1 transmission, we found no significant difference when KIR2DS4 alleles were paired 
with C1+C2 ligands (Table 5.2). However, M+I- mother-infant allele discordance 
(Figure 5.5B) revealed significantly higher representation of KIR2DS4-f in IP-TR mothers 
when compared to NT mothers (P=0.005, OR=3.84), which maintained significance post 
adjustments for mVL (P=0.007, OR=3.93), sdNVP (P=0.003, OR=4.44), CD4+ T cell count 
(P=0.014, OR=3.75) and the three combined (P=0.014, OR=4.35). However, this association 
was not evident when KIR2DS4-f was in combination with C1+C2 ligands (Table 5.2). 
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Figure 5.4 Frequencies of KIR2DS4-f, KIR2DS4-fv and KIR2DS4-v in the total group of 
mothers (A) and infants (B) in MTCT1; and the frequency of KIR2DS4 variants amongst mothers 
(C) and infants (D) with AA haplotype. Non-transmitting (NT); Transmitting (TR); Intrapartum 
(IP); In utero (IU); Exposed uninfected (EU) infant. KIR2DS4-f indicates the presence of one or 
two copies of functional KIR2DS4; KIR2DS4-fv indicates the presence of both functional and 
non-functional KIR2DS4; and KIR2DS4-v indicates the presence of one or two copies of 
non-functional KIR2DS4. 
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Table 5.2 Carrier frequencies of KIR2DS4 in combination with putative HLA-C1+C2 ligands in MTCT1 
KIR2DS4 and HLA-C ligands 
Representation, N (%) IP-TR/ IP vs. NT / EU IU-TR / IU vs. NT / EU IU2-TR / IU2 vs. NT / EU 
NT / EU IP-TR / IP IU-TR / IU IU2-TR / IU2 OR (95% CI) P OR (95% CI) P OR (95% CI) P 
Mothers 
N=143 
2DS4-f C1+C2 27 (18.88) 9 (31.03) 2 (11.11) 6 (14.29) 1.93 (0.79-4.71) 0.208 0.54 (0.12-2.47) 0.533 0.72 (0.27-1.87) 0.648 
2DS4-fv C1+C2 20 (13.99) 3 (10.34) 4 (22.22) 9 (21.43) 0.71 (0.19-2.56) 0.770 1.76 (0.52-5.88) 0.479 1.68 (0.69-4.03) 0.333 
2DS4-v C1+C2 6 (4.20) 1 (3.45) 0 (0.00) 2 (4.76) 0.82 (0.09-7.04) 1.000 - 0.620 1.14 (0.22-5.88) 1.000 
Infants 
N=143 
2DS4-f C1+C2 32 (22.38) 6 (20.69) 2 (11.11) 6 (14.29) 0.90 (0.33-2.41) 1.000 0.43 (0.09-1.98) 0.367 0.58 (0.22-1.49) 0.287 
2DS4-fv C1+C2 24 (16.78) 6 (20.69) 4 (22.22) 4 (9.52) 1.29 (0.47-3.51) 0.789 1.42 (0.43-4.68) 0.741 0.52 (0.17-1.60) 0.330 
2DS4-v C1+C2 5 (3.50) 2 (6.90) 1 (5.56) 7 (16.67) 2.04 (0.37-11.09) 0.603 1.62 (0.18-14.73) 1.000 5.52 (1.65-18.44) 0.006 
M+I+ 
N=141 
2DS4-f C1+C2 14 (9.93) 5 (17.24) 0 (0.00) 3 (7.14) 1.89 (0.63-5.74) 0.327 - 0.228 0.70 (0.19-2.55) 0.766 
2DS4-fv C1+C2 9 (6.38) 2 (6.90) 2 (11.11) 2 (4.76) 1.09 (0.22-5.31) 1.000 1.83 (0.37-9.24) 0.615 0.73 (0.15-3.53) 1.000 
2DS4-v C1+C2 2 (1.42) 1 (3.45 0 (0.00) 1 (2.38) 2.48 (0.22-28.32) 0.432 - 1.000 1.69 (0.14-19.17) 1.000 
M+I- 
N=141 
2DS4-f C1+C2 13 (9.22) 4 (13.79) 2 (11.11) 3 (7.14) 1.58 (0.47-5.23) 0.496 1.23 (0.25-5.96) 1.000 0.76 (0.20-2.79) 0.768 
2DS4-fv C1+C2 11 (7.80) 1 (3.45) 2 (11.11) 7 (16.67) 0.42 (0.05-3.40) 0.484 1.48 (0.30-7.27) 0.644 2.36 (0.85-6.54) 0.135 
2DS4-v C1+C2 4 (2.84) 0 (0.00) 0 (0.00) 1 (2.38) - 0.605 - 1.000 0.84 (0.09-7.68) 1.000 
M-I+ 
N=141 
2DS4-f C1+C2 18 (12.77) 1 (3.45) 2 (11.11) 3 (7.14) 0.24 (0.03-1.91) 0.203 0.85 (0.18-4.02) 1.000 0.53 (0.15-1.88) 0.415 
2DS4-fv C1+C2 15 (10.64) 4 (3.79) 2 (11.11) 2 (4.76) 1.34 (0.41-4.39) 0.745 1.05 (0.21-5.02) 1.000 0.42 (0.09-1.91) 0.367 
2DS4-v C1+C2 3 (2.13) 1 (3.45) 1 (5.56) 6 (14.29) 1.64 (0.16-16.38) 1.000 2.71 (0.26-27.49) 0.385 7.67 (1.83-32.2) 0.005 
C1+C2 constitutes one or more copies of HLA-C1 alleles (C*01:02, C*14:02 and C*16:01) and HLA-C2 alleles (C*02:02, C*04:01 and C*05:01). 
Non-transmitting mother (NT); Transmitting mother (TR); Intrapartum (IP); In utero (IU); Exposed Uninfected infant (EU). Matched mother and 
infant (M+I+); discordant mother-infant pair, where the mother possesses the KIR/HLA-C combination absent in the infant (M+I-) and when infant 
possesses the KIR/HLA-C combination absent in the mother (M-I+). Bold P values indicate significant differences (P<0.05). 
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Conversely in the M-I+ discordant group (Figure 5.5C), KIR2DS4-v was significantly 
increased in IU and IU2 infants compared to EU infants (P=0.048, OR=5.44 and P=0.002, 
OR=6.40, respectively). After adjusting for mVL, sdNVP and CD4+ T cell count alone, the 
frequency of KIR2DS4-v in IU2 infants remained significant (Table 5.3). Similarly, when 
KIR2DS4-v was combined with C1+C2 ligands, IU2 infants had significantly higher 
representation compared to EU infants (P=0.005, OR=7.67), and this association was 
maintained post adjustments for mVL, sdNVP and CD4+ T cell count. 
 
 
Figure 5.5 Comparison of KIR2DS4 variants in MTCT1 (KIR2DS4-f, KIR2DS4-fv and 
KIR2DS4-v) amongst (A) Concordant mother-infant pairs (M+I+: both mother and infant are 
matched for KIR2DS4 variant), (B) Discordant mother-infant pairs (M+I-: mothers possesses 
KIR2DS4 variant that is absent in the infant), and (C) Discordant mother-infant pairs 
(M+I-: infants possesses KIR2DS4 variant that is absent in the mother). Non-transmitting mother 
and exposed uninfected infant pair (NT/EU); intrapartum transmitting mother and intrapartum 
infected infant pair (IP-TR/IP); in utero transmitting mother and in utero infected infant pair 
(IU-TR/IU). The sum total of the frequencies in KIR2DS4 variants between the groups of M+I+, 
M+I- and M-I+ will not equate 100%, as discordance will be represent twice, in context of M+I- 
and of M-I+. 
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Table 5.3 logistic regression analyses, multivariable adjustment made for maternal viral load (mVL), single dose nevirapine (sdNVP) and 
CD4+ T cell count 
KIR or KIR/HLA combination Association 
Adjusted mVL Adjusted sdNVP Adjusted CD4+ T cell count 
OR (95% CI) P OR (95% CI) P OR (95%CI) P 
Infants 
2DS4-v EU IU2 2.33 (0.84-6.43) 0.101 2.25 (0.84-5.98) 0.105 2.98 (1.09-8.15) 0.033 
2DS4-v C1+C2 EU IU2 5.52 (1.43-21.3) 0.013 4.29 (1.21-15.3) 0.024 8.51 (1.97-36.7) 0.004 
AA-v EU IU 25.4 (0.66-966.0) 0.081 9.67 (0.97-95.7) 0.052 - 0.998 
AA-v EU IU2 16.8 (1.79-157.1) 0.013 8.70 (1.14-65.9) 0.036 14.47 (1.05-199.0) 0.046 
AA-v C1+C2 EU IU2 7.02 (0.79-62.14) 0.080 7.25 (0.98-53.2) 0.052 14.47 (1.05-199.0) 0.046 
M+I- 2DS4-f NT IP-TR 3.93 (1.44-10.7) 0.007 4.33 (1.63-11.5) 0.003 3.57 (1.29-9.89) 0.014 
M-I+ 
2DS4-v EU IU 4.26 (0.55-32.5) 0.163 5.10 (1.09-23.8) 0.038 2.50 (0.25-24.8) 0.433 
2DS4-v EU IU2 5.68 (1.54-20.9) 0.009 5.02 (1.46-17.2) 0.010 5.73 (1.51-21.8) 0.010 
2DS4-v C1+C2 EU IU2 7.40 (1.49-36.8) 0.014 4.93 (1.09-22.1) 0.037 9.66 (1.76-52.8) 0.009 
EU, exposed uninfected infant; IU, in utero infected infant; IU2, enriched group of in utero infected infants; IP-TR, intrapartum transmitting mother. 
Bold P indicates significant differences (P<0.05). 
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5.2.5 Comparison of KIR2DS4 variants in MTCT2 
For MTCT2, mother and infant samples were KIR2DS4 typed using the real-time PCR assay 
(Chapter 2, section 2.6). Out of the 79 mothers, KIR2DS4 was absent in four mothers, thus 
the total KIR2DS4 frequency was 94.9% (75/79) of which the frequencies for KIR2DS4-f and 
KIR2DS4-v were 86.7% (65/75) and 46.7% (35/75), respectively. In addition, out of the 
11 mothers who were homozygous for Group-A haplotype, only one was homozygous for 
KIR2DS4-v, therefore, in MTCT2, only one mother (1.3%) lacked a functional activating KIR 
gene. Comparison of the AA1 haplotype frequency between the two maternal groups showed 
that the AA1 haplotype was significantly under-represented in mothers from MTCT2 
compared to mothers from MTCT1 (13.9% vs. 27.2%, P=0.029). Thus, prevalence of 
KIR2DS4-v in mothers with the AA1 haplotype showed MTCT2 to cluster more closely to 
the South African Xhosa group (Figure 5.6). However, with regards to HIV-1 transmission, 
KIR2DS4 variants (KIR2DS4-f, KIR2DS4-fv and KIR2DS4-v), as well as AA1 genotypes with 
KIR2DS4 (AA-f, AA-fv and AA-v), did not significantly differ in the comparisons conducted 
within the maternal or the infant groups (Figure 5.7). Although, KIR2DS4-f showed a trend 
towards higher representation in IU-infected infants compared to EU infants (P=0.080, 
OR=2.61). With regards to paired mother-infant associations, neither KIR2DS4 concordance 
nor discordance between mother-infant pairs showed any significant differences (Table 5.4). 
 
 
Figure 5.6 A scatter plot comparison of the KIR2DS4-v and AA1 haplotype prevalence amongst 
MTCT1 (Blue) and MTCT2 (Red) and other population groups. Reproduced and modified from 
(Whang et al., 2005, Middleton et al., 2007a). 
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Figure 5.7 Frequencies of KIR2DS4-f, KIR2DS4-fv and KIR2DS4-v in the total group of 
mothers (A) and infants (B) in MTCT2; and the frequency of KIR2DS4 variants amongst mothers 
(C) and infants (D) with AA haplotype. KIR2DS4-f indicates the presence of one or two copies of 
functional KIR2DS4; KIR2DS4-fv indicates the presence of both functional and non-functional 
KIR2DS4; and KIR2DS4-v indicates the presence of one or two copies of non-functional 
KIR2DS4. 
 
Table 5.4 Carrier frequencies of maternal and infant KIR2DS4 variants, as well as concordant 
and discordant mother-infant pairs in MTCT2 
MTCT2* KIR2DS4 
Representation, N (%) IP-TR / IP vs. NT / EU IU-TR / IU vs. NT / EU 
NT / EU IP-TR / IP IU-TR / IU OR (95% CI) P OR (95% CI) P 
M+I+ 
(n=75) 
2DS4-f 12 (30.77) 5 (41.67) 12 (50.00) 1.60 (0.42-6.10) 0.728 2.25 (0.78-6.43) 0.182 
2DS4-fv 8 (20.51) 2 (16.67) 4 (16.67) 0.78 (0.14-4.27) 1.000 0.78 (0.21-2.91) 0.755 
2DS4-v 2 (5.13) 2 (16.67) 1 (4.17) 3.70 (0.46-29.6) 0.232 0.80 (0.07-9.37) 1.000 
M+I- 
(n=75) 
2DS4-f 5 (12.82) 3 (25.00) 3 (12.50) 2.26 (0.45-11.3) 0.372 0.97 (0.21-4.49) 1.000 
2DS4-fv 7 (17.95) 0 (0.00) 4 (16.67) - 0.177 0.91 (0.23-3.52) 1.000 
2DS4-v 5 (12.82) 0 (0.00) 0 (0.00) - 0.323 - 0.147 
M-I+ 
(n=75) 
2DS4-f 5 (12.82) 0 (0.00) 3 (12.50) - 0.323 0.97 (0.21-4.49) 1.000 
2DS4-fv 10 (25.64) 2 (16.67) 3 (12.50) 0.58 (0.11-3.11) 0.706 0.41 (0.10-1.69) 0.337 
2DS4-v 2 (5.13) 1 (8.33) 1 (4.17) 1.68 (0.14-20.3) 1.000 0.80 (0.07-9.37) 1.000 
Concordant mother-infant pair (M+I+); discordant mother-infant pair, where the mother 
possesses the KIR combination absent in the infant (M+I-) and when infant possesses the KIR 
combination absent in the mother (M-I+). *Maternal NT and TR groups were matched according 
to maternal VL, CD4+ T cell counts as well as antiretroviral therapy, thus negating multivariate 
adjustments. 
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5.3 Discussion  
Full-length functional variants of KIR2DS4 (KIR2DS4-f) have been associated with increased 
risk for HIV-1 transmission as well as higher VL (Merino et al., 2011). In addition, Merino 
et al. (2011) also found a positive association between KIR2DS4-f and the presence of genital 
ulcers in seroprevalent index partners. More recently, the same group reported that the 
expression of KIR2DS4-f on the NK cell surface promoted HIV-1 pathogenesis during 
chronic infection (Merino et al., 2014). NK cells expressing KIR2DS4-f from individuals with 
untreated, chronic HIV-1 infection were polyfunctional and capable of degranulation 
(CD107a) and secretion of INF- and MIP-1β. The authors proposed that prolonged or 
excessive NK cell activities as seen in chronic HIV-1 infection may promote HIV-1 
pathogenesis by means of creating a pro-inflammatory environment that promoted HIV-1 
replication and/or mucosal shedding. These studies, therefore, highlighted the role for 
KIR2DS4 in NK cell activation and function in adult HIV-1 infection and its potential as a 
biomarker of HIV-1 pathogenesis. However, the role of KIR2DS4 in MTCT of HIV-1 has not 
been determined. Thus, in this chapter we evaluated the role of allelic variants of KIR2DS4 in 
MTCT of HIV-1 using two South African mother-infant cohorts recruited during two 
different PMTCT programs. Wherein half the mothers from MTCT1 received sdNVP at the 
onset of labour (monotherapy) and all mothers from MTCT2 received dual therapy consisting 
of daily AZT from 28 - 37 weeks gestation as well as sdNVP at the onset of labour 
(Chapter 2, section 2.1).  
 
First we examined the allelic frequency of KIR2DS4-f and KIR2DS4-v across the two MTCT 
cohorts and then questioned the role of these variants in MTCT of HIV-1. Overall, maternal 
frequencies of KIR2DS4-f and KIR2DS4-v were similar in both MTCT cohorts and were 
comparable to the frequencies reported for Zambian (Merino et al., 2011) and Xhosa 
(Middleton et al., 2007a) individuals. Prevalence data for KIR2DS4-v and the AA1 haplotype 
across different population groups (Middleton et al. 2007a) showed that the two MTCT 
cohorts were clearly separate from the Asian and Caucasian population groups, however, 
MTCT1 clustered more closely to the Mexican group while MTCT2 clustered more closely 
to the Xhosa group. This deviation was the result of the significantly greater representation of 
the AA1 haplotype in MTCT1 compared to MTCT2 (27.2% vs. 13.9%, P=0.029). Given that 
the AA1 haplotype differed significantly across the two MTCT cohorts, we compared our 
KIR data to another cohort of HIV-1 negative Black South Africans (Gentle et al., 
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unpublished data). As mention previously, the KIR data represented a diverse cross-section of 
the Black ethnic groups of South Africa sourced from the ESKOM (Electricity Supply 
Commission) cohort, wherein the overall AA1 haplotype frequency (26.9%) was similar to 
the MTCT1 cohort (27.1%) but significantly lower in the MTCT2 cohort (13.9%). 
Stratification of the KIR data according to home language indicated that among the different 
languages, the frequency of the AA1 haplotype also differed. Both Tswana and Tsonga 
speaking individuals had high frequencies of the AA1 haplotype (45% and 40%, 
respectively), whereas individuals who spoke Xhosa, South Sotho or Northern Sotho had the 
lowest frequencies of the AA1 haplotype (12%, 13% and 17%, respectively). Therefore, it 
could be postulated that although our two cohorts of Black South African mothers were 
recruited from the same hospital and were living in similar areas, mothers from MTCT1 and 
MTCT2 differed on the basis of home language. Mothers from MTCT1 (the larger cohort) 
may represent a more diverse black ethnic group, while mothers from MTCT2 (the smaller 
cohort) may have been skewed towards individuals having a Xhosa or Sotho background.  
 
In MTCT1, of the mothers that carried the AA1 haplotype, six were homozygous for 
KIR2DS4-v, which meant that the overall percentage of mothers without any activating KIR 
gene was 2.8%, significantly lower than the 25.3% reported in the North Irish Caucasian 
population (Middleton et al., 2007b). However, KIR2DS4-f or KIR2DS4-v frequencies did not 
significantly differ amongst mothers who transmitted versus those that did not. Similarly, 
when maternal KIR2DS4 variants were in combination with their putative HLA-C ligands we 
found no significant associations. Furthermore, neither KIR2DS4-f nor KIR2DS4-v showed an 
association with maternal CD4+ T cell count or VL. It was only in infants that KIR2DS4-v 
carriage alone, and in combination with C1+C2 ligands, was significantly associated with 
increased risk of IU acquisition of HIV-1, and this association was enhanced in those infants 
who were homozygous for the group A haplotype. Additionally, when mother and infant 
were paired, discordance in either direction (M+I- or M-I+) revealed two important 
associations. Firstly, in the M+I- discordant group, IP-transmitting mothers had significantly 
greater proportion of KIR2DS4-f compared NT mothers, and secondly, in the M-I+ discordant 
group, IU infants, as well as IU2 infants, had significantly greater representation of 
KIR2DS4-v compared to EU infants. These findings suggested that in MTCT1 maternal 
possession of KIR2DS4-f and its absence in infants increased the risk for IP transmission, 
whilst infant possession KIR2DS4-v increased the risk for IU acquisition of HIV-1, 
particularly when infants were homozygous for the A haplotype.  
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Given that IP and sexual transmission share similarities in their mode of transmission i.e. 
across the mucosal barrier, IP transmission can occur when there is direct contact of infant 
mucosa with HIV-1 infected maternal blood, amniotic fluid, or cervical/vaginal secretions 
(Van de Perre, 1999, Kwiek et al., 2006), and sexual transmission can occur when the genital 
or rectal mucosa comes into direct contact with cell-free or cell-associated virus (Shattock 
and Moore, 2003), it is plausible that the maternal KIR2DS4-f association with IP 
transmission is similar to that of KIR2DS4-f with sexual transmission (Merino et al., 2011, 
Merino et al., 2014). Thus, in the same manner by which Merino et al. (2011 and 2014) 
proposed that KIR2DS4-f in HIV-1 seropositive partners might increase the risk for sexual 
transmission through increased NK cell activation, mucosal inflammation and viral shedding. 
Given our findings, regardless of the recipient being a sexual partner or an infant, maternal 
possession of KIR2DS4-f NK cells might also produce a pro-inflammatory state that would 
increase viral replication and promote the likelihood of IP transmission of HIV-1. 
 
Conversely, when infants carried the truncated KIR2DS4 alleles (KIR2DS4-v) there was a 
greater likelihood of IU acquisition of HIV-1, especially when infants harboured the AA1 
haplotype. Since the group A haplotype predominately consists of inhibitory KIRs (KIR2DL1, 
KIR2DL3, KIR2DL4, KIR3DL1, KIR3DL2 and KIR3DL3), KIR2DS4-v homozygous 
individuals would possess NK cells completely in favour of strong inhibition. Consequently, 
these NK cells would be unable to eliminate HIV-infected maternal cells due to lack of NK 
cell activation resulting in IU infection. Similarly in another study, KIR2DS4-v homozygosity 
was significantly higher in patients with syphilis than in uninfected controls (Zhuang et al., 
2012). In agreement with our findings, Zhuang et al. (2012) suggest that the lack of an 
activating KIR in individuals with AA1 haplotype would result in inhibition of NK cell 
cytotoxicity, thereby predisposing them to acquiring syphilis. Alternatively, since KIR2DS4-v 
alleles are able to encode soluble KIR2DS4 products (Maxwell et al., 2002), it has been 
speculated that soluble KIR2DS4 could possibly divert or obstruct NK cell function by acting 
as a ligand for another receptor or simply as a necessary decoy to mop up the available 
soluble HLA (Middleton et al., 2007a). However, these hypotheses are unlikely since the 
mRNA transcripts from KIR2DS4-v alleles were found to be unstable and associated with low 
expression levels (McErlean et al., 2010), and thus the true function of the molecules encoded 
by KIR2DS4-v alleles remains unknown.  
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Although full-length KIR2DS4 was previously shown to directly interact with HLA-C*04 
(Katz et al., 2001), in our analyses neither the individual HLA-C alleles (C*01:02, C*14:02, 
C*16:01, C*02:02, C*04:01 and C*05:01) nor the combination of C1 and C2 alleles with 
KIR2DS4-f showed any significant differences between NT and TR (IP, IU and IU2) mothers, 
suggesting that in our MTCT1 cohort these HLA-C alleles were not associated with HIV-1 
transmission. 
 
Overall, the role of KIR2DS4 in MTCT1 was striking and showed evidence that suggested 
that NK cell activation though KIR2DS4-f or the lack thereof with KIR2DS4-v influenced the 
outcome of HIV-1 transmission. In addition, the fact that these associations were maintained 
after correction for mVL, sdNVP and CD4+ T cell count lend credibility that KIR2DS4 has a 
significant role in transmission of HIV-1 in MTCT1. Immune activation has been shown to 
strongly correlate with viraemia during untreated disease (Catalfamo et al., 2008, Catalfamo 
et al., 2011, Klatt et al., 2013). Correspondingly, some studies reported that a higher level of 
systemic immune activation was associated with increased risk of HIV-1 acquisition, thus 
suggesting that a suppressed or “quiescent” immune environment may be protective (Begaud 
et al., 2006, Jennes et al., 2006a, McLaren et al., 2010, Naranbhai et al., 2012). However, 
several studies reported that immune activation in both EU adults and infants did not 
necessarily favour HIV-1 transmission, but, rather may be contributing to their resistance 
(Romano et al., 2006, Tran et al., 2006, Suy et al., 2007, Ono et al., 2008). Likewise, using a 
selection of cord-blood samples from MTCT1, haematological and immunological studies 
conducted in our own laboratory showed that infants born to HIV-1 positive mothers, 
regardless of NVP exposure, had increased levels of immune activation markers when 
compared to HIV-1 unexposed infants, in addition, immune activation was increased by 
exposure to sdNVP, particular in IU-infants (Schramm et al., 2006). Moreover, EU infants 
from mothers with high CD4+ T cell counts (> 500 cells/μl) that had taken sdNVP had 
significantly elevated white blood cells, monocytes and basophils when compared to newborn 
infants of mothers with similar CD4+ T cell counts that had not taken sdNVP (Schramm et 
al., 2010). Thus, the authors suggested that not all immune activation is necessarily 
deleterious and, if caused in vivo by sdNVP, may well assist infants to preventing the 
establishment of infection, however, in infants already infected when exposed to sdNVP 
(i.e. those with IU infection), increased immune activation may well be deleterious.  
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However in MTCT2, where TR and NT mothers were matched on the basis of maternal VL, 
CD4+ T cell count and ART, neither maternal nor infant possession of KIR2DS4-f or 
KIR2DS4-v showed any significant associations with regards to HIV-1 transmission or 
acquisition. Moreover when mother and infant were paired, neither concordance nor 
discordance for KIR2DS4 variants show any significant associations or tends. The absence of 
any significant KIR2DS4 association in MTCT2 could be due to fact that the AA1 haplotype 
frequency was relatively low in mothers from this cohort (13.9%), which would imply that 
the majority of mothers would possess the at least one B haplotype and have more than one 
activating KIR gene present. It could, therefore, be postulated that having more than one 
activating KIR may be negating the KIR2DS4-f association with HIV-1 transmission seen in 
MTCT1.  
 
Alternatively, dual ART consisting of AZT and sdNVP in mothers and infants could reduce 
the genetic influence of KIR2DS4. Unlike monotherapy consisting of sdNVP given at the 
onset of labour that has little time to reduce the maternal VL and primarily acts as an infant 
PrEP (Lehman and Farquhar, 2007), dual ART therapy with daily AZT given to the mothers 
from 28 weeks gestation may able to lower the maternal VL and improve maternal CD4+ T 
count cell prior to onset of labour. AZT given to pregnant women at least 2 days prior to 
anticipated delivery was shown to reduce VL (Jackson, 1995). Moreover, in another study 
that compared maternal CD4+ T cells counts before and after maternal AZT treatment 
starting at 36 weeks until start of labour showed that AZT treatment significantly improved 
the CD4+ T cell counts in mothers who did not transmit HIV-1 to their infants (Makokha et 
al., 2002). However, the increase in CD4+ T cells was not significant among mothers who 
infected their infants with HIV-1; and unfortunately, this study did not determine whether 
HIV-1 infected infants were IU- or IP- infected. Likewise, upon HAART, immune activation 
declines and there is a reduction in the amount of inflammatory cytokines and chemokines 
(Guihot et al., 2011, Klatt et al., 2013). However, this was not evident in MTCT2. Maternal 
VL was in fact found to be significantly higher in NT mothers from MTCT2 compared to 
MTCT1 and CD4+ T cell counts were significantly lower NT mothers from MTCT2 
compared to MTCT1 (Chapter 2, Figure 2.3). This is intriguing and implies that in MTCT2, 
NT mothers from despite having high VL and low CD4 + T cell count did not transmit HIV-1 
to their infants, and suggests there may be other factors involved in preventing HIV-1 
transmission.  
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In summary, this chapter highlights the importance of analysing KIR allelic variation in 
MTCT of HIV-1, as KIR2DS4-f and KIR2DS4-v variants were shown to have differential 
effects on HIV-1 transmission and acquisition. The data from MTCT1 suggested that 
maternal NK cell activation through KIR2DS4-f or the lack thereof with KIR2DS4-v in infants 
associated with IP transmission or IU acquisition of HIV-1, respectively. Given that we only 
found KIR2DS4 associations in MTCT1 and not in MTCT2, where mothers had significantly 
lower representation of the AA1 haplotype than MTCT1 mothers, suggests that future studies 
that investigate the role of NK cell function in HIV-1 transmission should match cases and 
controls on basis of their AA1 haplotype as this would control for the influence of other 
activating KIR genes. Taken together it is clear that aspects of immune activation (which 
cells, their numbers, timing relative to exposure, transmitter-recipient genotypes/phenotypes) 
need to be more clearly delineated to further our understanding as to which activated 
components are associated with protection as opposed to acquisition. Moreover, functional 
studies are necessary to understand the immune activation pathways in NK cells that express 
KIR2DS4-f and KIR2DS4-v alleles. 
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CHAPTER 6 
The influence of HLA-G polymorphisms in MTCT of HIV-1 
The findings from MTCT1 presented in this Chapter have been published: Hong et al. (2015) 
Infection, Genetics and Evolution, 30, 147 - 158. 
 
6.1 Introduction 
Recently there has been an increased interest in the role of HLA-G in MTCT, because of its 
preferential expression at the maternal-foetal interface on extravillous cytotrophoblasts, 
where it is plays an important tolerogenic role towards the semi-allogenic foetus. However, 
HLA-G expression is not limited to the maternal-foetal interface and has been found in the 
thymus, cornea, nail matrix, pancreas, and on erythroid and endothelial precursors as well as 
seminal plasma (Larsen et al., 2011, Dahl et al., 2014b, Lynge Nilsson et al., 2014). HLA-G 
can inhibit differentiation, proliferation, cytolysis, cytokine secretion and immunoglobulin 
production upon binding to their specific inhibitory receptors: immunoglobulin-like transcript 
(ILT)-2, ILT-4 and KIR2DL4 expressed by many immune cells, such as B and 
T lymphocytes as well as NK cells (Amiot et al., 2014).  
 
Unlike the classical HLA Class I molecules (HLA-A, -B and -C), the non-classical HLA-G 
molecule has limited allelic polymorphism with only 50 alleles described to date 
(IMGT/HLA, version 3.16.0, 2014/04/14). These alleles encode 16 distinct transmembrane 
proteins (G*01:01, G*01:02, G*01:03, G*01:04, G*01:06, G*01:07, G*01:08, G*01:09, 
G*01:10, G*01:11, G*01:12, G*01:14, G*01:15, G*01:16, G*01:17 and G*01:18) and two 
truncated proteins (G*01:05N and G*01:13N) (Robinson et al., 2013b). Nevertheless, 
alternative splicing of the HLA-G primary transcript can generate seven mRNAs that encode 
membrane-bound (HLA-G1, -G2, -G3, and -G4) and soluble (HLA-G5, -G6, and -G7) 
protein isoforms (Donadi et al., 2011). In addition, HLA-G1 can also be proteolytically 
cleaved from the membrane and released as soluble HLA-G1 (sHLA-G) allowing it to have 
systemic immunoregulatory effects in the absence of localized tissue expression (Solier et al., 
2002). Thus, the main isoforms present in plasma are shed HLA-G1 and secreted HLA-G5 
proteins. Of note, in contrast to other HLA class I genes, exon 6 of the HLA-G encodes a 
premature stop codon that results in a truncated cytoplasmic tail which prolongs the half-life 
of HLA-G on the cell surface as endocytosis is reduced (Park et al., 2001). 
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Unlike the coding region, a high degree of variation exists within 5‟ and 3‟ untranslated 
regions (UTRs) and these polymorphisms, particularly within the 3‟UTR, may affect the 
post-transcriptional regulation and biological functions of HLA-G (Castelli et al., 2010, Costa 
et al., 2012). Since the 3'UTR of HLA-G contains several regulatory elements (AU-rich 
motifs, a poly-A signal, as well as signals that regulate the spatial and temporal expression of 
an mRNA), polymorphisms within this region may alter mRNA stability, turnover, mobility, 
and splicing pattern (Lynge Nilsson et al., 2014). Indeed, several polymorphic sites within the 
3‟UTR have been associated with differential HLA-G expression profiles and at least eight of 
these polymorphic sites are frequently found in worldwide populations (Castelli et al., 2014). 
Well studied amongst these is the 14-bp insertion/deletion (rs66554220), wherein the 
presence of a 14-bp insertion (Ins) (5‟-ATTTGTTCATGCCT-3‟) introduces an alternative 
splicing site that generates a 92-bp deletion in the 3‟UTR that influences mRNA stability. 
Individuals with Ins/Ins genotype have been associated with lower mRNA production 
compared to Ins/Del and Del/Del genotypes (Hviid et al., 2003, Castelli et al., 2009, Castelli 
et al., 2010). Furthermore, other single nucleotide polymorphisms (SNPs) have also been 
implicated in the regulation of HLA-G expression. For example, the +3187 A/G SNP (located 
near an AU-rich motif in the HLA-G mRNA) has been associated with decreased in vitro 
mRNA stability, so that the presence of the +3187A allele may lead to decreased HLA-G 
expression due to the increased number of adenines in this AU-rich motif (Yie et al., 2008). 
 
In the context of MTCT of HIV-1, several studies have associated the 14-bp indel with the 
risk of MTCT (Aikhionbare et al., 2006, Fabris et al., 2009, Segat et al., 2009, Segat and 
Crovella, 2012, Sanches et al., 2013, Segat et al., 2014) and two have associated HLA-G 
alleles with HIV-1 transmission (Luo et al., 2013, Turk et al., 2013). However, some of these 
reports have been contradictory. For example, in Zambian infants, the Ins (associated with 
lower with lower mRNA production) was linked with protection from IU and IP HIV-1 
infection (Segat et al., 2014), yet in Brazilian children, the Del allele and Del/Del genotype 
(associated with more stable mRNA and increased HLA-G expression) was linked with 
protection from MTCT (Fabris et al., 2009). Whilst in other studies, G*01:03- alleles, which 
reportedly translate into lower plasma sHLA-G, were associated with a reduced risk of 
MTCT of HIV-1 (Luo et al., 2013). Whereas in the context of sexual transmission, 
G*01:04:04, an allele with reportedly higher levels of plasma sHLA-G, was associated with 
susceptibility to HIV-1 infection (Turk et al., 2013). Of note, amongst all these studies, few 
have assessed the role of HLA-G alleles and 3‟UTR SNPs collectively. 
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Thus, the aim of this chapter was to investigate the role of HLA-G alleles (defined by the 
extracellular α1, α2 and α3 domains) as well as the 3‟UTR in HIV-1 transmitting (TR) and 
non-transmitting (NT) mothers and their HIV-1 infected/uninfected infants in two unique 
MTCT cohorts recruited in Johannesburg, South Africa.  
 
6.2. Results 
6.2.1 HLA-G allele representation in MTCT1 
A total of 216 mother-infant pairs were genotyped from MTCT1 (N=217) which included 
144 NT/EU pairs and 72 TR/IP, IU or IU2 pairs (one NT/EU mother-infant pair was excluded 
due to insufficient DNA). Sixteen HLA-G alleles were identified in the study population 
(Table 6.1). These encoded six functional proteins (G*01:01, G*01:03, G*01:04, G*01:06, 
G*01:08 and G*01:11) and one truncated protein (G*01:05N). The three most common 
HLA-G alleles were G*01:01:01, G*01:01:02 and G*01:04:04 with frequencies greater than 
15% in both mothers and infants, which corresponded with the most common genotypes 
G*01:01:01/G*01:01:01, G*01:01:01/G*01:01:02 and G*01:01:01/G*01:04:04 (Table 
6.2). All mother and infant HLA-G allele frequencies were in HWE (P=0.120 and P=0.769, 
respectively). 
 
6.2.2 HLA-G alleles and transmission of HIV-1 in MTCT1 
To investigate the influence of HLA-G alleles and genotypes in vertical transmission of 
HIV-1 in MTCT1 we compared TR mothers to NT mothers as well as their respective infants. 
Maternal possession of the G*01:01:02 allele was associated with increased risk for IU 
HIV-1 transmission (Table 6.1). Representation of G*01:01:02 was higher in IU-TR and 
IU2-TR mothers compared to NT mothers (P=0.036, OR=2.26; P=0.078, OR=1.68, 
respectively). While G*01:01:02/G*01:01:02 genotype showed a strong trend (P=0.072, 
OR=4.31) towards increased representation in IU-TR mothers compared to NT mothers 
(Table 6.2). In addition, the combination G*01:01:02/G*01:03:01 was significantly higher 
in IU2-TR mothers compared to NT mothers (P=0.031, OR=4.61). All of these allele 
associations were significant post adjustments for mVL but only G*01:01:02 homozygosity 
maintained significance post adjustment for maternal sdNVP and infant KIR2DS4-v 
(Table 6.6). Infant HLA-G alleles and HLA-G genotypes showed no significant associations 
with regards to HIV-1 acquisition (Table 6.1 and Table 6.3, respectively). 
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6.2.3 HLA-G 3’UTR allele, genotype and haplotype frequencies in MTCT1 
Sequencing analysis of HLA-G 3‟UTR in mother-infant pairs from MTCT1 revealed the 
presence of 11 polymorphic sites. Nine of these have been previously described, namely: 
+2961Ins/Del (rs66554220), +3003T/C (rs1707), +3010C/G (rs1710), +3027C/A 
(rs17179101), +3032G/C (rs146339774), +3035C/T (rs17179108), +3142G/C (rs1063320), 
+3187A/G (rs9380142), and +3196C/G (rs1610696). Two new SNPs, +3076C/T and 
+3114G/A, were only found in EU infants, but had frequencies below 1% and were not 
considered in further analyses. Observed genotype frequencies at all variation sites were in 
adherence with HWE. Using HAPLOVIEW bioinformatics software (Barrett et al., 2005) and 
in combination with published 3‟UTR haplotypes (Sabbagh et al., 2014), we found eight 
distinct 3‟UTR haplotypes (UTR1-UTR7 and UTR20) within MTCT1 (Figure 6.1 and 
Figure 6.2, respectively). LD analysis amongst 3‟UTR SNPS revealed positions +3010C/G 
and +3142G/C were in complete linkage, whilst the 14-bp indel as well as position +3196C/G 
were in strong linkage disequilibrium (Figure 6.1). UTR1, UTR2 and UTR3 were the most 
frequent haplotypes (Figure 6.2), which together accounted for over 65% of the haplotypes 
in our South African study population, which was most comparable to the Senegalese 
population (SER, n=239) reported by Sabbagh et al. (2014). 
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Table 6.1 Representation of HLA-G allele frequencies in HIV-1 positive mothers and their infants from MTCT1, N (%) 
Maternal 
HLA-G Alleles 
NT 
(2n=288) 
IP-TR 
(2n=58) 
IU-TR 
(2n=38) 
IU2-TR 
(2n=86) 
IP-TR vs. NT IU-TR vs. NT IU2-TR vs. NT 
OR (95% CI) P OR (95% CI) P OR (95% CI) P 
G*01:01:01 85 (29.51) 19 (32.76) 15 (39.47) 25 (29.07) 1.16 (0.63-2.12) 0.639 1.55 (0.77-3.13) 0.261 0.97 (0.57-1.66) 1.000 
G*01:01:02 59 (20.49) 11 (18.97) 14 (36.84) 26 (30.23) 0.91 (0.44-1.86) 0.860 2.26 (1.10-4.64) 0.036 1.68 (0.97-2.89) 0.078 
G*01:01:08 8 (2.78) 3 (5.17) 1 (2.63) 2 (2.33) 1.91 (0.49-7.42) 0.403 0.94 (0.11-7.77) 1.000 0.83 (1.07-3.99) 1.000 
G*01:01:09 11 (3.82) 2 (3.45) 1 (2.63) 1 (1.16) 0.90 (0.19-4.16) 1.000 0.68 (0.08-5.42) 1.000 0.29 (0.04-2.32) 0.310 
G*01:01:15 1 (0.35) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
G*01:01:17 1 (0.35) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
G*01:01:19 8 (2.78) 2 (3.45) 0 (0.00) 4 (4.65) 1.25 (0.25-6.04) 1.000 - 0.603 1.70 (0.50-5.81) 0.483 
G*01:01:20 1 (0.35) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
G*01:03:01 23 (7.99) 3 (5.17) 3 (7.89) 7 (8.14) 0.63 (0.18-2.16) 0.592 0.98 (0.28-3.45) 1.000 1.02 (0.42-2.46) 1.000 
G*01:04:01 11 (3.82) 5 (8.62) 0 (0.00) 1 (1.16) 2.37 (0.79-7.11) 0.160 - 0.375 0.29 (0.04-2.32) 0.310 
G*01:04:04 53 (18.40) 10 (17.24) 3 (7.89) 15 (17.44) 0.92 (0.44-1.94) 1.000 0.38 (0.11-1.28) 0.116 0.93 (0.50-1.76) 0.875 
G*01:05N 27 (9.38) 2 (3.45) 0 (0.00) 4 (4.65) 0.34 (0.08-1.49) 0.194 - 0.056 0.47 (0.16-1.38) 0.188 
G*01:06 0 (0.00) 1 (1.72) 0 (0.00) 0 (0.00) - 0.168 - 1.000 - 1.000 
G*01:11 0 (0.00) 1 (1.72) 1 (2.63) 1 (1.16) - 1.000 - 0.117 - 0.230 
Infant 
HLA-G Alleles 
EU 
(2n=288) 
IP 
(2n=58) 
IU 
(2n=38) 
IU2 
(2n=86) 
IP vs. EU IU vs. EU IU2 vs. EU 
OR (95% CI) P OR (95%CI) P OR (95% CI) P 
G*01:01:01 96 (33.33) 22 (37.93) 13 (34.21) 21 (24.42) 1.22 (0.68-2.19) 0.545 1.04 (0.51-2.12) 1.000 0.64 (0.37-1.12) 0.145 
G*01:01:02 59 (20.49) 6 (10.34) 9 (23.68) 20 (23.26) 0.45 (0.18-1.09) 0.096 1.20 (0.54-2.68) 0.672 1.17 (0.66-2.09) 0.652 
G*01:01:08 10 (3.47) 4 (6.90) 3 (7.89) 4 (4.65) 2.05 (0.62-6.81) 0.265 2.38 (0.62-9.07) 0.377 1.35 (0.41-4.43) 0.746 
G*01:01:09 7 (2.43) 4 (6.90) 1 (2.63) 1 (1.16) 2.97 (0.84-10.5) 0.094 1.08 (0.12-9.06) 1.000 0.47 (0.05-3.89) 0.688 
G*01:01:19 11 (3.82) 2 (3.45) 0 (0.00) 5 (5.81) 0.90 (0.19-4.17) 1.000 - 0.375 1.55 (0.52-4.60) 0.542 
G*01:03:01 29 (10.07) 4 (6.90) 4 (10.53) 8 (9.30) 0.66 (0.22-1.95) 0.485 1.05 (0.35-3.17) 1.000 0.92 (0.40-2.08) 1.000 
G*01:04:01 11 (3.82) 1 (1.72) 1 (2.63) 3 (3.49) 0.44 (0.06-3.49) 0.497 0.68 (0.08-5.42) 1.000 0.91 (0.25-3.33) 1.000 
G*01:04:04 41 (14.24) 11 (18.97) 6 (15.79) 19 (22.09) 1.41 (0.67-2.94) 0.419 1.12 (0.44-2.87) 0.806 1.71 (0.93-3.13) 0.094 
G*01:04:05 1 (0.35) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
G*01:05N 21 (7.29) 3 (5.17) 1 (2.63) 5 (5.81) 0.69 (0.20-2.41) 0.600 0.34 (0.05-2.63) 0.343 0.78 (0.29-2.15) 0.810 
G*01:06 0 (0.00) 1 (1.72) 0 (0.00) 0 (0.00) - 0.168 - 1.000 - 1.000 
G*01:08 1 (0.35) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
G*01:11 1 (0.35) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
NT: HIV-1 non-transmitting mother; IP-TR: intrapartum HIV-1 transmitting mother; IU-TR: in utero HIV-1 transmitting mother; IU2-TR: enriched group of in utero 
transmitting mothers; EU: HIV-1 exposed uninfected infant; INF; IP: intrapartum infected infant; IU: in utero infected infant; IU2: enriched group of in utero 
infected infants. Highlighted and bold P values indicate significant differences (P<0.05) and bold P values indicate trends (P<0.090).  
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Table 6.2 Representation of maternal HLA-G genotypes in MTCT1, N (%) 
HLA-G Genotypes* 
NT 
(n=144) 
IP-TR 
(n=29) 
IU-TR 
(n=19) 
IU-TR 
(n=43) 
IP-TR vs. NT IU-TR vs. NT IU2-TR vs. NT 
OR (95% CI) P OR (95% CI) P OR (95% CI) P 
G*01:01:01/G*01:01:01 17 (11.81) 3 (10.34) 5 (26.32) 5 (11.63) 0.86 (0.23-3.16) 1.000 2.66 (0.85-8.34) 0.143 0.98 (0.34-2.84) 1.000 
G*01:01:01/G*01:01:02 15 (11.81) 4 (13.79) 3 (15.79) 4 (9.30) 1.37 (0.42-4.49) 0.744 1.61 (0.42-6.18) 0.698 0.88 (0.27-2.81) 1.000 
G*01:01:01/G*01:01:09 4 (2.78) 0 (0.00) 1 (5.26) 1 (2.33) - 0.608 1.94 (0.21-18.3) 1.000 0.83 (0.09-7.65) 1.000 
G*01:01:01/G*01:03:01 4 (2.78) 0 (0.00) 1 (5.26) 2 (4.65) - 0.608 1.94 (0.21-18.3) 1.000 1.71 (0.30-9.66) 0.622 
G*01:01:01/G*01:04:01 3 (2.08) 2 (6.90) 0 (0.00) 0 (0.00) 3.48 (0.56-21.8) 0.196 - 1.000 - 0.587 
G*01:01:01/G*01:04:04 17 (11.81) 4 (13.79) 0 (0.00) 6 (13.95) 1.19 (0.37-3.85) 0.758 - 0.224 1.21 (0.44-3.29) 0.792 
G*01:01:01/G*01:05N 7 (4.86) 1 (3.45) 0 (0.00) 0 (0.00) 0.70 (0.08-5.91) 1.000 - 0.602 - 0.205 
G*01:01:02/G*01:01:02 6 (4.17) 2 (6.90) 3 (15.79) 4 (9.30) 1.70 (0.33-8.89) 0.623 4.31 (0.98-18.9) 0.072 2.35 (0.63-8.77) 0.242 
G*01:01:02/G*01:01:08 3 (2.08) 1 (3.45) 0 (0.00) 1 (2.33) 1.67 (0.17-16.7) 1.000 - 1.000 1.11 (0.11-11.0) 1.000 
G*01:01:02/G*01:01:19 4 (2.78) 0 (0.00) 0 (0.00) 0 (0.00) - 0.608 - 1.000 - 0.575 
G*01:01:02/G*01:03:01 4 (2.78) 0 (0.00) 2 (10.53) 5 (11.63) - 0.608 4.11 (0.70-24.1) 0.145 4.61 (1.17-17.9) 0.031 
G*01:01:02/G*01:04:01 3 (2.08) 0 (0.00) 0 (0.00) 1 (2.33) - 1.000 - 1.000 1.11 (0.11-11.0) 1.000 
G*01:01:02/G*01:04:04 10 (6.94) 2 (6.90) 2 (10.53) 4 (9.30) 1.00 (0.21-4.78) 1.000 1.57 (0.32-7.81) 0.634 1.37 (0.41-4.62) 0.741 
G*01:01:02/G*01:05N 6 (4.17) 0 (0.00) 0 (0.00) 2 (4.65) - 0.387 - 0.615 1.12 (0.22-5.77) 1.000 
G*01:01:08/G*01:04:04 3 (2.08) 0 (0.00) 1 (5.26) 1 (2.33) - 1.000 2.61 (0.26-26.5) 0.394 1.11 (0.11-11.0) 1.000 
G*01:01:09/G*01:05N 3 (2.08) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 0.587 
G*01:03:01/G*01:04:04 3 (2.08) 1 (3.45) 0 (0.00) 0 (0.00) 1.67 (0.17-16.7) 1.000 - 1.000 - 0.587 
G*01:03:01/G*01:05N 4 (2.78) 0 (0.00) 0 (0.00) 0 (0.00) - 0.608 - 1.000 - 0.575 
G*01:04:04/G*01:04:04 6 (4.17) 0 (0.00) 0 (0.00) 0 (0.00) - 0.387 - 0.615 - 0.339 
G*01:04:04/G*01:05N 6 (4.17) 1 (3.45) 0 (0.00) 2 (4.65) 0.82 (0.09-7.09) 1.000 - 0.615 1.12 (0.22-5.77) 1.000 
* indicates HLA-G genotype frequencies > 2% in the NT group. NT: HIV-1 non-transmitting mother; IP-TR: intrapartum HIV-1 transmitting mother; 
IU-TR: in utero HIV-1 transmitting mother; IU2-TR: enriched group of in utero transmitting mothers. Highlighted and bold P values indicate 
significant differences (P<0.05) and bold P values indicate trends (P<0.090). 
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Table 6.3 Representation of infant HLA-G genotypes in MTCT1, N (%) 
HLA-G Genotypes* 
EU 
(n=144) 
IP 
(n=29) 
IU 
(n=19) 
IU2 
(n=43) 
IP-TR vs. EU IU-TR vs. EU IU2-TR vs. EU 
OR (95% CI) P OR (95% CI) P OR (95% CI) P 
G*01:01:01/G*01:01:01 17 (11.81) 4 (13.79) 3 (15.79) 3 (6.98) 1.19 (0.37-3.85) 0.751 1.40 (0.36-5.31) 0.708 0.56 (0.16-2.01) 0.421 
G*01:01:01/G*01:01:02 15 (10.42) 2 (6.90) 2 (10.53) 3 (6.98) 0.63 (0.14-2.94) 0.741 1.01 (0.21-4.81) 1.000 0.64 (0.18-2.34) 0.575 
G*01:01:01/G*01:01:09 3 (2.08) 2 (6.90) 0 (0.00) 0 (0.00) 3.48 (0.56-21.8) 0.196 - 1.000 - 0.587 
G*01:01:01/G*01:01:19 4 (2.78) 0 (0.00) 0 (0.00) 3 (6.98) - 0.608 - 1.000 2.62 (0.56-12.2) 0.355 
G*01:01:01/G*01:03:01 12 (8.33) 2 (6.90) 1 (5.26) 1 (2.33) 0.81 (0.17-3.85) 1.000 0.61 (0.07-4.98) 1.000 0.26 (0.03-2.07) 0.304 
G*01:01:01/G*01:04:01 4 (2.78) 1 (3.45) 0 (0.00) 1 (2.33) 1.25 (0.13-11.6) 1.000 - 1.000 0.83 (0.09-7.66) 1.000 
G*01:01:01/G*01:04:04 11 (7.64) 3 (10.34) 3 (15.79) 6 (13.95) 1.39 (0.36-5.34) 0.707 2.26 (0.57-8.99) 0.375 1.96 (0.67-5.65) 0.229 
G*01:01:01/G*01:05N 10 (6.94) 2 (6.90) 0 (0.00) 0 (0.00) 0.99 (0.21-4.78) 1.000 - 0.374 - 0.120 
G*01:01:02/G*01:01:02 9 (6.25) 0 (0.00) 0 (0.00) 2 (4.65) - 0.228 - 0.390 0.73 (0.15-3.52) 1.000 
G*01:01:02/G*01:01:08 3 (2.08) 2 (6.90) 2 (10.53) 3 (6.98) 3.48 (0.56-21.8) 0.196 5.52 (0.86-35.47) 0.104 3.52 (0.68-18.1) 0.136 
G*01:01:02/G*01:01:19 3 (2.08) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 0.587 
G*01:01:02/G*01:03:01 3 (2.08) 0 (0.00) 2 (10.53) 3 (6.98) - 1.000 5.52 (0.86-35.47) 0.104 3.52 (0.68-18.1) 0.136 
G*01:01:02/G*01:04:01 3 (2.08) 0 (0.00) 1 (5.26) 1 (2.33) - 1.000 2.61 (0.25-26.45) 0.394 1.11 (0.11-11.1) 1.000 
G*01:01:02/G*01:04:04 9 (6.25) 1 (3.45) 2 (10.53) 4 (9.30) 0.53 (0.06-4.39) 0.699 1.76 (0.35-8.85) 0.619 1.53 (0.45-5.26) 0.500 
G*01:01:02/G*01:05N 3 (2.08) 0 (0.00) 0 (0.00) 2 (4.65) - 1.000 - 1.000 2.29 (0.37-14.1) 0.591 
G*01:01:08/G*01:04:04 4 (2.78) 0 (0.00) 0 (0.00) 0 (0.00) - 0.608 - 1.000 - 0.575 
G*01:03:01/G*01:04:04 3 (2.08) 2 (6.90) 0 (0.00) 3 (6.98) 3.48 (0.56-21.8) 0.196 - 1.000 3.52 (0.68-18.1) 0.136 
G*01:03:01/G*01:05N 3 (2.08) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 0.587 
G*01:04:04/G*01:04:04 3 (2.08) 2 (6.90) 0 (0.00) 1 (2.33) 3.48 (0.56-21.8) 0.196 - 1.000 1.11 (0.11-11.1) 1.000 
G*01:04:04/G*01:05N 5 (3.47) 1 (3.45) 1 (5.26) 2 (4.65) 0.99 (0.11-8.83) 1.000 1.54 (0.17-13.9) 1.000 1.35 (0.25-7.25) 1.000 
* indicates HLA-G genotype frequencies > 2% in the EU group. EU: HIV-1 exposed uninfected infant; IP: intrapartum infected; IU: in utero infected 
infant; IU2: enriched group of in utero infected infants. 
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Figure 6.1 Linkage disequilibrium (LD) plot of HLA-G 3‟UTR polymorphisms. At the top the 
SNPs are shown according to their succession in the 3‟UTR of the HLA-G. Standard D‟/LOD 
colour scheme was used, white and blue squares indicate a non-significant LD (LOD <2) and red 
squares indicate pairs in strong LD (LOD ≥ 2). Numbers indicate the R-square value expressed as 
a percentage and an empty box indicates an r2 equal to 1. 
 
 
Figure 6.2 Polymorphisms in the 3‟ untranslated region (UTR) of the HLA-G gene and the 
3‟UTR haplotypes. Polymorphic positions are relative to the first ATG codon at exon 1. 
UTR haplotypes were numbered according previously published reports (Castelli et al., 2014, 
Sabbagh et al., 2014). Del, Deletion; Ins, insertion.  
a South Africa (SA) represents the total group of HIV-1 infected mothers from cohort 1 (n=216) 
b Represents 3‟UTR frequencies reported by (Sabbagh et al., 2014) which pooled some data 
from the 1000 genome project. ASW, people of African ancestry from the South Western 
United States (n=61); SER, Serer from Niakhar, Senegal (n=239); YAN, Yansi from 
Bandundu, Democratic Republic of the Congo (N=175); and LWK, Luhya from Webuye, 
Kenya (n=96). 
c Represents other 3‟UTR haplotypes not identified in SA 
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6.2.4 HLA-G 3’UTR polymorphisms and their association in MTCT1 
When comparing these nine polymorphic sites within the 3‟UTR with risk of MTCT, only 
one position (+3187A/G) showed an association with increased risk for IU MTCT 
(Table 6.4). Maternal frequencies of the G allele as well as G/G homozygosity at position 
+3187 were significantly over-represented in IU-TR mothers compared to NT mothers 
(P=0.011, OR=2.96 and P=0.011, OR=14.4, respectively). However, only G/G 
homozygosity maintained significance post adjustment for mVL (P=0.009, OR=29.6), but 
the confidence interval (CI) was considerably large (2.36-371.0), most likely due to the small 
number (Table 6.6). Comparison of haplotype associations in MTCT however confirmed the 
UTR1 haplotype (the only haplotype to have a G at position +3187), as well as the 
UTR1/UTR1 genotype (Table 6.5), were both significantly over-represented in IU-TR 
mothers compared to NT mothers (P=0.011, OR=2.96 and P=0.012, OR=13.3, respectively). 
The genotype UTR1/UTR2 also showed a strong trend towards increased representation in 
IU2-TR mothers compared to NT mothers (P=0.052, OR=3.66). Both UTR1/UTR1 and 
UTR1/UTR2 genotypes maintained significance after adjustment for mVL (P=0.009, 
OR=29.6 and P=0.019, OR=5.44, respectively) but not after adjustment for maternal sdNVP 
or KIR2DS4-v (Table 6.6). 
 
Taken together, a Guanine at +3187 and/or the UTR1 haplotype in MTCT1, showed a 
significant association with increased risk for IU transmission. In contrast, IP-TR mothers 
had a significantly higher representation of the UTR3/UTR4 genotype compared to NT 
mothers (P=0.034, OR=8.19), but this association was not significant post adjustment for 
mVL or maternal sdNVP (Table 6.6). Comparison between genotypes UTR1/UTR1 
(associated with IU transmission) and UTR3/UTR4 (associated with IP transmission) showed 
differences at four positions. The UTR3/UTR4 combination is heterozygous at positions 
+3003T/C, +3010C/G, +3142G/C, and has an Adenine at position +3187; while UTR1/UTR1 
is homozygous at positions +3003T, +3010G, +3142C, and has a Guanine at position +3187. 
 
Comparing the 3‟UTR polymorphisms, as well as the haplotypes between the respective 
infant groups from MTCT1 revealed no significant associations or trends (data not shown), 
suggesting that HLA-G polymorphisms within the 3‟UTR did not play a role in infant 
acquisition of HIV-1. 
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Table 6.4 Representation 3‟UTR polymorphisms of HLA-G in HIV-1 positive mothers from MTCT1, N (%) 
Polymorphism 
NT 
(n=144) 
IP-TR 
(n=29) 
IU-TR 
(n=19) 
IU2-TR 
(n=43) 
IP-TR vs. NT IU-TR vs. NT IU2-TR vs. NT 
OR (95% CI) P OR (95% CI) P OR (95% CI) P 
+2961 (Indel) 
D 166 (57.64) 36 (62.07) 19 (50.00) 43 (50.00) 1.20 (0.67-2.14) 0.562 0.73 (0.37-1.45) 0.388 0.73 (0.45-1.19) 0.218 
I 122 (42.36) 22 (37.93) 19 (50.00) 43 (50.00) 1  1  1  
DD 53 (36.81) 11 (37.93) 6 (31.58) 12 (27.91) 1.61 (0.47-5.48) 0.564 0.58 (0.17-1.97) 0.527 0.58 (0.23-1.45) 0.344 
ID 60 (41.67) 14 (48.28) 7 (36.84) 19 (44.19) 1.81 (0.55-5.96) 0.414 0.52 (0.16-1.69) 0.348 0.81 (0.35-1.90) 0.668 
II 3 (21.53) 4 (13.79) 6 (31.58) 12 (27.91) 1  1  1  
+3003.T/C 
C 31 (10.76) 9 (15.52) 1 (2.63) 4 (4.65) 1.52 (0.68-3.40) 0.366 0.22 (0.03-1.69) 0.149 0.40 (0.14-1.18) 0.095 
T 257 (89.24) 49 (84.48) 37 (97.37) 82 (95.35) 1  1  1  
CC 4 (2.78) 1 (3.45) 0 (0.00) 0 (0.00) 1.39 (0.15-13.1) 1.000 - 1.000 - 0.573 
TC 23 (15.97) 7 (24.14) 1 (5.26) 4 (9.30) 1.69 (0.36-4.45) 0.418 0.28 (0.03-2.22) 0.311 0.52 (0.17-1.60) 0.329 
TT 117 (81.25) 21 (72.41) 18 (94.74) 39 (90.70) 1  1  1  
+3010.C/G 
G 100 (34.72) 22 (37.93) 15 (39.47) 26 (30.23) 1.14 (0.64-2.06) 0.653 1.23 (0.61-2.45) 0.590 0.81 (0.48-1.37) 0.516 
C 188 (65.28) 36 (62.07) 23 (60.53) 60 (69.77) 1  1  1  
GG 23 (15.97) 4 (13.79) 5 (26.32) 5 (11.63) 1.06 (0.31-3.66) 1.000 1.61 (0.49-5.32) 0.518 0.66 (0.22-1.95) 0.609 
CG 54 (37.50) 14 (48.28 5 (26.32) 16 (37.21) 1.58 (0.66-3.76) 0.379 0.69 (0.22-2.18) 0.582 0.90 (0.43-1.89) 0.853 
CC 67 (46.53) 11 (37.93) 9 (47.37) 22 (51.16) 1  1  1  
+3027.C/A 
A 1 (0.35) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
C 287 (99.65) 58 (100.00) 38 (100.00) 86 (100.00) 1  1  1  
AA 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
CA 1 (0.69) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
CC 143 (99.31) 29 (100.00) 19 (100.00) 43 (100.00) 1  1  1  
+3032.G/C 
C 4 (1.39) 1 (1.72) 1 (2.63) 2 (2.33) 1.00 (0.11-8.66) 1.000 1.52 (0.17-13. 5) 1.000 1.34 (0.26-7.07) 1.000 
G 284 (98.61) 57 (98.28) 37 (97.37) 84 (97.67) 1  1  1  
CC 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
GC 4 (2.78) 1 (3.45) 1 (5.26) 2 (4.65) 1.67 (0.16-16.6) 1.000 2.59 (0.26-26.4) 0.396 2.28 (0.37-14.1) 0.591 
GG 140 (97.22) 28 (96.55) 18 (94.74) 41 (95.35) 1  1  1  
+3035.C/T 
C 263 (91.32 53 (91.38) 34 (89.47) 78 (90.70 1.01 (0.37-2.75) 1.000 0.81 (0.26-2.46) 0.760 0.93 (0.40-2.14) 1.000 
T 25 (8.68) 5 (8.62) 4 (10.53) 8 (9.30) 1  1  1  
CC 121 (84.03) 24 (82.76) 15 (78.95 35 (81.40) - 1.000 - 1.000 - 1.000 
CT 21 (14.58) 5 (17.24) 4 (21.05) 8 (18.60) - 1.000 - 1.000 - 1.000 
TT 2 (1.39) 0 (0.00) 0 (0.00) 0 (0.00) 1  1  1  
+3142.G/C 
C 100 (34.72) 22 (37.93) 15 (39.47) 26 (30.23) 1.14 (0.64-2.06) 0.653 1.23 (0.61-2.45) 0.590 0.81 (0.48-1.37) 0.516 
G 188 (65.28) 36 (62.07) 23 (60.53) 60 (69.77) 1  1  1  
CC 23 (15.97) 4 (13.79) 5 (26.32) 5 (11.63) 1.06 (0.31-3.65) 1.000 1.61 (0.49-5.33) 0.518 0.66 (0.22-1.95) 0.609 
GC 54 (37.50) 14 (48.28) 5 (26.32) 16 (37.21) 1.58 (0.66-3.76) 0.379 0.68 (0.21-2.18) 0.582 0.90 (0.43-1.89) 0.853 
GG 67 (46.53) 11 (37.93) 9 (47.37) 22 (51.16) 1  1  1  
+3187.A/G 
G 31 (10.76) 6 (10.34) 10 (26.32) 14 (16.28) 0.96 (0.37-2.41) 1.000 2.96 (1.31-6.67) 0.011 1.61 (0.81-3.19) 0.187 
A 257 (89.24) 52 (89.66) 28 (73.68) 72 (83.72) 1  1  1  
GG 2 (1.39) 0 (0.00) 3 (15.79) 3 (6.98) - 1.000 14.4 (2.18-94.7) 0.011 5.39 (0.86-33.7) 0.080 
AG 27 (18.75) 6 (20.69) 4 (21.05) 8 (18.60) 1.11 (0.41-2.99) 1.000 1.42 (0.42-4.74) 0.740 1.06 (0.44-2.57) 1.000 
AA 115 (79.86) 23 (79.31) 12 (63.16) 32 (74.42) 1  1  1  
+3196.C/G 
G 97 (33.68) 17 (29.31) 15 (39.47) 35 (40.70) 0.82 (0.44-1.51) 0.545 1.28 (0.64-2.57) 0.586 1.35 (0.82-2.21) 0.249 
C 191 (66.32) 41 (70.69) 23 (60.53) 51 (59.30) 1  1  1  
GG 18 (12.50) 2 (6.90) 4 (21.05) 7 (16.28) 0.52 (0.11-2.48) 0.514 1.81 (0.48-6.68) 0.464 1.68 (0.60-4.76) 0.399 
CG 61 (42.36) 13 (44.83) 7 (36.84) 21 (48.84) 0.98 (0.43-2.27) 1.000 0.93 (0.32-2.73) 1.000 1.49 (0.71-3.16) 0.347 
CC 65 (45.14) 14 (48.28) 8 (42.11) 15 (34.88) 1  1  1  
NT: HIV-1 non-transmitting mother; IP-TR: intrapartum HIV-1 transmitting mother; IU-TR: in utero HIV-1 transmitting mother; IU2-TR: enriched group of in 
utero transmitting mothers. Highlighted and bold P values indicate significant differences (P<0.05) and bold P values indicate trends (P<0.090). 
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Table 6.5 Representation of HLA-G 3‟UTR haplotype and genotype frequencies in mothers from MTCT1, N (%) 
3’UTR 
NT 
(n=144) 
IP-TR 
(n=29) 
IU-TR 
(n=19) 
IU2-TR 
(n=43) 
IP-TR vs. NT IU-TR vs. NT IU2-TR vs. NT 
OR (95% CI) P OR (95% CI) P OR (95% CI) P 
UTR1 31 (10.76) 6 (10.34) 10 (26.32) 14 (16.28) 0.96 (0.38-2.41) 1.000 2.96 (1.31-6.67) 0.011 1.61 (0.81-3.19) 0.187 
UTR2 97 (33.68) 17 (29.31) 15 (39.47) 35 (40.70) 0.82 (0.44-1.51) 0.545 1.28 (0.64-2.57) 0.586 1.44 (0.87-2.37) 0.155 
UTR3 66 (22.92) 14 (24.14) 4 (10.53) 17 (19.77) 1.07 (0.55-2.07) 0.865 0.39 (0.13-1.16) 0.094 0.82 (0.46-1.51) 0.559 
UTR4 31 (10.76) 9 (15.52) 1 (2.63) 4 (4.65) 1.52 (0.68-3.39) 0.366 0.22 (0.03-1.69) 0.149 0.40 (0.14-1.18) 0.095 
UTR5 24 (8.33) 5 (8.62) 4 (10.53) 8 (9.30) 1.03 (0.39-2.84) 1.000 1.29 (0.42-3.96) 0.756 1.13 (0.49-2.61) 0.826 
UTR6 34 (11.81) 6 (10.34) 3 (7.89) 6 (6.98) 0.86 (0.34-2.16) 0.827 0.64 (0.18-2.19) 0.596 0.56 (0.23-1.38) 0.238 
UTR7 1 (0.35) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
UTR20 4 (1.39) 1 (1.72) 1 (2.63) 2 (2.33) 1.24 (0.14-11.3) 1.000 1.91 (0.21-17.6) 0.464 1.69 (0.30-9.39) 0.624 
UTR1/UTR1 2 (1.39) 0 (0.00) 3 (15.79) 3 (6.98) - 1.000 13.3 (2.07-85.7) 0.012 5.32 (0.86-32.9) 0.081 
UTR1/UTR2 5 (3.47) 3 (10.34) 2 (10.53) 5 (11.63) 3.21 (0.72-14.3) 0.132 3.27 (0.59-18.2) 0.190 3.66 (1.01-13.3) 0.052 
UTR1/UTR3 12 (8.33) 1 (3.45) 0 (0.00) 0 (0.00) 0.39 (0.05-3.14) 0.475 - 0.363 - 0.071 
UTR1/UTR4 5 (3.47) 1 (3.45) 0 (0.00) 0 (0.00) 0.99 (0.11-8.83) 1.000 - 1.000 - 0.347 
UTR1/UTR5 2 (1.39) 0 (0.00) 1 (5.26) 2 (4.65) - 1.000 3.94 (0.34-45.7) 0.312 3.46 (0.47-25.4) 0.227 
UTR1/UTR6 3 (2.08) 0 (0.00) 1 (5.26) 1 (2.33) - 1.000 2.61 (0.26-26.5) 0.394 1.12 (0.11-11.0) 1.000 
UTR1/UTR20 0 (0.00) 1 (3.45) 0 (0.00) 0 (0.00) - 0.168 - 1.000 - 1.000 
UTR2/UTR2 18 (12.50) 2 (6.90) 4 (21.05) 7 (16.28) 0.52 (0.11-2.37) 0.534 1.87 (0.56-6.25) 0.474 1.36 (0.53-3.51) 0.610 
UTR2/UTR3 23 (15.97) 4 (13.79) 3 (15.79) 10 (23.26) 0.84 (0.27-2.64) 1.000 0.99 (0.26-3.66) 1.000 1.59 (0.69-3.68) 0.361 
UTR2/UTR4 12 (8.33) 3 (10.34) 0 (0.00) 1 (2.33) 1.27 (0.33-4.81) 0.719 - 0.363 0.26 (0.03-2.07) 0.304 
UTR2/UTR5 10 (6.94) 2 (6.90) 2 (10.53) 5 (11.63) 0.99 (0.21-4.78) 1.000 1.58 (0.32-7.81) 0.634 1.76 (0.57-5.47) 0.342 
UTR2/UTR6 9 (6.25) 1 (3.45) 0 (0.00) 0 (0.00) 0.54 (0.06-4.40) 0.699 - 0.390 - 0.121 
UTR2/UTR7 1 (0.69) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
UTR2/UTR20 1 (0.69) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
UTR3/UTR3 8 (5.56) 0 (0.00) 0 (0.00) 0 (0.00) - 0.355 - 0.598 - 0.201 
UTR3/UTR4 2 (1.39) 3 (10.34) 0 (0.00) 2 (4.65) 8.19 (1.30-51.5) 0.034 - 1.000 3.46 (0.47-25.4) 0.227 
UTR3/UTR5 5 (3.47) 3 (10.34) 0 (0.00) 0 (0.00) 3.21 (0.72-14.3) 0.132 - 1.000 - 0.347 
UTR3/UTR6 7 (4.86) 3 (10.34) 1 (5.26) 4 (9.30) 2.25 (0.55-9.31) 0.374 1.09 (0.12-9.35) 1.000 2.01 (0.56-7.21) 0.461 
UTR3/UTR20 1 (0.69) 0 (0.00) 0 (0.00) 1 (2.33) - 1.000 - 1.000 - 1.000 
UTR4/UTR4 4 (2.78) 1 (3.45) 0 (0.00) 0 (0.00) 1.25 (0.13-11.6) 1.000 - 1.000 - 0.575 
UTR4/UTR5 1 (0.69) 0 (0.00) 1 (5.26) 1 (2.33) - 1.000 7.94 (0.48-132.6) 0.220 3.40 (0.21-55.6) 0.408 
UTR4/UTR6 2 (1.39) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
UTR4/UTR20 1 (0.69) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 3.40 (0.21-55.6) 0.408 
UTR5/UTR5 2 (1.39) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
UTR5/UTR6 2 (1.39) 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 - 1.000 
UTR6/UTR6 5 (3.47) 1 (3.45) 0 (0.00) 0 (0.00) 0.99 (0.11-8.83) 1.000 - 1.000 - 0.347 
UTR6/UTR20 1 (0.69) 0 (0.00) 1 (5.26) 1 (2.33) - 1.000 7.94 (0.48-132.6) 0.220 3.40 (0.21-55.6) 0.408 
NT: HIV-1 non-transmitting mother; IP-TR: intrapartum HIV-1 transmitting mother; IU-TR: in utero HIV-1 transmitting mother; IU2-TR: enriched group of in 
utero transmitting mothers. Highlighted and bold P values indicate significant differences (P<0.05) and bold P values indicate trends (P<0.090). 
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Table 6.6 Multivariate analyses, adjustments made for maternal factors that influence HIV-1 transmission in MTCT1 
Allele/genotype Association 
Unadjusted Adjusted mVL Adjusted mNVP 
Adjusted Infant 
KIR2DS4-v 
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P 
G*01:01:02 IU-TR vs. NT 2.26 (1.10-4.64) 0.036 3.22 (1.03-10.1) 0.043 2.02 (0.74-5.52) 0.168 2.13 (0.79-5.78) 0.134 
G*01:01:02 IU2-TR vs. NT 1.68 (0.97-2.89) 0.078 2.39 (1.10-5.20) 0.027 1.54 (0.73-3.22) 0.252 1.79 (0.88-3.65) 0.105 
G*01:01:02/G*01:01:02 IU-TR vs. NT 4.31 (0.98-18.9) 0.072 8.79 (1.46-52.8) 0.017 4.81 (1.04-22.3) 0.044 5.08 (1.12-22.9) 0.035 
G*01:01:02/G*01:03:01 IU2-TR vs. NT 4.61 (1.17-17.9) 0.031 10.0 (2.15-46.8) 0.003 3.14 (0.73-13.5) 0.122 3.81 (0.89-16.3) 0.071 
3187G IU-TR vs. NT 2.96 (1.31-6.67) 0.011 2.17 (0.67-6.99) 0.192 2.56 (0.90-7.29) 0.077 2.42 (0.86-6.83) 0.094 
3187GG IU-TR vs. NT 14.4 (2.18-94.7) 0.011 29.6 (2.36-371.0) 0.009 - - - - 
3187GG IU2-TR vs. NT 5.39 (0.86-33.7) 0.080 6.69 (0.91-49.4) 0.062 10.9 (1.06-113.6) 0.044 6.51 (1.04-40.7) 0.045 
UTR1 IU-TR vs. NT 2.96 (1.31-6.67) 0.011 2.17 (0.67-6.99) 0.192 2.56 (0.90-7.29 0.077 2.42 (0.86-6.83) 0.094 
UTR1/UTR1 IU-TR vs. NT 13.3 (2.07-85.7) 0.012 29.6 (2.36-371.0) 0.009 - - - - 
UTR1/UTR2 IU2-TR vs. NT 3.66 (1.01-13.3) 0.052 5.44 (1.32-22.4) 0.019 3.43 (0.91-12.8) 0.067 3.57 (0.95-13.3) 0.058 
UTR3/UTR4 IP-TR vs. NT 8.19 (1.30-51.5) 0.034 6.17 (0.91-41.4) 0.061 4.24 (0.63-28.5) 0.137 N/A N/A 
Combined effect 
 
  
 
 
 
 
 
 
G*01:01:02 & 3187G IU-TR vs. NT 4.12 (0.70-24.2) 0.145 6.62 (0.82-52.9) 0.074 3.81 (0.64-22.5) 0.140 4.19 (0.70-24.9) 0.116 
G*01:01:02 or 3187G IU-TR vs. NT 4.51 (1.25-16.1) 0.014 4.93 (1.24-19.5) 0.023 4.14 (1.14-15.1) 0.031 4.12 (1.13-14.9) 0.031 
mVL: maternal viral load; mNVP: maternal single-dose Nevirapine; KIR2DS4-v: non-functional KIR2DS4; N/A: not an applicable adjustment, since 
infant possession of KIR2DS4-v has been association with IU HIV-1 transmission and not IP HIV-1 transmission. Highlighted and bold P values 
indicate significant differences (P<0.05). 
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6.2.5 Linkage disequilibrium (LD) between HLA-G alleles and the 3’UTR in MTCT1 
To further investigate the relationship between HLA-G alleles and polymorphisms within the 
3‟UTR of MTCT1 mothers, pairwise LD between the HLA-G alleles, the 14-bp indel, as well 
as the other 3‟UTR SNPs and haplotypes were calculated using the Lewontin method 
(Chapter 2, section 2.8.4.2). Table 6.7 shows LD results for significant pairwise 
combinations only. Seven of the HLA-G alleles were in strong LD with the 14-bp indel: 
G*01:01:01, G*01:04:01 and G*01:04:04 were significantly linked with the Del; while, 
G*01:01:02, G*01:03:01, G*01:05N and G*01:01:19 were significantly linked with the Ins. 
As such G*01:01:01 was in strong LD with UTR1, UTR6 and UTR20, while G*01:04:04 
and G*01:04:04 were in strong LD with UTR3, and HLA-G alleles associated with the Ins 
(G*01:01:02, G*01:03:01, G*01:05N and G*01:01:19) were found to be in significant LD 
with UTR2, UTR5 and UTR7. Thus, since the G*01:01:02 allele and +3187G (UTR1) are 
not in LD (D‟=-0.12; X2=0.09, P>0.1), the effects of these two genotypic variations on IU 
transmission are independent of each other. Accordingly the comparison of IU-TR mothers 
vs. NT mothers having both G*01:01:02 and +3187G (UTR1) did not show a significant 
additive association, likely due to the small number of individuals carrying both these 
variants (Table 6.6). However, comparison of IU-TR mothers with EU mothers and 
representation of G*01:01:02 or +3187G (UTR1), was more significant (P=0.014; OR=4.51) 
than possession of G*01:01:02 alone, but not more significant than having +3187G (UTR1) 
alone (Table 6.6). The significantly greater representation of having either G*01:01:02 or 
+3187G (UTR1) was the only association maintained throughout all adjustments (Table 6.6). 
 
6.2.6 HLA-G mother-infant concordance in MTCT1 
Mother-infant concordance amongst the classical HLA molecules (-A, -B and -C) 
(MacDonald et al., 1998), as well as a synonymous SNP in exon 2 of HLA-G (Aikhionbare et 
al., 2001), have been described as risk factors for MTCT, thus we wanted to determine if 
mother-infant concordance for HLA-G alleles and 3‟UTR had a similar effect. Within 
MTCT1 we found no significant associations with vertical transmission when mother-infant 
pairs were concordant for HLA-G alleles, the 14-bp indel, or 3‟UTR haplotypes (Table 6.8). 
However, concordance at SNP +3187 was found to be significantly lower in IU-TR/IU 
mother-infant pairs compared to NT/EU pairs (P=0.014, OR=0.29) and remained significant 
post all adjustments (Table 6.8). 
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Table 6.7 Linkage disequilibrium (LD) between HLA-G alleles, 14-bp indel and 3‟UTR in HIV-1 
positive mothers from MTCT1 (n=216) 
LD comparisons N (%) D' X2 P-value 
G*01:01:01 
Del 126 29.17 0.95 45.19 <0.001 
UTR1 44 10.19 0.80 37.70 <0.001 
UTR4 33 7.64 0.64 19.97 <0.001 
UTR6 45 10.42 0.94 47.47 <0.001 
UTR20 6 1.39 1.00 5.93 <0.05 
G*01:01:02 
Ins 96 22.22 1.00 66.88 <0.001 
UTR2 96 22.22 1.00 98.49 <0.001 
G*01:01:19 
Ins 14 3.24 1.00 6.98 <0.01 
UTR2 14 3.24 1.00 10.27 <0.01 
G*01:03:01 
Ins 33 7.64 1.00 17.64 <0.001 
UTR5 33 7.64 1.00 189.72 <0.001 
G*01:04:01 
Del 17 3.94 1.00 4.16 <0.05 
UTR3 17 3.94 1.00 27.24 <0.001 
G*01:04:04 
Del 78 18.06 1.00 24.37 <0.001 
UTR3 78 18.06 1.00 159.40 <0.001 
G*01:05N 
Ins 33 7.64 1.00 17.64 <0.001 
UTR2 33 7.64 1.00 25.98 <0.001 
UTR7 1 0.23 1.00 5.83 <0.05 
Del 
+3003 C 44 10.19 1.00 11.94 <0.01 
+3010 G 148 34.26 1.00 65.44 <0.001 
+3035 C 245 56.71 1.00 7.30 <0.05 
+3142 C 148 34.26 1.00 65.44 <0.001 
+3187 G 51 11.81 1.00 14.23 <0.001 
+3196 C 245 56.71 1.00 126.48 <0.001 
Ins 
+3003 T 187 43.29 1.00 4.78 <0.05 
+3010 C 187 43.29 1.00 60.58 <0.001 
+3035 T 38 8.80 1.00 20.71 <0.001 
+3142 G 187 43.29 1.00 60.58 <0.001 
+3187 A 187 43.29 1.00 6.44 <0.01 
+3196 G 149 34.49 1.00 136.23 <0.001 
N: the number of individuals; D‟: measure of linkage disequilibrium; X2: Chi-Square value from 
which the P-value was determined significant at P<0.05.  
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Table 6.8 Representation of HLA-G concordance amongst HIV-1 transmitting and non-transmitting mother-infant pairs in MTCT1, N (%) 
Concordance 
NT/EU 
(n=144) 
IP-TR/IP 
(n=29) 
IU-TR/IU 
(n=19) 
IU2-TR/IU2 
(n=43) 
IP-TR/IP vs. NT/EU IU-TR/IU vs. NT/EU IU2-TR/IU2 vs. NT/EU 
OR (95% CI) P OR (95% CI) P OR (95% CI) P 
HLA-G alleles 51 (35.42) 12 (41.38) 9 (47.37) 18 (41.86) 1.28 (0.57-2.90) 0.673 1.64 (0.63-4.30) 0.322 1.31 (0.65-2.63) 0.474 
14-bp 72 (50.00) 18 (62.07) 11 (57.89) 28 (65.12) 1.63 (0.72-3.71) 0.309 1.37 (0.52-3.62) 0.628 1.87 (0.92-3.78) 0.085 
Del/Del 30 (20.83) 8 (27.59) 5 (26.32) 10 (23.26) 1.45 (0.58-3.59) 0.463 1.35 (0.45-4.07) 0.767 1.15 (0.51-2.59) 0.832 
Del/Ins 31 (21.53) 9 (31.03) 5 (26.32) 13 (30.23) 1.64 (0.68-3.96) 0.333 1.30 (0.43-3.89) 0.768 1.58 (0.74-3.39) 0.305 
Ins/Ins 11 (7.64) 1 (3.45) 1 (5.26) 5 (11.63) 0.43 (0.05-3.48) 0.489 0.67 (0.08-5.51) 1.000 1.59 (0.52-4.86) 0.533 
UTR Haplotypes 62 (43.06) 10 (34.48) 8 (42.11) 16 (37.21) 0.69 (0.30-1.60) 0.418 0.96 (0.36-2.53) 1.000 0.78 (0.39-1.57) 0.598 
+3003 123 (85.42) 21 (72.41) 15 (78.95) 36 (83.72) 0.45 (0.17-1.14) 0.103 0.64 (0.19-2.11) 0.498 0.87 (0.34-2.23) 0.809 
+3010 84 (58.33) 18 (62.07) 10 (52.63) 26 (60.47) 1.16 (0.51-2.65) 0.837 0.79 (0.30-2.07) 0.806 1.09 (0.54-2.19) 0.861 
+3027 143 (99.31) 29 (100.00) 19 (100.00) 43 (100.00) - 1.000 - 1.000 - 1.000 
+3032 141 (97.92) 28 (96.55) 17 (89.47) 39 (90.70) 0.59 (0.06-5.94) 1.000 0.18 (0.03-1.16) 0.104 0.21 (0.04-0.96) 0.050 
+3035 115 (79.86) 26 (89.66) 14 (73.68) 36 (83.72) 2.19 (0.62-7.72) 0.297 0.71 (0.23-2.12) 0.552 1.29 (0.52-3.21) 0.664 
+3142 84 (58.33) 18 (62.07) 10 (52.63) 26 (60.47) 1.16 (0.51-2.65) 0.837 0.79 (0.30-2.07) 0.806 1.09 (0.54-2.19) 0.861 
+3187 109 (75.69) 21 (72.41) 9 (47.37) 26 (60.47) 0.84 (0.34-2.07) 0.814 0.29 (0.11-0.76) 0.014 0.49 (0.24-1.01) 0.055 
+3196 80 (55.56) 17 (58.62) 13 (68.42) 28 (65.12) 1.13 (0.50-2.54) 0.839 1.73 (0.62-4.81) 0.332 1.49 (0.74-3.03) 0.295 
NT/EU: paired HIV-1 non-transmitting mother and exposed infected infant; IP-TR/IP: paired intrapartum HIV-1 transmitting mother and intrapartum 
infected infant; IU-TR/IU: paired in utero HIV-1 transmitting mother and in utero infected infant; IU2-TR: enriched group of in utero transmitting 
mother and infant. Bold P values indicate trends (P<0.090). Multivariable logistic regression analysis on mother-infant concordance at SNP +3187, 
adjustments made for maternal viral load (P=0.023, OR=0.27, 95% CI=0.09-0.83), maternal sdNVP (P=0.012, OR=0.28, 95% CI=0.10-0.76) and 
infant possession of KIR2DS4-v (P=0.029, OR=0.33, 95% CI=0.12-0.89).  
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6.2.7  Comparison of maternal HLA-G alleles in MTCT2 
Given that HLA-G analysis in mother and infant groups from MTCT1 highlighted the role of 
maternal HLA-G alleles and the 3‟UTR in IU transmission of HIV-1 and showed no 
significant associations in the infant group, in MTCT2 due to infant sample availability, costs 
of HLA-G sequencing and time constraints we selected to first evaluate the role of HLA-G in 
mothers from MTCT2 and not their infants. Twelve HLA-G alleles were identified, which 
included four functional proteins (G*01:01, G*01:03, G*01:04 and G*01:10) as well as the 
null allele, G*01:05N (Table 6.8). As in MTCT1, G*01:01:01 (30%) was the most common 
allele, followed by G*01:01:02 (19%) and G*01:04:04 (18%) in mothers from MTCT2. 
Correspondingly, G*01:01:01 homozygosity was the most frequent genotype (Table 6.9). 
 
6.2.8  HLA-G alleles and 3’UTR in transmission of HIV-1 in mothers from MTCT2 
Unlike, in MTCT1 where representation of G*01:01:02 was significantly higher in IU-TR 
mothers compared to NT mothers (Table 6.1: P=0.036, OR=2.26), in MTCT2 G*01:01:01 
and the genotype G*01:01:01/G*01:01:04 were significantly over-represented in IP-TR 
mothers compared to NT mothers (P=0.028, OR=2.95 and P=0.001, OR=29.2, respectively). 
While representation of G*01:01:02 showed a strong trend towards over-representation in 
NT mothers compared to IP-TR mothers (P=0.069, OR=0.15) but was not reflected in any 
G*01:01:02 bearing genotypes (Table 6.9). In the 3‟UTR of HLA-G (Table 6.10), both 
UTR1 haplotype and UTR1/UTR3 genotype were over-represented in IP-TR mothers 
compared to NT mothers (P=0.024, OR=3.27, P=0.018, OR=10.00, respectively); whereas 
the haplotype UTR3 and UTR3/UTR3 genotype were over-represented in IU-TR mothers 
compared to NT mothers (P=0.010, OR=3.07 and P=0.024, OR=10.25, respectively). SNP 
analysis showed three positions (+3010, +3142 and +3187) were associated with increased 
risk for IP transmission (Table 6.11). Heterozygosity at positions +3010 and +3142 (SNPs 
that are in complete LD, r
2
=1) were significantly higher in IP-TR mothers compared to NT 
mothers (P=0.008) and at position +3187, a G allele as well as A/G heterozygosity were 
significantly over-represented in IP-TR mothers compared to NT mothers (P=0.024, 
OR=3.27 and P=0.002, OR=10.3, respectively). 
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Table 6.9 Representation of maternal HLA-G alleles and genotypes in MTCT2, N (%) 
HLA-G 
Alleles and Genotypes* 
NT 
(n=42) 
IP-TR 
(n=12) 
IU-TR 
(n=25) 
IP-TR vs. NT IU-TR vs. NT 
OR (95% CI) P OR (95% CI) P 
G*01:01:01 24 (28.57) 13 (54.17) 10 (20.00) 2.95 (1.16-7.50) 0.028 0.62 (0.27-1.45) 0.310 
G*01:01:02 19 (22.62) 1 (4.17) 10 (20.00) 0.15 (0.02-1.17) 0.069 0.85 (0.36-2.02) 0.830 
G*01:01:08 6 (7.14) 1 (4.17) 5 (10.00) 0.57 (0.06-4.93) 1.000 1.44 (0.42-5.00) 0.746 
G*01:01:09 4 (4.76) 0 (0.00) 0 (0.00) - 0.573 - 0.296 
G*01:01:19 2 (2.38) 1 (4.17) 0 (0.00) 1.78 (0.15-20.5) 1.000 - 0.529 
G*01:01:20 1 (1.19) 0 (0.00) 0 (0.00) - 1.000 - 1.000 
G*01:03:01 7 (8.33) 1 (4.17) 5 (10.00) 0.47 (0.06-4.09) 0.681 1.22 (0.37-4.08) 0.762 
G*01:04:01 1 (1.19) 0 (0.00) 2 (4.00) - 1.000 3.45 (0.31-39.1) 0.555 
G*01:04:04 11 (13.10) 5 (20.83) 12 (24.00) 1.74 (0.54-5.63) 0.515 2.09 (0.84-5.19) 0.154 
G*01:04:05 0 (0.00) 0 (0.00) 1 (2.00) - 1.000 - 0.373 
G*01:05N 9 (10.71) 2 (8.33) 3 (6.00) 0.75 (0.15-3.77) 1.000 0.53 (0.14-2.06) 0.534 
G*01:10 0 (0.00) 0 (0.00) 2 (4.00) - 1.000 - 0.137 
G*01:01:01/G*01:01:01 6 (14.29) 1 (8.33) 2 (8.00) 0.54 (0.06-5.03) 1.000 0.52 (0.09-2.81) 0.700 
G*01:01:01/G*01:01:02 3 (7.14) 1 (8.33) 3 (12.00) 1.18 (0.11-12.5) 1.000 1.77 (0.33-9.54) 0.664 
G*01:01:01/G*01:01:08 1 (2.38) 1 (8.33) 0 (0.00) 3.72 (0.21-64.5) 0.398 - 1.000 
G*01:01:01/G*01:01:19 1 (2.38) 1 (8.33) 0 (0.00) 3.72 (0.21-64.5) 0.398 - 1.000 
G*01:01:01/G*01:03:01 2 (4.76) 1 (8.33) 1 (4.00) 1.81 (0.15-21.9) 1.000 0.83 (0.07-9.69) 1.000 
G*01:01:01/G*01:04:04 1 (2.38) 5 (41.67) 1 (4.00) 29.2 (2.96-289.7) 0.001 1.71 (0.10-28.6) 1.000 
G*01:01:01/G*01:05N 2 (4.76) 2 (16.67) 0 (0.00) 4.00 (0.50-31.9) 0.210 - 0.525 
G*01:01:02/G*01:01:08 2 (4.76) 0 (0.00) 2 (8.00) - 1.000 1.73 (0.23-13.1) 0.626 
G*01:01:02/G*01:04:04 5 (11.90) 0 (0.00) 2 (8.00) - 0.336 0.64 (0.11-3.59) 0.704 
G*01:01:02/G*01:05N 5 (11.90) 0 (0.00) 2 (8.00) - 0.336 0.64 (0.11-3.59) 0.704 
G*01:03:01/G*01:03:01 1 (2.38) 0 (0.00) 1 (4.00) - 1.000 1.71 (0.10-28.6) 1.000 
G*01:03:01/G*01:04:04 1 (2.38) 0 (0.00) 1 (4.00) - 1.000 1.71 (0.10-28.6) 1.000 
G*01:04:04/G*01:04:04 1 (2.38) 0 (0.00) 3 (12.00) - 1.000 5.59 (0.54-56.9) 0.143 
* indicates HLA-G genotype frequencies > 2% in the NT, IP-TR or IU-TR group. NT: HIV-1 
non-transmitting mother; IP-TR: intrapartum HIV-1 transmitting mother; IU-TR: in utero HIV-1 
transmitting mother. Highlighted and bold P values indicate significant differences (P<0.05) and 
bold P values indicate trends (P<0.090). 
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Table 6.10 Representation of HLA-G 3‟UTR haplotype and genotype frequencies in mothers 
from MTCT2, N (%) 
3’UTR 
NT 
(n=42) 
IP-TR 
(n=12) 
IU-TR 
(n=25) 
IP-TR vs. NT IU-TR vs. NT 
OR (95% CI) P OR (95% CI) P 
UTR1 13 (15.48) 9 (37.50) 5 (10.00) 3.27 (1.18-9.05) 0.024 0.61 (0.20-1.82) 0.440 
UTR2 29 (34.52) 4(16.67) 13 (26.00) 0.38 (0.12-1.21) 0.132 0.67 (0.31-1.45) 0.340 
UTR3 13 (15.48) 5 (20.83) 18 (36.00) 1.43 (0.45-4.53) 0.758 3.07 (1.34-7.02) 0.010 
UTR4 12 (14.29) 0 (0.00) 3 (6.00) - 0.065 0.38 (0.10-1.43) 0.167 
UTR5 9 (10.71) 2 (8.33) 5 (10.00) 0.75 (0.15-3.77) 1.000 0.92 (0.29-2.93) 1.000 
UTR6 6 (7.14) 2 (8.33) 6 (12.00) 1.18 (0.22-6.27) 1.000 1.77 (0.54-5.83) 0.363 
UTR20 2 (2.38) 2 (8.33) 0 (0.00) 3.72 (0.49-27.9) 0.213 - 0.529 
UTR1/UTR2 3 (7.14) 2 (16.67) 2 (8.00) 2.6 (0.38-17.7) 0.575 1.13 (0.17-7.27) 1.000 
UTR1/UTR20 1 (2.38) 1 (8.33) 0 (0.00) 3.73 (0.21-64.4) 0.398 - 1.000 
UTR1/UTR3 2 (4.76) 4 (33.33) 0 (0.00) 10.00 (1.56-64.2) 0.018 - 0.525 
UTR1/UTR5 1 (2.38) 2 (16.67) 0 (0.00) 8.2 (0.67-99.7) 0.121 - 1.000 
UTR2/UTR2 5 (11.90) 0 (0.00) 2 (8.00) - 0.336 0.64 (0.12-3.59) 0.704 
UTR2/UTR20 1 (2.38) 1 (8.33) 0 (0.00) 3.73 (0.21-64.4) 0.398 - 1.000 
UTR2/UTR3 5 (11.90) 0 (0.00) 4 (16.00) - 0.336 1.41 (0.34-5.82) 0.718 
UTR2/UTR4 4 (9.52) 0 (0.00) 2 (8.00) - 0.564 0.83 (0.14-4.87) 1.000 
UTR2/UTR6 3 (7.14) 1 (8.33) 1 (4.00) 1.18 (0.11-12.5) 1.000 0.54 (0.05-5.51) 1.000 
UTR3/UTR3 1 (2.38) 0 (0.00) 5 (20.00) - 1.000 10.25 (1.12-93.7) 0.024 
UTR3/UTR5 1 (2.38) 0 (0.00) 2 (8.00) - 1.000 3.56 (0.31-41.5) 0.551 
UTR3/UTR6 1 (2.38) 1 (8.33) 2 (8.00) 3.73 (0.21-64.4) 0.398 3.56 (0.31-41.5) 0.551 
NT: HIV-1 non-transmitting mother; IP-TR: intrapartum HIV-1 transmitting mother; IU-TR: 
in utero HIV-1 transmitting mother. 3‟UTR genotypes represented are those with frequencies 
greater than > 2% in the NT, IP-TR or IU-TR group. Highlighted and bold P values indicate 
significant differences (P<0.05). 
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Table 6.11 Frequencies of HLA-G 3‟UTR polymorphisms in mothers from MTCT2, N (%) 
Polymorphism 
NT 
(n=42) 
IP-TR 
(n=12) 
IU-TR 
(n=25) 
IP-TR vs. NT IU-TR vs. NT 
OR (95% CI) P OR (95% CI) P 
+2961 (Indel) 
D 46 (54.76) 18 (75.00) 32 (64.00) 2.47 (0.89-6.86) 0.100 1.46 (0.71-3.02) 0.366 
I 38 (45.24) 6 (25.00) 18 (36.00) 1  1  
DD 13 (30.95) 6 (50.00) 10 (40.00) - 0.136 2.31 (0.49-10.8) 0.463 
ID 20 (47.62) 6 (50.00) 12 (48.00) - 0.169 1.80 (0.41-7.98) 0.500 
II 9 (21.43) 0 (0.00) 3 (12.00) 1  1  
+3003.T/C 
C 12 (14.29) 0 (0.00) 3 (6.00) - 0.065 0.38 (0.10-1.43) 0.167 
T 72 (85.71) 24 (100.00) 47 (94.00) 1  1  
CC 1 (2.38) 0 (0.00) 0 (0.00) - 1.000 - 1.000 
TC 10 (23.81) 0 (0.00) 3 (12.00) - 0.093 0.42 (0.10-1.72) 0.340 
TT 31 (73.81) 12 (100.00) 22 (88.00) 1  1  
+3010.C/G 
G 33 (39.29) 13 (54.17) 14 (28.00) 1.82 (0.73-4.56) 0.244 0.60 (0.28-1.28) 0.197 
C 51 (60.71) 11 (45.83) 36 (72.00) 1  1  
GG 7 (16.67) 1 (8.33) 3 (12.00) - 0.333 0.49 (0.11-2.26) 0.471 
CG 19 (45.24) 11 (91.67) 8 (32.00) - 0.008 0.48 (0.16-1.43) 0.276 
CC 16 (38.10) 0 (0.00) 14 (56.00) 1  1  
+3027.C/A 
A 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 
C 84 (100.00) 24 (100.00) 50 (100.00) 1  1  
AA 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 
CA 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 
CC 42 (100.00) 12 (100.00) 25 (100.00) 1  1  
+3032.G/C 
C 2 (2.38) 2 (8.33) 0 (0.00) 3.72 (0.49-27.9) 0.213 - 0.529 
G 82 (97.62) 22 (91.67) 50 (100.00) 1  1  
CC 0 (0.00) 0 (0.00) 0 (0.00) - 1.000 - 1.000 
GC 2 (4.76) 2 (16.67) 0 (0.00) 4.00 (0.50-31.9) 0.210 - 0.525 
GG 40 (95.24) 10 (83.33) 25 (100.00) 1  1  
+3035.C/T 
C 75 (89.29) 22 (91.67) 45 (90.00) 1.32 (0.26-6.56) 1.000 1.08 (0.34-3.42) 1.000 
T 9 (10.71) 2 (8.33) 5 (10.00) 1  1  
CC 34 (80.95) 10 (83.33) 21 (84.00) - 1.000 0.61 (0.04-10.4) 1.000 
CT 7 (16.67) 2 (16.67) 3 (12.00) - 0.421 0.43 (0.02-9.36) 1.000 
TT 1 (2.38) 0 (0.00) 1 (4.00) 1  1  
+3142.G/C 
C 33 (39.29) 13 (54.17) 14 (28.00) 1.82 (0.73-4.55) 0.244 0.60 (0.28-1.28) 0.197 
G 51 (60.71) 11 (45.83) 36 (72.00) 1  1  
CC 7 (16.67) 1 (8.33) 3 (12.00) - 0.333 0.49 (0.10-2.26) 0.471 
GC 19 (45.24) 11 (91.67) 8 (32.00) - 0.008 0.48 (0.16-1.43) 0.276 
GG 16 (38.10) 0 (0.00) 14 (56.00) 1  1  
+3187.A/G 
G 13 (15.48) 9 (37.50) 5 (10.00) 3.27 (0.18-9.05) 0.024 0.61 (0.20-1.82) 0.440 
A 71 (84.52) 15 (62.50) 45 (90.00) 1  1  
GG 2 (4.76) 0 (0.00) 1 (4.00) - 1.000 0.74 (0.06-8.67) 1.000 
AG 9 (21.43) 9 (75.00) 3 (12.00) 10.3 (2.29-46.4) 0.002 0.49 (0.12-2.03) 0.510 
AA 31 (73.81) 3 (25.00) 21 (84.00) 1  1  
+3196.C/G 
G 29 (34.52) 4 (16.67) 13 (26.00) 0.37 (0.12-1.21) 0.132 0.67 (0.31-1.45) 0.340 
C 55 (65.48) 20 (83.33) 37 (74.00) 1  1  
GG 5 (11.90) 0 (0.00) 2 (8.00) - 0.291 0.51 (0.09-3.05) 0.678 
CG 19 (45.24) 4 (33.33) 9 (36.00) 0.47 (0.12-1.85) 0.333 0.61 (0.21-1.75) 0.430 
CC 18 (42.86) 8 (66.67) 14 (56.00) 1  1  
NT: HIV-1 non-transmitting mother; IP-TR: intrapartum HIV-1 transmitting mother; IU-TR: 
in utero HIV-1 transmitting mother. Highlighted and bold P values indicate significant 
differences (P<0.05). 
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6.3. Discussion 
The role of HLA-G has become increasingly evident in many infectious diseases, primarily 
due to its inhibitory effect on the innate and adaptive immune system. By directly binding to 
the inhibitory receptors KIR2DL4, ILT-2 and ILT-4 that are present on NK and 
CD8+ T cells, HLA-G can also inhibit differentiation, proliferation, cytolysis, cytokine 
secretion, and immunoglobulin production (Amiot et al., 2014). Therefore, certain HLA-G 
alleles and/or 3‟UTR polymorphisms that alter HLA-G expression may influence the function 
of NK and CD8+ T cells and ultimately influence the susceptibility to HIV-1 transmission. 
Several studies have found associations between certain HLA-G alleles, as well as a 14-bp 
indel, with an altered risk for MTCT of HIV-1 (Aikhionbare et al., 2001, Aikhionbare et al., 
2006, Segat et al., 2009, Moodley and Bobat, 2011, Segat and Crovella, 2012, Luo et al., 
2013, Segat et al., 2014). However, these studies have largely focused on each of these 
parameters individually and, where studies have been comparable, the results have often not 
shown consensus. In addition, other SNPs within the 3‟UTR have not been extensively 
analyzed for their clinical relevance in MTCT. In this study, we report on the combined 
analysis of HLA-G alleles as well as the 3‟UTR of HLA-G in two Black South African MTCT 
cohorts recruited over the last 15 years. Although all infants born to HIV-1 positive mothers 
received sdNVP as a PEP soon after birth, maternal PMTCT therapies differed between 
MTCT1 and MTCT2 (Chapter 2, Section 2.1.1 and 2.1.2). In MTCT1, approximately half the 
mothers received sdNVP at the onset of labour while all mothers from MTCT2 received daily 
AZT from 28 - 37 weeks gestation as well as sdNVP at the onset of labour. 
 
In both MTCT cohorts G*01:01:01, G*01:01:02 and G*01:04:04 were the most common 
alleles which corresponded with the most frequent genotypes: G*01:01:01/G*01:01:01, 
G*01:01:01/G*01:01:02, and G*01:01:01/G*01:01:04. Likewise both cohorts had similar 
3‟UTR haplotype frequencies with UTR2 being the most frequent haplotype followed by 
UTR3 and UTR1, respectively. However with regards to vertical transmission, in MTCT1 
maternal possession of G*01:01:02, the UTR1 haplotype and a guanine at position +3187 of 
the 3‟UTR significantly associated with increased risk for IU transmission (Tables 6.1, 6.3 
and 6.4), whilst in MTCT2, maternal possession G*01:01:01, G*01:01:01/G*01:04:04 
genotype, UTR1 haplotype, UTR1/UTR3 genotype as well as heterozygosity at positions 
+3010, +3142 and +3187 within the 3‟UTR significantly associated with increased risk for 
IP transmission (Table 6.9, 6.10 and 6.11). LD analysis between HLA-G alleles and the 
3‟UTR polymorphisms indicated that two independent HLA-G factors were associated with 
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increased risk for IU transmission in MTCT1, namely: (1) G*01:01:02 in strong LD with the 
14-bp Ins, and (2) UTR1 haplotype in complete LD with the 14-bp Del as well as +3187G 
SNP. Interestingly, the 14-bp Ins was previously shown to generate a 92-bp deletion in the 
3‟UTR of the HLA-G mRNA that changed mRNA stability and splicing (Rousseau et al., 
2003b), and associated with lower mRNA levels (Hviid et al., 2003). On the contrary, the 
14-bp Del and +3187G SNP associated with more stable the mRNA and result in higher 
HLA-G expression (Martelli-Palomino et al., 2013, Alegre et al., 2014). Moreover our data 
highlighted that the effect of having either G*01:01:02 or +3187G (UTR1) was significantly 
over-represented in IU-TR mothers compared to NT mothers and was maintained throughout 
all adjustments, however, this association was stronger than the effect of G*01:01:02 alone, 
but weaker than that of UTR1 alone (Hong et al., 2014). Whereas in MTCT2, HLA-G alleles 
G*01:01:01 and G*01:04:04 (in strong LD with the 3‟UTR haplotypes UTR1 and UTR3, 
respectively) associated with IP transmission. Comparison of the UTR1 and UTR3 haplotype 
showed that while identical in six positions (including the 14-bp Del), UTR1 and UTR3 
differed at three positions, namely +3010, +3142 and +3187, of which the SNPs at +3010 and 
+3142 have both been implicated in affinity interactions with microRNAs (Alegre et al., 
2014).  
 
Recent studies have associated certain 3‟UTR haplotypes with differential levels of soluble 
HLA-G. UTR1 was found to associated with higher levels of plasma sHLA-G, whereas 
UTR5 and UTR7 (haplotypes containing the 14-bp Ins) were associated lower levels 
compared to subjects with haplotypes UTR3, UTR4 and UTR6 (haplotypes containing the 
14-bp Del) that exhibited intermediate levels (Martelli-Palomino et al., 2013). In fact, in their 
study Martelli-Palomino et al. (2013) stated that UTR-1 (14-bp Del, +3003T, +3010G, 
+3027C, +3032G, +3035C, +3142C, +3187G, +3196C) was the only haplotype to 
undoubtedly associate with higher levels of sHLA-G, given that the majority of the 
polymorphisms within UTR1 correlate with increased expression of HLA-G, namely: the 
14-bp Del that is associated with high levels of soluble HLA-G expression, cytosine at +3142 
that is less sensitive to specific miRNAs (miR-148a, miR-148b and miR-152) and guanine at 
+3187 that increases mRNA stability.  
 
Moreover, recent studies have associated HLA-G with heterosexual transmission of HIV-1. 
In the Pumwani sex worker cohort from Nairobi, Kenya, G*01:01:01 was significantly 
enriched in HIV-1 resistant sex workers, whereas G*01:04:04 was significantly associated 
Chapter 6: HLA-G polymorphisms in MTCT  153 
with susceptibility to HIV-1 infection (Turk et al., 2013). Yet in Zimbabwean women, 
G*01:01:08 was associated with an increased risk of HIV-1 infection, while G*01:05N 
offered protection from heterosexual HIV-1 infection (Matte et al., 2004). Rebmann et al. 
(2001) reported that individuals with G*01:04- had higher levels of sHLA-G than individuals 
with the more frequent G*01:01:01, whereas G*01:01:01 individuals had higher sHLA-G 
levels compared to individuals with G*01:01:03 and G*01:05N. Therefore, in both HIV-1 
transmission studies HLA-G alleles that potentially had higher levels of HLA-G expression 
were associated with increased risk of HIV-1 transmission.  
 
Therefore in our study, G*01:01:01 in strong LD with UTR1 haplotype, may share a similar 
mechanism to that of heterosexual HIV-1 transmission, through increased expression of 
HLA-G being a risk factor for both IU and IP transmission in MTCT1 and MTCT2, 
respectively. It can be postulated that higher HLA-G expression would exert greater NK and 
CD8+ T cell inhibition, which could result in the decreased ability of these cells to target 
viral-infected cells and thus increasing the risk for HIV-1 transmission (Matte et al., 2004, 
Moodley and Bobat, 2011, Luo et al., 2013, da Silva et al., 2014). As such, other studies have 
identified HLA-G1 is the major ligand by which HLA-G inhibits NK cell-mediated lysis 
(Navarro et al., 1999, Ponte et al., 1999, Marchal-Bras-Goncalves et al., 2001). In agreement 
with this hypothesis, it was reported that in ART naive mother-infant pairs from 
KwaZulu-Natal, South Africa, placental expression of HLA-G1 was 3.95 times more 
up-regulated in HIV-1 transmitting mothers compared to HIV-1 non-transmitting mothers 
(Moodley and Bobat, 2011). Furthermore, there was a significant correlation between 
placental HLA-G1 expression and the viral loads of the infants, which indicated that infants 
were more likely to become infected if placental HLA-G1 was increased.  
 
However, while certain HLA-G alleles and 3‟UTR polymorphisms predict either 
increased/decreased expression of HLA-G, this is not absolute. It was reported that even the 
null allele, G*0105N, had HLA-G protein expression (Le Discorde et al., 2005). G*01:05N is 
characterized by a single cytosine deletion in exon 3 that presents a stop codon in exon 4 
blocking the translation of HLA-G1 and HLA-G5 isoforms; it does however, encode both 
membrane-bound and soluble functional HLA-G proteins that are able to inhibit NK-cell 
cytolysis (Le Discorde et al., 2005). It is possible that even low expressing HLA-G alleles, 
such as G*01:01:02 and its strong LD with the 14-bp Ins, might have other mechanisms 
influencing HLA-G expression. Indeed, a fraction of HLA-G mRNA transcripts presenting 
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the 14-bp Ins can be alternatively spliced by the removal of 92 bases from the mature HLA-G 
mRNA, which yields smaller HLA-G transcripts, reported to be more stable than the 
complete mRNA forms (Rousseau et al., 2003b, Donadi et al., 2011). Using an in silico based 
study Donadi et al. (2011) reported that the deletion of 92 bases lead to a loss of key regions 
including the +3003 C/T and +3010 C/G polymorphic sites, which may be targeted by 
different microRNAs.  
 
Interestingly in another study, G*01:01:02, in the heterozygous and homozygous state, was 
associated with high levels of sHLA-G in the genital mucosa in ART naive HIV-1 infected 
sex workers compared with those in both the HIV-1 uninfected sex workers (P=0.051) and 
non-sex workers (P=0.002) groups (Thibodeau et al., 2011). Additionally in a Canadian 
Human Papillomavirus (HPV) study, one of the most common sexually transmitted 
infections, both G*01:01:02 and G*01:03- alleles (also in high LD with the 14-bp Ins) were 
associated with increased risk for HPV-16 infection and persistent infections with HPV types 
from the alpha species (Ferguson et al., 2011). It is likely that polymorphisms within the 
HLA-G promoter region (5‟URR, the upstream regulatory region) may also influence HLA-G 
expression. For example, in a study of recurrent pregnancy loss, the tri-allelic 
polymorphism -725C/G/T (rs1233334) within the 5‟URR was evaluated in relation to plasma 
levels of sHLA-G, and the CC genotype was found to have significantly lower levels of 
sHLA-G than the CG and CT genotypes (Jassem et al., 2012). Additionally, it was suggested 
that the presence of Guanine in position −725 may alter the methylation profile of CpG 
dinucleotides modifying gene expression (Costa et al., 2012). Indeed, G*01:01:02 alleles 
were reported in 5‟URR haplotypes having the -725C allele (Costa et al., 2012). However in 
our MTCT1 data, G*01:01:02 was in strong LD with the UTR2 haplotype, a haplotype 
different from low expressing haplotypes (UTR5 and UTR7). While UTR2 contains the 14-
bp Ins, it also bears the +3035C SNP which was associated with high levels of sHLA-G 
(Martelli-Palomino et al., 2013). Thus, it is possible that there may be other polymorphisms 
within the 5‟URR and 3‟UTR associated with either high/low expression of HLA-G which 
may be counteracting each other. 
 
It must be noted that while we corrected for administration of maternal sdNVP in MTCT1 
and had matched all MTCT2 mothers on the basis of their VL, CD4+ T cell count and ART 
regimens, it has been documented that ART can induce surface expression of HLA-G on 
blood peripheral monocytes from HIV-1-infected patients (Cabello et al., 2003, Rivero et al., 
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2007). Cabello et al. (2003) reported that NRTIs, such as sdNVP, given as part of HAART 
may be directly related to high levels of monocytes expressing HLA-G. It is possible that in 
our MTCT cohorts ART may have an additive effect on HLA-G production in conjunction 
with the HLA-G polymorphisms which we report. However, since sdNVP at the onset of 
labour primarily acts as an infant PEP (Lehman and Farquhar, 2007) and reduces the risk for 
IP transmission but has little effect on IU transmission; it is questionable to what extent 
maternal sdNVP given at onset of labour might have on increasing HLA-G expression given 
the timing of administration. Moreover, in MTCT1 we found HLA-G associations were 
directed towards IU-transmission. Thus, in MTCT1 it is unlikely that maternal ART with 
sdNVP might have increased HLA-G expression. However, in MTCT2 mothers received 
daily dose AZT from 28 - 37 weeks gestation as well as sdNVP at the onset of labour, 
therefore it may be possible that AZT increased HLA-G expression and increased the risk for 
HIV-1 transmission. Further studies are required to conclusively validate this theory. 
 
With regards to mother-infant concordance in MTCT1, we and others (Rousseau et al., 
2003b, Segat and Crovella, 2012, Luo et al., 2013) found no association for HLA-G alleles 
and the 14-bp indel with risk of vertical transmission. Only one study reported an association 
between HLA-G discordance at codon 57 in exon 2 in non-transmitting mother-infant pairs, 
but the sample size was small (n=34) and the study did not consider different routes of 
transmission (Aikhionbare et al., 2001). 
 
In conclusion, we show that certain maternal HLA-G alleles and 3‟UTR haplotypes associate 
with an increased risk for either IU or IP MTCT, and that this is likely through modulation of 
maternal HLA-G expression at the maternal-foetal interface. However, further investigations 
in larger cohorts are necessary to confirm these associations and future studies should 
collectively assess HLA-G alleles, the 5‟URR and 3‟UTR as well as plasma and cervical 
levels of sHLA-G as these polymorphisms and changes in HLA-G expression may influence 
susceptibility to MTCT as well as adult HIV-1 transmission. 
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CHAPTER 7 
Concluding Remarks 
 
This study, through establishing and comparing the representations of various KIRs and their 
HLA-ligands in HIV-1 infected mothers and their infants, has identified several genetic 
associations with specific modes of MTCT. A brief summation of the relevant findings from 
each of the chapters follows: 
 
From Chapter 3: (Hong et al. 2011. Tissue Antigens; 78, 185 - 194) 
1. We developed two real-time PCR assays for the detection of KIR and HLA-ligands. 
2. The real-time PCR assays were validated against well-known conventional KIR and 
HLA genotyping kits using reference samples that had been previously genotyped. 
3. We demonstrated that the two real-time PCR assays were 100% and 99% concordant 
with the conventional KIR and HLA genotyping methods, respectively.  
4. These two real-time PCR assays allowed for the quick, easy and cost-effective 
detection of all 16 KIR genes as well as their cognate HLA-A, -B and -C ligands. 
 
From Chapter 4: 
1. The influence of KIR genes and their HLA-ligands was evaluated in two distinct 
mother-infant cohorts that differed in ART and overall HIV-1 transmission rates.  
2. In MTCT1, we found that concordance for KIR2DL3/KIR2DL3+C2/C2 between 
mother and infant significantly increased the risk for IP transmission. In addition, 
“matched” allorecognition of infant KIR2DL2/KIR2DL3 and maternal HLA-C1/C1 
significantly associated with increased risk for IU acquisition of HIV-1.  
3. In MTCT2, total representation of the AA1 haplotype was significantly lower in the 
maternal group compared to the infant group. Moreover, the maternal AA1 haplotype 
was significantly under-represented in comparison to the frequency reported for 
MTCT1 mothers. However, the MTCT2 AA1 haplotype frequency did not associate 
with risk of vertical transmission. 
4. In MTCT2, both maternal and infant possession of HLA-A Bw4:80I significantly 
increased the risk for IU transmission and IU acquisition of HIV-1. In addition, 
maternal possession of KIR3DL1+Bw4:80I associated with increased risk for IU and 
IP transmission. 
5. In both MTCT cohorts, the Bx32 genotype was significantly higher in IP-TR mothers 
compared to the NT mothers and associated with increased risk of IP transmission.  
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From Chapter 5: (Hong et al. 2013. Clinical Immunology; 149, 498 - 508) 
1. The findings demonstrate that allelic variants of KIR2DS4 (functional, –f and non-
functional, –v) alter the risk of MTCT of HIV-1.  
2. In MTCT1, maternal possession of KIR2DS4-f while absent in their infants (i.e. M+I- 
discordance) associated with increased risk for IP transmission. However, infant 
possession of KIR2DS4-v significantly increased the risk of IU acquisition of HIV-1; 
this association was enhanced when infants possessed the AA1 haplotype.  
3. In MTCT2, while we observed no significant differences in frequencies of allelic 
variants of KIR2DS4 in the maternal, infant and paired mother-infant groups, a weak 
trend towards higher representation of KIR2DS4-f was observed in IU infants.  
4. Scatter plot comparisons of KIR2DS4-v and the AA1 haplotype frequency showed that 
the two mother-infant cohorts differed considerably. This was largely due to the 
significant difference in the AA1 haplotype frequency between the mothers.  
 
From Chapter 6: (Hong et al. 2015. Infection, Genetics and Evolution 30, 147 - 158) 
1. We characterised HLA-G and showed that specific HLA-G alleles and 3‟UTR 
haplotypes associated with IU or IP transmission of HIV-1. 
2. In MTCT1 and MTCT2, the most common HLA-G alleles and 3‟UTR haplotypes were 
G*01:01:01, G*01:01:02 and G*01:04:04, and UTR2, UTR3 and UTR1, respectively. 
Pairwise LD analysis between HLA-G alleles and the 3‟UTR polymorphisms showed 
G*01:01:01, G*01:04:01 and G*01:04:04 to be significantly linked with the 14-bp 
Del. However, the HLA-G alleles: G*01:01:02, G*01:03:01, G*01:05N and 
G*01:01:19 were in significant LD with the 14-bp Ins. Strong LD was also observed 
between G*01:01:01 and the haplotypes UTR1, UTR6 and UTR20, whereas 
G*01:01:02, G*01:03:01, G*01:05N and G*01:01:19 were found to be in significant 
LD with UTR2, UTR5 and UTR7. 
3. In MTCT1, maternal possession of G*01:01:02 and the UTR1 haplotype independently 
associated with increased risk for IU transmission. However, in the infant group neither 
HLA-G alleles nor 3‟UTR polymorphisms showed any significant association with 
HIV-1 acquisition.  
4. In MTCT2, maternal possession of G*01:01:01/G*01:04:04 genotype and the 
UTR1/UTR3 haplotype significantly associated with increased risk for IP transmission. 
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To date the correlates of protective immunity against HIV-1 remain elusive, as there are no 
documented cases of individuals with complete viral clearance having long lasting resistance 
in the presence or absence of ART intervention. However, there have been recognized cases 
of individuals who remain HIV-1 uninfected despite repeated exposure to the virus (Kulkarni 
et al., 2003, Shacklett, 2006, Piacentini et al., 2008, Horton et al., 2010). These exposed 
uninfected (EU) individuals have been identified around the world and well known cohorts 
include the Pumwani CSWs from Nairobi, Kenya (Fowke et al., 1996), HIV-1 serodiscordant 
couples which can be either heterosexual or homosexual (men who have sex with men) (Tang 
et al., 2002, Hladik et al., 2003, Jennes et al., 2013), and the non-sexually exposed groups 
such as Vietnamese injection drug users (Scott-Algara et al., 2003, Tran et al., 2006) and the 
EU infants born to HIV-infected mothers (Rowland-Jones et al., 1998, Tiemessen and Kuhn, 
2007, Tiemessen et al., 2009, Paximadis et al., 2011). Therefore, by studying the host 
genetics and the immune response in the EU individuals may offer key insights into what 
might qualify as protective responses for future vaccine design.  
 
We sought to determine which immunogenetic factors influenced resistance and/or 
susceptibility to HIV-1 infection using the mother-to-child transmission model. Unlike in 
adult EU cohorts where the accuracy of HIV-1 exposure is often a concern (i.e. most rely on 
the participant‟s self-reported sexual history), in mother-infant birth cohorts clinical 
information regarding the maternal VL, CD4+ T cell counts and ART regimens at the time of 
delivery is usually available. Thus, viral exposure can be quantified more accurately and 
corrected for when identifying correlates of resistance and/or susceptibility. Importantly, 
having clinical specimens from the mother (transmitter and non-transmitter) and infant 
(infected and uninfected) may provide insights into which immunological factors may 
contribute to maternal HIV-1 transmission as well as infant HIV-1 acquisition of HIV-1. 
Furthermore, given that the mechanism of infant infection likely differs in IU- and IP- 
infection, a major advantage of our MTCT study is the stratification of HIV-1 infected infants 
according to their mode of acquisition (IU or IP) which few MTCT studies report. Moreover, 
since the rates of vertical transmission of HIV-1 have dropped dramatically from 30% to less 
than 2% with effective administration of PMTCT programs and ART, we evaluated in two 
mother-infant cohorts (MTCT1 and MTCT2) recruited during two periods of time where 
implemented ART regimens differed (i.e. monotherapy including sdNVP vs. dual therapy 
including AZT and sdNVP, respectively). This allowed us to more accurately understand and 
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determine which immunogenetic factors were associated with increased/decreased risk of 
HIV-1 acquisition in the context of changing ART regimens. Indeed, while it is essential that 
PMTCT programs and maternal ART administration continues to improve and reduce the 
rates of MTCT, over time the numbers of HIV-1 infected infants will decline. Moreover, the 
expense of establishing and following MTCT cohorts from birth with meaningful sample 
numbers will becomes exorbitant. Nevertheless, even with reduced numbers the findings 
generated provide valuable information regarding susceptibility to HIV-1 infection despite 
both maternal (PrEP) and infant (PEP) ART administration. Therefore, the use of MTCT 
specifically as a model to understand protective immunity is increasingly complicated by 
increased ART usage for prevention, making existing stored specimens exceptionally 
precious for the continued identification of additional factors important in MTCT. 
 
Collective evidence has shown that NK cells through their KIR and HLA-ligand interactions 
have a role to play in the transmission and control of HIV-1 infection (Martin et al., 2002, 
Scott-Algara et al., 2003, Fauci et al., 2005, Tran et al., 2006, Martin et al., 2007, Ravet et al., 
2007, Carrington et al., 2008, Tang et al., 2008, Tiemessen et al., 2009, Tiemessen et al., 
2010, Wong et al., 2010, Paximadis et al., 2011, Pelak et al., 2011, Tiemessen et al., 2011, 
Martin and Carrington, 2013). In particular, the original work by Paximadis et al. (2011) from 
the greater MTCT1 cohort suggested that certain inhibitory KIR/HLA-ligand gene 
combinations associated with increased risk of vertical transmission of HIV-1. Moreover, the 
authors emphasized the need to further explore the relationship of concordance and 
allorecognition of KIR and HLA-ligands amongst mother-infant pairs. It was also noted that 
KIR allelic variance should be considered when determining associations for MTCT of HIV-1 
as KIR alleles are not equally expressed on the surface of NK cells. In addition, it was also 
suggested that HLA-G be evaluated given its role as the cognate ligand for the framework 
KIR2DL4. Thus, in order to better understand the role of KIR and HLA-ligand genes in risk of 
and/or protection from vertical transmission we used a selection mother and infant samples 
from MTCT1 and second mother-infant cohort (MTCT2) that differed with respect to overall 
HIV-1 transmission rate and ART regimens.  
 
Firstly, it was clear that the two MTCT cohorts differed significantly on the basis of their 
clinical and immunogenetic data. Although the overall rate of transmission was significantly 
lower in the MTCT2 compared to MTCT1, surprisingly this reduction in transmission was 
not due to reduced maternal VL. In fact, despite having received daily dose AZT starting 
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from 28 - 37 weeks gestation, VL in TR mothers was comparable in MTCT1 and MTCT2. 
Similarly, CD4+ T cells counts were significantly lower in TR mothers from MTCT2 
compared to TR mothers from MTCT1 suggesting that there were other factors contributing 
to the decreased rate of transmission. It is likely that in MTCT2, the administration of ART 
reduced HIV-1 transmission primarily by preventing the establishment of HIV-1 infection 
establishment most likely through the IP route, this being consistent with the proportion of IP 
versus IU infants relative to MTCT1.  
 
Additionally, representation of the common KIR AA1 haplotype was significantly lower in 
MTCT2 mothers (13.9%) when compared to their infants (33.7%), and in comparison to 
MTCT1 mothers (27.2%). This difference in the AA1 haplotype was marked when 
comparing scatter plot of the KIR2DS4-v and AA1 haplotype prevalence in MTCT1 versus 
MTCT2. Thus, to understand this difference we used KIR data from the Black ESKOM 
cohort, which represented a diverse cross-section of nine Black South African dialects 
(Gentle et al., unpublished data). While the overall representation for AA1 haplotype in the 
ESKOM cohort was 26.9% (similar to that of the MTCT1 cohort), individual representation 
of the AA1 haplotype across the dialects showed Tswana and Tsonga speaking individuals 
had the greatest representation of the AA1 haplotype (40-45%), whereas as Xhosa and 
Sesotho speaking individuals had the lowest representation of the AA1 haplotype (12-13%). 
The Xhosa KIR data also compared well with other published Xhosa KIR data (Middleton et 
al., 2007a). Thus, we speculated that mothers in MTCT1 represented a more diverse cross 
section of Black South African dialects, whereas mothers in MTCT2 may have been biased 
toward a larger proportion of Xhosa or Sesotho speaking individuals. Moreover, given the 
high proportion of the AA1 haplotype in MTCT2 infants, this also suggested that the majority 
of infants received a paternal copy of the A haplotype.  
 
Nevertheless, while the AA1 haplotype itself did not associate with risk of vertical 
transmission in either the MTCT1 or MTCT2, components of this inhibitory haplotype 
associated with risk of transmission. Paximadis et al. (2011) previously reported that both 
maternal KIR2DL3 homozygosity and possession of the Bx32 genotype significantly 
associated with IP transmission, and correspondingly, in this thesis we identified that 
concordance for KIR2DL3/KIR2DL3+C2/C2 between mother-infant significantly associated 
with increased risk for IP transmission. Moreover, when adjusting for maternal VL mother-
infant concordance for KIR2DL3/KIR2DL3+C2/C2 showed a nine-fold increased risk for IP 
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transmission. Importantly, in this regard given that (1) KIR2DL2 and KIR2DL3 segregate as 
alleles of a single genetic locus (Uhrberg et al., 2002), (2) the presence of KIR2DL2 
associates with the group B haplotype while presence of KIR2DL3 associates with group A 
haplotype (Hollenbach et al., 2009), and (3) KIR2DL3/KIR2DL3 in MTCT1 mothers included 
the following haplotypes: AA1 (83.1%), Bx32 (7.0%), Bx35 (2.8%), Bx10 (2.8%), 
Bx48 (1.4%), Bx27 (1.4%) and Bx2 (1.4%), respectively, then KIR2DL3 homozygosity likely 
correlated with the inhibitory AA1 haplotype. Thus, based on the principles of NK cell 
„arming‟ model (Raulet and Vance, 2006), we postulated that homozygous KIR2DL3 NK 
cells in the absence of their cognate C1 ligand would be unarmed and unresponsive to HIV-1 
infected cells allowing viral infected cells to escape targeted lysis by NK cells. Additionally, 
given that KIR2DL3 and KIR2DL1 are in strong LD whereby 90% of individuals who bear 
KIR2DL3 also possess KIR2DL1 (Hollenbach et al., 2009), we could further extrapolate that 
NK cells in both mother and infant through a KIR2DL1+C2/C2 interaction would promote 
NK cell inhibition and thus further contribute to increased risk of IP-transmission.  
 
Similarly, while KIR2DS4 can be found in B haplotypes it generally associates with the 
A haplotype (Gourraud et al., 2010). In MTCT1, we found maternal possession of KIR2DS4-f 
while absence in the infant (i.e. M+I- discordance) associated with increased risk for IP 
transmission. It may be that having one functional activating KIR on a predominantly 
inhibitory genotype with six other inhibitory KIRs is not sufficient to induce NK cell 
cytotoxicity toward viral infected cells. Alternatively, Merino et al. (2014) suggested that in 
chronic HIV-1 infection KIR2DS4-f promoted HIV-1 pathogenesis through the maintenance 
of an excessive pro-inflammatory state. The same group also reported that KIR2DS4-f 
associated with higher VL in HIV-1 positive partners and accelerated transmission of HIV-1 
(Merino et al., 2011). Therefore, it may be that KIR2DS4-f NK cells in mothers with chronic 
HIV-1 infection are in a state of activation releasing pro-inflammatory cytokines that might 
promote IP transmission. 
 
Conversely, in MTCT1 infant possession of KIR2DS4-v significantly associated with 
increased risk for IU acquisition of HIV-1 and this association was more prominent when 
infants were homozygous for the A haplotype. Accordingly, lack of a functional membrane 
bound KIR2DS4 in a KIR genotype would be in complete favour of NK cell inhibition, would 
suggest that infant NK cells are unable to eliminate viral infected cells. Interestingly, in the 
Chinese Han (a population with high proportions of the A haplotype) possession of 
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KIR2DS4-v associated with increased susceptibility to syphilis (Zhuang et al., 2012). 
Therefore, in MTCT2 where the AA1 haplotype was significantly underrepresented in 
mothers it is perhaps not surprising that the KIRDL3 and KIR2DS4-f associations were not 
evident. A greater proportion of Bx haplotypes would equate with the presence of more than 
three activating KIRs (i.e. KIR2DS1, KIR2DS2, KIR2DS3 and KIR2DS5) which may possibly 
negate the effect of KIR2DS4. Taken together our data indicate that KIR2DS4 variants are 
able to modulate the risk of vertical transmission, and this justifies further analysis into the 
direct and indirect roles of KIR2DS4 in NK cell function, but future studies should ideally 
match cases and controls in the context of the A haplotype. 
 
In keeping with the NK cell inhibitory theory, it was also interesting to note that a “matched” 
inhibitory KIR/HLA-ligand combination between infant KIR and maternal HLA also increased 
the risk for vertical transmission. Again, in the MTCT1, infant possession of 
KIR2DL2/KIR2DL3 paired with maternal C1/C1 ligands increased the risk for IU acquisition 
of HIV-1. This suggested that if inhibitory KIRs on infant NK cells engage with cognate 
HLA-ligands expressed by HIV-1 infected maternal cells, this “matched” inhibitory 
KIR/HLA combination would fail to activate the cytolytic activity of the infant NK cell 
thereby allowing escape of the viral-infected cell. Indeed, our data concurs with the principles 
of „self-recognition‟ (Hoglund and Brodin, 2010), and further supports the findings of 
“matched and miss matched” KIR/HLA allorecognition amongst HIV-1 concordant and 
discordant Senegalese couples (Jennes et al., 2013). Moreover, Jennes et al. (2013) in their in 
vitro NK cell alloreactivity assays using healthy blood donor derived NK cells and HIV-1 
patient derived CD4+ T cells showed functional evidence of NK cell-mediated CD4+ T cell 
killing, which correlated with the presence of matched or mismatched allogeneic KIR/HLA 
combinations.   
 
Although the concordant and allogeneic KIR/HLA associations were not evident in the 
MTCT2 cohort, the presence of a HLA-A Bw4:80I allele in mothers and infants significantly 
increased the risk for IU transmission and IU acquisition, respectively. Moreover, the 
combination KIR3DL1+HLA-A/B Bw4:80I was also significantly over-represented in both 
IP-TR and IU-TR mothers compared to NT mothers, notably another inhibitory 
KIR/HLA-ligand combination. However, since our real-time PCR assay broadly grouped the 
HLA-A alleles into those with an isoleucine at position 80 (A*23, A*24, A*25 and A*32) and 
those without, we extrapolated which HLA-A allele/s could be increasing the risk for MTCT 
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by using HLA-A background frequencies collected from Black South African population 
(Paximadis et al., 2012). Using their HLA-A data, it was likely that HLA-A Bw4:80I in the 
MTCT2 primarily consisted of A*23:01. Therefore our data was consistent with other studies 
which reported that A*23:01 associated with higher VL as well as increased the risk of 
transmission (MacDonald et al., 2000, Tang et al., 2008, Mackelprang et al., 2010). Similarly, 
in a Ugandan cohort of chronically HIV-1 infected individuals HLA-B Bw4 was associated 
with elevated frequencies of KIR3DL1+ CD56
dim
 NK cells, and the size of the KIR3DL1+ 
NK cell subset correlated directly with VL (Eller et al., 2011). The authors noted this effect 
occurred only in HLA-B Bw4+ patients, suggesting that these cells expand in response to 
viral replication but may have relatively poor antiviral capacity.  
 
Thus, collectively, in MTCT2 given that HLA-A Bw4:80I was significantly over-represented 
in TR mothers and their HIV-1 infected infants, and maternal HLA-A/B Bw4:80I in 
combination with KIR3DL1 showed an association with increased risk for IP and IU 
transmission of HIV-1, it is plausible that the engagement of this inhibitory KIR might 
prevent NK cell lysis of HIV-1 infected cells possibly promoting HIV-1 
transmission/acquisition. As such in light of these findings, while Paximadis et al. (2011) 
assessed only the HLA-B ligand groups and found no significant differences with regards to 
HLA-B Bw4:80I alone or paired with KIR3DL1, for future work it would be important to 
perform HLA-A Bw4 genotyping the MTCT1 cohort.  
 
Next, given that HLA-G is (1) the cognate ligand for KIR2DL4, a conserved framework KIR 
gene virtually expressed by all NK cells (Rajagopalan and Long, 2012), (2) can directly 
inhibit NK cell differentiation, proliferation, cytolysis and cytokine secretion (Amiot et al., 
2014), and (3) HLA-G is preferentially expressed at the maternal-foetal interface on 
extravillous cytotrophoblasts, where it is plays an important tolerogenic role towards the 
semi-allogeneic foetus (Castelli et al., 2014), we evaluated the effect of HLA-G 
polymorphisms on vertical transmission of HIV-1. HLA-G alleles and 3‟UTR haplotypes 
associations were evident in both MTCT cohorts. Representation of the UTR1 haplotype 
significantly associated with increased risk for IU- and IP- transmission in MTCT1 and 
MTCT2, respectively. Importantly, this haplotype has been reported to contain the majority 
of the polymorphisms that associate with increased expression of HLA-G, for example the 
14-bp Del, +3142C and +3187G (Castelli et al., 2014). Moreover, the UTR1 haplotype was in 
strong LD with G*01:01:01, a HLA-G alleles that associated with higher levels of plasma 
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HLA-G than other HLA-G alleles, such as G*01:01:03 and G*01:05N (Rebmann et al., 
2001). In agreement with our findings, placental expression of HLA-G1 was 3.95 times more 
up-regulated in HIV-1 transmitting mothers compared to HIV-1 non-transmitting mothers 
(Moodley and Bobat, 2011). Other studies also identified HLA-G1 was able to inhibit NK 
cell-mediated lysis (Navarro et al., 1999, Ponte et al., 1999, Marchal-Bras-Goncalves et al., 
2001).Thus in accordance with the NK cell inhibitory theory, we and others (Matte et al., 
2004, Moodley and Bobat, 2011, Luo et al., 2013, da Silva et al., 2014), postulated that 
higher HLA-G expression would exert greater NK cell inhibition, which could result in the 
decreased ability of these cells to target viral-infected cells thereby increasing the risk for 
HIV-1 transmission.  
 
Concerning HLA-G in infants, in MTCT1 we found no significant differences amongst the 
EU or HIV-1 infected infants, which suggested that HLA-G polymorphisms and potentially 
HLA-G expression by infant cells had little effect on HIV-1 acquisition. Thus, considering 
these findings as well as sample availability and cost of HLA-G genotyping we selected not to 
conduct HLA-G genotyping on the infant samples from MTCT2. This said, we cannot assume 
that HLA-G in MTCT2 infants would show no immunogenetic associations as found for 
MTCT1. 
 
Figure 7.1 shows a summary of the major immunogenetic factors that were found to 
associate with the risk of MTCT of HIV-1. Overall, the data represented in this thesis confirm 
that both maternal and infant NK cells through their KIR/HLA-ligand interactions are able to 
influence the risk of vertical transmission of HIV-1. Moreover, potential alloreactive 
KIR/HLA-ligand combinations between mother and her infant holds important relevance to 
predicting which infants may be more susceptible to infection. While MTCT1 and MTCT2 
received different ART regimens and were recruited almost a decade apart, the common 
emerging feature that appeared to associate with risk of transmission was a predicted overall 
inhibition of NK cell cytolysis, as indicated by representations of inhibitory KIR and their 
HLA-ligands.  
 
In conclusion, in the context of MTCT, it remains an open question as to whether the small 
subset of infants still becoming HIV-1 infected despite receiving improved ART regimens, 
are a smaller subset of the group that would have normally become infected, or whether they 
are a uniquely susceptible group based on the altered drug environment. Given our findings 
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showing some common and uncommon genetic factors evident between MTCT1 and 
MTCT2, it is reasonable to suggest that there may well be such a shift in infant susceptibility. 
The study of additional genetic factors over time may allow this question to be more 
convincingly answered.  
 
 
Figure 7.1 KIR and HLA-ligand factors that associate with risk of MTCT of HIV-1. NT/EU: 
HIV-1 non-transmitting mother and exposed infected infant; TR/IU or IP: HIV-1 transmitting 
mother and her in utero or intrapartum infected infant. 
 
The findings in this thesis have important relevance to vaccine design as most HIV-1 vaccine 
have focused on the induction of nAbs to block infection by free virions and not virus-
infected cells (Gooneratne et al., 2015). As both sexual and vertical transmission of HIV-1, 
transfer of HIV-1 infected lymphocytes takes place and evidence of this cell-to-cell 
transmission have been documented (Carr et al., 1999, Zhong et al., 2013), this implies 
vaccine design should incorporate the elicitation of immune responses capable of eliminating 
both cell-free and cell-associated virus. Given our KIR/HLA findings, as well as those 
reported in allogeneic stem cell transplantation, it is possible that allogeneic recognition of 
HIV-1 infected lymphocytes and their targeted lysis is achievable. Thus, future work should 
more thoroughly explore mechanisms to elicit these types of responses in the quest for a 
successful HIV-1 vaccine.  
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